Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,29905619,AUC0-12h,"The median values of AUC0-12h were 43.98 and 41.95 mcg·h/mL for MMF capsule and MMF dispersible tablet, respectively.",Pharmacokinetic Comparison of Two Mycophenolate Mofetil Formulations in Kidney Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905619/),[h·mcg] / [ml],43.98,1262,DB00688,Mycophenolate mofetil
,29905619,AUC0-12h,"The median values of AUC0-12h were 43.98 and 41.95 mcg·h/mL for MMF capsule and MMF dispersible tablet, respectively.",Pharmacokinetic Comparison of Two Mycophenolate Mofetil Formulations in Kidney Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29905619/),[h·mcg] / [ml],41.95,1263,DB00688,Mycophenolate mofetil
,15049798,Half-life (T(1/2)),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,9.7,1318,DB00688,Mycophenolate mofetil
,15049798,Half-life (T(1/2)),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,9.6,1319,DB00688,Mycophenolate mofetil
,15049798,terminal T(1/2),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,10.8,1320,DB00688,Mycophenolate mofetil
,15049798,terminal T(1/2),"Half-life (T(1/2)) and terminal T(1/2) were 9.7 (7.1-24.6) and 10.8 (4.4-95.2) hours (median, range) respectively at month 1, and were 9.6 (5-17.8) and 12.1 (4.7-71.0) hours respectively at month 3.",Short sirolimus half-life in pediatric renal transplant recipients on a calcineurin inhibitor-free protocol. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15049798/),h,12.1,1321,DB00688,Mycophenolate mofetil
>,18459999,trough,"The incidence of early, acute rejection episodes was higher for recipients who were younger, received a graft from an unrelated donor or failed to achieve adequate tacrolimus concentrations (trough > 10 ng/mL) in the first seven d after transplant.",Combination therapy with tacrolimus and mycophenolate mofetil: effects of early and late minimization of mycophenolate mofetil after renal transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18459999/),[ng] / [ml],10,1322,DB00688,Mycophenolate mofetil
,25707517,oral clearance,"Typical mean value of MPA oral clearance, estimated by base model (without covariates) was 0.741 L h(-1).",Variability of mycophenolic acid elimination in the renal transplant recipients – population pharmacokinetic approach. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25707517/),[l] / [h],0.741,1786,DB00688,Mycophenolate mofetil
,18440919,Cmax/AUC,The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 +/- 6.6 microg/mL/43.9 +/- 12.6 microg/mL.h vs deceased donor liver transplant patients: 10.7 +/- 2.0 microg/mL/28.9 +/- 7.1 microg/mL.h; P = .046/.002).,Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440919/),[μg] / [ml],16.1,1798,DB00688,Mycophenolate mofetil
,18440919,Cmax/AUC,The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 +/- 6.6 microg/mL/43.9 +/- 12.6 microg/mL.h vs deceased donor liver transplant patients: 10.7 +/- 2.0 microg/mL/28.9 +/- 7.1 microg/mL.h; P = .046/.002).,Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440919/),[μg] / [h·ml],43.9,1799,DB00688,Mycophenolate mofetil
,18440919,Cmax/AUC,The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 +/- 6.6 microg/mL/43.9 +/- 12.6 microg/mL.h vs deceased donor liver transplant patients: 10.7 +/- 2.0 microg/mL/28.9 +/- 7.1 microg/mL.h; P = .046/.002).,Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440919/),[μg] / [ml],10.7,1800,DB00688,Mycophenolate mofetil
,18440919,Cmax/AUC,The maximum concentration (Cmax) and the area under the plasma concentration versus time curve (AUC) for mycophenolic acid in live donor liver transplant patients were significantly higher than in deceased donor liver transplant patients (Cmax/AUC: live donor liver transplant patients: 16.1 +/- 6.6 microg/mL/43.9 +/- 12.6 microg/mL.h vs deceased donor liver transplant patients: 10.7 +/- 2.0 microg/mL/28.9 +/- 7.1 microg/mL.h; P = .046/.002).,Pharmacokinetics of mycophenolic acid in live donor liver transplant patients vs deceased donor liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18440919/),[μg] / [h·ml],28.9,1801,DB00688,Mycophenolate mofetil
,12780669,area under the concentration-time curve (AUC0-12),"The am and pm doses were independently adjusted to achieve a 12-h area under the concentration-time curve (AUC0-12) of 6600-7200 nghr/mL and morning trough level (C0) of 250-325 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],6600-7200,3025,DB00688,Mycophenolate mofetil
,12780669,trough level (C0),"The am and pm doses were independently adjusted to achieve a 12-h area under the concentration-time curve (AUC0-12) of 6600-7200 nghr/mL and morning trough level (C0) of 250-325 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],250-325,3026,DB00688,Mycophenolate mofetil
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7810,3027,DB00688,Mycophenolate mofetil
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],9057,3028,DB00688,Mycophenolate mofetil
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7674,3029,DB00688,Mycophenolate mofetil
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[nghr] / [ml],7132,3030,DB00688,Mycophenolate mofetil
,12780669,AUC0-12,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ngl] / [h],6503,3031,DB00688,Mycophenolate mofetil
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],301,3032,DB00688,Mycophenolate mofetil
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],316,3033,DB00688,Mycophenolate mofetil
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],275,3034,DB00688,Mycophenolate mofetil
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],273,3035,DB00688,Mycophenolate mofetil
,12780669,C0,"Mean AUC0-12 in 1 wk, 1, 3, 6, and 12 months were 7810 +/- 1880 nghr/mL, 9057 +/- 2097 nghr/mL, 7674 +/- 1912 nghr/mL, 7132 +/- 2040 nghr/mL, and 6503 +/- 1410 ngl/h with corresponding C0 of 301 +/- 79 ng/mL, 316 +/- 66 ng/mL, 275 +/- 59 ng/mL, 273 +/- 66 ng/mL, and 224 +/- 49 ng/mL, respectively.",Effect of cyclosporin pharmacokinetics on renal allograft outcome in African-Americans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12780669/),[ng] / [ml],224,3036,DB00688,Mycophenolate mofetil
,32858576,flow rate,"PBMCs were isolated from the whole blood of 27 Chinese renal transplant patients using Ficoll-Paque Plus solution, and cell number was determined; acetonitrile treatment for protein precipitation, and gradient elution was performed on an Agilent Eclipse XDB-C18 column (3.5 μm, 2.1 × 100 mm) with mobile phase: water and methanol (containing 2 mM ammonium formate); flow rate: 0.3 mL·min.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),min·ml,0.3,3532,DB00688,Mycophenolate mofetil
,32858576,extraction effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,70.4,3533,DB00688,Mycophenolate mofetil
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,93,3534,DB00688,Mycophenolate mofetil
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,72.7,3535,DB00688,Mycophenolate mofetil
,32858576,matrix effects,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,90.1,3536,DB00688,Mycophenolate mofetil
,32858576,relative recovery,"The extraction effects, matrix effects, and mean relative recovery of these immunosuppressants were 70.4%-93.2%, 72.7%-96.5%, and 90.1%-112.4%, respectively.",Establishment of a Liquid Chromatography-Tandem Mass Spectrometry Method for the Determination of Immunosuppressant Levels in the Peripheral Blood Mononuclear Cells of Chinese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32858576/),%,90.1,3537,DB00688,Mycophenolate mofetil
,25014074,AUC,"Thirty-four patients were started on MMF, and the area under the concentration-time curve (AUC) was measured by limited sampling strategies, and dosing was adjusted to achieve an AUC of 30-60 mg·h·L.",Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25014074/),h·l·mg,30-60,5348,DB00688,Mycophenolate mofetil
<,25014074,AUC,About 61.8% of patients had mycophenolic acid (MPA) AUC <30 mg·h·L with an empiric starting dose of 30 mg/kg.,Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25014074/),h·l·mg,30,5349,DB00688,Mycophenolate mofetil
,25014074,time to renal response,"About 79.4% of patients achieved renal response by 1 year, and the median time to renal response was 111 days.",Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25014074/),d,111,5350,DB00688,Mycophenolate mofetil
≥,25014074,AUC,Patients with serum albumin ≥35 g/L had a greater chance of having an AUC ≥30 mg·h·L.,Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25014074/),h·l·mg,30,5351,DB00688,Mycophenolate mofetil
≥,25014074,AUC,Patients with an AUC ≥30 mg·h·L had greater renal response at 1 year.,Pharmacokinetics of concentration-controlled mycophenolate mofetil in proliferative lupus nephritis: an observational cohort study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25014074/),h·l·mg,30,5352,DB00688,Mycophenolate mofetil
,11856782,AUC(0-12),"There was an association between the risk of acute rejection episodes and MPA-AUC(0-12) values or MPA predose levels; by receiver operating characteristic analysis, an AUC(0-12) of 33.8 mg x h/L in the initial phase posttransplant had a diagnostic sensitivity of 75% and a diagnostic specificity of 64% for discrimination of patients with acute rejections.",The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic Acid in pediatric renal transplant recipients: a report of the german study group on mycophenolate mofetil therapy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11856782/),[h·mg] / [l],33.8,5527,DB00688,Mycophenolate mofetil
,25498100,AUC0-12h,"MPA-AUC0-12h of doses 0.5, 1, and 2 g/m(2)/d was 22.00 ± 3.32, 57.57 ± 34.30, and 140.00 ± 19.70 μg × h/mL, respectively.",Short-term pharmacokinetic study of mycophenolate mofetil in neonatal swine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498100/),[h·μg] / [ml],22.00,7055,DB00688,Mycophenolate mofetil
,25498100,AUC0-12h,"MPA-AUC0-12h of doses 0.5, 1, and 2 g/m(2)/d was 22.00 ± 3.32, 57.57 ± 34.30, and 140.00 ± 19.70 μg × h/mL, respectively.",Short-term pharmacokinetic study of mycophenolate mofetil in neonatal swine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498100/),[h·μg] / [ml],57.57,7056,DB00688,Mycophenolate mofetil
,25498100,AUC0-12h,"MPA-AUC0-12h of doses 0.5, 1, and 2 g/m(2)/d was 22.00 ± 3.32, 57.57 ± 34.30, and 140.00 ± 19.70 μg × h/mL, respectively.",Short-term pharmacokinetic study of mycophenolate mofetil in neonatal swine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25498100/),[h·μg] / [ml],140.00,7057,DB00688,Mycophenolate mofetil
,26740371,AUC(0-24),"Based on steady-state pharmacokinetics, MMF was converted to CI to target a total MPA AUC(0-24) of 40 to 80 μg·hour/mL.",A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[h·μg] / [ml],40 to 80,8124,DB00688,Mycophenolate mofetil
,26740371,steady-state concentration (Css),The MMF dose was adjusted to maintain a total MPA steady-state concentration (Css) of 1.7 to 3.3 μg/mL.,A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[μg] / [ml],1.7 to 3.3,8125,DB00688,Mycophenolate mofetil
,26740371,AUC(0-24),"During the CI schedule, MPA AUC(0-24) was maintained at a mean of 40.1 μg·hour/mL (range, 20.6 to 63.8), and 17 of 19 patients (89%) achieved MPA Css within target of 1.7 to 3.3 μg/mL.",A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[h·μg] / [ml],40.1,8126,DB00688,Mycophenolate mofetil
,26740371,Css,"During the CI schedule, MPA AUC(0-24) was maintained at a mean of 40.1 μg·hour/mL (range, 20.6 to 63.8), and 17 of 19 patients (89%) achieved MPA Css within target of 1.7 to 3.3 μg/mL.",A Pilot Study of Continuous Infusion of Mycophenolate Mofetil for Prophylaxis of Graft-versus-Host-Disease in Pediatric Patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26740371/),[μg] / [ml],1.7 to 3.3,8127,DB00688,Mycophenolate mofetil
,20655577,AUC(0-12),Large interpatient variability in MPA exposure (AUC(0-12)) was observed (mean ± SE: 32 ± 4.2 mg h/L; coefficient of variation: 57%).,Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655577/),[h·mg] / [l],32,8741,DB00688,Mycophenolate mofetil
≥,20655577,AUC(0-12),An AUC(0-12) of ≥30 mg h/L was associated with decreased BILAG scores while on MMF therapy (P = 0.002).,Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655577/),[h·mg] / [l],30,8742,DB00688,Mycophenolate mofetil
at,20655577,AUC(0-12),Additional controlled studies are necessary to confirm that an MPA AUC(0-12) of at least 30 mg h/L is required for cSLE improvement.,Pharmacokinetics and pharmacodynamics of mycophenolic acid and their relation to response to therapy of childhood-onset systemic lupus erythematosus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20655577/),[h·mg] / [l],30,8743,DB00688,Mycophenolate mofetil
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.31,9164,DB00688,Mycophenolate mofetil
,11214772,Km,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),mM,0.28,9165,DB00688,Mycophenolate mofetil
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.2,9166,DB00688,Mycophenolate mofetil
,11214772,Vmax,Glucuronosyl transferase activity followed Michaelis-Menten kinetics and the Km (mean +/- SD; mM) was 0.31+/-0.06 (liver; n = 5) and 0.28+/-0.07 (kidney; n = 5; P = 0.555); the Vmax (mean SD; nmol/mg per minute) was 5.2+/-1.4 (liver; n = 5) and 10.5+/-1.2 (kidney; n = 5; P = 0.0005).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],10.5,9167,DB00688,Mycophenolate mofetil
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],3.3,9168,DB00688,Mycophenolate mofetil
,11214772,glucuronidation rates,The MPA glucuronidation rates (mean +/- SD; nmol/min/mg) were 3.3+/-0.9 (liver; n = 10) and 7.8+/-1.5 (kidney; n = 10; P = 0.0002).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],7.8,9169,DB00688,Mycophenolate mofetil
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9170,DB00688,Mycophenolate mofetil
,11214772,rate of,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9171,DB00688,Mycophenolate mofetil
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],2.0 and 5.1,9172,DB00688,Mycophenolate mofetil
,11214772,glucuronidation,The rate of MPA glucuronidation ranged between 2.0 and 5.1 nmol/ mg per minute with a 2.5-fold variation (liver) and between 5.7 and 9.8 nmol/mg per minute with a 1.7-fold variation (kidney).,Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,AUMC-Q20,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),[nM] / [mg·min],5.7 and 9.8,9173,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9174,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,19,9175,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,63,9176,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,109,9177,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,8,9178,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,13,9179,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,49,9180,DB00688,Mycophenolate mofetil
,11214772,IC50,"Their IC50 estimates (microM) were 8+/-1, 19+/-9, 63+/-8 and 109+/-15, respectively (liver), and 8+/-2, 13+/-2, 49+/-4 and 122+/-18, respectively (kidney).",Mycophenolic acid glucuronidation and its inhibition by non-steroidal anti-inflammatory drugs in human liver and kidney. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11214772/),μM,122,9181,DB00688,Mycophenolate mofetil
,22329639,k(a),"k(a), estimated at 1.7 h(-1) at age 8.7 years, exhibited large interindividual variability (308%).",Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),1/[h],1.7,9194,DB00688,Mycophenolate mofetil
,22329639,V/F,"V/F, estimated at 64.7 l, increased about 2.3 times in children during the immediate post transplantation period.",Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),l,64.7,9195,DB00688,Mycophenolate mofetil
,22329639,CL/F,CL/F was estimated at 12.7 l h(-1).,Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22329639/),[l] / [h],12.7,9196,DB00688,Mycophenolate mofetil
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],11.8,9335,DB00688,Mycophenolate mofetil
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[μg] / [ml],17.8,9336,DB00688,Mycophenolate mofetil
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],22.6,9337,DB00688,Mycophenolate mofetil
,18223462,Cmax,"The mean dose-unadjusted and -adjusted Cmax of MPA with 30 mg lansoprazole were significantly lower than those without PPI (11.8 vs. 17.8 microg/mL, P = 0.0197, and 22.6 vs. 33.1 ng/mL/mg MMF, P = 0.0222, respectively).",Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18223462/),[ng] / [mg·ml],33.1,9338,DB00688,Mycophenolate mofetil
,17488394,apparent half-life,"The mean apparent half-life of MPA was 5.3 +/- 4.3 h, (1.0-15.7).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),h,5.3,9641,DB00688,Mycophenolate mofetil
,17488394,t(max),Mean t(max) was 2.4 +/- 1.1 h (1.0-5.0).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),h,2.4,9642,DB00688,Mycophenolate mofetil
,17488394,area-under-curve,The mean area-under-curve was 45.3 +/- 23.1 microg-h/mL (17.3-90.0).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),[μg-h] / [ml],45.3,9643,DB00688,Mycophenolate mofetil
,17488394,Trough level concentrations (C(12 h)),Trough level concentrations (C(12 h)) showed large inter-individual variability (0-9.2 microg/mL).,Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17488394/),[μg] / [ml],0-9.2,9644,DB00688,Mycophenolate mofetil
,17445553,C(0),"The mean values for C(0) and AUC(0-6h) were 1.8 +/- 1.2 mg/L and 31.1 +/- 14.8 mg*h/L, respectively.",Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[mg] / [l],1.8,9878,DB00688,Mycophenolate mofetil
,17445553,AUC(0-6h),"The mean values for C(0) and AUC(0-6h) were 1.8 +/- 1.2 mg/L and 31.1 +/- 14.8 mg*h/L, respectively.",Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[h·mg] / [l],31.1,9879,DB00688,Mycophenolate mofetil
,17445553,dose-corrected AUC(0-6h),The dose-corrected AUC(0-6h) was 35.4 +/- 17.9 mg*h/L.,Therapeutic drug monitoring of mycophenolic acid in kidney transplant patients: a abbreviated sampling strategy. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445553/),[h·mg] / [l],35.4,9880,DB00688,Mycophenolate mofetil
,21646435,oral bioavailability,"Raloxifene is extensively glucuronidated in humans, effectively reducing its oral bioavailability (2%).",Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646435/),%,2,11527,DB00688,Mycophenolate mofetil
,21646435,hepatic availability,"In Gunn rats, the product of fraction absorbed and intestinal availability and hepatic availability of raloxifene were 0.63 and 0.43, respectively; these values were twice those observed in wild-type Wistar rats, indicating that raloxifene was glucuronidated in both the liver and intestine.",Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646435/),,0.63,11528,DB00688,Mycophenolate mofetil
,21646435,hepatic availability,"In Gunn rats, the product of fraction absorbed and intestinal availability and hepatic availability of raloxifene were 0.63 and 0.43, respectively; these values were twice those observed in wild-type Wistar rats, indicating that raloxifene was glucuronidated in both the liver and intestine.",Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene. ,FH-Q42,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21646435/),,0.43,11529,DB00688,Mycophenolate mofetil
,32539658,CL,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),[l] / [h],15.4,11955,DB00688,Mycophenolate mofetil
,32539658,Vc,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),l,22.86,11956,DB00688,Mycophenolate mofetil
,32539658,Vp,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),l,22.86,11957,DB00688,Mycophenolate mofetil
,32539658,Ka,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),l,22.86,11958,DB00688,Mycophenolate mofetil
,32539658,Q,"MPA CL, Vc, Vp, Ka and Q were 15.4 L/h, 22.86 L, 768 L, 1.28 h-1 and 20.3 L/h, respectively.",Population pharmacokinetics of mycophenolic acid in Mexican patients with lupus nephritis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32539658/),[l] / [h],20.3,11959,DB00688,Mycophenolate mofetil
,18708992,peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),[mg] / [l],15.0,12414,DB00688,Mycophenolate mofetil
,18708992,peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),[mg] / [l],16.1,12415,DB00688,Mycophenolate mofetil
,18708992,time to reach the peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),h,1.0,12416,DB00688,Mycophenolate mofetil
,18708992,time to reach the peak concentration,"Switching to TRL had minimal impact on peak concentration of MPA (15.0 +/- 6.9 mg/L with CsA versus 16.1 +/- 9.7 mg/L with TRL, P = 0.773) and time to reach the peak concentration (1.0 +/- 0.4 hours with CsA versus 1.2 +/- 0.8 hours with TRL, P = 0.461).",Impact of changing from cyclosporine to tacrolimus on pharmacokinetics of mycophenolic acid in renal transplant recipients with diabetes. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18708992/),h,1.2,12417,DB00688,Mycophenolate mofetil
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.36,12974,DB00688,Mycophenolate mofetil
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.73,12975,DB00688,Mycophenolate mofetil
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],3.26,12976,DB00688,Mycophenolate mofetil
,15917949,FTY720,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],7.15,12977,DB00688,Mycophenolate mofetil
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.36,12978,DB00688,Mycophenolate mofetil
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.73,12979,DB00688,Mycophenolate mofetil
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],3.26,12980,DB00688,Mycophenolate mofetil
,15917949,concentrations,"Mean FTY720 concentrations were 0.36 +/- 0.05 (0.25 mg), 0.73 +/- 0.12 (0.5 mg), 3.26 +/- 0.51 (1 mg), and 7.15 +/- 1.41 ng/ml (2.5 mg) between 4 and 12 weeks after transplantation.",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],7.15,12981,DB00688,Mycophenolate mofetil
,15917949,Emax,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),%,87.8,12982,DB00688,Mycophenolate mofetil
,15917949,ED50,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),mg,0.48,12983,DB00688,Mycophenolate mofetil
,15917949,Emax,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),%,78.3,12984,DB00688,Mycophenolate mofetil
,15917949,EC50,"The simple Emax model [E = (Emax * C)/(C + EC50)] was the best-fit PK/PD modeling for FTY720 dose (Emax = 87.8 +/- 5.3% and ED50 = 0.48 +/- 0.08 mg, r(2) = 0.94) or concentration (Emax = 78.3 +/- 2.9% and EC50 = 0.59 +/- 0.09 ng/ml, r(2) = 0.89) vs effect (% reduction in peripheral lymphocytes).",Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.59,12985,DB00688,Mycophenolate mofetil
,15917949,EC50,FTY720 PK/PD is dose dependent and follows an Emax model (EC50 = 0.5 mg or 0.6 ng/ml).,Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),mg,0.5,12986,DB00688,Mycophenolate mofetil
,15917949,EC50,FTY720 PK/PD is dose dependent and follows an Emax model (EC50 = 0.5 mg or 0.6 ng/ml).,Pharmacokinetic/pharmacodynamic relationships of FTY720 in kidney transplant recipients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15917949/),[ng] / [ml],0.6,12987,DB00688,Mycophenolate mofetil
,11272311,retention time,The retention time of MPA was approximately 4.5 min.,Rapid and simple determination of mycophenolic acid in human plasma by ion-pair RP-LC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11272311/),min,4.5,14035,DB00688,Mycophenolate mofetil
,11272311,run time,The HPLC run time was 8 min.,Rapid and simple determination of mycophenolic acid in human plasma by ion-pair RP-LC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11272311/),min,8,14036,DB00688,Mycophenolate mofetil
,11272311,limit of detection,A limit of detection was 0.05 microg/ml at a signal-to-noise ratio of 3.,Rapid and simple determination of mycophenolic acid in human plasma by ion-pair RP-LC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11272311/),[μg] / [ml],0.05,14037,DB00688,Mycophenolate mofetil
,11272311,signal-to-noise ratio,A limit of detection was 0.05 microg/ml at a signal-to-noise ratio of 3.,Rapid and simple determination of mycophenolic acid in human plasma by ion-pair RP-LC with fluorescence detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11272311/),,3,14038,DB00688,Mycophenolate mofetil
> or =,15659129,Cmax,A Cmax> or =10 microg/mL was seen in 20 (57%) of the patients.,The need of mycophenolic acid monitoring in long-term renal transplants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15659129/),[μg] / [ml],10,14142,DB00688,Mycophenolate mofetil
,25327506,CL/F,"MPA CL/F was 11.5 L/h for a 70-kg healthy subject, and the MPAG CL/F values were 1.36 and 1.90 L/h for 70-kg Chinese and Caucasian individuals, respectively.",Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327506/),[l] / [h],11.5,14647,DB00688,Mycophenolate mofetil
,25327506,CL/F,"MPA CL/F was 11.5 L/h for a 70-kg healthy subject, and the MPAG CL/F values were 1.36 and 1.90 L/h for 70-kg Chinese and Caucasian individuals, respectively.",Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327506/),[l] / [h],1.36,14648,DB00688,Mycophenolate mofetil
,25327506,CL/F,"MPA CL/F was 11.5 L/h for a 70-kg healthy subject, and the MPAG CL/F values were 1.36 and 1.90 L/h for 70-kg Chinese and Caucasian individuals, respectively.",Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: a comparison between healthy Chinese and Caucasian subjects receiving mycophenolate mofetil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25327506/),[l] / [h],1.90,14649,DB00688,Mycophenolate mofetil
,17318074,area under the curve,MPA concentration-time profiles in 21 patients showed that MPA exposure was similar with MMF or EC-MPS (mean area under the curve 39.9+/-11.6 microg x h/mL versus 43.7+/-17.4 microg x h/mL at day 14 post-conversion).,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·μg] / [ml],39.9,14993,DB00688,Mycophenolate mofetil
,17318074,area under the curve,MPA concentration-time profiles in 21 patients showed that MPA exposure was similar with MMF or EC-MPS (mean area under the curve 39.9+/-11.6 microg x h/mL versus 43.7+/-17.4 microg x h/mL at day 14 post-conversion).,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·μg] / [ml],43.7,14994,DB00688,Mycophenolate mofetil
,17318074,time to peak concentration,Median time to peak concentration was 0.5 hr with MMF and 1.5 hr with EC-MPS.,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),h,0.5,14995,DB00688,Mycophenolate mofetil
,17318074,time to peak concentration,Median time to peak concentration was 0.5 hr with MMF and 1.5 hr with EC-MPS.,"Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),h,1.5,14996,DB00688,Mycophenolate mofetil
,17318074,area under the enzyme activity time curve (AEC),"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·nM] / [h·mg·prot],124.2,14997,DB00688,Mycophenolate mofetil
,17318074,area under the enzyme activity time curve (AEC),"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[h·nM] / [h·mg·prot],130.3,14998,DB00688,Mycophenolate mofetil
,17318074,activity,"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[nM] / [h·mg],10.3,14999,DB00688,Mycophenolate mofetil
,17318074,activity,"Inosine monophosphate dehydrogenase (IMPDH) activity was almost identical: area under the enzyme activity time curve (AEC) was 124.2+/-32.0 nmol x h/mg prot/h with MMF and 130.3+/-36.6 nmol x h/mg prot/h with EC-MPS at 14 days post-conversion; average daytime IMPDH activity was 10.3+/-2.7 nmol/h/mg protein and 10.9+/-2.7 nmol/h/mg protein, respectively.","Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17318074/),[nM] / [h·mg],10.9,15000,DB00688,Mycophenolate mofetil
outside,19817503,AUC(12),Fifty-two percent of the observed AUC(12) values (three periods) in the 40 patients receiving a fixed dose of mycophenolate mofetil 750 mg twice daily were outside the recommended therapeutic range (30-60 microg x h/mL).,Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19817503/),[h·μg] / [ml],30-60,15549,DB00688,Mycophenolate mofetil
,8680052,Cmax,"The Cmax and Tmax for mycophenolic acid (MPA) were 3.6-35.2 micrograms/mL and 0.5-4 h, respectively, and did not significantly change over 6 months.",Mycophenolate mofetil in liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680052/),[μg] / [ml],3.6-35.2,16245,DB00688,Mycophenolate mofetil
,8680052,Tmax,"The Cmax and Tmax for mycophenolic acid (MPA) were 3.6-35.2 micrograms/mL and 0.5-4 h, respectively, and did not significantly change over 6 months.",Mycophenolate mofetil in liver transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8680052/),h,0.5-4,16246,DB00688,Mycophenolate mofetil
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],3.18,17449,DB00688,Mycophenolate mofetil
,14529944,C(0) MPA level,C(0) MPA level among the tacrolimus group were significantly higher than those in CsA group: 3.18 +/- 2.21 microg/mL versus 1.68 +/- 1.03 microg/mL (P </=.001).,The influence of calcineurin inhibitors on mycophenolic acid pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14529944/),[μg] / [ml],1.68,17450,DB00688,Mycophenolate mofetil
,27105859,AUC0-12,The median AUC0-12 was 44.3 ng h/mL.,Pharmacokinetics of mycophenolic acid in children with clinically stable idiopathic nephrotic syndrome receiving cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27105859/),[h·ng] / [ml],44.3,19446,DB00688,Mycophenolate mofetil
>,9653967,absolute recovery,Mean absolute recovery for all analytes was >99%.,High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9653967/),%,99,20430,DB00688,Mycophenolate mofetil
,15556544,total run time,The total run time was 18 min and the extraction recovery was 77% for MPA and 84% for MPAG.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),min,18,20477,DB00688,Mycophenolate mofetil
,15556544,extraction recovery,The total run time was 18 min and the extraction recovery was 77% for MPA and 84% for MPAG.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),%,77,20478,DB00688,Mycophenolate mofetil
,15556544,extraction recovery,The total run time was 18 min and the extraction recovery was 77% for MPA and 84% for MPAG.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),%,84,20479,DB00688,Mycophenolate mofetil
,15556544,flow rate,Analytical column was the same as the HPLC-UV method and the mobile phase was a gradient composition of methanol:0.05% formic acid with a flow rate of 0.6 ml/min for the first 3 min and 0.7 ml for the last 4 min.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),[ml] / [min],0.6,20480,DB00688,Mycophenolate mofetil
,15556544,flow rate,Analytical column was the same as the HPLC-UV method and the mobile phase was a gradient composition of methanol:0.05% formic acid with a flow rate of 0.6 ml/min for the first 3 min and 0.7 ml for the last 4 min.,Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),ml,0.7,20481,DB00688,Mycophenolate mofetil
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,319,20482,DB00688,Mycophenolate mofetil
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,190.9,20483,DB00688,Mycophenolate mofetil
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,356,20484,DB00688,Mycophenolate mofetil
,15556544,m/z,"Mass transitions in negative ionization mode for MPA and the internal standard, indomethacin were m/z: 319-->190.9 and m/z: 356-->312.2, respectively.",Determination of total mycophenolic acid and its glucuronide metabolite using liquid chromatography with ultraviolet detection and unbound mycophenolic acid using tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15556544/),,312.2,20485,DB00688,Mycophenolate mofetil
,31419321,extraction recovery,The linear range for MPA quantification was 0.2-30 mg/L with a limit of detection of 0.07 mg/L; the mean extraction recovery was 99.99%.,Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419321/),%,99.99,21114,DB00688,Mycophenolate mofetil
,31419321,maximal concentration,"Mean maximal concentration of 10 mg/L at 1.5 h, area under the concentration-time curve of 36.8 mg·h/L, elimination half-life of 3.9 h, clearance of 0.32 L/h/kg and volume of distribution of 1.65 L/kg were obtained from MPA pharmacokinetics profiles.",Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419321/),[mg] / [l],10,21115,DB00688,Mycophenolate mofetil
,31419321,area under the concentration-time curve,"Mean maximal concentration of 10 mg/L at 1.5 h, area under the concentration-time curve of 36.8 mg·h/L, elimination half-life of 3.9 h, clearance of 0.32 L/h/kg and volume of distribution of 1.65 L/kg were obtained from MPA pharmacokinetics profiles.",Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419321/),[h·mg] / [l],36.8,21116,DB00688,Mycophenolate mofetil
,31419321,elimination half-life,"Mean maximal concentration of 10 mg/L at 1.5 h, area under the concentration-time curve of 36.8 mg·h/L, elimination half-life of 3.9 h, clearance of 0.32 L/h/kg and volume of distribution of 1.65 L/kg were obtained from MPA pharmacokinetics profiles.",Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419321/),h,3.9,21117,DB00688,Mycophenolate mofetil
,31419321,clearance,"Mean maximal concentration of 10 mg/L at 1.5 h, area under the concentration-time curve of 36.8 mg·h/L, elimination half-life of 3.9 h, clearance of 0.32 L/h/kg and volume of distribution of 1.65 L/kg were obtained from MPA pharmacokinetics profiles.",Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419321/),[l] / [h·kg],0.32,21118,DB00688,Mycophenolate mofetil
,31419321,volume of distribution,"Mean maximal concentration of 10 mg/L at 1.5 h, area under the concentration-time curve of 36.8 mg·h/L, elimination half-life of 3.9 h, clearance of 0.32 L/h/kg and volume of distribution of 1.65 L/kg were obtained from MPA pharmacokinetics profiles.",Determination of mycophenolic acid in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry and its pharmacokinetic application in kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31419321/),[l] / [kg],1.65,21119,DB00688,Mycophenolate mofetil
,12644921,C(0),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],3.46,21628,DB00688,Mycophenolate mofetil
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21629,DB00688,Mycophenolate mofetil
,12644921,C(max),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21630,DB00688,Mycophenolate mofetil
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],13.5,21631,DB00688,Mycophenolate mofetil
,12644921,AUC (0-12),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],63.2,21632,DB00688,Mycophenolate mofetil
,12644921,T(max ),"Mean C(0), C(max), AUC (0-12), and T(max )were 3.46+/-1.32, 13.5+/-0.58 microg/ml, 63.2+/-24.4 microg x h/ml, and 1.3+/-0.6 h, respectively.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),h,1.3,21633,DB00688,Mycophenolate mofetil
>,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],54,21634,DB00688,Mycophenolate mofetil
<,12644921,AUC(0-12 ),"Six (30%) children were considered to have an adequate exposure (36-54 microg x h/ml) to MPA, 11 (55%) showed an AUC(0-12 )>54 microg.h/ml, and 3 (15%) showed an AUC(0-12 )<36 microg x h/ml.",Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[h·μg] / [ml],36,21635,DB00688,Mycophenolate mofetil
>/=,12644921,C(max ),A C(max )>/=10 microg/ml was seen in 13 (65%) children.,Mycophenolic acid pharmacokinetics in stable pediatric renal transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12644921/),[μg] / [ml],10,21636,DB00688,Mycophenolate mofetil
,22215359,area under the concentration-time curve (AUC),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[h·μg] / [l·mg],52.6,21832,DB00688,Mycophenolate mofetil
,22215359,maximum concentration (C(max)),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [l·mg],8.0,21833,DB00688,Mycophenolate mofetil
,22215359,time to C(max) (t(max)),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),h,1.8,21834,DB00688,Mycophenolate mofetil
,22215359,minimum concentration (C(min)),"The mean ± S.D. pharmacokinetic parameters for tacrolimus, normalized to a dose of 1 mg, were as follows: area under the concentration-time curve (AUC), 52.6 ± 24.8 μg · hr/L/mg; maximum concentration (C(max)), 8.0 ± 3.3 μg/L/mg; time to C(max) (t(max)), 1.8 ± 1.0 hr; and minimum concentration (C(min)), 2.6 ± 1.4 μg/L/mg.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [l·mg],2.6,21835,DB00688,Mycophenolate mofetil
,22215359,AUC,"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[h·μg] / [g·ml],26.9,21836,DB00688,Mycophenolate mofetil
,22215359,C(max),"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [g·ml],17.5,21837,DB00688,Mycophenolate mofetil
,22215359,t(max),"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),h,0.9,21838,DB00688,Mycophenolate mofetil
,22215359,C(min),"The mean ± S.D. pharmacokinetic parameters for mycophenolic acid, normalized to a mycophenolate mofetil dose of 1 g, were AUC, 26.9 ± 13.2 μg ·hr/mL/g; C(max), 17.5 ± 5.4 μg/mL/g; t(max), 0.9 ± 0.6 hr; and C(min), 1.5 ± 1.1 μg/mL/g.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),[μg] / [g·ml],1.5,21839,DB00688,Mycophenolate mofetil
,22215359,free fraction,The free fraction of mycophenolic acid was 1.8% ± 0.7%.,Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),%,1.8,21840,DB00688,Mycophenolate mofetil
,22215359,AUC ratios,"AUC ratios of MPAG:mycophenolic acid and AcMPAG:mycophenolic acid were 13.0 ± 5.8 and 0.1 ± 0.2, respectively.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),,13.0,21841,DB00688,Mycophenolate mofetil
,22215359,AUC ratios,"AUC ratios of MPAG:mycophenolic acid and AcMPAG:mycophenolic acid were 13.0 ± 5.8 and 0.1 ± 0.2, respectively.",Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22215359/),,0.1,21842,DB00688,Mycophenolate mofetil
,8560580,half-life,The half-life was calculated at approximately 8 hr for both dose groups.,Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8560580/),h,8,22132,DB00688,Mycophenolate mofetil
,19715843,trough,"Despite taking similar MMF doses, patients with delayed graft function (DGF) showed lower 12-hour trough MPA levels than patients without DGF 1.4 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P = .001).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.4,22770,DB00688,Mycophenolate mofetil
,19715843,trough,"Despite taking similar MMF doses, patients with delayed graft function (DGF) showed lower 12-hour trough MPA levels than patients without DGF 1.4 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P = .001).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],2.1,22771,DB00688,Mycophenolate mofetil
>,19715843,trough,Logistic regression analysis showed that creatinine clearance was a predictive factor of adequate 12-hour trough MPA levels (>1.6 microg/mL) at 7 days posttransplantation.,Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.6,22772,DB00688,Mycophenolate mofetil
,19715843,Twelve-hour,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.5,22773,DB00688,Mycophenolate mofetil
,19715843,Twelve-hour,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],2.1,22774,DB00688,Mycophenolate mofetil
,19715843,trough MPA levels,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],1.5,22775,DB00688,Mycophenolate mofetil
,19715843,trough MPA levels,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],2.1,22776,DB00688,Mycophenolate mofetil
,19715843,trough MPA levels,"Twelve-hour trough MPA levels at 7 days posttransplantation were lower among patients who developed an acute rejecton episode (1.5 +/- 0.1 vs 2.1 +/- 0.1 microg/mL; P < .001), whereas those with gastrointestinal side effects showed high levels (4.1 +/- 0.5 microg/mL).",Graft outcome and mycophenolic acid trough level monitoring in kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715843/),[μg] / [ml],4.1,22777,DB00688,Mycophenolate mofetil
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],16.1,24351,DB00688,Mycophenolate mofetil
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],32.2,24352,DB00688,Mycophenolate mofetil
,10440399,AUC,"A total of 154 adult recipients of a primary or secondary cadaveric kidney graft were randomly allocated, in this double-blind trial, to receive MMF treatment aimed at three predefined target MPA AUC values (16.1, 32.2, and 60.6 microg x hr/ml).","A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10440399/),[h·μg] / [ml],60.6,24353,DB00688,Mycophenolate mofetil
,26274696,time of the conversion,Mean time of the conversion was 61 months after transplantation.,Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),month,61,25023,DB00688,Mycophenolate mofetil
,26274696,trough blood concentration,"In the first 7 patients, the initial EVR dose of 3 mg BID resulted in mean EVR trough blood concentration of 14.7 ± 3.7 ng/mL at day 7.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],14.7,25024,DB00688,Mycophenolate mofetil
,26274696,trough blood concentration,"Four weeks after conversion, mean EVR dose was 1.7 ± 0.5 mg BID (7 patients were receiving 1 mg BID and 17 were receiving 2 mg BID) resulting in mean EVR trough blood concentration of 4.0 ± 1.4 ng/mL.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.0,25025,DB00688,Mycophenolate mofetil
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],13.4,25026,DB00688,Mycophenolate mofetil
,26274696,maximum concentration,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],22.9,25027,DB00688,Mycophenolate mofetil
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],232,25028,DB00688,Mycophenolate mofetil
,26274696,apparent clearance,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ml] / [min],366,25029,DB00688,Mycophenolate mofetil
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],78.2,25030,DB00688,Mycophenolate mofetil
,26274696,area under the curve,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[h·ng] / [ml],102.5,25031,DB00688,Mycophenolate mofetil
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],3.7,25032,DB00688,Mycophenolate mofetil
,26274696,C0,"Whereas mean maximum concentration (13.4 ± 2.8 versus 22.9 ± 7.4 ng/mL, P = 0.003) and mean apparent clearance (232 ± 79 versus 366 ± 173 mL/min, P = 0.016) were higher, mean area under the curve (78.2 ± 22.1 versus 102.5 ± 38.5 ng.h/mL, P = 0.067) and mean C0 (3.7 ± 1.3 versus 4.1 ± 1.5 ng/mL, P = 0.852) were no different comparing patients receiving 1 mg and 2 mg EVR BID.",Pharmacokinetics and Long-Term Safety and Tolerability of Everolimus in Renal Transplant Recipients Converted From Cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26274696/),[ng] / [ml],4.1,25033,DB00688,Mycophenolate mofetil
,21088289,area under the curve,"In renal transplant recipients, MMF therapy is optimal when the area under the curve of MPA is 30 to 60 mg·h/L.",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),[h·mg] / [l],30 to 60,26320,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,123,26321,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,111,26322,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,94,26323,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,90,26324,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,176,26325,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,133,26326,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,85,26327,DB00688,Mycophenolate mofetil
,21088289,relative bioavailability,"Compared with an MMF dose of 1000 mg (=100%), relative bioavailability was 123%, 111%, 94%, and 90% in patients receiving MMF doses of 250, 500, 1500, and 2000 mg in combination with cyclosporine (P < 0.001); respective values in tacrolimus-cotreated patients were 176%, 133%, 85%, and 76% (P < 0.001).",Nonlinear relationship between mycophenolate mofetil dose and mycophenolic acid exposure: implications for therapeutic drug monitoring. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21088289/),%,76,26328,DB00688,Mycophenolate mofetil
,31855839,flow rate,The chromatographic separation was achieved by a reverse phase ACE Excel 2 Super C18 column with a flow rate of 0.4 mL/min under gradient elution.,Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31855839/),[ml] / [min],0.4,26730,DB00688,Mycophenolate mofetil
,31855839,extraction recovery rates,"The matrix effect was non-significant and extraction recovery rates were within 87.99% and 109.69% in plasma and tongue homogenates, respectively.",Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31855839/),%,87.99,26731,DB00688,Mycophenolate mofetil
,31855839,extraction recovery rates,"The matrix effect was non-significant and extraction recovery rates were within 87.99% and 109.69% in plasma and tongue homogenates, respectively.",Determination and validation of mycophenolic acid by a UPLC-MS/MS method: Applications to pharmacokinetics and tongue tissue distribution studies in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31855839/),%,109.69,26732,DB00688,Mycophenolate mofetil
,10071348,time to reach peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),h,1.8,27847,DB00688,Mycophenolate mofetil
,10071348,time to reach peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),h,1.0,27848,DB00688,Mycophenolate mofetil
,10071348,trough plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],1.1,27849,DB00688,Mycophenolate mofetil
,10071348,trough plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],1.4,27850,DB00688,Mycophenolate mofetil
,10071348,peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],10.6,27851,DB00688,Mycophenolate mofetil
,10071348,peak plasma concentration,"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [ml],11.1,27852,DB00688,Mycophenolate mofetil
,10071348,area under the plasma concentration-versus-time curve (AUC),"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [h·ml],40.1,27853,DB00688,Mycophenolate mofetil
,10071348,area under the plasma concentration-versus-time curve (AUC),"There were no significant differences in the time to reach peak plasma concentration (1.8 +/- 1.7 v 1.0 +/- 0.5 hours), trough plasma concentration of MPA (1.1 +/- 1.4 v 1.4 +/- 1.1 microgram/mL), peak plasma concentration of MPA (10.6 +/- 7.5 v 11.1 +/- 4.6 microgram/mL), area under the plasma concentration-versus-time curve (AUC) (40.1 +/- 31.9 v 43.2 +/- 21.1 microgram/mL/h) of MPA, or the percentage of MPA that is free or unbound in the plasma (3.9% +/- 1.6% v 4.1% +/- 3.0%).",Effect of t-tube clamping on the pharmacokinetics of mycophenolic acid in liver transplant patients on oral therapy of mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071348/),[μg] / [h·ml],43.2,27854,DB00688,Mycophenolate mofetil
,8699340,plasma to erythrocyte concentration ratio,The plasma to erythrocyte concentration ratio was low (0.10-0.15).,"Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),,0.10-0.15,28435,DB00688,Mycophenolate mofetil
,8699340,bound fraction,MPA existed in rat plasma as the highly bound form (bound fraction was 9.79 +/- 0.57%).,"Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),%,9.79,28436,DB00688,Mycophenolate mofetil
,8699340,total clearance,"After i.v. administration of MPM at the doses of 8.3, 16.7, and 33.3 mg/kg, the total clearance of MPA was 0.241 +/- 0.056, 0.321 +/- 0.126, and 0.317 +/- 0.092 L/h/kg, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),[l] / [h·kg],0.241,28437,DB00688,Mycophenolate mofetil
,8699340,total clearance,"After i.v. administration of MPM at the doses of 8.3, 16.7, and 33.3 mg/kg, the total clearance of MPA was 0.241 +/- 0.056, 0.321 +/- 0.126, and 0.317 +/- 0.092 L/h/kg, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),[l] / [h·kg],0.321,28438,DB00688,Mycophenolate mofetil
,8699340,total clearance,"After i.v. administration of MPM at the doses of 8.3, 16.7, and 33.3 mg/kg, the total clearance of MPA was 0.241 +/- 0.056, 0.321 +/- 0.126, and 0.317 +/- 0.092 L/h/kg, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),[l] / [h·kg],0.317,28439,DB00688,Mycophenolate mofetil
,8699340,terminal elimination half-live,"The terminal elimination half-live were 5.17 +/- 1.44, 8.89 +/- 2.76, and 7.94 +/- 2.94 h, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),h,5.17,28440,DB00688,Mycophenolate mofetil
,8699340,terminal elimination half-live,"The terminal elimination half-live were 5.17 +/- 1.44, 8.89 +/- 2.76, and 7.94 +/- 2.94 h, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),h,8.89,28441,DB00688,Mycophenolate mofetil
,8699340,terminal elimination half-live,"The terminal elimination half-live were 5.17 +/- 1.44, 8.89 +/- 2.76, and 7.94 +/- 2.94 h, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),h,7.94,28442,DB00688,Mycophenolate mofetil
,8699340,terminal elimination half-live,"After i.d. administration of MPM at the doses of 8.3, 16.7, 33.3, and 50.0 mg/kg, the terminal elimination half-live were 6.41 +/- 4.16, 4.49 +/- 2.20, 7.58 +/- 3.72, and 8.18 +/- 1.32 h, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),h,6.41,28443,DB00688,Mycophenolate mofetil
,8699340,terminal elimination half-live,"After i.d. administration of MPM at the doses of 8.3, 16.7, 33.3, and 50.0 mg/kg, the terminal elimination half-live were 6.41 +/- 4.16, 4.49 +/- 2.20, 7.58 +/- 3.72, and 8.18 +/- 1.32 h, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),h,4.49,28444,DB00688,Mycophenolate mofetil
,8699340,terminal elimination half-live,"After i.d. administration of MPM at the doses of 8.3, 16.7, 33.3, and 50.0 mg/kg, the terminal elimination half-live were 6.41 +/- 4.16, 4.49 +/- 2.20, 7.58 +/- 3.72, and 8.18 +/- 1.32 h, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),h,7.58,28445,DB00688,Mycophenolate mofetil
,8699340,terminal elimination half-live,"After i.d. administration of MPM at the doses of 8.3, 16.7, 33.3, and 50.0 mg/kg, the terminal elimination half-live were 6.41 +/- 4.16, 4.49 +/- 2.20, 7.58 +/- 3.72, and 8.18 +/- 1.32 h, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),h,8.18,28446,DB00688,Mycophenolate mofetil
within,8699340,peak times,The mean peak times were within 30 min.,"Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),min,30,28447,DB00688,Mycophenolate mofetil
,8699340,systemic availability,"The systemic availability of MPA after i.d. administration of MPM (at 8.3, 16.7, and 33.3 mg/kg) was calculated using the corresponding mean AUCiv, and the values were 84.3 +/- 35.0%, 69.9 +/- 25.7%, and 63.6 +/- 8.8%, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),%,84.3,28448,DB00688,Mycophenolate mofetil
,8699340,systemic availability,"The systemic availability of MPA after i.d. administration of MPM (at 8.3, 16.7, and 33.3 mg/kg) was calculated using the corresponding mean AUCiv, and the values were 84.3 +/- 35.0%, 69.9 +/- 25.7%, and 63.6 +/- 8.8%, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),%,69.9,28449,DB00688,Mycophenolate mofetil
,8699340,systemic availability,"The systemic availability of MPA after i.d. administration of MPM (at 8.3, 16.7, and 33.3 mg/kg) was calculated using the corresponding mean AUCiv, and the values were 84.3 +/- 35.0%, 69.9 +/- 25.7%, and 63.6 +/- 8.8%, respectively.","Pharmacokinetics of mycophenolate mofetil, a new immunosuppressant, in rats. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8699340/),%,63.6,28450,DB00688,Mycophenolate mofetil
,17465638,AUC(12),The mean MPA AUC(12) was 52.97 +/- 15.09 mg .,Pharmacokinetics of mycophenolic acid and estimation of exposure using multiple linear regression equations in Chinese renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17465638/),mg,52.97,29790,DB00688,Mycophenolate mofetil
,32265712,Apparent clearance (CL/F),"Apparent clearance (CL/F) and central volume of distribution (VC/F) of uMPA (CLuMPA/F and VCuMPA/F, respectively) and protein binding rate constant (k B) were estimated to be 851 L/h [relative standard error (RSE), 7.1%], 718 L (18.5%) and 53.4/h (2.3%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),[l] / [h],851,30373,DB00688,Mycophenolate mofetil
,32265712,central volume of distribution (VC/F),"Apparent clearance (CL/F) and central volume of distribution (VC/F) of uMPA (CLuMPA/F and VCuMPA/F, respectively) and protein binding rate constant (k B) were estimated to be 851 L/h [relative standard error (RSE), 7.1%], 718 L (18.5%) and 53.4/h (2.3%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),l,718,30374,DB00688,Mycophenolate mofetil
,32265712,central volume of distribution (VC/F),"Apparent clearance (CL/F) and central volume of distribution (VC/F) of uMPA (CLuMPA/F and VCuMPA/F, respectively) and protein binding rate constant (k B) were estimated to be 851 L/h [relative standard error (RSE), 7.1%], 718 L (18.5%) and 53.4/h (2.3%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),1/[h],53.4,30375,DB00688,Mycophenolate mofetil
,32265712,CL/F,"For uMPAG, the population values (RSE) of CL/F (CLuMPAG) and VC/F (VCuMPAG/F) were 5.71 L/h (4.4%) and 29.9 L (7.7%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),[l] / [h],5.71,30376,DB00688,Mycophenolate mofetil
,32265712,VC/F (VCuMPAG/F,"For uMPAG, the population values (RSE) of CL/F (CLuMPAG) and VC/F (VCuMPAG/F) were 5.71 L/h (4.4%) and 29.9 L (7.7%), respectively.",Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32265712/),l,29.9,30377,DB00688,Mycophenolate mofetil
,28856214,Total I,The %CV for Within Run Imprecision ranged from 5.5% at 1.2 mg/L to 1.5% at 14.1 mg/L and Total Imprecision ranged from 9.3% to 2.5%.,The Roche Total Mycophenolic Acid® assay: An application protocol for the ABX Pentra 400 analyzer and comparison with LC-MS in children with idiopathic nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28856214/),%,9.,30658,DB00688,Mycophenolate mofetil
,17969194,area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)],The aim of this study was to assess the pharmacokinetics of MMF in stable pediatric liver transplant patients and estimate the dose of MMF required to provide a mycophenolic acid (MPA) exposure similar to that observed in adult liver transplant recipients receiving the recommended dose of MMF (target area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)] for MPA of 29 mug.hour/mL in the immediate posttransplantation period and 58 microg x hour/mL after 6 months).,Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],29,30884,DB00688,Mycophenolate mofetil
,17969194,area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)],The aim of this study was to assess the pharmacokinetics of MMF in stable pediatric liver transplant patients and estimate the dose of MMF required to provide a mycophenolic acid (MPA) exposure similar to that observed in adult liver transplant recipients receiving the recommended dose of MMF (target area under the plasma concentration-time curve from 0 to 12 hours [AUC(0-12)] for MPA of 29 mug.hour/mL in the immediate posttransplantation period and 58 microg x hour/mL after 6 months).,Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],58,30885,DB00688,Mycophenolate mofetil
,17969194,AUC(0-12),"Of 8 patients, 7 had a MPA AUC(0-12) (range, 11.0-37.2 microg x hour/mL) well below the target.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],11.0-37.2,30886,DB00688,Mycophenolate mofetil
> or =,17969194,AUC(0-12),One patient had an AUC(0-12) > or = 58 microg x hour/mL but was considered an outlier and was excluded from analyses.,Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],58,30887,DB00688,Mycophenolate mofetil
,17969194,AUC(0-12),"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],22.7,30888,DB00688,Mycophenolate mofetil
,17969194,AUC(0-12),"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],47.0,30889,DB00688,Mycophenolate mofetil
,17969194,maximum plasma concentration,"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[μg] / [ml],7.23,30890,DB00688,Mycophenolate mofetil
,17969194,maximum plasma concentration,"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[h·μg] / [ml],47.0,30891,DB00688,Mycophenolate mofetil
,17969194,maximum plasma concentration,"Mean MPA AUC(0-12) and maximum plasma concentration values were 22.7 +/- 10.5 microg x hour/mL and 7.23 +/- 3.27 microg/mL, respectively; values normalized to 600 mg/m(2) (the approved pediatric dose in renal transplantation) were 47.0 +/- 21.8 microg x hour/mL and 14.5 +/- 4.21 microg/mL.",Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17969194/),[μg] / [ml],14.5,30892,DB00688,Mycophenolate mofetil
,19307937,area under the concentration-time curves (AUCs),MPA area under the concentration-time curves (AUCs) ranged from 31.8 to 102.1 (median: 52.9) mg.h(-1).,Pharmacokinetics of mycophenolic acid and its glucuronide metabolites in stable adult liver transplant recipients with renal dysfunction on a low-dose calcineurin inhibitor regimen and mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19307937/),[mg] / [h],52.9,30923,DB00688,Mycophenolate mofetil
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],25.8,30938,DB00688,Mycophenolate mofetil
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],33.8,30939,DB00688,Mycophenolate mofetil
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],45.2,30940,DB00688,Mycophenolate mofetil
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],26.2,30941,DB00688,Mycophenolate mofetil
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],34.4,30942,DB00688,Mycophenolate mofetil
,19214147,AUCs-LC-MS/MS,"MPA exposure determined with either method at different time points after transplantation agreed well (eg, 25th/50th/75th percentile of day 10 AUCs-LC-MS/MS: 25.8/33.8/45.2 versus enzymatic assay: 26.2/34.4/45.3 mg.h/L).",Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],45.3,30943,DB00688,Mycophenolate mofetil
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],39.6,30944,DB00688,Mycophenolate mofetil
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],56.4,30945,DB00688,Mycophenolate mofetil
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],40.5,30946,DB00688,Mycophenolate mofetil
,19214147,AUCs,AUCs calculated for both methods were lower at the first 3 time points in patients on cyclosporine compared with tacrolimus (week 4 median cyclosporine/tacrolimus: LC-MS/MS 39.6/56.4 versus enzymatic assay 40.5/56.0 mg.h/L).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[h·mg] / [l],56.0,30947,DB00688,Mycophenolate mofetil
,19214147,AUCs,Both LC-MS/MS and the enzymatic methods revealed a tendency toward lower AUCs and predose levels in patients with biopsy-proven acute rejection (BPAR) (day 10 median: 0.9 mg/L with BPAR and 1.7 mg/L without BPAR).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[mg] / [l],0.9,30948,DB00688,Mycophenolate mofetil
,19214147,AUCs,Both LC-MS/MS and the enzymatic methods revealed a tendency toward lower AUCs and predose levels in patients with biopsy-proven acute rejection (BPAR) (day 10 median: 0.9 mg/L with BPAR and 1.7 mg/L without BPAR).,Clinical utility of a new enzymatic assay for determination of mycophenolic acid in comparison with an optimized LC-MS/MS method. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19214147/),[mg] / [l],1.7,30949,DB00688,Mycophenolate mofetil
,27445161,area under the concentration-time curve,The findings indicate individual dose adaptation in 53 patients (38%) to achieve an area under the concentration-time curve target of 30-60 mg·h/L.,Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27445161/),[h·mg] / [l],30-60,31092,DB00688,Mycophenolate mofetil
>,27445161,area under the concentration-time curve,"In a multivariable negative binomial model including sex, age at disease onset, time to start of mycophenolate mofetil, previous immunomodulatory treatment, and concomitant prednisone dose, a level of area under the concentration-time curve of mycophenolic acid >45 mg·h/L was significantly associated with a lower relapse rate (rate ratio, 0.65; 95% confidence interval, 0.46 to 0.89; P=0.01).",Mycophenolic Acid Pharmacokinetics and Relapse in Children with Steroid-Dependent Idiopathic Nephrotic Syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27445161/),[h·mg] / [l],45,31093,DB00688,Mycophenolate mofetil
,21572388,area under the concentration-time curve from 0 to 12 hours (AUC0-12),Routine therapeutic drug monitoring of mycophenolic acid (MPA) is generally performed using the area under the concentration-time curve from 0 to 12 hours (AUC0-12) with recommended values between 30 and 60 μg·h/mL.,Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[h·μg] / [ml],30 and 60,31127,DB00688,Mycophenolate mofetil
<,21572388,AUC0-12,"Recipients with MPA AUC0-12 levels<30 μg·h/mL on day 28 and 1 year after transplantation had an MPA C0 of <2.0 μg/mL, with a sensitivity of 90.9% and a specificity of 70.7%.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[h·μg] / [ml],30,31128,DB00688,Mycophenolate mofetil
<,21572388,C0,"Recipients with MPA AUC0-12 levels<30 μg·h/mL on day 28 and 1 year after transplantation had an MPA C0 of <2.0 μg/mL, with a sensitivity of 90.9% and a specificity of 70.7%.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[μg] / [ml],2.0,31129,DB00688,Mycophenolate mofetil
>,21572388,AUC0-12,"To keep the MPA AUC0-12>30 μg·h/mL, the plasma threshold for maintaining the MPA C0 with tacrolimus should be set >2.0 μg/mL as determined by high-performance liquid chromatography.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[h·μg] / [ml],30,31130,DB00688,Mycophenolate mofetil
>,21572388,C0,"To keep the MPA AUC0-12>30 μg·h/mL, the plasma threshold for maintaining the MPA C0 with tacrolimus should be set >2.0 μg/mL as determined by high-performance liquid chromatography.",Monitoring of mycophenolic acid predose concentrations in the maintenance phase more than one year after renal transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21572388/),[μg] / [ml],2.0,31131,DB00688,Mycophenolate mofetil
,20430188,area-under-the-curve from 0 to 2 hours (AUC0-2),"The mean area-under-the-curve from 0 to 2 hours (AUC0-2) was 30.0+/-11.6 microg.h/mL (range, 7.8-60.7).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[h·μg] / [ml],30.0,31279,DB00688,Mycophenolate mofetil
,20430188,trough,"Of 114 pharmacokinetic profiles, 40 (35%) AUC and 7 (6.1%) trough values were within the target value (30-60 microg.h/mL and 1.7-4.0 microg/mL, respectively).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],1.7-4.0,31280,DB00688,Mycophenolate mofetil
,20430188,C0,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.01-4.46,31281,DB00688,Mycophenolate mofetil
,20430188,C1/2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.14-36.86,31282,DB00688,Mycophenolate mofetil
,20430188,C2,"The C0, C1/2, and C2 concentrations showed large interindividual variability: C0 (0.01-4.46 microg/mL), C1/2 (0.14-36.86 microg/mL), and C2 (0.79-18.19 microg/mL).",Pharmacokinetics of mycophenolic acid in living donor liver transplantation. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20430188/),[μg] / [ml],0.79-18.19,31283,DB00688,Mycophenolate mofetil
<,17322623,AUC(0-12 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·μg] / [ml],30,31388,DB00688,Mycophenolate mofetil
,17322623,AUC (AUC(0-4 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"2,408",31389,DB00688,Mycophenolate mofetil
,17322623,AUC (AUC(0-4 h),"Two patients (man in his 30 s; woman in her 40 s) had acute rejection with a mycophenolic acid (MPA) AUC(0-12 h) <30 microg x h x ml(-1) and low CsA AUC (AUC(0-4 h); 2,408 ng x h x ml-1, 1,735 ng x h x ml-1).",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"1,735",31390,DB00688,Mycophenolate mofetil
,17322623,AUC(0-4 h),"However, 1 patient (man in his 30 s) with a high CsA AUC(0-4 h) (4,019 ng x h x ml-1) did not develop cardiac allograft rejection even if the MMF was temporarily stopped.",Relationship between acute rejection and cyclosporine or mycophenolic acid levels in Japanese heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17322623/),[h·ng] / [ml],"4,019",31391,DB00688,Mycophenolate mofetil
,23813218,trough level,"We conducted a randomized, multicenter, open-label, crossover study comparing the efficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients with FR-SSNS.",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[μg] / [ml],1.5-2.5,31840,DB00688,Mycophenolate mofetil
,23813218,trough level,"We conducted a randomized, multicenter, open-label, crossover study comparing the efficacy and safety of a 1-year treatment with mycophenolate mofetil (MMF; target plasma mycophenolic acid trough level of 1.5-2.5 µg/ml) or CsA (target trough level of 80-100 ng/ml) in 60 pediatric patients with FR-SSNS.",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[ng] / [ml],80-100,31841,DB00688,Mycophenolate mofetil
<,23813218,AUC,"In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 µg⋅h/ml) experienced 1.4 relapses per year compared with 0.27 relapses per year in those with high exposure (AUC>50 µg⋅h/ml; P<0.05).",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[h·μg] / [ml],50,31842,DB00688,Mycophenolate mofetil
>,23813218,AUC,"In post hoc analysis, patients with low mycophenolic acid exposure (AUC <50 µg⋅h/ml) experienced 1.4 relapses per year compared with 0.27 relapses per year in those with high exposure (AUC>50 µg⋅h/ml; P<0.05).",Mycophenolate mofetil versus cyclosporin A in children with frequently relapsing nephrotic syndrome. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23813218/),[h·μg] / [ml],50,31843,DB00688,Mycophenolate mofetil
,11897977,free fraction,"The average MPA free fraction in healthy adult individuals, stable renal transplant recipients, and heart transplant recipients is approximately 2 to 3%.",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),%,2 to 3,32179,DB00688,Mycophenolate mofetil
,11897977,AUC,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[h·μg] / [ml],45.78,32180,DB00688,Mycophenolate mofetil
,11897977,Cmax,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[μg] / [ml],17.37,32181,DB00688,Mycophenolate mofetil
,11897977,Tmax,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),h,1.2,32182,DB00688,Mycophenolate mofetil
,11897977,Cmin,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[μg] / [ml],3.12,32183,DB00688,Mycophenolate mofetil
,11897977,f,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),%,2.90,32184,DB00688,Mycophenolate mofetil
,11897977,AUC,"Mean (+/- SD) AUC was 45.78 +/- 18.35 microg.h/mL (range, 16.56-74.22 microg.h/mL), Cmax was 17.37 +/- 7.69 microg/mL (range, 4.92-26.63 microg/mL), Tmax was 1.2 +/- 0.4 hours (range, 1.0-2.0 h), Cmin was 3.12 +/- 1.41 microg/mL (range, 1.47-4.82 microg/mL), f was 2.90 +/- 0.56% (range, 2.00-3.40%), and free MPA AUC was 1.29 +/- 0.50 microg.h/mL (range, 0.54-1.88 microg.h/mL).",Pharmacokinetics and protein binding of mycophenolic acid in stable lung transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11897977/),[h·μg] / [ml],1.29,32185,DB00688,Mycophenolate mofetil
,24365986,AUC,"When analyzing visits on Tac, TacMR, and back on Tac combined, the MPA AUC for all 20 patients at baseline was 42.24 (16.98), 37.18 (13.75), and 40.09 (16.69) mg·h·L(-1), respectively, which was not statistically significant using repeated measures (P = 0.1327, R(2) = 0.1109).",Similar MPA exposure on modified release and regular tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365986/),[h·mg] / [l],42.24,32359,DB00688,Mycophenolate mofetil
,24365986,AUC,"When analyzing visits on Tac, TacMR, and back on Tac combined, the MPA AUC for all 20 patients at baseline was 42.24 (16.98), 37.18 (13.75), and 40.09 (16.69) mg·h·L(-1), respectively, which was not statistically significant using repeated measures (P = 0.1327, R(2) = 0.1109).",Similar MPA exposure on modified release and regular tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365986/),[h·mg] / [l],37.18,32360,DB00688,Mycophenolate mofetil
,24365986,AUC,"When analyzing visits on Tac, TacMR, and back on Tac combined, the MPA AUC for all 20 patients at baseline was 42.24 (16.98), 37.18 (13.75), and 40.09 (16.69) mg·h·L(-1), respectively, which was not statistically significant using repeated measures (P = 0.1327, R(2) = 0.1109).",Similar MPA exposure on modified release and regular tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24365986/),[h·mg] / [l],40.09,32361,DB00688,Mycophenolate mofetil
,14749551,area under the curve (AUC),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],4019,34870,DB00688,Mycophenolate mofetil
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[h·ng] / [ml],3971,34871,DB00688,Mycophenolate mofetil
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],998,34872,DB00688,Mycophenolate mofetil
,14749551,maximum concentration (C(max)),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34873,DB00688,Mycophenolate mofetil
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],1021,34874,DB00688,Mycophenolate mofetil
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],707,34875,DB00688,Mycophenolate mofetil
,14749551,concentration at the second hour (C2),"Mean +/- SD of area under the curve (AUC), maximum concentration (C(max)), and concentration at the second hour (C2) of Zinograf were not statistically different from those with Neoral (4019 +/- 1466 vs 3971 +/- 1325 ng x h/mL, 998 +/- 376 vs 1021 +/- 356 ng/mL, and 707 +/- 254 vs 734 +/- 229 ng/mL, respectively).",Bioequivalence of a new cyclosporine a formulation to Neoral. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749551/),[ng] / [ml],734,34876,DB00688,Mycophenolate mofetil
,24837828,CL/F,"The final population PK parameter estimates (and their 95% confidence intervals) were CL/F, 22 (14.8, 25.2) l h(-1) 70 kg(-1) ; Vc /F, 45.4 (29.6, 55.6) l; Vp /F, 411 (152.6, 1472.6)l; Q/F, 22.4 (16.0, 32.5) l h(-1) ; Ka , 2.5 (1.45, 4.93) h(-1) .",Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),[l] / [70·h·kg],22,36140,DB00688,Mycophenolate mofetil
,24837828,Vc /F,"The final population PK parameter estimates (and their 95% confidence intervals) were CL/F, 22 (14.8, 25.2) l h(-1) 70 kg(-1) ; Vc /F, 45.4 (29.6, 55.6) l; Vp /F, 411 (152.6, 1472.6)l; Q/F, 22.4 (16.0, 32.5) l h(-1) ; Ka , 2.5 (1.45, 4.93) h(-1) .",Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),l,45.4,36141,DB00688,Mycophenolate mofetil
,24837828,Vp /F,"The final population PK parameter estimates (and their 95% confidence intervals) were CL/F, 22 (14.8, 25.2) l h(-1) 70 kg(-1) ; Vc /F, 45.4 (29.6, 55.6) l; Vp /F, 411 (152.6, 1472.6)l; Q/F, 22.4 (16.0, 32.5) l h(-1) ; Ka , 2.5 (1.45, 4.93) h(-1) .",Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),l,411,36142,DB00688,Mycophenolate mofetil
,24837828,Q/F,"The final population PK parameter estimates (and their 95% confidence intervals) were CL/F, 22 (14.8, 25.2) l h(-1) 70 kg(-1) ; Vc /F, 45.4 (29.6, 55.6) l; Vp /F, 411 (152.6, 1472.6)l; Q/F, 22.4 (16.0, 32.5) l h(-1) ; Ka , 2.5 (1.45, 4.93) h(-1) .",Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),[l] / [h],22.4,36143,DB00688,Mycophenolate mofetil
,24837828,Ka,"The final population PK parameter estimates (and their 95% confidence intervals) were CL/F, 22 (14.8, 25.2) l h(-1) 70 kg(-1) ; Vc /F, 45.4 (29.6, 55.6) l; Vp /F, 411 (152.6, 1472.6)l; Q/F, 22.4 (16.0, 32.5) l h(-1) ; Ka , 2.5 (1.45, 4.93) h(-1) .",Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),1/[h],2.5,36144,DB00688,Mycophenolate mofetil
,24837828,E0,"The final population PK-PD parameter estimates (and their 95% confidence intervals) were: E0 , 3.45 (2.61, 4.56) nmol h(-1) mg(-1) protein and EC50 , 1.73 (1.16, 3.01) mg l(-1) .",Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),[nM] / [h·mg],3.45,36145,DB00688,Mycophenolate mofetil
,24837828,EC50,"The final population PK-PD parameter estimates (and their 95% confidence intervals) were: E0 , 3.45 (2.61, 4.56) nmol h(-1) mg(-1) protein and EC50 , 1.73 (1.16, 3.01) mg l(-1) .",Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),[mg] / [l],1.73,36146,DB00688,Mycophenolate mofetil
,24837828,Emax,Emax was fixed to 0.,Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),,0,36147,DB00688,Mycophenolate mofetil
,24837828,baseline activities (E0 ),There were two African-American patients in our study cohorts and both had low IMPDH baseline activities (E0 ) compared with Caucasian patients (mean value 2.13 mg l(-1) vs. 3.86 mg l(-1) ).,Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),[mg] / [l],2.13,36148,DB00688,Mycophenolate mofetil
,24837828,baseline activities (E0 ),There were two African-American patients in our study cohorts and both had low IMPDH baseline activities (E0 ) compared with Caucasian patients (mean value 2.13 mg l(-1) vs. 3.86 mg l(-1) ).,Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24837828/),[mg] / [l],3.86,36149,DB00688,Mycophenolate mofetil
,28991252,half-maximal inhibitory concentration (IC50),Inosine-5'-monophosphate dehydrogenase (IMPDH) activity was modeled as a maximal inhibitory model with a half-maximal inhibitory concentration (IC50) of 3.59 μg/mL against MPA concentrations.,Population pharmacokinetics and pharmacodynamics of mycophenolic acid using the prospective data in patients undergoing hematopoietic stem cell transplantation. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28991252/),[μg] / [ml],3.59,36269,DB00688,Mycophenolate mofetil
,12372043,AUC0-12,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[h·ng] / [ml],6600-7200,41559,DB00688,Mycophenolate mofetil
,12372043,C0,"Morning and evening doses were independently adjusted to reach an AUC0-12 of 6600-7200 ng h/mL and a C0 of 250-325 ng/mL, respectively.",Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),[ng] / [ml],250-325,41560,DB00688,Mycophenolate mofetil
,12372043,AUCs,An average of 8 AUCs (range 5-13) were measured in the first 3 months.,Can a pharmacokinetic approach to immunosuppression eliminate ethnic disparities in renal allograft outcome? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12372043/),,8,41561,DB00688,Mycophenolate mofetil
greater,20973683,AUC,"In an exploratory analysis, occurrences of rejection, infection, anemia, and leukopenia were associated with an AcMPAG AUC greater than 50 μg·hour/ml and an AcMPAG:MPA ratio greater than 2.",Pharmacogenetic impact of UDP-glucuronosyltransferase metabolic pathway and multidrug resistance-associated protein 2 transport pathway on mycophenolic acid in thoracic transplant recipients: an exploratory study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20973683/),[h·μg] / [ml],50,42847,DB00688,Mycophenolate mofetil
,17253887,maximum plasma concentration (C(max)),"In the total of 72 profiles, the mean maximum plasma concentration (C(max)) and time to reach C(max) (t(max)) were 9.79 +/- 5.26 mg/L and 1.43 +/- 0.78 hours, respectively.",Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253887/),[mg] / [l],9.79,42928,DB00688,Mycophenolate mofetil
,17253887,time to reach C(max) (t(max)),"In the total of 72 profiles, the mean maximum plasma concentration (C(max)) and time to reach C(max) (t(max)) were 9.79 +/- 5.26 mg/L and 1.43 +/- 0.78 hours, respectively.",Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253887/),h,1.43,42929,DB00688,Mycophenolate mofetil
,17253887,AUC(12),The mean MPA AUC(12) was 46.50 +/- 17.42 mg . h/L (range 17.99-98.73 mg . h/L).,Pharmacokinetics of mycophenolic acid and determination of area under the curve by abbreviated sampling strategy in Chinese liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17253887/),[h·mg] / [l],46.50,42930,DB00688,Mycophenolate mofetil
,19584690,trough level,"In a 12-month multicenter open-label study, cardiac transplant patients received everolimus (trough level 3-8 ng/mL) with reduced cyclosporine A (CsA) or MMF (3 g/day) with standard CsA, both with corticosteroids+/-induction therapy.",Everolimus with reduced cyclosporine versus MMF with standard cyclosporine in de novo heart transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19584690/),[ng] / [ml],3-8,42949,DB00688,Mycophenolate mofetil
,21157403,predose drug concentration (C0),Sotrastaurin predose drug concentration (C0) was 0.6±0.4 μg/mL and did not differ when combined with standard-exposure versus reduced-exposure tacrolimus (P=0.99) nor when tacrolimus was replaced by MPA (P=0.11).,Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157403/),[μg] / [ml],0.6,43328,DB00688,Mycophenolate mofetil
,21157403,peak concentration,"Sotrastaurin peak concentration was 1.6±0.6 μg/mL, and area under the drug concentration-time curve over a dosing interval (AUC) was 12.2±4.2 μg hr/mL.",Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157403/),[μg] / [ml],1.6,43329,DB00688,Mycophenolate mofetil
,21157403,area under the drug concentration-time curve over a dosing interval (AUC),"Sotrastaurin peak concentration was 1.6±0.6 μg/mL, and area under the drug concentration-time curve over a dosing interval (AUC) was 12.2±4.2 μg hr/mL.",Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21157403/),[h·μg] / [ml],12.2,43330,DB00688,Mycophenolate mofetil
,16049701,apparent clearance (CL/F),The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%).,Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049701/),[l] / [h],29,43642,DB00688,Mycophenolate mofetil
,16049701,apparent volume of the central compartment,The best base model had bi-exponential elimination with a typical population (SE%) apparent clearance (CL/F) of 29 l/h (5%) and apparent volume of the central compartment of 65 l (7%).,Population pharmacokinetics of mycophenolic acid during the first week after renal transplantation. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16049701/),l,65,43643,DB00688,Mycophenolate mofetil
,23089531,Trough levels,"Trough levels were fairly consistent at 7.9-18 ng·h/mL in all the patients included in this study, and this did not show variation with age or sex.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[h·ng] / [ml],7.9-18,45100,DB00688,Mycophenolate mofetil
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],202-290,45101,DB00688,Mycophenolate mofetil
,23089531,AUC0-6,"The AUC0-6 was higher [202-290 ng/mL at 3-8 mg bis-daily (b.d.) dosage] in patients who received kidneys from cadavers compared to recipients from live donors (60.5-171 ng/mL at 3-8 mg b.d. dosage), but the clinical significance of this is not known.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],60.5-171,45102,DB00688,Mycophenolate mofetil
,23089531,AUC0-6,"The highest AUC0-6 was 246 ng/mL, observed at 4.5 mg b.d. dosage.",Pharmacokinetics of tacrolimus in adult renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23089531/),[ng] / [ml],246,45103,DB00688,Mycophenolate mofetil
,9664950,Apparent clearance,Apparent clearance of MPA decreased from 5 to 1 ml/min per kg within 2 weeks.,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[ml] / [kg·min],5,45694,DB00688,Mycophenolate mofetil
,9664950,Apparent clearance,Apparent clearance of MPA decreased from 5 to 1 ml/min per kg within 2 weeks.,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[ml] / [kg·min],1,45695,DB00688,Mycophenolate mofetil
,9664950,area under the curve (AUC),The MPA dose ranged from 178 to 1008 mg/m2 per day to achieve an area under the curve (AUC) of 59.9 micrograms x h/ml +/- 10.5 SD (range 49-65 micrograms).,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[h·μg] / [ml],59.9,45696,DB00688,Mycophenolate mofetil
,9664950,AUC,FK506 dose ranged from 1.3 to 8.8 mg/m2 per day to achieve an AUC of 116 ng x h/ml +/- 27 SD (range 83-145).,Dosing of MMF in combination with tacrolimus for steroid-resistant vascular rejection in pediatric renal allografts. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9664950/),[h·ng] / [ml],116,45697,DB00688,Mycophenolate mofetil
,17924828,AUC(0-12),"Differences in the MPA pharmacokinetic profiles confirmed large interpatient variability of MPA exposure, with AUC(0-12) values ranging from 7.9 to 50.1 mg*h/ml.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [ml],7.9 to 50.1,47677,DB00688,Mycophenolate mofetil
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],61.5,47678,DB00688,Mycophenolate mofetil
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],45.4,47679,DB00688,Mycophenolate mofetil
,17924828,AUC(0-12),"MPA AUC(0-12) was significantly associated with the presence of UGT1A9 -440/-331 genotypes (TT/CC: 61.5 +/- 2.7 mg*h/ml/g MMF; TC/CT: 45.4 +/- 14.0 mg*h/ml/g MMF; CC/TT: 40.8 +/- 10.8 mg*h/ml/g MMF; p = 0.005), whereas MPAG exposure was mainly influenced by renal function.",C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17924828/),[h·mg] / [g·ml],40.8,47680,DB00688,Mycophenolate mofetil
,16130190,C(max),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),[μg] / [ml],21.88,48538,DB00688,Mycophenolate mofetil
,16130190,t(max),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),h,1.20,48539,DB00688,Mycophenolate mofetil
,16130190,AUC((0-12)),"The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively.",Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16130190/),[h·μg] / [ml],52.546,48540,DB00688,Mycophenolate mofetil
,32571700,ICU stay,ICU stay was 14 ± 11 vs 15 ± 15 days; P = .76.,Tacrolimus and Mycophenolic Acid Blood Concentration and Cellular Rejection After Heart Transplantation in First Endomyocardial Biopsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32571700/),d,14,49143,DB00688,Mycophenolate mofetil
,32571700,ICU stay,ICU stay was 14 ± 11 vs 15 ± 15 days; P = .76.,Tacrolimus and Mycophenolic Acid Blood Concentration and Cellular Rejection After Heart Transplantation in First Endomyocardial Biopsy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32571700/),d,15,49144,DB00688,Mycophenolate mofetil
,12183689,K(i),"VX-148 is a novel, uncompetitive IMPDH inhibitor with a K(i) value of 6 nM against IMPDH type II enzyme.","Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183689/),nM,6,49374,DB00688,Mycophenolate mofetil
,12183689,IC(50),VX-148 is slightly more potent than mycophenolic acid and VX-497 in inhibiting the proliferation of mitogen-stimulated primary human lymphocytes (IC(50) value of ~80 nM).,"Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183689/),nM,80,49375,DB00688,Mycophenolate mofetil
,12183689,ED(50),VX-148 is orally bioavailable in rats and mice; oral administration of VX-148 inhibits primary antibody response in mice in a dose-dependent manner with an ED(50) value of 38 mg/kg b.i.d.,"Characterization of pharmacological efficacy of VX-148, a new, potent immunosuppressive inosine 5'-monophosphate dehydrogenase inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12183689/),[mg] / [kg],38,49376,DB00688,Mycophenolate mofetil
,15251324,AUC,We used first-order PK modeling to calculate the doses for a mycophenolic acid (MPA) AUC of 60 ug*h/mL and a Tac AUC of 150 ng*h/mL.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],60,50026,DB00688,Mycophenolate mofetil
,15251324,AUC,We used first-order PK modeling to calculate the doses for a mycophenolic acid (MPA) AUC of 60 ug*h/mL and a Tac AUC of 150 ng*h/mL.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ng] / [ml],150,50027,DB00688,Mycophenolate mofetil
,15251324,AUC,"The mean Tac dose was 2.6 +/- 1.2 mg/m2/d or 0.086 +/- 0.038 mg/kg/d, resulting in an average AUC of 120.6 +/- 30.4 ng*h/mL.",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ng] / [ml],120.6,50028,DB00688,Mycophenolate mofetil
,15251324,AUC,"The MMF dose was not normally distributed; the median dose was 549 mg/m2/d (range, 146-1413) and the median MPA AUC was 49.8 ug*h/mL (range, 26.7-156.0).",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],49.8,50029,DB00688,Mycophenolate mofetil
,15251324,AUC,The mean dose for a Tac AUC of 150 ng*h/mL was 3.50 +/- 1.77 mg/m2/d (0.117 +/- 0.058 mg/kg) and was independent of age or time after transplantation.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[mg] / [d·m2],150,50030,DB00688,Mycophenolate mofetil
,15251324,AUC,The mean dose for a Tac AUC of 150 ng*h/mL was 3.50 +/- 1.77 mg/m2/d (0.117 +/- 0.058 mg/kg) and was independent of age or time after transplantation.,Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[mg] / [d·m2],3.50,50031,DB00688,Mycophenolate mofetil
,15251324,AUC,"By contrast, we found a negative relationship between the dose per m2 (r2 = 0.29; P = 0.0038) or per kg (r2 = 0.58; P < .0001) required for an MPA AUC of 60 ug*h/mL and patient age.",Age-dependency of mycophenolate mofetil dosing in combination with tacrolimus after pediatric renal transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15251324/),[h·ug] / [ml],60,50032,DB00688,Mycophenolate mofetil
,31423655,Area under the curve limit of quantification (AUC0-LOQh ),Area under the curve limit of quantification (AUC0-LOQh ) of MPA ranged from 1.27 to 2.03 hours·μg/mL and from 1.77 to 8.54 hours·μg/mL after the first and last PO dose of 10 mg/kg.,Pharmacokinetics of mycophenolic acid and its effect on CD4+ and CD8+ T cells after oral administration of mycophenolate mofetil to healthy cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31423655/),[h·μg] / [ml],1.27 to 2.03,50816,DB00688,Mycophenolate mofetil
,31423655,Area under the curve limit of quantification (AUC0-LOQh ),Area under the curve limit of quantification (AUC0-LOQh ) of MPA ranged from 1.27 to 2.03 hours·μg/mL and from 1.77 to 8.54 hours·μg/mL after the first and last PO dose of 10 mg/kg.,Pharmacokinetics of mycophenolic acid and its effect on CD4+ and CD8+ T cells after oral administration of mycophenolate mofetil to healthy cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31423655/),[h·μg] / [ml],1.77 to 8.54,50817,DB00688,Mycophenolate mofetil
,31423655,AUC0-loqh,The AUC0-loqh of MPA ranged from 2.18 to 31 hours·μg/mL after the first dose of 15 mg/kg of MMF.,Pharmacokinetics of mycophenolic acid and its effect on CD4+ and CD8+ T cells after oral administration of mycophenolate mofetil to healthy cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31423655/),[h·μg] / [ml],2.18 to 31,50818,DB00688,Mycophenolate mofetil
,29374217,AUC0-inf,"AUC0-inf of TAC increased by 22.1% (322.4 ± 174.1 to 393.6 ± 121.7 ng·h/mL; P < 0.05) when co-administered with MMF, whereas the pharmacokinetic parameters of MPA and its metabolites were not changed by TAC.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[h·ng] / [ml],322.4,50918,DB00688,Mycophenolate mofetil
,29374217,AUC0-inf,"AUC0-inf of TAC increased by 22.1% (322.4 ± 174.1 to 393.6 ± 121.7 ng·h/mL; P < 0.05) when co-administered with MMF, whereas the pharmacokinetic parameters of MPA and its metabolites were not changed by TAC.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[h·ng] / [ml],393.6,50919,DB00688,Mycophenolate mofetil
,29374217,Apparent clearance (CL/F),"Apparent clearance (CL/F) of TAC was 17.8 L/h [relative standard error (RSE) 11%] or 13.8 L/h (RSE 11%) without or with MMF, respectively.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[l] / [h],17.8,50920,DB00688,Mycophenolate mofetil
,29374217,Apparent clearance (CL/F),"Apparent clearance (CL/F) of TAC was 17.8 L/h [relative standard error (RSE) 11%] or 13.8 L/h (RSE 11%) without or with MMF, respectively.",Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29374217/),[l] / [h],13.8,50921,DB00688,Mycophenolate mofetil
,17391132,Area under the plasma mycophenolic acid,Area under the plasma mycophenolic acid (MPA) concentration-time curve with EC-MPS (57.4 +/- 15.0 microg h/mL) fulfilled bioequivalence criteria (geometric mean 0.98 (90% CI: 0.87-1.11) compared to MMF (58.4 +/- 14.1 microg h/mL).,Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391132/),[h·μg] / [ml],57.4,51256,DB00688,Mycophenolate mofetil
,17391132,Area under the plasma mycophenolic acid,Area under the plasma mycophenolic acid (MPA) concentration-time curve with EC-MPS (57.4 +/- 15.0 microg h/mL) fulfilled bioequivalence criteria (geometric mean 0.98 (90% CI: 0.87-1.11) compared to MMF (58.4 +/- 14.1 microg h/mL).,Pharmacokinetic and pharmacodynamic comparison of enteric-coated mycophenolate sodium and mycophenolate mofetil in maintenance renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17391132/),[h·μg] / [ml],58.4,51257,DB00688,Mycophenolate mofetil
,25163792,AUC0-12h,"When considering to UGT1A9, SLCO1B1 genotypes, and renal function, the new recommended dose of 540 mg twice daily resulted in a higher success of achieving the target AUC0-12h in the 30-60 mg.h/L.",Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25163792/),[h·mg] / [l],30-60,51750,DB00688,Mycophenolate mofetil
>,21976740,trough concentrations,"In 18 patients, mycophenolate mofetil (MMF) (adjusted to achieve blood mycophenolic acid trough concentrations > 2 μg/mL) was sequentially added, and 16 patients were converted to MMF monotherapy.",Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21976740/),[μg] / [ml],2,52509,DB00688,Mycophenolate mofetil
,24081206,area under the concentration-time curve (AUC(0-12 hours)),"The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 μg h/L, whereas the predose concentrations (C₀) were 0.0-17.9 μg/L.",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·μg] / [l],78.6,52621,DB00688,Mycophenolate mofetil
,24081206,area under the concentration-time curve (AUC(0-12 hours)),"The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 μg h/L, whereas the predose concentrations (C₀) were 0.0-17.9 μg/L.",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·μg] / [l],3.8 to 267,52622,DB00688,Mycophenolate mofetil
,24081206,concentrations (C₀),"The area under the concentration-time curve (AUC(0-12 hours)) for tacrolimus was low early after Tx (eg, median 78.6 around day 4) and variable in all 4 periods ranging from 3.8 to 267 μg h/L, whereas the predose concentrations (C₀) were 0.0-17.9 μg/L.",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[μg] / [l],0.0-17.9,52623,DB00688,Mycophenolate mofetil
,24081206,AUC(0-12 hours),"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·mg] / [l],8.6-57.4,52624,DB00688,Mycophenolate mofetil
,24081206,AUC(0-12 hours),"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[h·mg] / [l],21.9 to 27.8,52625,DB00688,Mycophenolate mofetil
,24081206,C₀,"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[mg] / [l],0.0 and 7.3,52626,DB00688,Mycophenolate mofetil
,24081206,C₀,"The AUC(0-12 hours) of MPA was in the range 8.6-57.4 mg h/L, with median values from 21.9 to 27.8 mg h/L, whereas C₀ was between 0.0 and 7.3 mg/L in the 4 periods (medians from 1.2 to 1.6 mg/L).",Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),[mg] / [l],1.2 to 1.6,52627,DB00688,Mycophenolate mofetil
,24081206,maximum inhibition,The maximum inhibition of inosine monophosphate dehydrogenase within a dose interval ranged from 9.5% to 100%.,Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),%,9.5,52628,DB00688,Mycophenolate mofetil
,24081206,maximum inhibition,The maximum inhibition of inosine monophosphate dehydrogenase within a dose interval ranged from 9.5% to 100%.,Tacrolimus exposure and mycophenolate pharmacokinetics and pharmacodynamics early after liver transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24081206/),%,100,52629,DB00688,Mycophenolate mofetil
,20418509,activity,Mean pretransplant IMPDH activity (6.4 ± 4.6 nmol/h/mg protein) was lower than previously reported in adults.,Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418509/),[nM] / [h·mg],6.4,54898,DB00688,Mycophenolate mofetil
,20418509,EC(50),The overall relationship between MPA concentration and IMPDH activity was described by a direct inhibitory E(max) model (EC(50) = 0.97 mg/L).,Inosine monophosphate dehydrogenase (IMPDH) activity as a pharmacodynamic biomarker of mycophenolic acid effects in pediatric kidney transplant recipients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20418509/),[mg] / [l],0.97,54899,DB00688,Mycophenolate mofetil
,26923724,AUC0-12h,Therapeutic targets were set at: AUC0-12h of 30-60 mg h/L.,Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26923724/),[h·mg] / [l],30-60,55492,DB00688,Mycophenolate mofetil
,26923724,AUC0-12h,"AUC0-12h was 29.7 mg h/L in Group 1 and 56.6 mg h/L in Group 2, despite a lower dosage in Group 2 (584 and 426 mg/m(2) , respectively).",Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26923724/),[h·mg] / [l],29.7,55493,DB00688,Mycophenolate mofetil
,26923724,AUC0-12h,"AUC0-12h was 29.7 mg h/L in Group 1 and 56.6 mg h/L in Group 2, despite a lower dosage in Group 2 (584 and 426 mg/m(2) , respectively).",Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26923724/),[h·mg] / [l],56.6,55494,DB00688,Mycophenolate mofetil
,31219949,total C0,"There were no significant differences between FD and CC participants in any pharmacokinetic parameters across the study visits, except for total C0 (FD 2.0 ± 0.3 mg/L versus CC 1.1 ± 0.3; P = 0.01) and dose-normalized C0 (FD 2.9 ± 0.2 mg/L/g versus CC 2.1 ± 0.7 mg/L/g; P = 0.04) at the second visit and total AUC0-12 (FD 66.6 ± 6.0 mg·h/L versus CC 35.2 ± 11.4 mg·h/L; P = 0.03) at the third visit.",Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31219949/),[mg] / [l],2.0,57017,DB00688,Mycophenolate mofetil
,31219949,total C0,"There were no significant differences between FD and CC participants in any pharmacokinetic parameters across the study visits, except for total C0 (FD 2.0 ± 0.3 mg/L versus CC 1.1 ± 0.3; P = 0.01) and dose-normalized C0 (FD 2.9 ± 0.2 mg/L/g versus CC 2.1 ± 0.7 mg/L/g; P = 0.04) at the second visit and total AUC0-12 (FD 66.6 ± 6.0 mg·h/L versus CC 35.2 ± 11.4 mg·h/L; P = 0.03) at the third visit.",Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31219949/),,1.1,57018,DB00688,Mycophenolate mofetil
,31219949,dose-normalized C0,"There were no significant differences between FD and CC participants in any pharmacokinetic parameters across the study visits, except for total C0 (FD 2.0 ± 0.3 mg/L versus CC 1.1 ± 0.3; P = 0.01) and dose-normalized C0 (FD 2.9 ± 0.2 mg/L/g versus CC 2.1 ± 0.7 mg/L/g; P = 0.04) at the second visit and total AUC0-12 (FD 66.6 ± 6.0 mg·h/L versus CC 35.2 ± 11.4 mg·h/L; P = 0.03) at the third visit.",Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31219949/),[mg] / [g·l],2.9,57019,DB00688,Mycophenolate mofetil
,31219949,dose-normalized C0,"There were no significant differences between FD and CC participants in any pharmacokinetic parameters across the study visits, except for total C0 (FD 2.0 ± 0.3 mg/L versus CC 1.1 ± 0.3; P = 0.01) and dose-normalized C0 (FD 2.9 ± 0.2 mg/L/g versus CC 2.1 ± 0.7 mg/L/g; P = 0.04) at the second visit and total AUC0-12 (FD 66.6 ± 6.0 mg·h/L versus CC 35.2 ± 11.4 mg·h/L; P = 0.03) at the third visit.",Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31219949/),[mg] / [g·l],2.1,57020,DB00688,Mycophenolate mofetil
,31219949,total AUC0-12,"There were no significant differences between FD and CC participants in any pharmacokinetic parameters across the study visits, except for total C0 (FD 2.0 ± 0.3 mg/L versus CC 1.1 ± 0.3; P = 0.01) and dose-normalized C0 (FD 2.9 ± 0.2 mg/L/g versus CC 2.1 ± 0.7 mg/L/g; P = 0.04) at the second visit and total AUC0-12 (FD 66.6 ± 6.0 mg·h/L versus CC 35.2 ± 11.4 mg·h/L; P = 0.03) at the third visit.",Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31219949/),[h·mg] / [l],66.6,57021,DB00688,Mycophenolate mofetil
,31219949,total AUC0-12,"There were no significant differences between FD and CC participants in any pharmacokinetic parameters across the study visits, except for total C0 (FD 2.0 ± 0.3 mg/L versus CC 1.1 ± 0.3; P = 0.01) and dose-normalized C0 (FD 2.9 ± 0.2 mg/L/g versus CC 2.1 ± 0.7 mg/L/g; P = 0.04) at the second visit and total AUC0-12 (FD 66.6 ± 6.0 mg·h/L versus CC 35.2 ± 11.4 mg·h/L; P = 0.03) at the third visit.",Pharmacokinetics of Enteric-Coated Mycophenolate Sodium in Lupus Nephritis (POEMSLUN). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31219949/),[h·mg] / [l],35.2,57022,DB00688,Mycophenolate mofetil
,18336056,maximum plasma concentration,"The mean maximum plasma concentration, trough plasma concentration, time to reach the maximum plasma concentration and AUC from 0 to 12 hours (AUC(12)) were 13.6 +/- 8.4 microg/mL, 1.4 +/- 1.2 microg/mL, 1.1 +/- 1.2 hours and 32.2 +/- 17.1microg .",Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18336056/),[μg] / [ml],13.6,57923,DB00688,Mycophenolate mofetil
,18336056,AUC from 0 to 12 hours (AUC(12)),"The mean maximum plasma concentration, trough plasma concentration, time to reach the maximum plasma concentration and AUC from 0 to 12 hours (AUC(12)) were 13.6 +/- 8.4 microg/mL, 1.4 +/- 1.2 microg/mL, 1.1 +/- 1.2 hours and 32.2 +/- 17.1microg .",Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18336056/),μg,32.2,57924,DB00688,Mycophenolate mofetil
,18336056,free fraction,The mean free fraction of MPA was 1.7%.,Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18336056/),%,1.7,57925,DB00688,Mycophenolate mofetil
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],300.8,59514,DB00688,Mycophenolate mofetil
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],287.7,59515,DB00688,Mycophenolate mofetil
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],303.05,59516,DB00688,Mycophenolate mofetil
,20970603,AUC0-24,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[h·ng] / [ml],275.26,59517,DB00688,Mycophenolate mofetil
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.76,59518,DB00688,Mycophenolate mofetil
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.8,59519,DB00688,Mycophenolate mofetil
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],7.30,59520,DB00688,Mycophenolate mofetil
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],8.80,59521,DB00688,Mycophenolate mofetil
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],7.19,59522,DB00688,Mycophenolate mofetil
,20970603,blood levels,"There were no significant differences in the AUC0-24 of tacrolimus (QD/BID) at 3 days (300.8±60.15 vs 287.7±125.78 ng.h/mL) or 21 days (303.05±99.79 vs 275.26±75.37 ng.h/mL), nor in blood levels (ng/mL) at 1 month (8.76±2.46 vs 8.8±1.89), 3 months (7.30±1.72 vs 8.80±1.89) and 6 months (7.19±1.89 vs 6.60±1.71).","Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970603/),[ng] / [ml],6.60,59523,DB00688,Mycophenolate mofetil
,17928466,time of occurrence for maximum drug concentration,Patients who were taking the enteric-coated formulation had mycophenolic acid time of occurrence for maximum drug concentration that ranged from 0 to 480 min and higher dosage-adjusted mycophenolic acid trough levels compared with patients who were given mycophenolate mofetil.,Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17928466/),min,0 to 480,60208,DB00688,Mycophenolate mofetil
,19481022,serum concentrations (C(0)),"In the PPI group, the mean daily MMF dose was 1,912 +/- 1,023 mg with mean pre-dose serum concentrations (C(0)) of 1.9 +/- 1.4 mg/liter, without a significant difference from controls.",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],1.9,60240,DB00688,Mycophenolate mofetil
,19481022,concentrations at 30 minutes (C(0.5h),"Mean post-dose MPA concentrations at 30 minutes (C(0.5h)) were significantly higher in the control group (control, 17.9 +/- 11.5 mg/liter; PPI, 6.7 +/- 4.6 mg/liter; p < 0.001).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],17.9,60241,DB00688,Mycophenolate mofetil
,19481022,concentrations at 30 minutes (C(0.5h),"Mean post-dose MPA concentrations at 30 minutes (C(0.5h)) were significantly higher in the control group (control, 17.9 +/- 11.5 mg/liter; PPI, 6.7 +/- 4.6 mg/liter; p < 0.001).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],6.7,60242,DB00688,Mycophenolate mofetil
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],13.8,60243,DB00688,Mycophenolate mofetil
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],7.7,60244,DB00688,Mycophenolate mofetil
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],7.6,60245,DB00688,Mycophenolate mofetil
,19481022,"C(1h, 2h)","One- and 2-hour (C(1h, 2h)) MPA concentrations were persistently higher in the control group (1 hour: control, 13.8 +/- 9.1 mg/liter; PPI, 7.7 +/- 4.1 mg/liter; 2 hours: control, 7.6 +/- 4.2; PPI, 5.0 +/- 2.8 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],5.0,60246,DB00688,Mycophenolate mofetil
,19481022,C(12h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],3.3,60247,DB00688,Mycophenolate mofetil
,19481022,C(12h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],1.6,60248,DB00688,Mycophenolate mofetil
,19481022,AUC C(0-3h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],59.5,60249,DB00688,Mycophenolate mofetil
,19481022,AUC C(0-3h),"In the subgroup with full AUC measurements, the control group had higher MPA levels 12 hours after dosing (C(12h): control, 3.3 +/- 2.4 mg/liter; PPI, 1.6 +/- 1.3 mg/liter; p < 0.05) and a significantly higher dose-adjusted AUC C(0-3h) (control, 59.5 +/- 20.7 mg/liter; PPI, 41.7 +/- 23.4 mg/liter; p < 0.05).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],41.7,60250,DB00688,Mycophenolate mofetil
,19481022,maximum plasma concentration of mycophenolic acid (,"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],10.1,60251,DB00688,Mycophenolate mofetil
,19481022,maximum plasma concentration of mycophenolic acid (,"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),[mg] / [l],45.5,60252,DB00688,Mycophenolate mofetil
,19481022,t(max),"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),h,1.1,60253,DB00688,Mycophenolate mofetil
,19481022,t(max),"In the subgroup, the maximum plasma concentration of mycophenolic acid (MPA C(max)) in the PPI group was significantly lower (10.1 +/- 4.7 mg/liter) than in the control group (45.5 +/- 53.5 mg/liter, p < 0.0001), whereas t(max) revealed no differences (control: 1.1 +/- 0.77 hours; PPI: 1.1 +/- 0.97 hours).",Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19481022/),h,1.1,60254,DB00688,Mycophenolate mofetil
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.67,60927,DB00688,Mycophenolate mofetil
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,1.36,60928,DB00688,Mycophenolate mofetil
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),10,0.42,60929,DB00688,Mycophenolate mofetil
,17192769,Dose/trough concentration ratios,Dose/trough concentration ratios were 0.67+/-0.3 and 1.36+/-0.73 x 10(3) l (P<0.00001) for tacrolimus and 0.42+/-0.17 and 0.84+/-0.46 x 10(3) l (P=0.18) for sirolimus in CYP3A5 non-expressors and expressors.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),l,0.84,60930,DB00688,Mycophenolate mofetil
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],106.8,60931,DB00688,Mycophenolate mofetil
,17192769,area under curve (AUC)(0-12),The unadjusted tacrolimus area under curve (AUC)(0-12) was 106.8+/-17.5 ng/ml x h compared with 133.3+/-42.2 ng/ml x h (P=0.37) without affecting serum creatinine.,CYP3A5 genotype markedly influences the pharmacokinetics of tacrolimus and sirolimus in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192769/),[ng] / [h·ml],133.3,60932,DB00688,Mycophenolate mofetil
,16721583,half-life,"Enteric-coated mycophenolate sodium (EC-MPS) has a mean half-life of 11.7 hours, which encouraged hope of using this drug once daily in a nonadherent adolescent SLE patient.",Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721583/),h,11.7,63272,DB00688,Mycophenolate mofetil
,16721583,areas under the time-concentration curves (AUC),The average of three 12-hour areas under the time-concentration curves (AUC) on 1 g of MMF BID was 59.0 mgxh/L.,Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721583/),[h·mg] / [l],59.0,63273,DB00688,Mycophenolate mofetil
,16721583,24-hour,"In contrast, the 24-hour AUC after 1.44 g EC-MPS OD was 283.2 mgxh/L, more than double the expected 118.0 mgxh/L of two MMF dosing intervals.",Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721583/),[h·mg] / [l],283.2,63274,DB00688,Mycophenolate mofetil
,16721583,AUC,"In contrast, the 24-hour AUC after 1.44 g EC-MPS OD was 283.2 mgxh/L, more than double the expected 118.0 mgxh/L of two MMF dosing intervals.",Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721583/),[h·mg] / [l],283.2,63275,DB00688,Mycophenolate mofetil
,16721583,AUC,"In contrast, the 24-hour AUC after 1.44 g EC-MPS OD was 283.2 mgxh/L, more than double the expected 118.0 mgxh/L of two MMF dosing intervals.",Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721583/),[h·mg] / [l],118.0,63276,DB00688,Mycophenolate mofetil
,16721583,AUC,A repeat 24-hour AUC after 1.08 g of EC-MPS was 218.2 mgxh/L.,Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16721583/),[h·mg] / [l],218.2,63277,DB00688,Mycophenolate mofetil
,26192348,AUC threshold,"An AUC threshold of 50 mg×h/L was proposed (sensitivity=77%, specificity=25%) beyond which the risk of rejection was significantly increased (low vs. high: HR=3.48 [1.21-10.0], p=0.0204).","Mycophenolic mofetil optimized pharmacokinetic modelling, and exposure-effect associations in adult heart transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26192348/),[h·mg] / [l],50,63833,DB00688,Mycophenolate mofetil
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],57.4,64141,DB00688,Mycophenolate mofetil
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],38.2,64142,DB00688,Mycophenolate mofetil
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],59.3,64143,DB00688,Mycophenolate mofetil
,24673714,AUC levels,"The mean AUC levels at day 3 and day 5 in the SD group were significantly higher than in the LD group (57.4 mg·h/l vs. 38.2 mg·h/l and 59.3 mg·h/l vs. 44.8 mg·h/l, respectively, p < 0.01).",Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],44.8,64144,DB00688,Mycophenolate mofetil
<,24673714,AUC,There were significantly more acute rejections (all definitions) in patients with MPA AUC levels < 30 mg·h/l compared with those with MPA AUC levels ≥ 30 mg·h/l within 6 months (p < 0.05).,Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],30,64145,DB00688,Mycophenolate mofetil
≥,24673714,AUC,There were significantly more acute rejections (all definitions) in patients with MPA AUC levels < 30 mg·h/l compared with those with MPA AUC levels ≥ 30 mg·h/l within 6 months (p < 0.05).,Which is more suitable for kidney transplantation at the early post-transplantation phase in China - low dosing or standard dosing of enteric-coated mycophenolate sodium? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673714/),[h·mg] / [l],30,64146,DB00688,Mycophenolate mofetil
greater,25511793,AUC12,MPA AUC12 was greater than 60 mg·h/L in 57 % of renal transplant recipients (RTR) with 71 % of patients demonstrating gastrointestinal AEs and a higher score noted in females.,Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25511793/),[h·mg] / [l],60,65086,DB00688,Mycophenolate mofetil
,10565830,Maximum percent inhibitions (I(max)),"Maximum percent inhibitions (I(max)) of lymphocyte functions and concentrations of MPA (mg/l in blood) inhibiting 50% of I(max) (IC(50)) were 99%/0.14 mg/l for [(3)H]TdR, 93%/0.28 mg/l for S-G(2)M, 74%/0.29 mg/l for CD25, and 83%/0.24 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,99,65279,DB00688,Mycophenolate mofetil
,10565830,Maximum percent inhibitions (I(max)),"Maximum percent inhibitions (I(max)) of lymphocyte functions and concentrations of MPA (mg/l in blood) inhibiting 50% of I(max) (IC(50)) were 99%/0.14 mg/l for [(3)H]TdR, 93%/0.28 mg/l for S-G(2)M, 74%/0.29 mg/l for CD25, and 83%/0.24 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),[mg] / [l],0.14,65280,DB00688,Mycophenolate mofetil
,10565830,Maximum percent inhibitions (I(max)),"Maximum percent inhibitions (I(max)) of lymphocyte functions and concentrations of MPA (mg/l in blood) inhibiting 50% of I(max) (IC(50)) were 99%/0.14 mg/l for [(3)H]TdR, 93%/0.28 mg/l for S-G(2)M, 74%/0.29 mg/l for CD25, and 83%/0.24 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,93,65281,DB00688,Mycophenolate mofetil
,10565830,Maximum percent inhibitions (I(max)),"Maximum percent inhibitions (I(max)) of lymphocyte functions and concentrations of MPA (mg/l in blood) inhibiting 50% of I(max) (IC(50)) were 99%/0.14 mg/l for [(3)H]TdR, 93%/0.28 mg/l for S-G(2)M, 74%/0.29 mg/l for CD25, and 83%/0.24 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),[mg] / [l],0.28,65282,DB00688,Mycophenolate mofetil
,10565830,Maximum percent inhibitions (I(max)),"Maximum percent inhibitions (I(max)) of lymphocyte functions and concentrations of MPA (mg/l in blood) inhibiting 50% of I(max) (IC(50)) were 99%/0.14 mg/l for [(3)H]TdR, 93%/0.28 mg/l for S-G(2)M, 74%/0.29 mg/l for CD25, and 83%/0.24 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,74,65283,DB00688,Mycophenolate mofetil
,10565830,Maximum percent inhibitions (I(max)),"Maximum percent inhibitions (I(max)) of lymphocyte functions and concentrations of MPA (mg/l in blood) inhibiting 50% of I(max) (IC(50)) were 99%/0.14 mg/l for [(3)H]TdR, 93%/0.28 mg/l for S-G(2)M, 74%/0.29 mg/l for CD25, and 83%/0.24 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),[mg] / [l],0.29,65284,DB00688,Mycophenolate mofetil
,10565830,Maximum percent inhibitions (I(max)),"Maximum percent inhibitions (I(max)) of lymphocyte functions and concentrations of MPA (mg/l in blood) inhibiting 50% of I(max) (IC(50)) were 99%/0.14 mg/l for [(3)H]TdR, 93%/0.28 mg/l for S-G(2)M, 74%/0.29 mg/l for CD25, and 83%/0.24 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,83,65285,DB00688,Mycophenolate mofetil
,10565830,I(max),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,98,65286,DB00688,Mycophenolate mofetil
,10565830,I(max),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,88,65287,DB00688,Mycophenolate mofetil
,10565830,I(max),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,60,65288,DB00688,Mycophenolate mofetil
,10565830,I(max),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,72,65289,DB00688,Mycophenolate mofetil
,10565830,IC(50),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,98,65290,DB00688,Mycophenolate mofetil
,10565830,IC(50),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,99,65291,DB00688,Mycophenolate mofetil
,10565830,IC(50),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,88,65292,DB00688,Mycophenolate mofetil
,10565830,IC(50),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,60,65293,DB00688,Mycophenolate mofetil
,10565830,IC(50),"I(max) (%) and IC(50) (mg/l in plasma by HPLC) were 98 to 99%/0.18 to 0.19 mg/l for [(3)H]TdR, 88 to 98%/0.70 to 0.83 mg/l for S-G(2)M, 60 to 63%/0.65 to 0.81 mg/l for CD25, and 72 to 77%/0.61 to 0.74 mg/l for CD134.",Pharmacodynamics of immunosuppression by mycophenolic acid: inhibition of both lymphocyte proliferation and activation correlates with pharmacokinetics. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10565830/),%,72,65294,DB00688,Mycophenolate mofetil
,23689735,AUC(0-12h),"The mean values of AUC(0-12h), pre-dose MPA trough concentration (C0), maximum concentrations (C(max)), and time to reach C(max) (T(max)) were 61.17 ± 26.39 mg·h/l (range 22.9-123.0 mg·h/l), 4.98 ± 4.65 mg/l (range 0.13-20.04 mg/l), 17.54 ± 10.67 mg/l (range 4.08-42.36 mg/l), and 5.0 ± 2.6 h (range 1.0-10.5 h), respectively.",Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23689735/),[h·mg] / [l],61.17,65299,DB00688,Mycophenolate mofetil
,23689735,time to reach C(max) (T(max)),"The mean values of AUC(0-12h), pre-dose MPA trough concentration (C0), maximum concentrations (C(max)), and time to reach C(max) (T(max)) were 61.17 ± 26.39 mg·h/l (range 22.9-123.0 mg·h/l), 4.98 ± 4.65 mg/l (range 0.13-20.04 mg/l), 17.54 ± 10.67 mg/l (range 4.08-42.36 mg/l), and 5.0 ± 2.6 h (range 1.0-10.5 h), respectively.",Evaluation of mycophenolic acid exposure using a limited sampling strategy in renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23689735/),h,5.0,65300,DB00688,Mycophenolate mofetil
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],954,66805,DB00688,Mycophenolate mofetil
,16012079,Cmax,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66806,DB00688,Mycophenolate mofetil
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],167,66807,DB00688,Mycophenolate mofetil
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],4787,66808,DB00688,Mycophenolate mofetil
,16012079,AUC0-24,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[nghml],451,66809,DB00688,Mycophenolate mofetil
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.3,66810,DB00688,Mycophenolate mofetil
,16012079,elimination half-life,"The mean Cmax and AUC0-24 of (R)-lansoprazole compared to (S)-lansoprazole in renal transplant recipients were 12-fold (954+/-522 vs. 167+/-137 ngml(-1), respectively) and 6.9-fold (4787+/-3454 vs. 451+/-354 nghml(-1), respectively) greater, and its elimination half-life was 2.1-fold (2.3+/-1.0 vs. 1.2+/-0.6h, respectively) longer.",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.2,66811,DB00688,Mycophenolate mofetil
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,2.1,66812,DB00688,Mycophenolate mofetil
,16012079,elimination half-life,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),h,1.3,66813,DB00688,Mycophenolate mofetil
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],186,66814,DB00688,Mycophenolate mofetil
,16012079,Cmax,"In contrast, although the elimination half-life of (R)-rabeprazole was significantly longer than that of the (S)-enantiomer (2.1+/-0.5 vs. 1.3+/-0.9h, respectively; P<0.05), there was no difference in Cmax between the (R)- and (S)-enantiomer (186+/-40 vs. 200+/-92 ngml(-1), respectively).",Comparison of enantioselective disposition of rabeprazole versus lansoprazole in renal-transplant recipients who are CYP2C19 extensive metabolizers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16012079/),1/[ngml],200,66815,DB00688,Mycophenolate mofetil
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.20,67246,DB00688,Mycophenolate mofetil
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.25,67247,DB00688,Mycophenolate mofetil
,17429314,Km,"Km values were 0.20, 0.25 and 0.44 mmol/l for the GG-842, G-842A and -842AA genotypes, respectively.",Influence of the UGT2B7 promoter region and exon 2 polymorphisms and comedications on Acyl-MPAG production in vitro and in adult renal transplant patients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17429314/),[mM] / [l],0.44,67248,DB00688,Mycophenolate mofetil
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],43.1,67746,DB00688,Mycophenolate mofetil
,29159710,K B,"The protein-binding rate constant (KB [relative standard error, RSE%]) increased nonlinearly with renal function according to K B = 43.1 (3.13)·(CLCR/59.51)0.394(10.66) h-1.",Prediction of Free from Total Mycophenolic Acid Concentrations in Stable Renal Transplant Patients: A Population-Based Approach. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29159710/),1/[h],0.394,67747,DB00688,Mycophenolate mofetil
,19691368,CL(CR),"A reduction in CL(CR) from 60 to 25 mL/min correlated with an increase in f(u) from 2.7% to 3.5%, accumulation of MPAG(t) concentrations from 50 to 150 mg/L correlated with an increase in f(u) from 2.8% to 3.7%, and a decrease in plasma albumin concentration from 40 to 30 g/L correlated with an increase in f(u) from 2.6% to 3.5%.",Pharmacokinetic modelling of the plasma protein binding of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19691368/),[ml] / [min],60,68087,DB00688,Mycophenolate mofetil
,12451233,survival time (MST),"The median survival time (MST) was 6 days for placebo, 6, 14.5, and more than 56 days for doses 3, 10, and 30 mg/kg per day MPS, with severe side effects (diarrhea, weight loss, lymphopenia) at the highest dose, and 7 and 8 days for the 0.03 and 0.1 mg/kg per day FTY720.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,6,68378,DB00688,Mycophenolate mofetil
,12451233,survival time (MST),"The median survival time (MST) was 6 days for placebo, 6, 14.5, and more than 56 days for doses 3, 10, and 30 mg/kg per day MPS, with severe side effects (diarrhea, weight loss, lymphopenia) at the highest dose, and 7 and 8 days for the 0.03 and 0.1 mg/kg per day FTY720.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,14.5,68379,DB00688,Mycophenolate mofetil
,12451233,survival time (MST),"The median survival time (MST) was 6 days for placebo, 6, 14.5, and more than 56 days for doses 3, 10, and 30 mg/kg per day MPS, with severe side effects (diarrhea, weight loss, lymphopenia) at the highest dose, and 7 and 8 days for the 0.03 and 0.1 mg/kg per day FTY720.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,more,68380,DB00688,Mycophenolate mofetil
,12451233,survival time (MST),"The median survival time (MST) was 6 days for placebo, 6, 14.5, and more than 56 days for doses 3, 10, and 30 mg/kg per day MPS, with severe side effects (diarrhea, weight loss, lymphopenia) at the highest dose, and 7 and 8 days for the 0.03 and 0.1 mg/kg per day FTY720.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,56,68381,DB00688,Mycophenolate mofetil
,12451233,survival time (MST),"The median survival time (MST) was 6 days for placebo, 6, 14.5, and more than 56 days for doses 3, 10, and 30 mg/kg per day MPS, with severe side effects (diarrhea, weight loss, lymphopenia) at the highest dose, and 7 and 8 days for the 0.03 and 0.1 mg/kg per day FTY720.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,7,68382,DB00688,Mycophenolate mofetil
,12451233,survival time (MST),"The median survival time (MST) was 6 days for placebo, 6, 14.5, and more than 56 days for doses 3, 10, and 30 mg/kg per day MPS, with severe side effects (diarrhea, weight loss, lymphopenia) at the highest dose, and 7 and 8 days for the 0.03 and 0.1 mg/kg per day FTY720.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,8,68383,DB00688,Mycophenolate mofetil
,12451233,MSTs,"However, 10 mg/kg per day MPS in combination with 0.03 or 0.1 mg/kg per day FTY720 yielded MSTs of 41 and 43.5 days, respectively, well beyond the 4-week treatment period.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,41,68384,DB00688,Mycophenolate mofetil
,12451233,MSTs,"However, 10 mg/kg per day MPS in combination with 0.03 or 0.1 mg/kg per day FTY720 yielded MSTs of 41 and 43.5 days, respectively, well beyond the 4-week treatment period.",Efficacy of mycophenolate sodium as monotherapy and in combination with FTY720 in a DA-to-Lewis-rat heart-transplantation model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12451233/),d,43.5,68385,DB00688,Mycophenolate mofetil
,15848557,AUC,"The percentage of patients with adequate therapeutic exposure (target AUC 30-60 microg.h/mL) of mycophenolic acid is 55%, 86%, and 100% at days 14, 90, and 180 postgrafting.",Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848557/),[h·μg] / [ml],30-60,68914,DB00688,Mycophenolate mofetil
,15848557,AUC0-12 h,The patients' mean +/- SD body weight was 48.1 +/- 8.8 kg; their mean (range) values of AUC0-12 h for MPA were 73.9 +/- 49.5 microg.h/ml (31.9-190) on day 1 and 74.3 +/- 44.3 (30.5-178) microg.h/ml on day 14.,Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848557/),[h·μg] / [ml],73.9,68915,DB00688,Mycophenolate mofetil
,15848557,AUC0-12 h,The patients' mean +/- SD body weight was 48.1 +/- 8.8 kg; their mean (range) values of AUC0-12 h for MPA were 73.9 +/- 49.5 microg.h/ml (31.9-190) on day 1 and 74.3 +/- 44.3 (30.5-178) microg.h/ml on day 14.,Standard dose enteric-coated mycophenolate sodium (myfortic) delivers rapid therapeutic mycophenolic acid exposure in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848557/),[h·μg] / [ml],74.3,68916,DB00688,Mycophenolate mofetil
,15030883,total ch,Separation was achieved within a total chromatographic run time of 18 min at 1.0 ml/min flow rate using a Hv PURITY C18 column.,Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),min,18,69843,DB00688,Mycophenolate mofetil
,15030883,flow rate,Separation was achieved within a total chromatographic run time of 18 min at 1.0 ml/min flow rate using a Hv PURITY C18 column.,Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),[ml] / [min],1.0,69844,DB00688,Mycophenolate mofetil
,15030883,limit of detection,The limit of detection was 0.1 microg/ml for both MPAG and MPA.,Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),[μg] / [ml],0.1,69845,DB00688,Mycophenolate mofetil
,15030883,extraction recovery,"The average extraction recovery from plasma was 93.06%, for MPA and 92.41% for MPAG.",Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),%,93.06,69846,DB00688,Mycophenolate mofetil
,15030883,extraction recovery,"The average extraction recovery from plasma was 93.06%, for MPA and 92.41% for MPAG.",Development of a high pressure liquid chromatography method for the determination of mycophenolic acid and its glucuronide metabolite in small volumes of plasma from paediatric patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15030883/),%,92.41,69847,DB00688,Mycophenolate mofetil
,19113793,Time to maximum concentration,Time to maximum concentration was variable (0.5-8 hrs).,Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19113793/),h,0.5-8,70150,DB00688,Mycophenolate mofetil
,19113793,oral clearance (Cl/F),"Mean +/- SD fraction of unbound mycophenolic acid was 2.6 +/- 1.9%, and oral clearance (Cl/F) was about 2-fold higher (343 +/- 200 ml/min) than previously reported.",Pharmacokinetics of mycophenolic acid in patients with lupus nephritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19113793/),[ml] / [min],343,70151,DB00688,Mycophenolate mofetil
,18489992,Relapse rate,Relapse rate was 25% at 2 years.,Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18489992/),%,25,71153,DB00688,Mycophenolate mofetil
,11737117,area under the curve (AUC) from 0 to 12 h,"Despite a comparable MMF dose, a large interindividual variability in both MPA area under the curve (AUC) from 0 to 12 h (range 10.1-99.8 microg/mL. h) and in trough levels (range 0.24-7.04 microg/mL) was found.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[μg] / [h·ml],10.1-99.8,71215,DB00688,Mycophenolate mofetil
,11737117,trough levels,"Despite a comparable MMF dose, a large interindividual variability in both MPA area under the curve (AUC) from 0 to 12 h (range 10.1-99.8 microg/mL. h) and in trough levels (range 0.24-7.04 microg/mL) was found.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[μg] / [ml],0.24-7.04,71216,DB00688,Mycophenolate mofetil
>,11737117,AUC,"Patients with AUC >40 microg/mL. h showed a better (p<0.05) renal function than patients with lower AUC (creatinine clearance 85.7+/-23.2 versus 64.5+/-17.5 mL/min), despite no difference in CsA dose, CsA AUC and blood CsA trough level.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[μg] / [h·ml],40,71217,DB00688,Mycophenolate mofetil
,11737117,AUC,"Patients with AUC >40 microg/mL. h showed a better (p<0.05) renal function than patients with lower AUC (creatinine clearance 85.7+/-23.2 versus 64.5+/-17.5 mL/min), despite no difference in CsA dose, CsA AUC and blood CsA trough level.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[ml] / [min],85.7,71218,DB00688,Mycophenolate mofetil
,11737117,AUC,"Patients with AUC >40 microg/mL. h showed a better (p<0.05) renal function than patients with lower AUC (creatinine clearance 85.7+/-23.2 versus 64.5+/-17.5 mL/min), despite no difference in CsA dose, CsA AUC and blood CsA trough level.",Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11737117/),[ml] / [min],64.5,71219,DB00688,Mycophenolate mofetil
,10831074,AUC(0-12),"The MPA AUC(0-12) was higher for i.v. MMF than p.o. MMF (40.8 +/- 11.4 microg x h/ mL vs. 32.9 +/- 15, p < 0.001).","Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10831074/),[h·μg] / [ml],40.8,71253,DB00688,Mycophenolate mofetil
,10831074,AUC(0-12),"The MPA AUC(0-12) was higher for i.v. MMF than p.o. MMF (40.8 +/- 11.4 microg x h/ mL vs. 32.9 +/- 15, p < 0.001).","Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10831074/),,32.9,71254,DB00688,Mycophenolate mofetil
,25041114,C0,"In both autoimmune diseases, at PK assessment, median MPA C0 for patients with uncontrolled disease was significantly lower than that of patients with stable disease or in remission, 1.6 mg l(-1) (IQR 0.9-2.1 mg l(-1)) vs. 2.95 mg l(-1) (IQR 1.38-3.73 mg l(-1)) for SLE (P = 0.048) and 1.55 mg l(-1) (IQR 0.98-2.18 mg l(-1)) vs. 3 mg l(-1) (IQR 2.2-4.4 mg l(-1)) for vasculitis (P = 0.016).",Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25041114/),[mg] / [l],1.6,71782,DB00688,Mycophenolate mofetil
,25041114,C0,"In both autoimmune diseases, at PK assessment, median MPA C0 for patients with uncontrolled disease was significantly lower than that of patients with stable disease or in remission, 1.6 mg l(-1) (IQR 0.9-2.1 mg l(-1)) vs. 2.95 mg l(-1) (IQR 1.38-3.73 mg l(-1)) for SLE (P = 0.048) and 1.55 mg l(-1) (IQR 0.98-2.18 mg l(-1)) vs. 3 mg l(-1) (IQR 2.2-4.4 mg l(-1)) for vasculitis (P = 0.016).",Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25041114/),[mg] / [l],2.95,71783,DB00688,Mycophenolate mofetil
,25041114,C0,"In both autoimmune diseases, at PK assessment, median MPA C0 for patients with uncontrolled disease was significantly lower than that of patients with stable disease or in remission, 1.6 mg l(-1) (IQR 0.9-2.1 mg l(-1)) vs. 2.95 mg l(-1) (IQR 1.38-3.73 mg l(-1)) for SLE (P = 0.048) and 1.55 mg l(-1) (IQR 0.98-2.18 mg l(-1)) vs. 3 mg l(-1) (IQR 2.2-4.4 mg l(-1)) for vasculitis (P = 0.016).",Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25041114/),[mg] / [l],1.55,71784,DB00688,Mycophenolate mofetil
,25041114,C0,"In both autoimmune diseases, at PK assessment, median MPA C0 for patients with uncontrolled disease was significantly lower than that of patients with stable disease or in remission, 1.6 mg l(-1) (IQR 0.9-2.1 mg l(-1)) vs. 2.95 mg l(-1) (IQR 1.38-3.73 mg l(-1)) for SLE (P = 0.048) and 1.55 mg l(-1) (IQR 0.98-2.18 mg l(-1)) vs. 3 mg l(-1) (IQR 2.2-4.4 mg l(-1)) for vasculitis (P = 0.016).",Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25041114/),[mg] / [l],3,71785,DB00688,Mycophenolate mofetil
,25041114,C0 threshold,"According to our receiver operating characteristics curve analysis, a C0 threshold of 2.5-3 mg l(-1) was best able to discriminate a flare (SLE: 88% sensitivity, 80% specificity; vasculitis: 100% sensitivity, 90% specificity).",Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25041114/),[mg] / [l],2.5-3,71786,DB00688,Mycophenolate mofetil
≥,25041114,C0,Patients with C0 ≥ 2.5-3 mg l(-1) at inclusion had better clinical outcomes during the 12 months following PK assessment.,Pre-dose plasma concentration monitoring of mycophenolate mofetil in patients with autoimmune diseases. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25041114/),[mg] / [l],2.5-3,71787,DB00688,Mycophenolate mofetil
,15601803,maximum concentration,The maximum concentration of mycophenolic acid in plasma increased significantly (P < or = .05) with time from 9.1 +/- 7.2 microg/mL (<1 week) to 36.7 +/- 15.6 microg/mL (1 month).,Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601803/),[μg] / [ml],9.1,72491,DB00688,Mycophenolate mofetil
,15601803,maximum concentration,The maximum concentration of mycophenolic acid in plasma increased significantly (P < or = .05) with time from 9.1 +/- 7.2 microg/mL (<1 week) to 36.7 +/- 15.6 microg/mL (1 month).,Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601803/),[μg] / [ml],36.7,72492,DB00688,Mycophenolate mofetil
,15601803,area under the plasma concentration versus time curve,"The area under the plasma concentration versus time curve of mycophenolic acid also increased significantly with time, from 50.8 +/- 42.1 microg x h/mL to 118.0 +/- 57.6 microg x h/mL (P < or = .05).",Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601803/),[h·μg] / [ml],50.8,72493,DB00688,Mycophenolate mofetil
,15601803,area under the plasma concentration versus time curve,"The area under the plasma concentration versus time curve of mycophenolic acid also increased significantly with time, from 50.8 +/- 42.1 microg x h/mL to 118.0 +/- 57.6 microg x h/mL (P < or = .05).",Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601803/),[h·μg] / [ml],118.0,72494,DB00688,Mycophenolate mofetil
,15601803,apparent oral clearance [CL/F],"The plasma protein binding of mycophenolic acid increased from 92% to 98%, and the apparent oral clearance [CL/F] decreased from 32.9 +/- 21.4 L/h during the first study period to 9.0 +/- 4.4 L/h (P < or = .05) during the third study period.",Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601803/),[l] / [h],32.9,72495,DB00688,Mycophenolate mofetil
,15601803,apparent oral clearance [CL/F],"The plasma protein binding of mycophenolic acid increased from 92% to 98%, and the apparent oral clearance [CL/F] decreased from 32.9 +/- 21.4 L/h during the first study period to 9.0 +/- 4.4 L/h (P < or = .05) during the third study period.",Intraindividual and interindividual variations in the pharmacokinetics of mycophenolic acid in liver transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15601803/),[l] / [h],9.0,72496,DB00688,Mycophenolate mofetil
,19038099,AUC,"Regarding mycophenolate mofetil, the targeted AUC has been defined between 30 and 60 mg/h/l.",[Recents advances in the pharmacology of immunosuppressive drugs used in organ transplantation]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19038099/),[mg] / [h·l],30 and 60,72503,DB00688,Mycophenolate mofetil
,10071016,trough blood level,"The mean trough blood level of MPA in 10 patients was 0.28 microg/ml, and 5.7 microg/ml for MPA glucoronide.",Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071016/),[μg] / [ml],0.28,74256,DB00688,Mycophenolate mofetil
,10071016,trough blood level,"The mean trough blood level of MPA in 10 patients was 0.28 microg/ml, and 5.7 microg/ml for MPA glucoronide.",Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10071016/),[μg] / [ml],5.7,74257,DB00688,Mycophenolate mofetil
,32612988,size,"The size of prepared MPA-LNPs and QC-LNPs were found to be 183 ± 13 and 157 ± 09.8, respectively.",Liposomal Delivery of Mycophenolic Acid With Quercetin for Improved Breast Cancer Therapy in SD Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32612988/),,183,74888,DB00688,Mycophenolate mofetil
,32612988,size,"The size of prepared MPA-LNPs and QC-LNPs were found to be 183 ± 13 and 157 ± 09.8, respectively.",Liposomal Delivery of Mycophenolic Acid With Quercetin for Improved Breast Cancer Therapy in SD Rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32612988/),,157,74889,DB00688,Mycophenolate mofetil
greater,27898598,area under the plasma concentration-time curve from 0 to 12 hours (AUC0-12),The aim of this study was to determine the MMF/MPS dosage required to achieve an area under the plasma concentration-time curve from 0 to 12 hours (AUC0-12) for mycophenolic acid (MPA) greater than 30 mg·h·L in children after intestinal transplantation.,Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27898598/),h·l·mg,30,75092,DB00688,Mycophenolate mofetil
below,27898598,AUC0-12,One of the 3 patients who received MPS and 2 of the 6 patients who received MMF had an MPA AUC0-12 value below 30 mg.h.L.,Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27898598/),h·l·mg,30,75093,DB00688,Mycophenolate mofetil
above,27898598,AUC0-12,The median MMF dosage had to be increased by 91% (1319 mg·m·d versus 687 mg·m·d) to reach AUC0-12 values above the defined target level of 30 mg·h·L.,Pharmacokinetics of Mycophenolic Acid and Dose Optimization in Children After Intestinal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27898598/),h·l·mg,30,75094,DB00688,Mycophenolate mofetil
,24828287,half-life,MPA half-life in the vitreous was 5.0±0.3 days.,"Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828287/),d,5.0,75886,DB00688,Mycophenolate mofetil
,24828287,half-life,MPA vitreous half-life is 5.0 days.,"Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24828287/),d,5.0,75887,DB00688,Mycophenolate mofetil
,20736896,apparent nonrenal clearance (ClNR/F),"The MPA population mean estimates for apparent nonrenal clearance (ClNR/F) and apparent central volume of distribution were 14.3 L/hr and 21.1 L, respectively.",Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736896/),[l] / [h],14.3,76212,DB00688,Mycophenolate mofetil
,20736896,apparent central volume of distribution,"The MPA population mean estimates for apparent nonrenal clearance (ClNR/F) and apparent central volume of distribution were 14.3 L/hr and 21.1 L, respectively.",Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736896/),l,21.1,76213,DB00688,Mycophenolate mofetil
,20736896,apparent renal clearance (ClR/F),The mean population estimate for apparent renal clearance (ClR/F) was dependent on estimated creatinine clearances (eClcr); 0.0975 L/hr for eClcr 80 mL/min or less and 0.157 L/hr for eClcr greater than 80 mL/min.,Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736896/),[l] / [h],0.0975,76214,DB00688,Mycophenolate mofetil
,20736896,apparent renal clearance (ClR/F),The mean population estimate for apparent renal clearance (ClR/F) was dependent on estimated creatinine clearances (eClcr); 0.0975 L/hr for eClcr 80 mL/min or less and 0.157 L/hr for eClcr greater than 80 mL/min.,Population pharmacokinetics of mycophenolic acid and metabolites in patients with glomerulonephritis. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20736896/),[l] / [h],0.157,76215,DB00688,Mycophenolate mofetil
,28892209,AUC0-14 h,The mean AUC0-14 h ranged from 6 to 50 h*mg/L after IV dosing of MMF.,Pharmacokinetics of Mycophenolic Acid after Intravenous Administration of Mycophenolate Mofetil to Healthy Cats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28892209/),[h·mg] / [l],6 to 50,77825,DB00688,Mycophenolate mofetil
,21168674,time after transplantation,"Mean patient age was 58.2 ± 8.8 years, and mean time after transplantation was 2.3 ± 4.0 years (range, 0.2-13.0 years).",Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),years,2.3,78356,DB00688,Mycophenolate mofetil
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.5,78357,DB00688,Mycophenolate mofetil
,21168674,serum concentrations,Mean predose (C0) MPA serum concentrations were insignificantly lower with PPI comedication (2.5 ± 2.2 mg/L vs 2.8 ± 1.7 mg/L; P = .15).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[mg] / [l],2.8,78358,DB00688,Mycophenolate mofetil
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],45.2,78359,DB00688,Mycophenolate mofetil
,21168674,AUCs,Dose-adjusted abbreviated MPA AUCs (adjusted to morning dose) were significantly lower during PPI therapy (45.2 ± 20.3 vs 65.2 ± 38.8 mg·h/L·g [MMF]; P = .02).,Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21168674/),[h·mg] / [g·l],65.2,78360,DB00688,Mycophenolate mofetil
,19177449,time to the maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),h,1.25,78917,DB00688,Mycophenolate mofetil
,19177449,time to the maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),h,1.28,78918,DB00688,Mycophenolate mofetil
,19177449,maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[μg] / [ml],15.5,78919,DB00688,Mycophenolate mofetil
,19177449,maximum plasma concentration,"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[μg] / [ml],13.6,78920,DB00688,Mycophenolate mofetil
,19177449,area under the concentration-time curve from 0 to 12 hours (AUC(0-12),"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[h·μg] / [ml],53.0,78921,DB00688,Mycophenolate mofetil
,19177449,area under the concentration-time curve from 0 to 12 hours (AUC(0-12),"No significant differences between the tacrolimus standard-dose and reduced-dose groups were seen in dose-normalized MPA values of the time to the maximum plasma concentration (1.25 versus 1.28 hours), the maximum plasma concentration (15.5 +/- 7.93 versus 13.6 +/- 7.03 microg/mL), or the area under the concentration-time curve from 0 to 12 hours (AUC(0-12); 53.0 +/- 20.6 versus 43.8 +/- 15.5 microg h/mL) at week 26 or at any other time point.","Pharmacokinetics, efficacy, and safety of mycophenolate mofetil in combination with standard-dose or reduced-dose tacrolimus in liver transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19177449/),[h·μg] / [ml],43.8,78922,DB00688,Mycophenolate mofetil
above,25663618,area under the time-concentration curve (AUC0-12),All patients reached MPA area under the time-concentration curve (AUC0-12) above 30 µg h/mL.,Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25663618/),[h·μg] / [ml],30,79134,DB00688,Mycophenolate mofetil
,22105586,Cl,"Of 19 volunteers, 12 were men, with age (mean ± SD) 46 ± 11 years, weight 83 ± 19 kg, and calculated Cl(creatinine) 64 ± 27 mL/min.","Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22105586/),,64,79249,DB00688,Mycophenolate mofetil
,26103520,maximum dose,"The median maximum dose of MMF was 60 mg/kg/day (range, 34-107).",Mycophenolate mofetil for treatment of steroid-refractory acute graft-versus-host disease after pediatric hematopoietic stem cell transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26103520/),[mg] / [d·kg],60,80473,DB00688,Mycophenolate mofetil
<,15257072,AUC(0-4),"Patients with an AUC(0-4) < 4400 microg x h/L at both PK sampling periods in the first 3 weeks posttransplant had an adjusted relative risk of 48.4% to suffer an acute rejection episode (ARE), whereas in patients with at least 1 AUC0-4 above this threshold, the adjusted relative risk for an ARE was only 13.1% (P < 0.02).",Cyclosporin A absorption profiles in pediatric renal transplant recipients predict the risk of acute rejection. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15257072/),[h·μg] / [l],4400,81067,DB00688,Mycophenolate mofetil
,20047676,Area-Under-The-(Time-Concentration)-Curves (AUCs),"The MPA Area-Under-The-(Time-Concentration)-Curves (AUCs) on MMF and EC-MPS were comparable (54.4 mg x h/L on MMF and 44.0 mg x h/L on EC-MPS, n.s., Mann Whitney).",Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047676/),[h·mg] / [l],54.4,82612,DB00688,Mycophenolate mofetil
,20047676,Area-Under-The-(Time-Concentration)-Curves (AUCs),"The MPA Area-Under-The-(Time-Concentration)-Curves (AUCs) on MMF and EC-MPS were comparable (54.4 mg x h/L on MMF and 44.0 mg x h/L on EC-MPS, n.s., Mann Whitney).",Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047676/),[h·mg] / [l],44.0,82613,DB00688,Mycophenolate mofetil
,20047676,time to maximum concentration,"However, PK profiles on EC-MPS were quite random, and time to maximum concentration varied from 30 minutes to 720 minutes.",Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047676/),min,30,82614,DB00688,Mycophenolate mofetil
,20047676,time to maximum concentration,"However, PK profiles on EC-MPS were quite random, and time to maximum concentration varied from 30 minutes to 720 minutes.",Random pharmacokinetic profiles of EC-MPS in children with autoimmune disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047676/),min,720,82615,DB00688,Mycophenolate mofetil
>,19925875,total,"Mycophenolic acid (MPA) pharmacokinetic measurements from weeks 1 and 2 did not correlate with CR at either day 28 or day 56 (P > .07); however, if the mean of weeks 1 and 2 total MPA troughs was >0.5 microg/mL or that of an unbound trough was >0.015 microg/mL, then a significantly greater proportion achieved CR + PR at days 28 and 56.",Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925875/),[μg] / [ml],0.5,82960,DB00688,Mycophenolate mofetil
>,19925875,troughs,"Mycophenolic acid (MPA) pharmacokinetic measurements from weeks 1 and 2 did not correlate with CR at either day 28 or day 56 (P > .07); however, if the mean of weeks 1 and 2 total MPA troughs was >0.5 microg/mL or that of an unbound trough was >0.015 microg/mL, then a significantly greater proportion achieved CR + PR at days 28 and 56.",Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925875/),[μg] / [ml],0.5,82961,DB00688,Mycophenolate mofetil
>,19925875,unbound trough,"Mycophenolic acid (MPA) pharmacokinetic measurements from weeks 1 and 2 did not correlate with CR at either day 28 or day 56 (P > .07); however, if the mean of weeks 1 and 2 total MPA troughs was >0.5 microg/mL or that of an unbound trough was >0.015 microg/mL, then a significantly greater proportion achieved CR + PR at days 28 and 56.",Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925875/),[μg] / [ml],0.015,82962,DB00688,Mycophenolate mofetil
>,19925875,total trough,"CR + PR at day 28 was observed in 19 of 19 patients (100%) with a mean total trough >0.5 mg/mL, but in only 7 of 13 (54%) with a mean total trough < or =0.5 microg/mL (P = .002).",Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925875/),[mg] / [ml],0.5,82963,DB00688,Mycophenolate mofetil
< or =,19925875,total trough,"CR + PR at day 28 was observed in 19 of 19 patients (100%) with a mean total trough >0.5 mg/mL, but in only 7 of 13 (54%) with a mean total trough < or =0.5 microg/mL (P = .002).",Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925875/),[μg] / [ml],0.5,82964,DB00688,Mycophenolate mofetil
>,19925875,unbound trough concentration,"Similarly, CR + PR at day 28 was seen in 15 of 15 patients (100%) with an unbound trough concentration >0.015 microg/mL, but in only 11 of 17 (65%) with an unbound trough concentration < or =0.015 microg/mL (P = .02).",Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925875/),[μg] / [ml],0.015,82965,DB00688,Mycophenolate mofetil
< or =,19925875,unbound trough concentration,"Similarly, CR + PR at day 28 was seen in 15 of 15 patients (100%) with an unbound trough concentration >0.015 microg/mL, but in only 11 of 17 (65%) with an unbound trough concentration < or =0.015 microg/mL (P = .02).",Mycophenolate pharmacokinetics and association with response to acute graft-versus-host disease treatment from the Blood and Marrow Transplant Clinical Trials Network. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19925875/),[μg] / [ml],0.015,82966,DB00688,Mycophenolate mofetil
,20357699,area under the curve,Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[h·μg] / [ml],42.9,83387,DB00688,Mycophenolate mofetil
,20357699,dose-normalized AUC,Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[h·μg] / [g·ml],52.9,83388,DB00688,Mycophenolate mofetil
,20357699,maximal concentration (Cmax),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[μg] / [ml],13.0,83389,DB00688,Mycophenolate mofetil
,20357699,time to Cmax (tmax),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),h,1.2,83390,DB00688,Mycophenolate mofetil
,20357699,minimum concentration (Cmin),Pharmacokinetic parameters for MPA were area under the curve 42.9 +/- 21.6 microg h/mL; dose-normalized AUC 52.9 +/- 25.4 microg h/mL/g; maximal concentration (Cmax) 13.0 +/- 6.2 microg/mL; time to Cmax (tmax) 1.2 +/- 0.4 hours; minimum concentration (Cmin) 1.4 +/- 1.0 microg/mL; and MPA-free fraction 1.2% +/- 1.0%.,Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),[μg] / [ml],1.4,83391,DB00688,Mycophenolate mofetil
,20357699,Area under the curve ratios,"Area under the curve ratios of MPAG/MPA and AcMPAG/MPA were 17.8 +/- 12.4 and 0.1 +/- 0.1, respectively.",Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),,17.8,83392,DB00688,Mycophenolate mofetil
,20357699,Area under the curve ratios,"Area under the curve ratios of MPAG/MPA and AcMPAG/MPA were 17.8 +/- 12.4 and 0.1 +/- 0.1, respectively.",Pharmacokinetics of mycophenolic acid and its glucuronidated metabolites in stable islet transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357699/),,0.1,83393,DB00688,Mycophenolate mofetil
,17889124,C2,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[ng] / [ml],138,83527,DB00688,Mycophenolate mofetil
,17889124,AUC,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·ng] / [ml],6377,83528,DB00688,Mycophenolate mofetil
,17889124,C0 MPA,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[μg] / [ml],1.0,83529,DB00688,Mycophenolate mofetil
,17889124,AUC,"At day 7, CsA C2 and AUC median values were 138 ng/mL and 6377 ng x h/mL, while C0 MPA was 1.0 microg/mL and AUC = 23.9 microg x h/mL.",Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·μg] / [ml],23.9,83530,DB00688,Mycophenolate mofetil
,17889124,C2,CsA C2 medians at 3 and 6 months were 1468 and 1720 ng/mL.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[ng] / [ml],1468,83531,DB00688,Mycophenolate mofetil
,17889124,C2,CsA C2 medians at 3 and 6 months were 1468 and 1720 ng/mL.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[ng] / [ml],1720,83532,DB00688,Mycophenolate mofetil
,17889124,AUC,MPA-AUC reached therapeutic targets at 3 months (32.3 microg x h/mL) and was 48.3 microg x h/mL at 6 months.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·μg] / [ml],32.3,83533,DB00688,Mycophenolate mofetil
,17889124,AUC,MPA-AUC reached therapeutic targets at 3 months (32.3 microg x h/mL) and was 48.3 microg x h/mL at 6 months.,Pharmacokinetics and pharmacodynamics in renal transplant recipients under treatment with cyclosporine and Myfortic. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889124/),[h·μg] / [ml],48.3,83534,DB00688,Mycophenolate mofetil
,15168391,area under the plasma mycophenolic acid concentration versus time curves (AUC(0-12)),"The interindividual variability of the 12-hour area under the plasma mycophenolic acid concentration versus time curves (AUC(0-12)) under control conditions was small (89.5 +/- 27.8 and 87.6 +/- 39.1 mg x h/L, respectively).",Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15168391/),[h·mg] / [l],89.5,84169,DB00688,Mycophenolate mofetil
,15168391,area under the plasma mycophenolic acid concentration versus time curves (AUC(0-12)),"The interindividual variability of the 12-hour area under the plasma mycophenolic acid concentration versus time curves (AUC(0-12)) under control conditions was small (89.5 +/- 27.8 and 87.6 +/- 39.1 mg x h/L, respectively).",Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15168391/),[h·mg] / [l],87.6,84170,DB00688,Mycophenolate mofetil
,15168391,AUC(0-12),"Concomitant or subsequent administration of MMF and ferrous sulfate did not affect the bioavailabilty of MMF (AUC(0-12), 91.9 +/- 30.4 mg x h/L and 96.0 +/- 31.7 mg x h/L).",Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15168391/),[h·mg] / [l],91.9,84171,DB00688,Mycophenolate mofetil
,15168391,AUC(0-12),"Concomitant or subsequent administration of MMF and ferrous sulfate did not affect the bioavailabilty of MMF (AUC(0-12), 91.9 +/- 30.4 mg x h/L and 96.0 +/- 31.7 mg x h/L).",Ferrous sulfate does not affect mycophenolic acid pharmacokinetics in kidney transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15168391/),[h·mg] / [l],96.0,84172,DB00688,Mycophenolate mofetil
,19552842,C(0),No side effect or acute rejection episode occurred with the median MPA-C(0) value of 0.74 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],0.74,84570,DB00688,Mycophenolate mofetil
,19552842,C(0),Side effects occurred with the median MPA-C(0) value of 1.32 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],1.32,84571,DB00688,Mycophenolate mofetil
,19552842,C(0),Sixteen case-times demonstrated acute rejection episode with the median MPA-C(0) value of 0.39 mg/L.,[Correlation of mycophenolic acid pharmacokinetic parameters with clinical events in kidney transplant patients treated with mycophenolate mofetil]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19552842/),[mg] / [l],0.39,84572,DB00688,Mycophenolate mofetil
,16144801,concentration steady state (Css),"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],1.9,84891,DB00688,Mycophenolate mofetil
,16144801,concentration steady state (Css),"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],3.1,84892,DB00688,Mycophenolate mofetil
,16144801,unbound Css,"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[ng] / [ml],18,84893,DB00688,Mycophenolate mofetil
,16144801,unbound Css,"Comparing the twice-daily and 3-times-daily MMF groups, the mean total MPA concentration steady state (Css) was 1.9 and 3.1 microg/mL; the unbound Css was 18 and 36 ng/mL, respectively (P < .001).",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[ng] / [ml],36,84894,DB00688,Mycophenolate mofetil
less,16144801,Css,"Sixteen patients with a total MPA Css less than 3 microg/mL had low (< 50%) donor T-cell chimerism (P = .03), and 6 patients with MPA Css less than 2.5 microg/mL had graft rejection.",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],3,84895,DB00688,Mycophenolate mofetil
less,16144801,Css,"Sixteen patients with a total MPA Css less than 3 microg/mL had low (< 50%) donor T-cell chimerism (P = .03), and 6 patients with MPA Css less than 2.5 microg/mL had graft rejection.",Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],2.5,84896,DB00688,Mycophenolate mofetil
greater,16144801,Css's,We conclude that increased MPA Css's predicted higher degrees of donor T-cell chimerism after unrelated donor nonmyeloablative HCT and suggest that targeting MPA Css's greater than 2.5 microg/mL could prevent graft rejection.,Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16144801/),[μg] / [ml],2.5,84897,DB00688,Mycophenolate mofetil
,17290612,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) and area under concentration-time curve (AUC(0-12 h)) were (12 +/- 7) microg x mL(-1) and (44 +/- 16) microg x h x mL(-1), respectively.",[Pharmacokinetics of mycophenolic acid in Chinese patients with liver transplant]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290612/),[μg] / [ml],12,88785,DB00688,Mycophenolate mofetil
,17290612,area under concentration-time curve (AUC(0-12 h)),"The mean peak plasma concentration (C(max)) and area under concentration-time curve (AUC(0-12 h)) were (12 +/- 7) microg x mL(-1) and (44 +/- 16) microg x h x mL(-1), respectively.",[Pharmacokinetics of mycophenolic acid in Chinese patients with liver transplant]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17290612/),[h·μg] / [ml],44,88786,DB00688,Mycophenolate mofetil
,11389708,trough blood levels,Mean trough blood levels of MPA ranged between 68.8 and 340 ng/mL with a median of 146.7 ng/mL.,Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389708/),[ng] / [ml],146.7,88825,DB00688,Mycophenolate mofetil
,11389708,AUC0-12 h,The mean MPA AUC0-12 h after first dose ranged between 19349+/-5087 ng * h/mL and 25705+/-3042 ng * h/mL and correlated with the dose level of MMF.,Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389708/),[h·ng] / [ml],19349,88826,DB00688,Mycophenolate mofetil
,11389708,AUC0-12 h,The mean MPA AUC0-12 h after first dose ranged between 19349+/-5087 ng * h/mL and 25705+/-3042 ng * h/mL and correlated with the dose level of MMF.,Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11389708/),[h·ng] / [ml],25705,88827,DB00688,Mycophenolate mofetil
,17214827,CL,The model predicted the mean CL to decrease from 35 l h(-1) (CV = 44%) in the first week after transplantation to 17 l h(-1) (CV = 38%) after 6 months.,Time-dependent clearance of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214827/),[l] / [h],35,89414,DB00688,Mycophenolate mofetil
,17214827,CL,The model predicted the mean CL to decrease from 35 l h(-1) (CV = 44%) in the first week after transplantation to 17 l h(-1) (CV = 38%) after 6 months.,Time-dependent clearance of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214827/),[l] / [h],17,89415,DB00688,Mycophenolate mofetil
,17214827,CL,"In a covariate model without a term for time-dependent CL, changes during the first 6 months after transplantation in creatinine clearance from 19 to 71 ml min(-1), in albumin concentration from 35 to 40 g l(-1), in haemoglobin from 9.7 to 12 g dl(-1) and in cyclosporin predose concentration from 225 to 100 ng ml(-1) corresponded with a decrease of CL from 32 to 19 l h(-1).",Time-dependent clearance of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17214827/),,32,89416,DB00688,Mycophenolate mofetil
,18206330,flow rate,"The analysis was carried out on an ACQUITY UPLCTM BEH C18 column (50 mm x 2.1 mm, i.d., 1.7 microm) with flow rate of 0.35 ml/min.",Determination of lovastatin in human plasma by ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometry and its application in a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18206330/),[ml] / [min],0.35,91537,DB00688,Mycophenolate mofetil
,18946804,T(9),"A statistical significant increase in the dose-adjusted AUC(6-12) level of MPA was found in patients bearing the -118(dT)(10) allele of the UGT1A9 gene (T(9) = 7.34 +/- 4.11 mg h ml(-1) g(-1); T(9)/T(10) = 11.54 +/- 7.62 mg h ml(-1) g(-1); and T(10) = 11.89 +/-8.76 mg h ml(-1) g(-1), p = 0.041).",Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18946804/),[h·mg] / [g·ml],7.34,92454,DB00688,Mycophenolate mofetil
,18946804,T(9)/T(10),"A statistical significant increase in the dose-adjusted AUC(6-12) level of MPA was found in patients bearing the -118(dT)(10) allele of the UGT1A9 gene (T(9) = 7.34 +/- 4.11 mg h ml(-1) g(-1); T(9)/T(10) = 11.54 +/- 7.62 mg h ml(-1) g(-1); and T(10) = 11.89 +/-8.76 mg h ml(-1) g(-1), p = 0.041).",Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18946804/),[h·mg] / [g·ml],11.54,92455,DB00688,Mycophenolate mofetil
,18946804,T(10),"A statistical significant increase in the dose-adjusted AUC(6-12) level of MPA was found in patients bearing the -118(dT)(10) allele of the UGT1A9 gene (T(9) = 7.34 +/- 4.11 mg h ml(-1) g(-1); T(9)/T(10) = 11.54 +/- 7.62 mg h ml(-1) g(-1); and T(10) = 11.89 +/-8.76 mg h ml(-1) g(-1), p = 0.041).",Influence of uridine diphosphate (UDP)-glucuronosyltransferases and ABCC2 genetic polymorphisms on the pharmacokinetics of mycophenolic acid and its metabolites in Chinese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18946804/),[h·mg] / [g·ml],11.89,92456,DB00688,Mycophenolate mofetil
,19151792,Css target,"The previously proposed total MPA Css target of 3 microg/ml and trough >or=1 micro/ml were achieved in only 13-27% and 20-53% of patients, respectively, on 3 g/day.",Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151792/),[μg] / [ml],3,93179,DB00688,Mycophenolate mofetil
>,19151792,trough,"The previously proposed total MPA Css target of 3 microg/ml and trough >or=1 micro/ml were achieved in only 13-27% and 20-53% of patients, respectively, on 3 g/day.",Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151792/),[μ] / [ml],1,93180,DB00688,Mycophenolate mofetil
,19151792,unbound 24-h,"However, the 3 g/day regimens readily achieved satisfactory unbound 24-h cumulative AUC targets of 0.600 microg(*)h/ml in 87-100% of subjects.",Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151792/),[)h·μg(] / [ml],0.600,93181,DB00688,Mycophenolate mofetil
,19151792,cumulative AUC,"However, the 3 g/day regimens readily achieved satisfactory unbound 24-h cumulative AUC targets of 0.600 microg(*)h/ml in 87-100% of subjects.",Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151792/),[)h·μg(] / [ml],0.600,93182,DB00688,Mycophenolate mofetil
,15183289,trough concentrations,"In maintenance adult patients after conversion to a calcineurin inhibitor-free regimen, sirolimus trough concentrations of 5-10 microg/l are proposed in combination with mycophenolate mofetil.",Immunosuppressive drug monitoring of sirolimus and cyclosporine in pediatric patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15183289/),[μg] / [l],5-10,93468,DB00688,Mycophenolate mofetil
,19531983,AUC0-12h,"From April 2007 to December 2007, MMF was given to 14 patients at a dose of 1 g twice a day until day 7 and was then adapted to reach an MPA AUC0-12h target of 30-60 mg x h/L.",Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531983/),[h·mg] / [l],30-60,93870,DB00688,Mycophenolate mofetil
below,19531983,AUC0-12h,The proportion of patients with MPA AUC0-12h below 30 mg x h/L tended to be higher in the fixed dose group within the first month posttransplant.,Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531983/),[h·mg] / [l],30,93871,DB00688,Mycophenolate mofetil
below,19531983,AUC0-12h,There was a trend toward a lower proportion of patients with MPA AUC0-12h below 30 mg x h/L in the concentration-controlled group.,Mycophenolic acid 12-hour area under the curve in de novo liver transplant patients given mycophenolate mofetil at fixed versus concentration-controlled doses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19531983/),[h·mg] / [l],30,93872,DB00688,Mycophenolate mofetil
,16213292,area under the curve,"In the study group, the mean area under the curve was significantly below the average therapeutic range before (3154 ng/mL/ho) versus 5532 ng/mL/h after shifting to the single-dose regimen (which was therapeutic).",Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213292/),[ng] / [ho·ml],3154,94161,DB00688,Mycophenolate mofetil
,16213292,area under the curve,"In the study group, the mean area under the curve was significantly below the average therapeutic range before (3154 ng/mL/ho) versus 5532 ng/mL/h after shifting to the single-dose regimen (which was therapeutic).",Single daily dose administration of cyclosporine in renal transplant recipients: a preliminary report. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213292/),[ng] / [h·ml],5532,94162,DB00688,Mycophenolate mofetil
,15752372,free fraction,"Mycophenolic acid free fraction was on average 70% higher in patients with albumin concentrations below a specified albumin cut-off concentration of 31 g l(-1)[free fraction = 7 +/- 4% for lower albumin and 4 +/- 3% for higher albumin, respectively; P = 0.001; 95% confidence interval (CI) for the difference 1.9, 4.2].",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),%,7,94667,DB00688,Mycophenolate mofetil
,15752372,free fraction,"Mycophenolic acid free fraction was on average 70% higher in patients with albumin concentrations below a specified albumin cut-off concentration of 31 g l(-1)[free fraction = 7 +/- 4% for lower albumin and 4 +/- 3% for higher albumin, respectively; P = 0.001; 95% confidence interval (CI) for the difference 1.9, 4.2].",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),%,4,94668,DB00688,Mycophenolate mofetil
,15752372,Free AUC0-6,"Free AUC0-6 was significantly higher in those patients with thrombocytopenic, leukopenic and/or infectious outcomes than in those without (mean +/- SD 1.9 +/- 0.3 mg h(-1) l(-1) and 1.1 +/- 0.1 mg h(-1) l(-1), P = 0.0043; 95% CI for the difference 0.3, 1.4).",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),[mg] / [h·l],1.9,94669,DB00688,Mycophenolate mofetil
,15752372,Free AUC0-6,"Free AUC0-6 was significantly higher in those patients with thrombocytopenic, leukopenic and/or infectious outcomes than in those without (mean +/- SD 1.9 +/- 0.3 mg h(-1) l(-1) and 1.1 +/- 0.1 mg h(-1) l(-1), P = 0.0043; 95% CI for the difference 0.3, 1.4).",Mycophenolic acid pharmacokinetics and related outcomes early after renal transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15752372/),[mg] / [h·l],1.1,94670,DB00688,Mycophenolate mofetil
,15256815,blood trough levels,Administration of a low dosis of sirolimus (1 mg/day) led to relevant sirolimus (4.16 +/- 1.85 ng/ml) and MMF blood trough levels (month 1: 6.8 +/- 3.46; month 3: 4.67 +/- 1.78 mg/l).,Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15256815/),[mg] / [l],6.8,95575,DB00688,Mycophenolate mofetil
,15256815,blood trough levels,Administration of a low dosis of sirolimus (1 mg/day) led to relevant sirolimus (4.16 +/- 1.85 ng/ml) and MMF blood trough levels (month 1: 6.8 +/- 3.46; month 3: 4.67 +/- 1.78 mg/l).,Low-dose sirolimus in combination with mycophenolate mofetil improves kidney graft function late after renal transplantation and suggests pharmacokinetic interaction of both immunosuppressive drugs. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15256815/),[mg] / [l],4.67,95576,DB00688,Mycophenolate mofetil
,15058591,flow rate,The mobile phase consisted of 0.02 M potassium dihydrogenphosphate solution adjusted to pH 6.9 with 2 M potassium hydroxide solution-acetonitrile (80:20 (v/v)) at a flow rate of 1.5 ml/min.,Determination of mycophenolic acid in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058591/),[ml] / [min],1.5,95751,DB00688,Mycophenolate mofetil
,15058591,total run time,The total run time was 21.0 min.,Determination of mycophenolic acid in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058591/),min,21.0,95752,DB00688,Mycophenolate mofetil
,15058591,recoveries,"The observed mean recoveries were 89.3 and 98.0% for drug and internal standard, respectively.",Determination of mycophenolic acid in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058591/),%,89.3,95753,DB00688,Mycophenolate mofetil
,15058591,recoveries,"The observed mean recoveries were 89.3 and 98.0% for drug and internal standard, respectively.",Determination of mycophenolic acid in human plasma by high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15058591/),%,98.0,95754,DB00688,Mycophenolate mofetil
,20406220,apparent oral clearance,"The population pharmacokinetic parameters were apparent oral clearance 9.7 l h(-1), apparent central volume of distribution 22.3 l, apparent peripheral volume of distribution 250 l, inter-compartment clearance 18.8 l h(-1), absorption rate constant 5.16 h(-1), lag time 0.215 h.",Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406220/),[l] / [h],9.7,95873,DB00688,Mycophenolate mofetil
,20406220,apparent central volume of distribution,"The population pharmacokinetic parameters were apparent oral clearance 9.7 l h(-1), apparent central volume of distribution 22.3 l, apparent peripheral volume of distribution 250 l, inter-compartment clearance 18.8 l h(-1), absorption rate constant 5.16 h(-1), lag time 0.215 h.",Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406220/),l,22.3,95874,DB00688,Mycophenolate mofetil
,20406220,apparent peripheral volume of distribution,"The population pharmacokinetic parameters were apparent oral clearance 9.7 l h(-1), apparent central volume of distribution 22.3 l, apparent peripheral volume of distribution 250 l, inter-compartment clearance 18.8 l h(-1), absorption rate constant 5.16 h(-1), lag time 0.215 h.",Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406220/),l,250,95875,DB00688,Mycophenolate mofetil
,20406220,inter-compartment clearance,"The population pharmacokinetic parameters were apparent oral clearance 9.7 l h(-1), apparent central volume of distribution 22.3 l, apparent peripheral volume of distribution 250 l, inter-compartment clearance 18.8 l h(-1), absorption rate constant 5.16 h(-1), lag time 0.215 h.",Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406220/),[l] / [h],18.8,95876,DB00688,Mycophenolate mofetil
,20406220,absorption rate constant,"The population pharmacokinetic parameters were apparent oral clearance 9.7 l h(-1), apparent central volume of distribution 22.3 l, apparent peripheral volume of distribution 250 l, inter-compartment clearance 18.8 l h(-1), absorption rate constant 5.16 h(-1), lag time 0.215 h.",Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406220/),1/[h],5.16,95877,DB00688,Mycophenolate mofetil
,20406220,lag time,"The population pharmacokinetic parameters were apparent oral clearance 9.7 l h(-1), apparent central volume of distribution 22.3 l, apparent peripheral volume of distribution 250 l, inter-compartment clearance 18.8 l h(-1), absorption rate constant 5.16 h(-1), lag time 0.215 h.",Population pharmacokinetics and Bayesian estimator of mycophenolic acid in children with idiopathic nephrotic syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406220/),h,0.215,95878,DB00688,Mycophenolate mofetil
,12682891,plasma trough concentration (C(0)),"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [l],1.81,99872,DB00688,Mycophenolate mofetil
,12682891,maximal concentration,"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [l],10.5,99873,DB00688,Mycophenolate mofetil
,12682891,AUC(0-7),"MPA plasma trough concentration (C(0)), maximal concentration, and AUC(0-7) values ranged 9- to 14-fold at a median of 1.81 mg/L (range, 0.4 to 3.7 mg/L), 10.5 mg/L (range, 2.8 to 40.0 mg/L), and 30.2 mg/L.hr (range, 9.3 to 80.3 mg/L.hr), respectively.",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],30.2,99874,DB00688,Mycophenolate mofetil
,12682891,AUC(0-7),Median AUC(0-7) (29.6 v 31.4 mg/L.hr; P =.918) was similar in children comedicated with CsA or Tac.,Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],29.6,99875,DB00688,Mycophenolate mofetil
,12682891,AUC(0-7),Median AUC(0-7) (29.6 v 31.4 mg/L.hr; P =.918) was similar in children comedicated with CsA or Tac.,Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[mg] / [h·l],31.4,99876,DB00688,Mycophenolate mofetil
,12682891,AUC(0-7),"Consequently, median AUC(0-7) was significantly lower in the CsA group when equalized for dose and body weight (2.02 v 3.85 microg/L.hr per mg of MMF dose per kg of weight; P =.002).",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[μg] / [h·l·mg],2.02,99877,DB00688,Mycophenolate mofetil
,12682891,AUC(0-7),"Consequently, median AUC(0-7) was significantly lower in the CsA group when equalized for dose and body weight (2.02 v 3.85 microg/L.hr per mg of MMF dose per kg of weight; P =.002).",Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12682891/),[μg] / [h·l·mg],3.85,99878,DB00688,Mycophenolate mofetil
,28317040,concentration,"The normal renal function group (n=15) showed a mean 12-hour MPA concentration of 2.5±0.5 µg/ml (range, 1.8±0.5 to 3.6±0.7 µg/ml) and a mean CV of 20.4±7.7% (range, 8.7% to 39.4%).",Intra-individual variability of mycophenolic acid concentration according to renal function in liver transplant recipients receiving mycophenolate monotherapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28317040/),,2,100162,DB00688,Mycophenolate mofetil
,23176542,peak level,The mean first mycophenolic acid peak level was 10 ± 5 mg/L.,Mycophenolic Acid pharmacokinetics early after kidney transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176542/),[mg] / [l],10,100665,DB00688,Mycophenolate mofetil
,23176542,area under the curve,The mean mycophenolic acid area under the curve was 26 ± 19 mgh/L and apparent clearance was 57 ± 55 L/h.,Mycophenolic Acid pharmacokinetics early after kidney transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176542/),[mgh] / [l],26,100666,DB00688,Mycophenolate mofetil
,23176542,apparent clearance,The mean mycophenolic acid area under the curve was 26 ± 19 mgh/L and apparent clearance was 57 ± 55 L/h.,Mycophenolic Acid pharmacokinetics early after kidney transplant. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176542/),[l] / [h],57,100667,DB00688,Mycophenolate mofetil
,23176542,area under the curve,The mycophenolic acid area under the curve values of only 8 patients (26%) were within the therapeutic range (30-60 mgh/L).,Mycophenolic Acid pharmacokinetics early after kidney transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176542/),[mgh] / [l],26,100668,DB00688,Mycophenolate mofetil
,23176542,area under the curve,The mycophenolic acid area under the curve values of only 8 patients (26%) were within the therapeutic range (30-60 mgh/L).,Mycophenolic Acid pharmacokinetics early after kidney transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23176542/),[mgh] / [l],30-60,100669,DB00688,Mycophenolate mofetil
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],28,101581,DB00688,Mycophenolate mofetil
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],40,101582,DB00688,Mycophenolate mofetil
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],65,101583,DB00688,Mycophenolate mofetil
,20406219,AUC(0-12),"MPA AUC(0-12) of patients with early biopsy-proven acute rejection was significantly lower compared with patients without a rejection (median MPA AUC(0-12) 28 microg*h ml(-1) (7-45) vs. 40 microg*h ml(-1) (16-130), P < 0.01), MPA AUC(0-12) of patients with recurrent infections was significantly higher compared with patients without infections (median MPA AUC(0-12) 65 microg*h ml(-1) (range 37-130) vs. 37 microg*h ml(-1) (range 7-120), P < 0.005).",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],37,101584,DB00688,Mycophenolate mofetil
,20406219,AEC(0-12),"Low 12-h IMPDH enzyme activity curve (AEC(0-12)) was associated with an increased frequency of gastrointestinal side-effects (median IMPDH AEC(0-12) 43 nmol*h mg(-1) protein h(-1)[range 12-67) vs. 75 nmol*h mg(-1) protein h(-1) (range 15-371), P < 0.01].",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·nM] / [h·mg],43,101585,DB00688,Mycophenolate mofetil
,20406219,AEC(0-12),"Low 12-h IMPDH enzyme activity curve (AEC(0-12)) was associated with an increased frequency of gastrointestinal side-effects (median IMPDH AEC(0-12) 43 nmol*h mg(-1) protein h(-1)[range 12-67) vs. 75 nmol*h mg(-1) protein h(-1) (range 15-371), P < 0.01].",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·nM] / [h·mg],75,101586,DB00688,Mycophenolate mofetil
,20406219,AUC(0-12),"Regarding adverse events, the suggested MPA-target AUC(0-12) from 30 to 60 microg*h ml(-1) seems to be appropriate in renal allograft recipients.",Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20406219/),[h·μg] / [ml],30 to 60,101587,DB00688,Mycophenolate mofetil
over,18823076,extraction recovery,The extraction recovery was over 93% and reproducible.,HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823076/),%,93,101798,DB00688,Mycophenolate mofetil
,18823076,Detection limits,"Detection limits were 0.04 mg/L and 2 microg/L for total and unbound MPA, respectively.",HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823076/),[mg] / [l],0.04,101799,DB00688,Mycophenolate mofetil
,18823076,Detection limits,"Detection limits were 0.04 mg/L and 2 microg/L for total and unbound MPA, respectively.",HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823076/),[μg] / [l],2,101800,DB00688,Mycophenolate mofetil
,18823076,unbound drug concentrations,In these patients MPA concentrations ranged from 0.07 to 7.83 mg/L and unbound drug concentrations ranged from 2.1 to 107.5 microg/L.,HPLC-UV assay for monitoring total and unbound mycophenolic acid concentrations in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18823076/),[μg] / [l],2.1 to 107.5,101801,DB00688,Mycophenolate mofetil
,11427455,c(min),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],2.63,101864,DB00688,Mycophenolate mofetil
,11427455,c(min),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.75,101865,DB00688,Mycophenolate mofetil
,11427455,c(30),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],10.47,101866,DB00688,Mycophenolate mofetil
,11427455,c(30),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],7.66,101867,DB00688,Mycophenolate mofetil
,11427455,c(60),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],9.67,101868,DB00688,Mycophenolate mofetil
,11427455,c(60),"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],5.83,101869,DB00688,Mycophenolate mofetil
,11427455,-AUC((0-12))],"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,48.38,101870,DB00688,Mycophenolate mofetil
,11427455,-AUC((0-12))],"The following PK parameters were increased in the side-effects group compared with the non-side effects group: mean MPA c(min), 2.63 +/- 1.58 vs 1.75 +/- 0.82 mg/L (P = 0.016); mean c(30), 10.47 +/- 6.27 vs 7.66 +/- 8.95 mg/L (P = 0.009); mean c(60), 9.67 +/- 5.42 vs 5.83 +/- 2.6 mg/L (P = 0.0002); mean area under the MPA time-concentration curve from 0 to 12 h [MPA-AUC((0-12))], 48.38 +/- 18.5 vs 36.04 +/- 10.82 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,36.04,101871,DB00688,Mycophenolate mofetil
,11427455,dose-normalized MP,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.16,101872,DB00688,Mycophenolate mofetil
,11427455,-AUC,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.16,101873,DB00688,Mycophenolate mofetil
,11427455,-AUC,"h/L (P = 0.0006); mean dose-normalized MPA-AUC, 0.16 +/- 0.05 vs 0.12 +/- 0.04 (mg. h/L)/(mg/m(2)) (P = 0.0015).",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[h·l·mg·mg] / [m(2],0.12,101874,DB00688,Mycophenolate mofetil
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.86,101875,DB00688,Mycophenolate mofetil
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],1.76,101876,DB00688,Mycophenolate mofetil
,11427455,c(min),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],3.83,101877,DB00688,Mycophenolate mofetil
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,37.7,101878,DB00688,Mycophenolate mofetil
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,24.9,101879,DB00688,Mycophenolate mofetil
,11427455,AUC((0-12)),"For the three AR patients, MPA concentrations obtained at the time of AR revealed MPA c(min) values of 1.86, 1.76, and 3.83 mg/L, respectively, and MPA-AUC((0-12)) values of 37.7, 24.9, and 104.9 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),mg,104.9,101880,DB00688,Mycophenolate mofetil
,11427455,maximum,"h/L. The threshold of toxicity was 3 mg/L (sensitivity, 38.7%; specificity, 91.5%) for c(min), 8.09 mg/L for maximum MPA concentration during the first hour (sensitivity, 77.8%; specificity, 67.4%), and 37.6 mg.",Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11427455/),[mg] / [l],8.,101881,DB00688,Mycophenolate mofetil
,26829599,Tmax,"Consistent with enteric coating, the mean Tmax was significantly longer after the intake of EC-MPS compared with MMF (2.2 versus 0.8 hours; P = 0.0002).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h,2.2,102552,DB00688,Mycophenolate mofetil
,26829599,Tmax,"Consistent with enteric coating, the mean Tmax was significantly longer after the intake of EC-MPS compared with MMF (2.2 versus 0.8 hours; P = 0.0002).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h,0.8,102553,DB00688,Mycophenolate mofetil
,26829599,AUC0-12,"Exposures as reflected by the median AUC0-12 values were 50.7 and 58.7 mg·h·L with MMF and EC-MPS, respectively (P = 0.340).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,50.7,102554,DB00688,Mycophenolate mofetil
,26829599,AUC0-12,"Exposures as reflected by the median AUC0-12 values were 50.7 and 58.7 mg·h·L with MMF and EC-MPS, respectively (P = 0.340).",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,58.7,102555,DB00688,Mycophenolate mofetil
>,26829599,AUC,"All patients achieved a target AUC of >30 mg·h·L, and 61% had an AUC of >50 mg·h·L.",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,30,102556,DB00688,Mycophenolate mofetil
>,26829599,AUC,"All patients achieved a target AUC of >30 mg·h·L, and 61% had an AUC of >50 mg·h·L.",Pharmacokinetic Analysis of Mycophenolate Mofetil and Enteric-Coated Mycophenolate Sodium in Calcineurin Inhibitor-Free Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26829599/),h·l·mg,50,102557,DB00688,Mycophenolate mofetil
,23217391,maximum plasma concentration,"The mean maximum plasma concentration, the mean time for it to reach peak (T(max)), and the mean MPA AUC were (11.38 ± 2.49) mg/L, (4.85 ± 3.32) hours, and (63.19 ± 13.54) mg×h×L(-1), respectively.",Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217391/),[mg] / [l],11.38,103247,DB00688,Mycophenolate mofetil
,23217391,time for it to reach peak (T(max)),"The mean maximum plasma concentration, the mean time for it to reach peak (T(max)), and the mean MPA AUC were (11.38 ± 2.49) mg/L, (4.85 ± 3.32) hours, and (63.19 ± 13.54) mg×h×L(-1), respectively.",Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217391/),h,4.85,103248,DB00688,Mycophenolate mofetil
,23217391,AUC,"The mean maximum plasma concentration, the mean time for it to reach peak (T(max)), and the mean MPA AUC were (11.38 ± 2.49) mg/L, (4.85 ± 3.32) hours, and (63.19 ± 13.54) mg×h×L(-1), respectively.",Pharmacokinetics of enteric-coated mycophenolate sodium in Chinese renal transplantation recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23217391/),[h·mg] / [l],63.19,103249,DB00688,Mycophenolate mofetil
,11180021,area under the curve,"The area under the plasma concentration-time curve from 0 to 12 hours and the maximum concentration of mycophenolic acid in study 2 were significantly less than in study 1 (area under the curve, 32.9 +/- 14.7 versus 2.92 +/- 0.883 microg x h/mL, P < .001, maximum concentration, 20.1 +/- 9.21 versus 1.30 +/- 0.367 microg x h/mL, P < .001).",Impairment of mycophenolate mofetil absorption by iron ion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180021/),[h·μg] / [ml],32.9,103653,DB00688,Mycophenolate mofetil
,11180021,area under the curve,"The area under the plasma concentration-time curve from 0 to 12 hours and the maximum concentration of mycophenolic acid in study 2 were significantly less than in study 1 (area under the curve, 32.9 +/- 14.7 versus 2.92 +/- 0.883 microg x h/mL, P < .001, maximum concentration, 20.1 +/- 9.21 versus 1.30 +/- 0.367 microg x h/mL, P < .001).",Impairment of mycophenolate mofetil absorption by iron ion. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180021/),[h·μg] / [ml],2.92,103654,DB00688,Mycophenolate mofetil
,11180021,maximum concentration,"The area under the plasma concentration-time curve from 0 to 12 hours and the maximum concentration of mycophenolic acid in study 2 were significantly less than in study 1 (area under the curve, 32.9 +/- 14.7 versus 2.92 +/- 0.883 microg x h/mL, P < .001, maximum concentration, 20.1 +/- 9.21 versus 1.30 +/- 0.367 microg x h/mL, P < .001).",Impairment of mycophenolate mofetil absorption by iron ion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180021/),[h·μg] / [ml],20.1,103655,DB00688,Mycophenolate mofetil
,11180021,maximum concentration,"The area under the plasma concentration-time curve from 0 to 12 hours and the maximum concentration of mycophenolic acid in study 2 were significantly less than in study 1 (area under the curve, 32.9 +/- 14.7 versus 2.92 +/- 0.883 microg x h/mL, P < .001, maximum concentration, 20.1 +/- 9.21 versus 1.30 +/- 0.367 microg x h/mL, P < .001).",Impairment of mycophenolate mofetil absorption by iron ion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11180021/),[h·μg] / [ml],1.30,103656,DB00688,Mycophenolate mofetil
,17175302,trough level (C0),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],7.9,103909,DB00688,Mycophenolate mofetil
,17175302,area under the curve over a dosing interval (AUC),At study entry tacrolimus trough level (C0) was 7.9 +/- 3.9 ng/mL and area under the curve over a dosing interval (AUC) was 132 +/- 56 ng x h/mL.,Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],132,103910,DB00688,Mycophenolate mofetil
,17175302,C0,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.4,103911,DB00688,Mycophenolate mofetil
,17175302,AUC,"The addition of everolimus in period 1 did not change tacrolimus exposure: C0 8.4 +/- 4.0 ng/mL, AUC 134 +/- 70 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],134,103912,DB00688,Mycophenolate mofetil
,17175302,C0,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.3,103913,DB00688,Mycophenolate mofetil
,17175302,Cmax,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],10.4,103914,DB00688,Mycophenolate mofetil
,17175302,AUC,"Everolimus pharmacokinetics in the presence of tacrolimus in period 1 were: C0 3.3 +/- 1.2 ng/mL, Cmax 10.4 +/- 5.1 ng/mL, AUC 58 +/- 20 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],58,103915,DB00688,Mycophenolate mofetil
,17175302,C0,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],3.0,103916,DB00688,Mycophenolate mofetil
,17175302,Cmax,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[ng] / [ml],8.2,103917,DB00688,Mycophenolate mofetil
,17175302,AUC,"After tacrolimus dose reduction in period 2, there was no clinically relevant change in everolimus exposure: C0 3.0 +/- 1.1 ng/mL, Cmax 8.2 +/- 1.3 ng/mL, AUC 49 +/- 10 ng x h/mL.",Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17175302/),[h·ng] / [ml],49,103918,DB00688,Mycophenolate mofetil
,26383052,flow rate,"The chromatographic separation was achieved on Luna(®) C18(2) (100×4.60 mm) column using mobile phase consisting of a mixture of 1±0.05 mM ammonium formate in water, titrated to pH 3.1±0.1 with formic acid, and methanol (20:80, v/v), at a flow rate of 0.7 mL/min.",Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26383052/),[ml] / [min],0.7,104329,DB00688,Mycophenolate mofetil
,26383052,m/z ratios,"The detection was led at m/z ratios of 434.4→ 114.2 and 438.4→ 118.3, for mycophenolate mofetil and mycophenolate mofetil-D4, respectively.",Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26383052/),,434.4,104330,DB00688,Mycophenolate mofetil
,26383052,m/z ratios,"The detection was led at m/z ratios of 434.4→ 114.2 and 438.4→ 118.3, for mycophenolate mofetil and mycophenolate mofetil-D4, respectively.",Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26383052/),,114.2,104331,DB00688,Mycophenolate mofetil
,26383052,m/z ratios,"The detection was led at m/z ratios of 434.4→ 114.2 and 438.4→ 118.3, for mycophenolate mofetil and mycophenolate mofetil-D4, respectively.",Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26383052/),,438.4,104332,DB00688,Mycophenolate mofetil
,26383052,m/z ratios,"The detection was led at m/z ratios of 434.4→ 114.2 and 438.4→ 118.3, for mycophenolate mofetil and mycophenolate mofetil-D4, respectively.",Liquid chromatography tandem mass spectrometry method for the quantitation of mycophenolate mofetil in human plasma: Application to a bioequivalence study and metabolite identification. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26383052/),,118.3,104333,DB00688,Mycophenolate mofetil
,21347736,ME,"After 21 days of treatment, there was an insignificant bias ME (0.22 ± 2.59 ng/ml), a reasonable precision MAE (1.97 ± 1.69 ng/ml) and RMSE (1.28 ± 0.58 ng/ml).",Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347736/),[ng] / [ml],0.22,104966,DB00688,Mycophenolate mofetil
,21347736,MAE,"After 21 days of treatment, there was an insignificant bias ME (0.22 ± 2.59 ng/ml), a reasonable precision MAE (1.97 ± 1.69 ng/ml) and RMSE (1.28 ± 0.58 ng/ml).",Prediction tacrolimus blood levels based on the Bayesian method in adult kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21347736/),[ng] / [ml],1.97,104967,DB00688,Mycophenolate mofetil
,22182476,time to platelet recovery,RAD001/CsA caused a more pronounced reduction of platelet counts to median 2 × 10(9)/L (range: 0-21 × 10(9)/L) and longer time to platelet recovery of 21 days (range: 14-24 days) compared with MMF/CsA.,Everolimus in combination with cyclosporin a as pre- and posttransplantation immunosuppressive therapy in nonmyeloablative allogeneic hematopoietic stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22182476/),d,21,105054,DB00688,Mycophenolate mofetil
,9402690,Cmin,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],50.2,105168,DB00688,Mycophenolate mofetil
,9402690,area under the curve,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],32.1,105169,DB00688,Mycophenolate mofetil
,9402690,AUC,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],50.2,105170,DB00688,Mycophenolate mofetil
,9402690,AUC,"However, patients receiving tacrolimus and MMF displayed significantly higher levels (Cmin and area under the curve) of mycophenolic acid (MPA) than those receiving CsA (Sandimmune or Neoral) and the same dose of MMF (50.2 +/- 16.5 vs 32.1 +/- 16.7 micrograms h/ml AUC, p < 0.02).","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],32.1,105171,DB00688,Mycophenolate mofetil
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],755,105172,DB00688,Mycophenolate mofetil
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],1230,105173,DB00688,Mycophenolate mofetil
,9402690,AUC,"There were also significantly lower levels of the glucuronide metabolite of MPA (MPAG) (755 +/- 280 vs 1230 +/- 250 micrograms h/ml AUC, p = 0.02), suggesting a specific inhibition (either direct or indirect) of the conversion of MPA to MPAG in tacrolimus patients, as opposed to those receiving CsA.","Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[h·μg] / [ml],250,105174,DB00688,Mycophenolate mofetil
,9402690,trough concentrations,Culture media containing MPA and tacrolimus equal to clinical therapeutic trough concentrations (10 ng/ml) were significantly more MLC inhibitory than CsA at equivalent clinical therapeutic trough concentrations (200 ng/ml) with equivalent MPA levels.,"Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[ng] / [ml],10,105175,DB00688,Mycophenolate mofetil
,9402690,trough concentrations,Culture media containing MPA and tacrolimus equal to clinical therapeutic trough concentrations (10 ng/ml) were significantly more MLC inhibitory than CsA at equivalent clinical therapeutic trough concentrations (200 ng/ml) with equivalent MPA levels.,"Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9402690/),[ng] / [ml],200,105176,DB00688,Mycophenolate mofetil
<,18758392,AUC0-12,"Presuming a therapeutic window of 30-60 mg h/L, 15 (60%) of 25 patients at day 7 had an MPA-AUC0-12 <30 mg h/L, indicating potential underexposure, whereas the proportion of patients with an MPA-AUC0-12 <30 mg h/L between months 3 and 36 was low (5%-17%).",Long-term pharmacokinetics of mycophenolic acid in pediatric renal transplant recipients over 3 years posttransplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18758392/),[h·mg] / [l],30,106622,DB00688,Mycophenolate mofetil
,22595383,AUC,Median MPA AUC was constantly within the therapeutic window of 30 - 60 mg/l × h throughout the three months of evaluation.,Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595383/),[mg] / [h·l],30 - 60,107762,DB00688,Mycophenolate mofetil
above,22595383,AUC,More than 75% of patients had a MPA AUC above 30 mg/l × h at Day 2 and Day 7 post-transplant.,Mycophenolate sodium dosing in combination with tacrolimus: pharmacokinetic evaluation of a novel regimen in de novo tacrolimus-treated kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22595383/),[mg] / [h·l],30,107763,DB00688,Mycophenolate mofetil
,30229398,clearance,The mean estimated total body MPA clearance of the elderly recipients was not significantly different from that of the controls at any analyzed time point (the mean clearance across all time points was 0.31 ± 0.17 vs 0.30 ± 0.25 L/h/kg).,Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[l] / [h·kg],0.31,107867,DB00688,Mycophenolate mofetil
,30229398,clearance,The mean estimated total body MPA clearance of the elderly recipients was not significantly different from that of the controls at any analyzed time point (the mean clearance across all time points was 0.31 ± 0.17 vs 0.30 ± 0.25 L/h/kg).,Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[l] / [h·kg],0.30,107868,DB00688,Mycophenolate mofetil
,30229398,exposure,"MPA exposure, as evaluated from the area under the 12-h time versus measured MPA concentration (adjusted for dose/body weight) curve, did not differ between the groups at any time point (mean exposure across all time points was 4.68 ± 3.61 vs 5.95 ± 4.29 µg·h/mL per mg/kg for the elderly recipients and the controls).",Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[h·μg] / [kg·mg·ml],4.68,107869,DB00688,Mycophenolate mofetil
,30229398,exposure,"MPA exposure, as evaluated from the area under the 12-h time versus measured MPA concentration (adjusted for dose/body weight) curve, did not differ between the groups at any time point (mean exposure across all time points was 4.68 ± 3.61 vs 5.95 ± 4.29 µg·h/mL per mg/kg for the elderly recipients and the controls).",Longitudinal Pharmacokinetics of Mycophenolic Acid in Elderly Renal Transplant Recipients Compared to a Younger Control Group: Data from the nEverOld Trial. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30229398/),[h·μg] / [kg·mg·ml],5.95,107870,DB00688,Mycophenolate mofetil
,32387086,CL/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),[l] / [h],12.4,108066,DB00688,Mycophenolate mofetil
,32387086,Q/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),l,45.6,108067,DB00688,Mycophenolate mofetil
,32387086,V2/F,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),l,45.6,108068,DB00688,Mycophenolate mofetil
,32387086,Ka,"MPA CL/F, V1/F, Q/F, V2/F, and Ka were 12.4 L/h, 45.6 L, 29.9 L/h, 658 L, and 1.67 h-1, respectively.",Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32387086/),1/[h],1.67,108069,DB00688,Mycophenolate mofetil
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.056,108525,DB00688,Mycophenolate mofetil
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.080,108526,DB00688,Mycophenolate mofetil
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.053,108527,DB00688,Mycophenolate mofetil
,23444283,AUC*,"Significant R × D was identified for MPA AUC* for EC-MPS (AA, 0.056 ± 0.029 [mg·h/L]/mg; C, 0.080 ± 0.044 [mg·h/L]/mg) compared with MMF (AA, 0.053 ± 0.019 [mg·h/L]/mg; C, 0.060 ± 0.025 [mg·h/L]/mg), P = .022.",Race and drug formulation influence on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23444283/),[h·mg] / [l],0.060,108528,DB00688,Mycophenolate mofetil
,15871638,area under the plasma concentration-time curve,"In the 35 post-dose curves analysed, no differences were found in MPA levels between days 7, 28, 120 and 150: area under the plasma concentration-time curve - mean value 15.3 mg .","Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871638/),mg,15.3,110139,DB00688,Mycophenolate mofetil
,15871638,minimum plasma concentration,"h/L; minimum plasma concentration - mean value 0.60 mg/L, range 0.20-4.67 mg/L; maximum plasma concentration mean value 2.60 mg/L, range 0.94-7.98 mg/L. Pretreatment patients' sera did not inhibit CEM proliferation.","Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. ",Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871638/),[mg] / [l],0.60,110140,DB00688,Mycophenolate mofetil
,15871638,maximum plasma concentration,"h/L; minimum plasma concentration - mean value 0.60 mg/L, range 0.20-4.67 mg/L; maximum plasma concentration mean value 2.60 mg/L, range 0.94-7.98 mg/L. Pretreatment patients' sera did not inhibit CEM proliferation.","Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871638/),[mg] / [l],2.60,110141,DB00688,Mycophenolate mofetil
,15871638,maximum drug effect (EC(50)),The MPA level versus CEM proliferation inhibition had a concentration that produces 50% of the maximum drug effect (EC(50)) of 0.33 mg/L.,"Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15871638/),[mg] / [l],0.33,110142,DB00688,Mycophenolate mofetil
,24509827,AUC(0-12) h,"Mean MPA AUC(0-12) h did not differ significantly under MMF and EC-MPS, ie, 40.13±14 and 38.24±15.5 mg*h/L, respectively.",Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24509827/),[h·mg] / [l],40.13,110492,DB00688,Mycophenolate mofetil
,24509827,AUC(0-12) h,"Mean MPA AUC(0-12) h did not differ significantly under MMF and EC-MPS, ie, 40.13±14 and 38.24±15.5 mg*h/L, respectively.",Comparison of the exposure of mycophenolate mofetil and enteric-coated mycophenolate sodium in recipients of kidney-pancreas transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24509827/),[h·mg] / [l],38.24,110493,DB00688,Mycophenolate mofetil
,15848555,C0,Predose levels (C0) increased significantly during the first 6 months after transplantation: C0 at 6 and 180 days after transplantation was 0.8 +/- 0.6 and 1.9 +/- 1.1 microg/mL (P < .0001).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[μg] / [ml],0.8,111154,DB00688,Mycophenolate mofetil
,15848555,C0,Predose levels (C0) increased significantly during the first 6 months after transplantation: C0 at 6 and 180 days after transplantation was 0.8 +/- 0.6 and 1.9 +/- 1.1 microg/mL (P < .0001).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[μg] / [ml],1.9,111155,DB00688,Mycophenolate mofetil
,15848555,AUC(0-12),A significant time-dependent increase in the AUC of MPA was also observed during the first 6 posttransplant months: AUC(0-12) at 6 and 180 days after transplantation was 23.3 +/- 10.8 and 40 +/- 11.6 mg*h/L (P = .003).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[h·mg] / [l],23.3,111156,DB00688,Mycophenolate mofetil
,15848555,AUC(0-12),A significant time-dependent increase in the AUC of MPA was also observed during the first 6 posttransplant months: AUC(0-12) at 6 and 180 days after transplantation was 23.3 +/- 10.8 and 40 +/- 11.6 mg*h/L (P = .003).,Mycophenolate mofetil pharmacokinetic monitoring in pediatric kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848555/),[h·mg] / [l],40,111157,DB00688,Mycophenolate mofetil
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],45.97,111701,DB00688,Mycophenolate mofetil
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],39.23,111702,DB00688,Mycophenolate mofetil
,32824803,activity,"Mean IMPDH activity in volunteers was 45.97 ± 6.24 µmoL·s-1·moL-1 AMP, whereas for children, the values were variable and amounted to 39.23 ± 27.40 µmoL·s-1·moL-1 AMP and 17.97 ± 15.24 µmoL·s-1·moL-1 AMP before the next MMF dose and 1 h afterward, respectively.",The Application of Inosine 5'-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32824803/),[μM] / [mol·s],17.97,111703,DB00688,Mycophenolate mofetil
,19318398,AUC(0-4h),"Mean MPA AUC(0-4h) was 28.4 +/- 13.6 mg h/L, mean dose-normalised AUC(0-4h) was 35.5 +/- 13.8 mg h/L and mean MPA C(0) was 3.1 +/- 2.2 mg/L.",Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19318398/),[h·mg] / [l],28.4,111746,DB00688,Mycophenolate mofetil
,19318398,dose-normalised AUC(0-4h),"Mean MPA AUC(0-4h) was 28.4 +/- 13.6 mg h/L, mean dose-normalised AUC(0-4h) was 35.5 +/- 13.8 mg h/L and mean MPA C(0) was 3.1 +/- 2.2 mg/L.",Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19318398/),[h·mg] / [l],35.5,111747,DB00688,Mycophenolate mofetil
,19318398,C(0),"Mean MPA AUC(0-4h) was 28.4 +/- 13.6 mg h/L, mean dose-normalised AUC(0-4h) was 35.5 +/- 13.8 mg h/L and mean MPA C(0) was 3.1 +/- 2.2 mg/L.",Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19318398/),[mg] / [l],3.1,111748,DB00688,Mycophenolate mofetil
,30610275,detection limit,"The liquid chromatography coupled to mass spectrometry (LC-MS) method was developed and validated for determining mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) in oral fluid and plasma, with both matrices presenting a detection limit of 1 ng/mL for MPA and 5 ng/mL for MPAG.",Comparison of plasma and oral fluid concentrations of mycophenolic acid and its glucuronide metabolite by LC-MS in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610275/),[ng] / [ml],1,112563,DB00688,Mycophenolate mofetil
,30610275,detection limit,"The liquid chromatography coupled to mass spectrometry (LC-MS) method was developed and validated for determining mycophenolic acid (MPA) and its glucuronide metabolite (MPAG) in oral fluid and plasma, with both matrices presenting a detection limit of 1 ng/mL for MPA and 5 ng/mL for MPAG.",Comparison of plasma and oral fluid concentrations of mycophenolic acid and its glucuronide metabolite by LC-MS in kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30610275/),[ng] / [ml],5,112564,DB00688,Mycophenolate mofetil
,18164890,flow rate of the mobile phase,"The flow rate of the mobile phase was 1ml/min, and the wavelength of determination by UV detection was 250 nm (run time, 16 min).",Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164890/),[ml] / [min],1,112680,DB00688,Mycophenolate mofetil
,18164890,run time,"The flow rate of the mobile phase was 1ml/min, and the wavelength of determination by UV detection was 250 nm (run time, 16 min).",Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164890/),min,16,112681,DB00688,Mycophenolate mofetil
more,18164890,Extraction efficiencies,Extraction efficiencies were more than 85% for all analytes.,Simultaneous determination of mycophenolic acid and its glucuronides in human plasma using isocratic ion pair high-performance liquid chromatography. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18164890/),%,85,112682,DB00688,Mycophenolate mofetil
,26915840,BW,"The mean ± standard deviation MMF dose, MPA AUC, and BW of all patients were 581 ± 207 mg/d, 36.2 ± 18.7 μg·h/mL, and 56.3 ± 11.1 kg, respectively.",Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26915840/),kg,56.3,113206,DB00688,Mycophenolate mofetil
,26915840,AUC,The rate of MPA AUC between 30 and 60 μg·h/mL with the MMF dose:BW ratio of 10-16 mg/kg was 73.7%.,Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26915840/),[h·μg] / [ml],30 and 60,113207,DB00688,Mycophenolate mofetil
,26915840,dose:BW ratio,The MMF dose:BW ratio of 10-16 mg/kg could predict MPA AUC between 30 and 60 μg·h/mL with a probability of approximately 75%.,Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26915840/),[mg] / [kg],10-16,113208,DB00688,Mycophenolate mofetil
,26915840,AUC,The MMF dose:BW ratio of 10-16 mg/kg could predict MPA AUC between 30 and 60 μg·h/mL with a probability of approximately 75%.,Implications of Clinical Mycophenolate Mofetil Dose According to Individual Body Weight in Japanese Renal Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26915840/),[h·μg] / [ml],30 and 60,113209,DB00688,Mycophenolate mofetil
<,9231509,steady state AUC0-12 h plasma levels,"To date, all available data are assessed and more particularly:--the doses of 1 or 1.5 g administered twice daily,--a pilot, open-label multicentre study which showed a decreased incidence of acute rejection episodes in patients with steady state AUC0-12 h plasma levels < 40 micrograms.","[Mycophenolate mofetil, a new immunosuppressive agent. Is pharmacokinetic monitoring justified?]. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9231509/),μg,40,113229,DB00688,Mycophenolate mofetil
,20155737,CL/F,Fast metabolizers (expressers) had a CL/F of 28.3 l/h whilst slow metabolizers (non-expressers) had a CL/F of 14.1 l/h.,Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20155737/),[l] / [h],28.3,113366,DB00688,Mycophenolate mofetil
,20155737,CL/F,Fast metabolizers (expressers) had a CL/F of 28.3 l/h whilst slow metabolizers (non-expressers) had a CL/F of 14.1 l/h.,Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20155737/),[l] / [h],14.1,113367,DB00688,Mycophenolate mofetil
,20155737,trough,"Here, in simulation, a standard 10 mg QD SRL was contrasted with a higher frequency of 5 mg BID SRL as related to the proportion of next dosed patients being within the 15-30 ng/ml trough levels on day 7 after transplantation.",Simulation of sirolimus exposures and population variability immediately post renal transplantation: importance of the patient's CYP3A5 genotype in tailoring treatment. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20155737/),ng,15-30,113368,DB00688,Mycophenolate mofetil
,22624503,area under the blood concentration-time curve from time zero to 12 hours (AUC(12)),Everolimus blood concentrations were analysed in whole blood using liquid chromatography-tandem mass spectrometry during routine therapeutic drug monitoring targeting an area under the blood concentration-time curve from time zero to 12 hours (AUC(12)) of 120 μg · h/L.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114932,DB00688,Mycophenolate mofetil
,22624503,AUC(12),Maintaining everolimus systemic exposure at an AUC(12) of 120 μg · h/L resulted in low rejection rates but considerable numbers of adverse events and toxicity.,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[h·μg] / [l],120,114933,DB00688,Mycophenolate mofetil
,22624503,oral clearance,Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),[l] / [h],17.9,114934,DB00688,Mycophenolate mofetil
,22624503,volume of distribution of the central compartment after oral administration [V(1)/F],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),l,148,114935,DB00688,Mycophenolate mofetil
,22624503,first-order absorption rate constant [k(a)],Everolimus pharmacokinetics were best described by a two-compartment model with lag-time (oral clearance = 17.9 L/h; volume of distribution of the central compartment after oral administration [V(1)/F] = 148 L and first-order absorption rate constant [k(a)] = 7.36 h-1).,Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22624503/),1/[h],7.36,114936,DB00688,Mycophenolate mofetil
,15987748,Cockcroft calculated clearance,Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 +/- 18.7 versus 56.5 +/- 18.0 ml/min; P = 0.023).,"Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[ml] / [min],64.7,114965,DB00688,Mycophenolate mofetil
,15987748,Cockcroft calculated clearance,Renal function was improved in the MMF group compared with the CsA group (Cockcroft calculated clearance 64.7 +/- 18.7 versus 56.5 +/- 18.0 ml/min; P = 0.023).,"Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[ml] / [min],56.5,114966,DB00688,Mycophenolate mofetil
,15987748,area under the curve,"The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P = 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 +/- 9 versus 58 +/- 22 mg/h per L; P = 0.045).","Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[mg] / [h·l],43,114967,DB00688,Mycophenolate mofetil
,15987748,area under the curve,"The 10 patients who developed acute rejection after CsA withdrawal had a significantly higher incidence of borderline changes on the randomization biopsy than the 44 rejection-free patients (five of 10 versus eight of 44; P = 0.034), and they displayed a lower area under the curve of mycophenolic acid (43 +/- 9 versus 58 +/- 22 mg/h per L; P = 0.045).","Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15987748/),[mg] / [h·l],58,114968,DB00688,Mycophenolate mofetil
,17529894,apparent oral MPA clearance (CL/F),"Median apparent oral MPA clearance (CL/F), apparent half-life, and total MPA area under the curve for hours 0 to 12 (AUC0-12, normalized to 1000 mg MMF) were, respectively, 56 L/h (range: 29-98 L/h), 2.3 hours (range: 0.8-5.7 hours), and 18.0 mg*h/L (range: 10-35 mg*h/L).",Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529894/),[l] / [h],56,116327,DB00688,Mycophenolate mofetil
,17529894,apparent half-life,"Median apparent oral MPA clearance (CL/F), apparent half-life, and total MPA area under the curve for hours 0 to 12 (AUC0-12, normalized to 1000 mg MMF) were, respectively, 56 L/h (range: 29-98 L/h), 2.3 hours (range: 0.8-5.7 hours), and 18.0 mg*h/L (range: 10-35 mg*h/L).",Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529894/),h,2.3,116328,DB00688,Mycophenolate mofetil
,17529894,total MPA area under the curve for hours 0 to 12 (AUC0-12,"Median apparent oral MPA clearance (CL/F), apparent half-life, and total MPA area under the curve for hours 0 to 12 (AUC0-12, normalized to 1000 mg MMF) were, respectively, 56 L/h (range: 29-98 L/h), 2.3 hours (range: 0.8-5.7 hours), and 18.0 mg*h/L (range: 10-35 mg*h/L).",Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529894/),[h·mg] / [l],18.0,116329,DB00688,Mycophenolate mofetil
,17529894,AUC0-12,Median free MPA AUC0-12 (normalized to 1000 mg MMF) was 224 microg*h/L (range: 56-411 microg*h/L).,Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529894/),[h·μg] / [l],224,116330,DB00688,Mycophenolate mofetil
,15866686,S-Crea,"The study included 13 adolescents (mean posttransplantation time, 3.5 +/- 2.55 years) with stable renal transplant function (S-Crea 121 +/- 40 micromol/L).",Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866686/),μ,121,116558,DB00688,Mycophenolate mofetil
,15866686,C2,"Whereas C2 (mean 743.2 +/- 221.8 ng/mL) was the single point with the closest correlation to AUC(0-6h) (r2 = 0.86; P < .001), C0 (mean 120.5 +/- 35.2 ng/mL) showed the weakest correlation (r2 = 0.61, P = .002).",Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866686/),[ng] / [ml],743.2,116559,DB00688,Mycophenolate mofetil
,15866686,C0,"Whereas C2 (mean 743.2 +/- 221.8 ng/mL) was the single point with the closest correlation to AUC(0-6h) (r2 = 0.86; P < .001), C0 (mean 120.5 +/- 35.2 ng/mL) showed the weakest correlation (r2 = 0.61, P = .002).",Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15866686/),[ng] / [ml],120.5,116560,DB00688,Mycophenolate mofetil
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],95,117546,DB00688,Mycophenolate mofetil
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],98,117547,DB00688,Mycophenolate mofetil
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],99,117548,DB00688,Mycophenolate mofetil
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],88,117549,DB00688,Mycophenolate mofetil
,17529886,area under the plasma concentration-time curve from zero to 12 hours (AUC0-12),"The mean dose-adjusted area under the plasma concentration-time curve from zero to 12 hours (AUC0-12) of MPA in UGT1A7*1/*1, *1/*2, *1/*3, *2/*3, and *3/*3 were 95, 98, 99, 88, and 86 ng.h/mL/mg, respectively (P = 0.9475).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],86,117550,DB00688,Mycophenolate mofetil
,17529886,AUC0-12,"The mean dose-adjusted AUC0-12 of MPA in UGT1A9 I399C/C, C/T, and T/T were 87, 99, and 95 ng.h/mL/mg, respectively (P = 0.6937).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],87,117551,DB00688,Mycophenolate mofetil
,17529886,AUC0-12,"The mean dose-adjusted AUC0-12 of MPA in UGT1A9 I399C/C, C/T, and T/T were 87, 99, and 95 ng.h/mL/mg, respectively (P = 0.6937).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],99,117552,DB00688,Mycophenolate mofetil
,17529886,AUC0-12,"The mean dose-adjusted AUC0-12 of MPA in UGT1A9 I399C/C, C/T, and T/T were 87, 99, and 95 ng.h/mL/mg, respectively (P = 0.6937).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[h·ng] / [mg·ml],95,117553,DB00688,Mycophenolate mofetil
,17529886,trough levels,"The dose-adjusted trough levels of MPA in UGT1A9 I399C/C, C/T, and T/T were 5.4, 5.5, and 4.7 ng/mL/mg (P = 0.5845).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[ng] / [mg·ml],5.4,117554,DB00688,Mycophenolate mofetil
,17529886,trough levels,"The dose-adjusted trough levels of MPA in UGT1A9 I399C/C, C/T, and T/T were 5.4, 5.5, and 4.7 ng/mL/mg (P = 0.5845).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[ng] / [mg·ml],5.5,117555,DB00688,Mycophenolate mofetil
,17529886,trough levels,"The dose-adjusted trough levels of MPA in UGT1A9 I399C/C, C/T, and T/T were 5.4, 5.5, and 4.7 ng/mL/mg (P = 0.5845).",Influence of UGT1A7 and UGT1A9 intronic I399 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17529886/),[ng] / [mg·ml],4.7,117556,DB00688,Mycophenolate mofetil
,27686146,apparent clearance,"Both MPA and MPAG apparent clearance values were significantly elevated (>65%) in patients with CF (24.1 and 1.95 L/h, respectively) compared to the values in the NCF patients (14.5 and 1.12 L/h, respectively), suggesting a notable influence of CF on MPA absorption and disposition.",Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686146/),[l] / [h],24.1,117789,DB00688,Mycophenolate mofetil
,27686146,apparent clearance,"Both MPA and MPAG apparent clearance values were significantly elevated (>65%) in patients with CF (24.1 and 1.95 L/h, respectively) compared to the values in the NCF patients (14.5 and 1.12 L/h, respectively), suggesting a notable influence of CF on MPA absorption and disposition.",Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686146/),[l] / [h],1.95,117790,DB00688,Mycophenolate mofetil
,27686146,apparent clearance,"Both MPA and MPAG apparent clearance values were significantly elevated (>65%) in patients with CF (24.1 and 1.95 L/h, respectively) compared to the values in the NCF patients (14.5 and 1.12 L/h, respectively), suggesting a notable influence of CF on MPA absorption and disposition.",Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686146/),[l] / [h],14.5,117791,DB00688,Mycophenolate mofetil
,27686146,apparent clearance,"Both MPA and MPAG apparent clearance values were significantly elevated (>65%) in patients with CF (24.1 and 1.95 L/h, respectively) compared to the values in the NCF patients (14.5 and 1.12 L/h, respectively), suggesting a notable influence of CF on MPA absorption and disposition.",Population pharmacokinetics of mycophenolic acid and its glucuronide metabolite in lung transplant recipients with and without cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27686146/),[l] / [h],1.12,117792,DB00688,Mycophenolate mofetil
,10935703,trough concentration,"The mean Mycophenolic acid (MPA) trough concentration was 4.0 +/- 2.0 microg/ml, range 1.4-7.9 microg/ml.",Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935703/),[μg] / [ml],4.0,117816,DB00688,Mycophenolate mofetil
,10935703,AUC,Mean 12 h MPA AUC was 70.6 +/- 28.1 (range 31.9-127) microg x h/ml.,Effect of adding Mycophenolate mofetil in paediatric renal transplant recipients with chronical cyclosporine nephrotoxicity. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10935703/),[h·μg] / [ml],70.6,117817,DB00688,Mycophenolate mofetil
,12962871,Cmax,A Cmax (30.5+/-13.8 ng/mL) was reached at 2.3+/-1.5 h.,Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],30.5,118331,DB00688,Mycophenolate mofetil
,12962871,trough levels,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[ng] / [ml],10-20,118332,DB00688,Mycophenolate mofetil
,12962871,exposure,"When target trough levels were achieved (10-20 ng/mL), the mean tacrolimus exposure was 230.6+/-59.2 ng h/mL (120.14-327.7) (n=19).",Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12962871/),[h·ng] / [ml],230.6,118333,DB00688,Mycophenolate mofetil
,18084333,AUC,"Using a twice daily MMF regimen, we conclude that an AUC of 30-60 mug/ml h as recommended for SOT cannot be reached in HSCT.",Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18084333/),[μg] / [h·ml],30-60,118647,DB00688,Mycophenolate mofetil
higher,22552204,recoveries,The recoveries for MPA and MPAG from the collection device's swab were higher than 90%.,Liquid chromatography-tandem mass spectrometry method for the quantification of mycophenolic acid and its phenolic glucuronide in saliva and plasma using a standardized saliva collection device. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22552204/),%,90,118683,DB00688,Mycophenolate mofetil
,16198654,area under concentration-time curve [AUC] from 0 to 12 hours,"Only in patients taking 2 g mycophenolate mofetil daily was a decreased MPA exposure observed in those who carried either the T-275 A or the C-2152 T polymorphism (or both) compared with those who did not (area under concentration-time curve [AUC] from 0 to 12 hours, 31.7+/--17.6 mg.h/L versus 63.6+/--30.9 mg.h/L [P=.009]; predose trough plasma concentration, 1.23 +/--.25 mg/L versus 2.84+/--1.64 mg/L [P=.04]).",The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198654/),[h·mg] / [l],31.7,118822,DB00688,Mycophenolate mofetil
,16198654,area under concentration-time curve [AUC] from 0 to 12 hours,"Only in patients taking 2 g mycophenolate mofetil daily was a decreased MPA exposure observed in those who carried either the T-275 A or the C-2152 T polymorphism (or both) compared with those who did not (area under concentration-time curve [AUC] from 0 to 12 hours, 31.7+/--17.6 mg.h/L versus 63.6+/--30.9 mg.h/L [P=.009]; predose trough plasma concentration, 1.23 +/--.25 mg/L versus 2.84+/--1.64 mg/L [P=.04]).",The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198654/),[h·mg] / [l],63.6,118823,DB00688,Mycophenolate mofetil
,16198654,trough plasma concentration,"Only in patients taking 2 g mycophenolate mofetil daily was a decreased MPA exposure observed in those who carried either the T-275 A or the C-2152 T polymorphism (or both) compared with those who did not (area under concentration-time curve [AUC] from 0 to 12 hours, 31.7+/--17.6 mg.h/L versus 63.6+/--30.9 mg.h/L [P=.009]; predose trough plasma concentration, 1.23 +/--.25 mg/L versus 2.84+/--1.64 mg/L [P=.04]).",The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198654/),[mg] / [l],1.23,118824,DB00688,Mycophenolate mofetil
,16198654,trough plasma concentration,"Only in patients taking 2 g mycophenolate mofetil daily was a decreased MPA exposure observed in those who carried either the T-275 A or the C-2152 T polymorphism (or both) compared with those who did not (area under concentration-time curve [AUC] from 0 to 12 hours, 31.7+/--17.6 mg.h/L versus 63.6+/--30.9 mg.h/L [P=.009]; predose trough plasma concentration, 1.23 +/--.25 mg/L versus 2.84+/--1.64 mg/L [P=.04]).",The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198654/),[mg] / [l],2.84,118825,DB00688,Mycophenolate mofetil
,16198654,AUC6--12,"The partial MPA AUC from 6 to 12 hours (AUC6--12)-an estimate of MPA enterohepatic recirculation-and the ratio between partial MPA AUC6--12 and dose-interval AUC from 0 to 12 hours decreased when either or both UGT1A9 promoter region SNPs were present (AUC6--12, 6.2+/-5.4 mg.h/L versus 21.5+/-14.9 mg.h/L [P=.002]; ratio, 18.4%+/- 7.8% versus 31.7%+/- 8.8% [P=.002]).",The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198654/),[h·mg] / [l],6.2,118826,DB00688,Mycophenolate mofetil
,16198654,AUC6--12,"The partial MPA AUC from 6 to 12 hours (AUC6--12)-an estimate of MPA enterohepatic recirculation-and the ratio between partial MPA AUC6--12 and dose-interval AUC from 0 to 12 hours decreased when either or both UGT1A9 promoter region SNPs were present (AUC6--12, 6.2+/-5.4 mg.h/L versus 21.5+/-14.9 mg.h/L [P=.002]; ratio, 18.4%+/- 7.8% versus 31.7%+/- 8.8% [P=.002]).",The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16198654/),[h·mg] / [l],21.5,118827,DB00688,Mycophenolate mofetil
,22174435,total systemic clearance,"The mean estimated values (coefficient of variation, %) for total systemic clearance, distributional clearance, and central and peripheral compartment volumes of MPA were 36.9 L/h (34.5%), 15.3 L/h (80.4%), 11.9 L (71.7%), and 182 L (127%), respectively.",A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22174435/),[l] / [h],36.9,119615,DB00688,Mycophenolate mofetil
,22174435,distributional clearance,"The mean estimated values (coefficient of variation, %) for total systemic clearance, distributional clearance, and central and peripheral compartment volumes of MPA were 36.9 L/h (34.5%), 15.3 L/h (80.4%), 11.9 L (71.7%), and 182 L (127%), respectively.",A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22174435/),[l] / [h],15.3,119616,DB00688,Mycophenolate mofetil
,22174435,distributional clearance,"The mean estimated values (coefficient of variation, %) for total systemic clearance, distributional clearance, and central and peripheral compartment volumes of MPA were 36.9 L/h (34.5%), 15.3 L/h (80.4%), 11.9 L (71.7%), and 182 L (127%), respectively.",A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22174435/),l,11.9,119617,DB00688,Mycophenolate mofetil
,22174435,central,"The mean estimated values (coefficient of variation, %) for total systemic clearance, distributional clearance, and central and peripheral compartment volumes of MPA were 36.9 L/h (34.5%), 15.3 L/h (80.4%), 11.9 L (71.7%), and 182 L (127%), respectively.",A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22174435/),[l] / [h],15.3,119618,DB00688,Mycophenolate mofetil
,22174435,peripheral compartment volumes,"The mean estimated values (coefficient of variation, %) for total systemic clearance, distributional clearance, and central and peripheral compartment volumes of MPA were 36.9 L/h (34.5%), 15.3 L/h (80.4%), 11.9 L (71.7%), and 182 L (127%), respectively.",A limited sampling schedule to estimate mycophenolic Acid area under the concentration-time curve in hematopoietic cell transplantation recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22174435/),l,182,119619,DB00688,Mycophenolate mofetil
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],55.1,120123,DB00688,Mycophenolate mofetil
,12021639,area under the concentration-time curve (AUC),"The 12-hour area under the concentration-time curve (AUC) values for MPA and its major metabolite the phenolic glucuronide MPAG were 55.1 mg.h/L and 800 mg.h/L, respectively.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],800,120124,DB00688,Mycophenolate mofetil
,12021639,12-h,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120125,DB00688,Mycophenolate mofetil
,12021639,AUC,"An unusually high concentration (12-h AUC, 165 mg.h/L) of the phenolic glucose conjugate of MPA was found.",Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[h·mg] / [l],165,120126,DB00688,Mycophenolate mofetil
,12021639,apparent renal clearance,The apparent renal clearance of MPAG was only 2.2 mL/min.,Atypical pharmacokinetics and metabolism of mycophenolic acid in a young kidney transplant recipient with impaired renal function. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021639/),[ml] / [min],2.2,120127,DB00688,Mycophenolate mofetil
,26919549,concentrations,"In TAC (STN → MPS) group, dose-adjusted TAC concentrations decreased from baseline to first week (2.3 ± 1.1 versus 1.5 ± 1.0 ng·mL·mg, P < 0.05).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),,1.5,121430,DB00688,Mycophenolate mofetil
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,3.,121431,DB00688,Mycophenolate mofetil
,26919549,concentrations,"In EVR (STN → TAC) group, dose-adjusted EVR concentrations decreased from baseline to first week (3.6 ± 2.3 ng·mL·mg versus 1.9 ± 0.8 ng·mL·mg, P < 0.01).",Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26919549/),mg·ml·ng,1.9,121432,DB00688,Mycophenolate mofetil
,19274604,V(max),"V(max) and K(m) values of MMF hydrolysis in pooled human liver microsomes were 1368 +/- 44 nmol min(-1) mg(-1) protein and 1030 +/- 65 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),[nM] / [mg·min],1368,121494,DB00688,Mycophenolate mofetil
,19274604,K(m),"V(max) and K(m) values of MMF hydrolysis in pooled human liver microsomes were 1368 +/- 44 nmol min(-1) mg(-1) protein and 1030 +/- 65 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,1030,121495,DB00688,Mycophenolate mofetil
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,77.1,121496,DB00688,Mycophenolate mofetil
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,3.59,121497,DB00688,Mycophenolate mofetil
,19274604,IC(50),"Hydrolytic activity was inhibited by the CES inhibitors phenylmethylsulfonylfluoride, bis-p-nitorophenylphosphate and diisopropylfluorophosphate, with IC(50) values of 77.1, 3.59 and 0.0312 microM, respectively.",Influence of carboxylesterase 2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19274604/),μM,0.0312,121498,DB00688,Mycophenolate mofetil
,27060685,plasma protein binding,The plasma protein binding of MPA was significantly higher in males compared to females in both pediatric (98.3 ± 1.1% vs 97.4 ± 1.1%) and adult (98.1 ± 0.7% vs 97.4 ± 1.2%) patients (P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),%,98.3,121774,DB00688,Mycophenolate mofetil
,27060685,plasma protein binding,The plasma protein binding of MPA was significantly higher in males compared to females in both pediatric (98.3 ± 1.1% vs 97.4 ± 1.1%) and adult (98.1 ± 0.7% vs 97.4 ± 1.2%) patients (P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),%,97.4,121775,DB00688,Mycophenolate mofetil
,27060685,plasma protein binding,The plasma protein binding of MPA was significantly higher in males compared to females in both pediatric (98.3 ± 1.1% vs 97.4 ± 1.1%) and adult (98.1 ± 0.7% vs 97.4 ± 1.2%) patients (P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),%,98.1,121776,DB00688,Mycophenolate mofetil
,27060685,plasma protein binding,The plasma protein binding of MPA was significantly higher in males compared to females in both pediatric (98.3 ± 1.1% vs 97.4 ± 1.1%) and adult (98.1 ± 0.7% vs 97.4 ± 1.2%) patients (P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),%,97.4,121777,DB00688,Mycophenolate mofetil
,27060685,/,The MPAG/MPA ratios on a milligram-per-kilogram dose basis in adult patients were significantly higher than those in pediatric patients (4.3 ± 3.4 vs 2.4 ± 2.6; P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),,4.3,121778,DB00688,Mycophenolate mofetil
,27060685,/,The MPAG/MPA ratios on a milligram-per-kilogram dose basis in adult patients were significantly higher than those in pediatric patients (4.3 ± 3.4 vs 2.4 ± 2.6; P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),,2.4,121779,DB00688,Mycophenolate mofetil
,27060685,ratios,The MPAG/MPA ratios on a milligram-per-kilogram dose basis in adult patients were significantly higher than those in pediatric patients (4.3 ± 3.4 vs 2.4 ± 2.6; P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),,4.3,121780,DB00688,Mycophenolate mofetil
,27060685,ratios,The MPAG/MPA ratios on a milligram-per-kilogram dose basis in adult patients were significantly higher than those in pediatric patients (4.3 ± 3.4 vs 2.4 ± 2.6; P < .05).,Pharmacokinetic Variability of Mycophenolic Acid in Pediatric and Adult Patients With Hematopoietic Stem Cell Transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27060685/),,2.4,121781,DB00688,Mycophenolate mofetil
,10579476,AUC(0-12),"The mean +/- SE AUC(0-12) for mycophenolic acid on day 28 was 38.5 +/- 1.6 mg x h/L, with a secondary peak 4 to 8 hours after dosing that was attributable to enterohepatic recirculation.",The kinetics of mycophenolic acid and its glucuronide metabolite in adult kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10579476/),[h·mg] / [l],38.5,121875,DB00688,Mycophenolate mofetil
,25249327,AUC0-12h,"After standard induction therapy with MMF, MMF was titrated to achieve a stable target of MPA-AUC0-12h of 45-60 mg.h/l during the maintenance treatment.",Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25249327/),[h·mg] / [l],45-60,122533,DB00688,Mycophenolate mofetil
,25249327,AUC0-12h,"The mean MPA-AUC0-12h of MMF at the last visit [56.74 (±2.9) mg.h/l] was significantly lower than MPA-AUC0-12h at baseline [98.7 (±24.6) mg.h/l] (p = 0.009), since the dose of MMF was significantly reduced in all the patients [from 2.8 g/day (±0.4) to 1.9 g/day (±0.4) (p = 0.018)] based on the target MPA-AUC.",Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25249327/),[h·mg] / [l],56.74,122534,DB00688,Mycophenolate mofetil
,25249327,AUC0-12h,"The mean MPA-AUC0-12h of MMF at the last visit [56.74 (±2.9) mg.h/l] was significantly lower than MPA-AUC0-12h at baseline [98.7 (±24.6) mg.h/l] (p = 0.009), since the dose of MMF was significantly reduced in all the patients [from 2.8 g/day (±0.4) to 1.9 g/day (±0.4) (p = 0.018)] based on the target MPA-AUC.",Optimizing the dose of mycophenolate mofetil for the maintenance treatment of lupus nephritis by therapeutic drug monitoring. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25249327/),[h·mg] / [l],98.7,122535,DB00688,Mycophenolate mofetil
,12595508,concentrations,"In AID, mean MPA concentrations at 12 h were significantly higher compared with RTX (4.1 +/- 3.27 versus 1.8 +/- 1.15 mg/L; P = 0.018), whereas peak concentrations were lower (P = 0.017).",Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12595508/),,4.1,123733,DB00688,Mycophenolate mofetil
,12595508,concentrations,"In AID, mean MPA concentrations at 12 h were significantly higher compared with RTX (4.1 +/- 3.27 versus 1.8 +/- 1.15 mg/L; P = 0.018), whereas peak concentrations were lower (P = 0.017).",Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12595508/),,1.8,123734,DB00688,Mycophenolate mofetil
,31425441,AUC0-12,Mean daily dose of MMF was 927 ± 209 mg/m of body surface area resulting in a mean MPA-AUC0-12 value of 59.2 ± 29.3 mg × h/L and a predose level of 3.03 ± 2.24 mg/L.,Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425441/),[h·mg] / [l],59.2,125768,DB00688,Mycophenolate mofetil
,31425441,AUC0-12,Mean daily dose of MMF was 927 ± 209 mg/m of body surface area resulting in a mean MPA-AUC0-12 value of 59.2 ± 29.3 mg × h/L and a predose level of 3.03 ± 2.24 mg/L.,Generation and Validation of a Limited Sampling Strategy to Monitor Mycophenolic Acid Exposure in Children With Nephrotic Syndrome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31425441/),,3,125769,DB00688,Mycophenolate mofetil
,24673713,maximum plasma concentrations (Cmax ),"The mean maximum plasma concentrations (Cmax ) of MPA in the CsA and Tac groups were 11.365 ± 9.522 and 9.748 ± 7.523 μg/ml, respectively (p = 0.137).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[μg] / [ml],11.365,125813,DB00688,Mycophenolate mofetil
,24673713,maximum plasma concentrations (Cmax ),"The mean maximum plasma concentrations (Cmax ) of MPA in the CsA and Tac groups were 11.365 ± 9.522 and 9.748 ± 7.523 μg/ml, respectively (p = 0.137).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[μg] / [ml],9.748,125814,DB00688,Mycophenolate mofetil
,24673713,maximum times to Cmax (Tmax ),"The maximum times to Cmax (Tmax ) were 2.54 ± 1.53 and 2.67 ± 1.08 h, respectively (p = 0.341).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,2.54,125815,DB00688,Mycophenolate mofetil
,24673713,maximum times to Cmax (Tmax ),"The maximum times to Cmax (Tmax ) were 2.54 ± 1.53 and 2.67 ± 1.08 h, respectively (p = 0.341).",Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,2.67,125816,DB00688,Mycophenolate mofetil
,24673713,areas under the curve (MPA-AUC0-12 h ),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[h·μg] / [ml],59.463,125817,DB00688,Mycophenolate mofetil
,24673713,areas under the curve (MPA-AUC0-12 h ),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),[h·μg] / [ml],77.535,125818,DB00688,Mycophenolate mofetil
,24673713,mean residence times (MRT),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,3.71,125819,DB00688,Mycophenolate mofetil
,24673713,mean residence times (MRT),The mean MPA 12-h areas under the curve (MPA-AUC0-12 h ) were 59.463 ± 16.252 and 77.535 ± 33.615 μg h/ml (p = 0.003) and the mean residence times (MRT) were 3.71 ± 0.829 and 3.928 ± 0.923 h (p = 0.038).,Cyclosporine A and tacrolimus combined with enteric-coated mycophenolate sodium influence the plasma mycophenolic acid concentration - a randomised controlled trial in Chinese live related donor kidney transplant recipients. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673713/),h,3.928,125820,DB00688,Mycophenolate mofetil
>,17326777,Cmax,"While only 2 (28.6%) of seven pigs with Cmax > 3 microg/ml during the first 2 weeks had AMR, 7 (87.5%) of eight pigs with Cmax < 3 microg/ml elicited anti-donor Abs and experienced AMR (P = 0.0406).",Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127304,DB00688,Mycophenolate mofetil
<,17326777,Cmax,"While only 2 (28.6%) of seven pigs with Cmax > 3 microg/ml during the first 2 weeks had AMR, 7 (87.5%) of eight pigs with Cmax < 3 microg/ml elicited anti-donor Abs and experienced AMR (P = 0.0406).",Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127305,DB00688,Mycophenolate mofetil
over,17326777,Cmax,Effective Cmax seemed to be over 3 microg/ml at minimum.,Prophylactic treatment of antibody-mediated rejection with high-dose mizoribine and pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17326777/),[μg] / [ml],3,127306,DB00688,Mycophenolate mofetil
,16476117,area under the curve (AUC),"Despite a comparable MMF dose, a large inter-patient variability in both MPA area under the curve (AUC) from 0 to 12 h (range 10.03-135.4 microg h/mL) and in predose concentrations (0.31-6.09 microg/mL) was observed.",Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],10.03-135.4,127533,DB00688,Mycophenolate mofetil
>,16476117,AUC,Patients with AUC > 35 microg h/mL showed better (P < 0.1) renal function than patients with AUC < 20 microg h/mL (mean creatinine concentration 1.48 +/- 0.12 vs. 3.35 +/- 0.4 mg/dL respectively).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],35,127534,DB00688,Mycophenolate mofetil
<,16476117,AUC,Patients with AUC > 35 microg h/mL showed better (P < 0.1) renal function than patients with AUC < 20 microg h/mL (mean creatinine concentration 1.48 +/- 0.12 vs. 3.35 +/- 0.4 mg/dL respectively).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[h·μg] / [ml],20,127535,DB00688,Mycophenolate mofetil
,16476117,trough level,A higher trough level of the metabolite MPA glucuronide (MPAG) in the 1 week after transplantation was found when compared with the 3-month level (mean 150.1 +/- 146.7; range 17.1 to 560 vs. 75.8 +/- 40.0; range 27.3 to 174.2 microg/mL).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[μg] / [ml],150.1,127536,DB00688,Mycophenolate mofetil
,16476117,trough level,A higher trough level of the metabolite MPA glucuronide (MPAG) in the 1 week after transplantation was found when compared with the 3-month level (mean 150.1 +/- 146.7; range 17.1 to 560 vs. 75.8 +/- 40.0; range 27.3 to 174.2 microg/mL).,Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16476117/),[μg] / [ml],75.8,127537,DB00688,Mycophenolate mofetil
,15848556,AUC0-9 level,MPA AUC0-9 level was significantly higher among the AR-negative group (n = 33; 34.2 +/- 16.8 ng.hr/mL) compared with AR-positive group (n = 3; 28.2 +/- 1.9 ng.hr/mL; P = .04085) over the 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],34.2,128192,DB00688,Mycophenolate mofetil
,15848556,AUC0-9 level,MPA AUC0-9 level was significantly higher among the AR-negative group (n = 33; 34.2 +/- 16.8 ng.hr/mL) compared with AR-positive group (n = 3; 28.2 +/- 1.9 ng.hr/mL; P = .04085) over the 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],28.2,128193,DB00688,Mycophenolate mofetil
,15848556,AUC0-9 level,MPA AUC0-9 level was higher among the adverse event (AE-positive) group (n = 15; 39.2 +/- 22.8 ng.hr/mL) compared with the negative group (n = 21; 30.1 +/- 8.0 ng.hr/mL; P = .08772) within 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],39.2,128194,DB00688,Mycophenolate mofetil
,15848556,AUC0-9 level,MPA AUC0-9 level was higher among the adverse event (AE-positive) group (n = 15; 39.2 +/- 22.8 ng.hr/mL) compared with the negative group (n = 21; 30.1 +/- 8.0 ng.hr/mL; P = .08772) within 2 weeks after transplantation.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],30.1,128195,DB00688,Mycophenolate mofetil
,15848556,AUC0-9,The possible target level of MPA AUC0-9 would be approximately 30 ng.hr/mL using the present immunosuppressive regimen.,Therapeutic drug monitoring of mycophenolic acid in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848556/),[h·ng] / [ml],30,128196,DB00688,Mycophenolate mofetil
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],30.2,128319,DB00688,Mycophenolate mofetil
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],45.6,128320,DB00688,Mycophenolate mofetil
,20720518,clearance,"Median clearance was 30.2, 45.6, and 10.7 L/h in RTx, HSCTx, and AID patients, respectively.","Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20720518/),[l] / [h],10.7,128321,DB00688,Mycophenolate mofetil
,30215770,C1,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],8.3,128963,DB00688,Mycophenolate mofetil
,30215770,C2,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],7.2,128964,DB00688,Mycophenolate mofetil
,30215770,C12,"C1, C2 and C12 were 8.3 ± 6.6 , 7.2 ± 5.2 and 2.0 ± 1.4 mg/L and all correlated with the 12-h area under the curve (AUC0-12; r = 0.51, 0.85 and 0.73; P = 0.02, <0.001 and <0.001, respectively).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.0,128965,DB00688,Mycophenolate mofetil
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.3,128966,DB00688,Mycophenolate mofetil
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],4.3,128967,DB00688,Mycophenolate mofetil
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.9,128968,DB00688,Mycophenolate mofetil
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],2.4,128969,DB00688,Mycophenolate mofetil
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.8,128970,DB00688,Mycophenolate mofetil
,30215770,C12,"Five renal flares, 11 episodes of infection and 10 episodes of anemia (hemoglobin <10 g/dL) occurred over 96 weeks, with a corresponding C12 of 1.3 ± 0.5, 4.3 ± 2.6 and 2.9 ± 1.5 mg/L, respectively (versus 2.4 ± 1.2, 1.8 ± 1.2 and 1.7 ± 1.1 mg/L in patients without these complications; P = 0.041, <0.001 and 0.004).",Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30215770/),[mg] / [l],1.7,128971,DB00688,Mycophenolate mofetil
,29427741,AUC0-24,"Receiver-operating characteristic model analyses showed that cutoff values of AUC0-24 for successful GI aGVHD prevention were .689 and 15.6 µg⋅hour⋅mL-1 for free MPA and AcMPAG, respectively.",Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427741/),[h·μg] / [ml],.689,130029,DB00688,Mycophenolate mofetil
,29427741,AUC0-24,"Receiver-operating characteristic model analyses showed that cutoff values of AUC0-24 for successful GI aGVHD prevention were .689 and 15.6 µg⋅hour⋅mL-1 for free MPA and AcMPAG, respectively.",Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427741/),[h·μg] / [ml],15.6,130030,DB00688,Mycophenolate mofetil
,29427741,AUC0-24,"In addition, the cut-off value of free MPA AUC0-24 for neutrophil engraftment by day 25 was .405 µg⋅hour⋅mL-1.",Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427741/),[h·μg] / [ml],.405,130031,DB00688,Mycophenolate mofetil
,29427741,AUC0-24,"Hence, monitoring of the free MPA AUC0-24 between .405 and .689 µg⋅hour⋅mL-1 could be considered informative of individualized MPA treatments in CBT patients.",Pharmacokinetic and Pharmacodynamic Markers of Mycophenolic Acid Associated with Effective Prophylaxis for Acute Graft-Versus-Host Disease and Neutrophil Engraftment in Cord Blood Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427741/),[h·μg] / [ml],.,130032,DB00688,Mycophenolate mofetil
below,21709602,AUC0-12,MPA exposure significantly increased when CsA AUC0-12 was below 2000 ng hr/mL.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·ng] / [ml],2000,130430,DB00688,Mycophenolate mofetil
,21709602,AUC0-12,Stratification of MPA profiles according to stages of renal dysfunction showed that dose-adjusted MPA AUC0-12 was higher (P<0.001) in patients with severe (stage 4: 70.37±27.93 μg hr/mL/g MMF) than in those with mild (stage 2: 47.46±11.66 μg hr/mL/g MMF) or moderate (stage 3; 47.48±15.22 μg hr/mL/g MMF) renal insufficiency.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·μg] / [g·ml],70.37,130431,DB00688,Mycophenolate mofetil
,21709602,AUC0-12,Stratification of MPA profiles according to stages of renal dysfunction showed that dose-adjusted MPA AUC0-12 was higher (P<0.001) in patients with severe (stage 4: 70.37±27.93 μg hr/mL/g MMF) than in those with mild (stage 2: 47.46±11.66 μg hr/mL/g MMF) or moderate (stage 3; 47.48±15.22 μg hr/mL/g MMF) renal insufficiency.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·μg] / [g·ml],47.46,130432,DB00688,Mycophenolate mofetil
,21709602,AUC0-12,Stratification of MPA profiles according to stages of renal dysfunction showed that dose-adjusted MPA AUC0-12 was higher (P<0.001) in patients with severe (stage 4: 70.37±27.93 μg hr/mL/g MMF) than in those with mild (stage 2: 47.46±11.66 μg hr/mL/g MMF) or moderate (stage 3; 47.48±15.22 μg hr/mL/g MMF) renal insufficiency.,Renal graft function and low-dose cyclosporine affect mycophenolic acid pharmacokinetics in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21709602/),[h·μg] / [g·ml],47.48,130433,DB00688,Mycophenolate mofetil
,26906299,level,The mean MPA level for patients in CR was 3.26 ± 2.02 μg/mL compared with 3.02 ± 1.76 μg/mL for patients not in CR.,Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26906299/),μ,3,130822,DB00688,Mycophenolate mofetil
,26906299,level,The mean MPA level for patients in CR was 3.26 ± 2.02 μg/mL compared with 3.02 ± 1.76 μg/mL for patients not in CR.,Use of Glucuronidated Mycophenolic Acid Levels for Therapeutic Monitoring in Pediatric Lupus Nephritis Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26906299/),μ,3.02,130823,DB00688,Mycophenolate mofetil
,15518751,AUC,The median MPA AUC was 34.3 ug.h/mL (range 14.1-65.4).,The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],34.3,131352,DB00688,Mycophenolate mofetil
,15518751,AUC,"Thirty-one of 45 (68.9%) patients had a MPA AUC within 20 to 40 ug.h/mL, which is the most reasonable risk: benefit ratio in terms of preventing acute rejection episodes.",The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],20 to 40,131353,DB00688,Mycophenolate mofetil
,15518751,AUC,"Forty-one of 45 (91.1%) patients had MPA AUC within 20 to 60 ug.h/mL, which is the MPA therapeutic range.",The pharmacokinetics of mycophenolate mofetil in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518751/),[h·ug] / [ml],20 to 60,131354,DB00688,Mycophenolate mofetil
,8728345,phase systemic plasma clearance,"During the intravenous infusion, phase systemic plasma clearance of MMF was approximately 10 L/min and the half-life (t1/2) was a few minutes.",Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728345/),[l] / [min],10,132128,DB00688,Mycophenolate mofetil
,8728345,half-life (t1/2),"During the intravenous infusion, phase systemic plasma clearance of MMF was approximately 10 L/min and the half-life (t1/2) was a few minutes.",Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728345/),min,few,132129,DB00688,Mycophenolate mofetil
,8728345,apparent plasma t1/2,Mean apparent plasma t1/2 of MPA was similar for both routes (approximately 17 hours).,Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728345/),h,17,132130,DB00688,Mycophenolate mofetil
,8728345,bioavailability,"The area under the concentration-time curve (AUC) from time 0 to 24 hours was statistically higher for intravenous than for oral administration, but total AUC showed statistical equivalence (80-120 rule), with mean bioavailability of MPA from oral administration of MMF estimated as 94.1% relative to the intravenous route.",Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728345/),%,94.1,132131,DB00688,Mycophenolate mofetil
,8728345,recovery,Total 48-hour MPAG recovery in urine was statistically equivalent for the two routes and represented a mean of 70% of administered drug; corresponding MPA recovery was less than 1%.,Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728345/),%,70,132132,DB00688,Mycophenolate mofetil
less,8728345,recovery,Total 48-hour MPAG recovery in urine was statistically equivalent for the two routes and represented a mean of 70% of administered drug; corresponding MPA recovery was less than 1%.,Pharmacokinetics and bioavailability of mycophenolate mofetil in healthy subjects after single-dose oral and intravenous administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8728345/),%,1,132133,DB00688,Mycophenolate mofetil
,16044096,C0,"Mean +/- SD values for CsA dose, C0, and C2 were 4.8 +/- 1.4 mg/kg/d, 240 +/- 62 microg/L, and 1319 +/- 469 microg/L, respectively.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],240,133047,DB00688,Mycophenolate mofetil
,16044096,C2,"Mean +/- SD values for CsA dose, C0, and C2 were 4.8 +/- 1.4 mg/kg/d, 240 +/- 62 microg/L, and 1319 +/- 469 microg/L, respectively.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1319,133048,DB00688,Mycophenolate mofetil
,16044096,C0,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],215,133049,DB00688,Mycophenolate mofetil
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],215,133050,DB00688,Mycophenolate mofetil
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],949,133051,DB00688,Mycophenolate mofetil
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],242,133052,DB00688,Mycophenolate mofetil
,16044096,C2,"The mean +/- SD values for C0 (microg/L) and C2 (microg/L) for rejectors (n = 3) were 215 +/- 68 and 949 +/- 204 versus 242 +/- 62 and 1359 +/- 474 for the nonrejectors (P = 0.66 and 0.12, respectively).",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1359,133053,DB00688,Mycophenolate mofetil
,16044096,C0,"Fisher exact test P values using the median as threshold value for C0 and C2 (234 microg/L and 1251 microg/L, respectively) were 0.6 and 0.1.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],234,133054,DB00688,Mycophenolate mofetil
,16044096,C2,"Fisher exact test P values using the median as threshold value for C0 and C2 (234 microg/L and 1251 microg/L, respectively) were 0.6 and 0.1.",Cyclosporine monitoring with 2-hour postdose levels in heart transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16044096/),[μg] / [l],1251,133055,DB00688,Mycophenolate mofetil
,18367972,Sir AUC,The average Sir AUC was 64.9 +/- 29.7 ng*h/mL.,Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],64.9,133309,DB00688,Mycophenolate mofetil
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],7.6,133310,DB00688,Mycophenolate mofetil
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.1,133311,DB00688,Mycophenolate mofetil
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133312,DB00688,Mycophenolate mofetil
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.5,133313,DB00688,Mycophenolate mofetil
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],3.6,133314,DB00688,Mycophenolate mofetil
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],5.0,133315,DB00688,Mycophenolate mofetil
,18367972,AUC,"The median (range) AUC for each metabolite was as follows: 12-hydroxy-Sir, 7.6 (0.2-18.8); 46-hydroxy-Sir, 3.1 (0.0-12.4); 24-hydroxy-Sir, 4.3 (0.0-12.6); piperidine-hydroxy-Sir, 3.5 (0.0-8.3); 39-desmethyl-Sir, 3.6 (0.0-11.3); 16-desmethyl-Sir, 5.0 (0.1-9.9); and di-hydroxy-Sir, 4.3 (0.0-32.5) ng*h/mL.",Pharmacokinetics of mycophenolate mofetil and sirolimus in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18367972/),[h·ng] / [ml],4.3,133316,DB00688,Mycophenolate mofetil
,30195818,survival times (MSTs),"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,16.5,133331,DB00688,Mycophenolate mofetil
,30195818,survival times (MSTs),"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,33,133332,DB00688,Mycophenolate mofetil
,30195818,MST,"In MMF monotherapy, oral administration of 20 or 40 mg/kg/day prolonged graft survival with median survival times (MSTs) of 16.5 days and 33 days, respectively, whereas untreated animals showed MST of 6 days.","Replacement of mycophenolate mofetil with a JAK inhibitor, AS2553627, in combination with low-dose tacrolimus, for renal allograft rejection in non-human primates. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30195818/),d,6,133333,DB00688,Mycophenolate mofetil
,9646007,Systemic plasma clearance,"Systemic plasma clearance of intravenous mycophenolate mofetil was around 10 L/min in healthy individuals, and plasma mycophenolate mofetil concentrations fell below the quantitation limit (0.4 mg/L) within 10 minutes of the cessation of infusion.",Clinical pharmacokinetics of mycophenolate mofetil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646007/),[l] / [min],10,134126,DB00688,Mycophenolate mofetil
,9646007,maximum plasma mycophenolic acid concentration (Cmax),"The mean maximum plasma mycophenolic acid concentration (Cmax) after a mycophenolate mofetil 1 g dose in healthy individuals was around 25 mg/L, occurred at 0.8 hours postdose, decayed with a mean apparent half-life (t1/2) of around 16 hours, and generated a mean total area under the plasma concentration-time curve (AUC infinity) of around 64 mg.h/L.",Clinical pharmacokinetics of mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646007/),[mg] / [l],25,134127,DB00688,Mycophenolate mofetil
,9646007,apparent half-life (t1/2),"The mean maximum plasma mycophenolic acid concentration (Cmax) after a mycophenolate mofetil 1 g dose in healthy individuals was around 25 mg/L, occurred at 0.8 hours postdose, decayed with a mean apparent half-life (t1/2) of around 16 hours, and generated a mean total area under the plasma concentration-time curve (AUC infinity) of around 64 mg.h/L.",Clinical pharmacokinetics of mycophenolate mofetil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646007/),h,16,134128,DB00688,Mycophenolate mofetil
,9646007,total area under the plasma concentration-time curve (AUC infinity),"The mean maximum plasma mycophenolic acid concentration (Cmax) after a mycophenolate mofetil 1 g dose in healthy individuals was around 25 mg/L, occurred at 0.8 hours postdose, decayed with a mean apparent half-life (t1/2) of around 16 hours, and generated a mean total area under the plasma concentration-time curve (AUC infinity) of around 64 mg.h/L.",Clinical pharmacokinetics of mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9646007/),[h·mg] / [l],64,134129,DB00688,Mycophenolate mofetil
,24657835,Tmax,Tmax of MPA remained similar whatever the circadian time of injection mean Tmax=30 min).,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),min,30,134693,DB00688,Mycophenolate mofetil
,24657835,Maximum,Maximum and minimum Cmax were obtained when MMF was injected at 7 HALO (69.1 μg/ml) and at 19 HALO (22.7 ± 1.74 μg/ml) respectively.,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[μg] / [ml],69.1,134694,DB00688,Mycophenolate mofetil
,24657835,minimum Cmax,Maximum and minimum Cmax were obtained when MMF was injected at 7 HALO (69.1 μg/ml) and at 19 HALO (22.7 ± 1.74 μg/ml) respectively.,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[μg] / [ml],22.7,134695,DB00688,Mycophenolate mofetil
,24657835,AUC0-24,AUC0-24 varied significantly according to the circadian-time of injection (166.33 ± 10.54 mg h/L at 7 HALO vs 80.27 ± 2.33 mg h/L at 19 HALO) (p<0.05).,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[h·mg] / [l],166.33,134696,DB00688,Mycophenolate mofetil
,24657835,AUC0-24,AUC0-24 varied significantly according to the circadian-time of injection (166.33 ± 10.54 mg h/L at 7 HALO vs 80.27 ± 2.33 mg h/L at 19 HALO) (p<0.05).,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[h·mg] / [l],80.27,134697,DB00688,Mycophenolate mofetil
,24657835,plasma clearance (CL,The highest and lowest mean values of plasma clearance (CL calculated as Dos/AUC) were observed at 19 HALO (2.45 ± 0.07 L/h/kg) and at 7 HALO (1.08 ± 0.06 L/h/kg) respectively (p<0.05).,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[l] / [h·kg],2.45,134698,DB00688,Mycophenolate mofetil
,24657835,plasma clearance (CL,The highest and lowest mean values of plasma clearance (CL calculated as Dos/AUC) were observed at 19 HALO (2.45 ± 0.07 L/h/kg) and at 7 HALO (1.08 ± 0.06 L/h/kg) respectively (p<0.05).,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[l] / [h·kg],1.08,134699,DB00688,Mycophenolate mofetil
,24657835,Dos/AUC,The highest and lowest mean values of plasma clearance (CL calculated as Dos/AUC) were observed at 19 HALO (2.45 ± 0.07 L/h/kg) and at 7 HALO (1.08 ± 0.06 L/h/kg) respectively (p<0.05).,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[l] / [h·kg],2.45,134700,DB00688,Mycophenolate mofetil
,24657835,Dos/AUC,The highest and lowest mean values of plasma clearance (CL calculated as Dos/AUC) were observed at 19 HALO (2.45 ± 0.07 L/h/kg) and at 7 HALO (1.08 ± 0.06 L/h/kg) respectively (p<0.05).,Circadian variation of mycophenolate mofetil pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24657835/),[l] / [h·kg],1.08,134701,DB00688,Mycophenolate mofetil
,26082342,-,Previously targeted MPA-TL are 1.5-3.0 μg/mL.,The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082342/),[μg] / [ml],1.5-3.0,135503,DB00688,Mycophenolate mofetil
,26082342,TL,Previously targeted MPA-TL are 1.5-3.0 μg/mL.,The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082342/),[μg] / [ml],1.5-3.0,135504,DB00688,Mycophenolate mofetil
,26082342,-,Mean MPA-TL was 1.7 ± 0.9 μg/mL.,The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082342/),[μg] / [ml],1.7,135505,DB00688,Mycophenolate mofetil
,26082342,TL,Mean MPA-TL was 1.7 ± 0.9 μg/mL.,The effect of MMF dose and trough levels on adverse effects in pediatric heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26082342/),[μg] / [ml],1.7,135506,DB00688,Mycophenolate mofetil
,24727337,IC50,The overall relationship between MPA concentration and IMPDH activity was described by a direct inhibitory maximum effect model with an IC50 of 3.23 mg/L total MPA and 57.3 ng/mL unbound MPA.,Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24727337/),[mg] / [l],3.23,135633,DB00688,Mycophenolate mofetil
,24727337,IC50,The overall relationship between MPA concentration and IMPDH activity was described by a direct inhibitory maximum effect model with an IC50 of 3.23 mg/L total MPA and 57.3 ng/mL unbound MPA.,Pharmacokinetic and pharmacodynamic analysis of inosine monophosphate dehydrogenase activity in hematopoietic cell transplantation recipients treated with mycophenolate mofetil. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24727337/),[ng] / [ml],57.3,135634,DB00688,Mycophenolate mofetil
,19491317,clearance (Cl/F,MPA clearance (Cl/F 288 +/- 154 mL/min) was approximately 2-fold higher than previously reported from transplant patients and predicted by weight and race (ranked MPA Cl/F = -11.766 + 0.2035 [wt] + 4.9578 [race]; R(2) 41.8%; p = 0.005).,Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491317/),[ml] / [min],288,135762,DB00688,Mycophenolate mofetil
,19491317,metabolic ratio (MPAG(AUC)/MPA(AUC)),The metabolic ratio (MPAG(AUC)/MPA(AUC)) of 8.67 +/- 5.57 was lower than that previously reported in renal transplant recipients.,Influence of clinical and demographic variables on mycophenolic acid pharmacokinetics in antineutrophil cytoplasmic antibody-associated vasculitis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19491317/),,8.67,135763,DB00688,Mycophenolate mofetil
,16815317,AUC/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,26.6,136172,DB00688,Mycophenolate mofetil
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,51.1,136173,DB00688,Mycophenolate mofetil
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,4.8,136174,DB00688,Mycophenolate mofetil
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,7.7,136175,DB00688,Mycophenolate mofetil
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,1.5,136176,DB00688,Mycophenolate mofetil
,16815317,C(max)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,3.0,136177,DB00688,Mycophenolate mofetil
,16815317,C(0)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,1.5,136178,DB00688,Mycophenolate mofetil
,16815317,C(0)/dose,"Significantly lower AUC/dose, C(max)/dose, and C(0)/dose values were found at steady state (n = 47) in individuals carrying at least 1 CYP3A5*1 allele (n = 6) than in *3/*3 patients (26.6 +/- 15.7 versus 51.1 +/- 21.1 [P = .008], 4.8 +/- 3.3 versus 7.7 +/- 3.3 [P = .02], and 1.5 +/- 0.8 versus 3.0 +/- 1.5 [P = .01], respectively), as well as during all posttransplant periods in the subgroup of 21 patients who were followed up for the first 3 months after transplantation (n = 21) (P < .05 always).",CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16815317/),,3.0,136179,DB00688,Mycophenolate mofetil
,16995865,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) and area under the concentration-time curve (AUC(0-12)) were 19.67 +/- 8.21 microg ml(-1) and 52.16 +/- 12.50 microg h ml(-1), but there was large variability in these pharmacokinetic parameters.",Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995865/),[μg] / [ml],19.67,136481,DB00688,Mycophenolate mofetil
,16995865,area under the concentration-time curve (AUC(0-12)),"The mean peak plasma concentration (C(max)) and area under the concentration-time curve (AUC(0-12)) were 19.67 +/- 8.21 microg ml(-1) and 52.16 +/- 12.50 microg h ml(-1), but there was large variability in these pharmacokinetic parameters.",Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995865/),[h·μg] / [ml],52.16,136482,DB00688,Mycophenolate mofetil
,18362900,trough blood levels,Tacrolimus was given orally from day -1 to achieve trough blood levels of 5-10 ng/ml.,Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362900/),[ng] / [ml],5-10,137652,DB00688,Mycophenolate mofetil
,18362900,AUC,The MMF dose was modified to achieve an MPA AUC of 35-60 microg/ml/h.,Targeting mycophenolate mofetil for graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18362900/),[μg] / [h·ml],35-60,137653,DB00688,Mycophenolate mofetil
,23061766,trough level,"The average tacrolimus trough level at the time of discontinuation and one wk after stopping fluconazole was unchanged (11.69 ± 3.18 and 11.15 ± 3.69 ng/mL, p = 0.145, n = 103).",Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061766/),[ng] / [ml],11.69,137674,DB00688,Mycophenolate mofetil
,23061766,trough level,"The average tacrolimus trough level at the time of discontinuation and one wk after stopping fluconazole was unchanged (11.69 ± 3.18 and 11.15 ± 3.69 ng/mL, p = 0.145, n = 103).",Low-dose fluconazole prophylaxis in kidney transplant recipients receiving tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23061766/),[ng] / [ml],11.15,137675,DB00688,Mycophenolate mofetil
,21517926,plasma concentrations,"Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2μg/mL (interquartile ranges, 0·94-2·96 and 18·6-53·7 μg/mL).",Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517926/),[μg] / [ml],1·95,137794,DB00688,Mycophenolate mofetil
,21517926,plasma concentrations,"Median predose plasma concentrations of MPA and MPAG were 1·95 and 26·2μg/mL (interquartile ranges, 0·94-2·96 and 18·6-53·7 μg/mL).",Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21517926/),[μg] / [ml],26·2,137795,DB00688,Mycophenolate mofetil
,15244498,tmax,"Following coadministration of valaciclovir and MMF, aciclovir pharmacokinetic parameters were not significantly modified except for tmax (about 0.5 hour shorter with MMF).",Evaluation of pharmacokinetic interactions after oral administration of mycophenolate mofetil and valaciclovir or aciclovir to healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244498/),h,0.5,138002,DB00688,Mycophenolate mofetil
,20171422,T(max),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),h,0.68,138004,DB00688,Mycophenolate mofetil
,20171422,T(max),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),h,0.81,138005,DB00688,Mycophenolate mofetil
,20171422,C(max),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),[mg] / [l],25.58,138006,DB00688,Mycophenolate mofetil
,20171422,C(max),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),[mg] / [l],26.47,138007,DB00688,Mycophenolate mofetil
,20171422,AUC(0-48),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),[mg] / [h·l],59.19,138008,DB00688,Mycophenolate mofetil
,20171422,AUC(0-48),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),[mg] / [h·l],58.32,138009,DB00688,Mycophenolate mofetil
,20171422,t((1/2)),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),h,15.12,138010,DB00688,Mycophenolate mofetil
,20171422,t((1/2)),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),h,16.04,138011,DB00688,Mycophenolate mofetil
,20171422,AUC(0-infinity)),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),[mg] / [h·l],63.28,138012,DB00688,Mycophenolate mofetil
,20171422,AUC(0-infinity)),"The main PK parameters of the MMF test and reference formulations were as follows: mean (SD) T(max), 0.68 (0.21) and 0.81 (0.18) hour, respectively; C(max), 25.58 (4.79) and 26.47 (3.67) mg/L; AUC(0-48), 59.19 (9.23) and 58.32 (9.28) mg/L/h; t((1/2)), 15.12 (3.17) and 16.04 (4.22) hours; AUC(0-infinity)), 63.28 (10.23) and 62.41 (10.28) mg/L/h.","Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),[mg] / [h·l],62.41,138013,DB00688,Mycophenolate mofetil
,20171422,relative bioavailability,The mean (SD) relative bioavailability was 101.5% (10.3%).,"Bioequivalence and pharmacokinetic comparison of two mycophenolate mofetil formulations in healthy Chinese male volunteers: an open-label, randomized-sequence, single-dose, two-way crossover study. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20171422/),%,101.5,138014,DB00688,Mycophenolate mofetil
,8044285,detection limit,The detection limit was 5 ng per injection volume.,"Determination of a new immunosuppressant, mycophenolate mofetil, and its active metabolite, mycophenolic acid, in rat and human body fluids by high-performance liquid chromatography. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8044285/),[ng] / [injection·volume],5,138075,DB00688,Mycophenolate mofetil
,20970601,concentration/dose ratios,Tacrolimus concentration/dose ratios in heterozygote patients for CYP3A5*3 genotypes was >120% lower than for the homozygote CYP3A5*3 genotype (0.65±0.04 vs 1.45±0.05; P<.0001).,Genetic polymorphisms and individualized tacrolimus dosing. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20970601/),,1,139189,DB00688,Mycophenolate mofetil
,21099740,time to peak concentration,"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),h,2.5,139588,DB00688,Mycophenolate mofetil
,21099740,time to peak concentration,"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),h,4.6,139589,DB00688,Mycophenolate mofetil
,21099740,peak concentration (Cmax),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[mg] / [l],19.3,139590,DB00688,Mycophenolate mofetil
,21099740,peak concentration (Cmax),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[mg] / [l],109.4,139591,DB00688,Mycophenolate mofetil
,21099740,area under the curve from 6 to 12 hours (AUC6-12),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],32.2,139592,DB00688,Mycophenolate mofetil
,21099740,area under the curve from 6 to 12 hours (AUC6-12),"For MPA and MPAG, the time to peak concentration was 2.5 ± 1.3 hours and 4.6 ± 3.1 hours, respectively; the peak concentration (Cmax) was 19.3 ± 17.2 mg/L and 109.4 ± 49.2 mg/L; and the area under the curve from 6 to 12 hours (AUC6-12) was 32.2 ± 19.3 mg·hr/L and 373.7 ± 235.8 mg·hr/L, respectively, which represents 41.3% and 43.0% of AUC0-12.",The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],373.7,139593,DB00688,Mycophenolate mofetil
,21099740,AUC0-12,The AUC0-12 for MPA measured 77.8 ± 53.1 mg·hr/L and for MPAG 869.2 ± 388.8 mg·hr/L.,The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],77.8,139594,DB00688,Mycophenolate mofetil
,21099740,AUC0-12,The AUC0-12 for MPA measured 77.8 ± 53.1 mg·hr/L and for MPAG 869.2 ± 388.8 mg·hr/L.,The pharmacokinetics of enteric-coated mycophenolate sodium and its gastrointestinal side effects in de novo renal transplant recipients of Hispanic ethnicity. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21099740/),[h·mg] / [l],869.2,139595,DB00688,Mycophenolate mofetil
,12164891,AUC0-12h,"Despite that the MMF dose did not change significantly with time, dose-normalized MPA AUC0-12h was lower during the first month (triple therapy, high doses of steroids) than at month 6 post-surgery (triple therapy, low maintenance dose of steroids (32.94 +/- 10.98 vs. 50.87 +/- 22.37 microg/mL. h; P < 0.01).",Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12164891/),[μg] / [h·ml],32.94,139829,DB00688,Mycophenolate mofetil
,12164891,AUC0-12h,"Despite that the MMF dose did not change significantly with time, dose-normalized MPA AUC0-12h was lower during the first month (triple therapy, high doses of steroids) than at month 6 post-surgery (triple therapy, low maintenance dose of steroids (32.94 +/- 10.98 vs. 50.87 +/- 22.37 microg/mL. h; P < 0.01).",Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12164891/),[μg] / [h·ml],50.87,139830,DB00688,Mycophenolate mofetil
<,10701434,run times,"The method has a lower limit of quantification (LLOQ) adequate for sensitive pharmacokinetic studies ( < or = 0.05 microg/ml), has run times of < or = 15 min, and uses aliquot volumes adequate for pediatric studies (0.25 ml).","A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),min,15,140499,DB00688,Mycophenolate mofetil
,10701434,lambda(ex),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,278,140500,DB00688,Mycophenolate mofetil
,10701434,lambda(em),Detection and quantification of ganciclovir is by fluorescence (lambda(ex) = 278 nm; lambda(em) = 380 nm).,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),,380,140501,DB00688,Mycophenolate mofetil
<,10701434,% C.V.,All intra- and inter-assay % C.V. values were < 8%; all recoveries (accuracy) were within 7% of nominal values.,"A rapid, sensitive HPLC method for the determination of ganciclovir in human plasma and serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10701434/),%,8,140502,DB00688,Mycophenolate mofetil
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],36.7,140632,DB00688,Mycophenolate mofetil
,18043470,area under the curve(0-12),"Median (range) of MPA area under the curve(0-12) was 36.7 (range, 16.4-116.4) mg*h/L in diabetic and 48.2 (range, 34.9-80.1) mg*h/L in nondiabetic patients (P=0.49).",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[h·mg] / [l],48.2,140633,DB00688,Mycophenolate mofetil
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],17.5,140634,DB00688,Mycophenolate mofetil
,18043470,activity,"In contrast, IMPDH activity was 17.5+/-2.8 versus 46.6+/-2.5 nmol XMP/h/microg protein in diabetics and nondiabetics, respectively (P<0.0001) and was significantly lower in the diabetics irrespective of concomitant therapy with cyclosporine or tacrolimus.",Effect of diabetes mellitus on mycophenolate sodium pharmacokinetics and inosine monophosphate dehydrogenase activity in stable kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043470/),[Mp·nM] / [h·μg],46.6,140635,DB00688,Mycophenolate mofetil
≥,33741807,AUC value from 0 to 12 h (AUC0-12h),Retrospective series have reported improved clinical outcomes when a minimum AUC value from 0 to 12 h (AUC0-12h) ≥30 mg h/l is achieved.,The use of mycophenolate mofetil area under the curve. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33741807/),[h·mg] / [l],30,141407,DB00688,Mycophenolate mofetil
,17144102,AUC(0-4),"There was statistically significant difference for MPA AUC(0-4), C40, C(max) between patients with acute rejection and patients with uneventful outcomes: mean MPA AUC(0-4): 11,4 +/- 7,23 microg x h/ml versus 34,0 26,8 microgxh/ml (p 0,01).",[Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144102/),[h·μg] / [ml],"11,4",142114,DB00688,Mycophenolate mofetil
,17144102,AUC(0-4),"There was statistically significant difference for MPA AUC(0-4), C40, C(max) between patients with acute rejection and patients with uneventful outcomes: mean MPA AUC(0-4): 11,4 +/- 7,23 microg x h/ml versus 34,0 26,8 microgxh/ml (p 0,01).",[Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144102/),[h·μg] / [ml],"34,0",142115,DB00688,Mycophenolate mofetil
<,17144102,AUC(0-4),Recipients with MPA AUC(0-4) <20 g x h/ml had a greater risk of acute rejection.,[Mycophenolic acid concentration profiles may select recipients with high-risk of acute rejection in renal transplant recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17144102/),[g·h] / [ml],20,142116,DB00688,Mycophenolate mofetil
,16891160,limit of detection (LOD),"The limit of detection (LOD) and theoretical limit of quantification (LOQ) for MPA in plasma were 0.10 and 0.32microg/ml, respectively.",Molecularly imprinted solid-phase extraction for rapid screening of mycophenolic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16891160/),[μg] / [ml],0.10,142305,DB00688,Mycophenolate mofetil
more,16891160,recoveries,Both recoveries for the extraction (more than 74%) and for the analytical method (more than 87%) were acceptable for screening MPA in plasma samples.,Molecularly imprinted solid-phase extraction for rapid screening of mycophenolic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16891160/),%,74,142306,DB00688,Mycophenolate mofetil
more,16891160,recoveries,Both recoveries for the extraction (more than 74%) and for the analytical method (more than 87%) were acceptable for screening MPA in plasma samples.,Molecularly imprinted solid-phase extraction for rapid screening of mycophenolic acid in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16891160/),%,87,142307,DB00688,Mycophenolate mofetil
,17425625,minimal clearance,The typical value of minimal clearance was 1.8 +/- 0.2 l h(-1).,Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [h],1.8,143249,DB00688,Mycophenolate mofetil
,17425625,maximal,"Clearance increased with time post transplantation to reach 50% of maximal value after 3.8 +/- 0.5 days, with a maximal value of 5.6 l h(-1).",Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [h],5.6,143250,DB00688,Mycophenolate mofetil
,17425625,"volume of distribution, V","The typical value for volume of distribution, V, (98 +/- 13 l kg(-1)) was similar to reported values in kidney transplant patients.",Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),[l] / [kg],98,143251,DB00688,Mycophenolate mofetil
,17425625,oral bioavailability,The oral bioavailability of tacrolimus was poor and ranged from 11.2 to 19.1%.,Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17425625/),%,11.2 to 19.1,143252,DB00688,Mycophenolate mofetil
,12919182,dose-adjusted,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],83,143834,DB00688,Mycophenolate mofetil
,12919182,dose-adjusted,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],119,143835,DB00688,Mycophenolate mofetil
,12919182,C0,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],83,143836,DB00688,Mycophenolate mofetil
,12919182,C0,At month 1 the tacrolimus dose-adjusted C0 in the corticosteroid group was 83 +/- 8 vs 119 +/- 17 ng ml-1 mg-1 kg-1 in the daclizumab group.,Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12919182/),[ng] / [kg·mg·ml],119,143837,DB00688,Mycophenolate mofetil
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],40.50,144481,DB00688,Mycophenolate mofetil
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.08,144482,DB00688,Mycophenolate mofetil
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],43.00,144483,DB00688,Mycophenolate mofetil
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],28.85,144484,DB00688,Mycophenolate mofetil
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],56.75,144485,DB00688,Mycophenolate mofetil
,28353583,AUC(0-12),"The patients treated with a higher mean dose of CsA displayed higher MPA AUC(0-12) exposure in the low-dose MMF group (1000 mg/day) (40.50 ± 10.97 vs 28.08 ± 11.03 h mg/L; rs = 0.497, P < 0.05), medium-dose MMF group (2000 mg/day) (43.00 ± 6.27 vs 28.85 ± 11.08 h mg/L; rs = 0.437, P < 0.01), and high-dose MMF group (3000 mg/day) (56.75 ± 16.78 vs 36.20 ± 3.70 h mg/L; rs = 0.608, P < 0.05).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[h·mg] / [l],36.20,144486,DB00688,Mycophenolate mofetil
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.83,144487,DB00688,Mycophenolate mofetil
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],12.08,144488,DB00688,Mycophenolate mofetil
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],22.77,144489,DB00688,Mycophenolate mofetil
,28353583,Cmax,"A positive correlation was also observed between the mean CsA dose and the MPA Cmax in the low-dose MMF group (Cmax 22.83 ± 10.82 vs 12.08 ± 5.59 mg/L; rs = 0.507, P < 0.05) and in the medium-dose MMF group (22.77 ± 8.86 vs 13.00 ± 6.82 mg/L; rs = 0.414, P < 0.01).",Influence of cyclosporine and everolimus on the main mycophenolate mofetil pharmacokinetic parameters: Cross-sectional study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28353583/),[mg] / [l],13.00,144490,DB00688,Mycophenolate mofetil
,19566116,time to peak concentration,There was a rapid rise in MPA concentrations (median time to peak concentration 0.72-1.25 hours).,Mycophenolic acid exposure after administration of mycophenolate mofetil in the presence and absence of cyclosporin in renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19566116/),h,0.72-1.25,145318,DB00688,Mycophenolate mofetil
,15199079,C(max),"The mean C(max) and AUC were 8.73 +/- 4.65 microg/mL and 18.45 +/- 4.25 microg*h/mL, respectively.",Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199079/),[μg] / [ml],8.73,147028,DB00688,Mycophenolate mofetil
,15199079,AUC,"The mean C(max) and AUC were 8.73 +/- 4.65 microg/mL and 18.45 +/- 4.25 microg*h/mL, respectively.",Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199079/),[h·μg] / [ml],18.45,147029,DB00688,Mycophenolate mofetil
,15199079,fraction of free,The mean fraction of free MPA was 1.60% +/- 0.23%.,Pharmacokinetic study of mycophenolic acid in Korean kidney transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15199079/),%,1.60,147030,DB00688,Mycophenolate mofetil
,16386613,trough level (C(0)),"Mean CsA trough level (C(0)) measured at first week posttransplant was significantly lower in the rejection than the no-rejection group (125.17 +/- 56.9 ng/mL versus 169.33 +/- 48.27 ng/mL, P = .001).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],125.17,148675,DB00688,Mycophenolate mofetil
,16386613,trough level (C(0)),"Mean CsA trough level (C(0)) measured at first week posttransplant was significantly lower in the rejection than the no-rejection group (125.17 +/- 56.9 ng/mL versus 169.33 +/- 48.27 ng/mL, P = .001).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],169.33,148676,DB00688,Mycophenolate mofetil
,16386613,C(0),ROC analysis showed that C(0) of 150 ng/mL provided the optimal cutoff.,Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148677,DB00688,Mycophenolate mofetil
>,16386613,C(0),"Patients with mean C(0) >150 ng/mL over the first week had less incidence of acute rejection than patients with levels <150 ng/mL (30.3% versus 64.9%) (P = .009, Cochran-Mantel-Haenszel test).",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148678,DB00688,Mycophenolate mofetil
above,16386613,early trough levels,"In conclusion, our data suggest that in heart transplant patients it may be crucial to target early trough levels above 150 ng/mL during the first days postsurgery to avoid rejection.",Relationship between pharmacokinetic parameters of cyclosporin and the incidence of acute rejection after heart transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386613/),[ng] / [ml],150,148679,DB00688,Mycophenolate mofetil
,20853464,flow rate,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.50 mL/min on an X-Terra RP(18) column with a total run time of 2.5 min.","Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853464/),[ml] / [min],0.50,149836,DB00688,Mycophenolate mofetil
,20853464,total run time,"Chromatographic separation was achieved with 0.2% formic acid-acetonitrile (25:75, v/v) at a flow rate of 0.50 mL/min on an X-Terra RP(18) column with a total run time of 2.5 min.","Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20853464/),min,2.5,149837,DB00688,Mycophenolate mofetil
>,10966158,plasma trough level,"At plasma trough level > 4 microg/ml some serious toxic effects were observed, whereas at Cmin < 2 microg/ml, there were some cases of interstitial rejection.",Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966158/),[μg] / [ml],4,150678,DB00688,Mycophenolate mofetil
<,10966158,Cmin,"At plasma trough level > 4 microg/ml some serious toxic effects were observed, whereas at Cmin < 2 microg/ml, there were some cases of interstitial rejection.",Pharmacokinetic monitoring of mycophenolate mofetil in kidney transplanted patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10966158/),[μg] / [ml],2,150679,DB00688,Mycophenolate mofetil
,19800973,AUC,"On the other hand, a second AUC estimated by multiple linear regression could only be provided for 84% of the profiles and showed a large overestimation with respect to Bayesian estimates for AUC values between 10 and 55mgh/L.","Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19800973/),[mgh] / [l],10 and 55,150836,DB00688,Mycophenolate mofetil
,19800973,AUCs,"In the CC arm, a very good physicians' compliance was observed (85%) and application of the dose recommendations led to higher values of AUCs (42.1+/-14.6mgh/L versus 36.7+/-16.3mgh/L, p=0.0035) and to more AUCs in the target range (69% versus 56%, p=0.0343) than when dose recommendations were not applied.","Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19800973/),[mgh] / [l],42.1,150837,DB00688,Mycophenolate mofetil
,19800973,AUCs,"In the CC arm, a very good physicians' compliance was observed (85%) and application of the dose recommendations led to higher values of AUCs (42.1+/-14.6mgh/L versus 36.7+/-16.3mgh/L, p=0.0035) and to more AUCs in the target range (69% versus 56%, p=0.0343) than when dose recommendations were not applied.","Feasibility of, and critical paths for mycophenolate mofetil Bayesian dose adjustment: pharmacological re-appraisal of a concentration-controlled versus fixed-dose trial in renal transplant recipients. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19800973/),[mgh] / [l],36.7,150838,DB00688,Mycophenolate mofetil
,21176194,areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [h·l],37.7,151136,DB00688,Mycophenolate mofetil
,21176194,areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [h·l],73.1,151137,DB00688,Mycophenolate mofetil
,21176194,trough concentrations (C(12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],1.5,151138,DB00688,Mycophenolate mofetil
,21176194,trough concentrations (C(12 h)),"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],3.7,151139,DB00688,Mycophenolate mofetil
,21176194,C(12 h) ratios,"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),,18.7,151140,DB00688,Mycophenolate mofetil
,21176194,C(12 h) ratios,"For failures and successes, respectively, entry MPA areas under the time-concentration curve between 0 and 12 hours (AUC(0-12 h)) (medians: 37.7 vs 73.1 mg/h/L, P = 0.003) and MPA 12-hour trough concentrations (C(12 h)) (medians: 1.5 vs 3.7 mg/L, P = 0.008) were significantly lower, and inclusion MPAG/MPA C(12 h) ratios (medians: 18.7 vs 10.2, P = 0.02) were significantly higher.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),,10.2,151141,DB00688,Mycophenolate mofetil
<,21176194,steady-state,"For our SLE patients without renal manifestations, clinical flares developing under maintenance therapy were associated with steady-state inclusion MPA C(12 h) < 3 mg/L.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],3,151142,DB00688,Mycophenolate mofetil
<,21176194,C(12 h),"For our SLE patients without renal manifestations, clinical flares developing under maintenance therapy were associated with steady-state inclusion MPA C(12 h) < 3 mg/L.",Steady-state mycophenolate mofetil pharmacokinetic parameters enable prediction of systemic lupus erythematosus clinical flares: an observational cohort study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21176194/),[mg] / [l],3,151143,DB00688,Mycophenolate mofetil
,16102443,AUC(0-4),"Mean AUC(0-4) was 3,700 ng . h/ml during Year 1 post-transplant, 2,400 ng . h/ml during Years 1 to 3, and 1,500 ng . h/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[h·ng] / [ml],"3,700",151304,DB00688,Mycophenolate mofetil
,16102443,AUC(0-4),"Mean AUC(0-4) was 3,700 ng . h/ml during Year 1 post-transplant, 2,400 ng . h/ml during Years 1 to 3, and 1,500 ng . h/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[h·ng] / [ml],"2,400",151305,DB00688,Mycophenolate mofetil
,16102443,AUC(0-4),"Mean AUC(0-4) was 3,700 ng . h/ml during Year 1 post-transplant, 2,400 ng . h/ml during Years 1 to 3, and 1,500 ng . h/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[h·ng] / [ml],"1,500",151306,DB00688,Mycophenolate mofetil
,16102443,C(2),"Mean C(2) values were 1.2 microg/ml during Year 1, 0.8 microg/ml during Years 1 to 3, and 0.5 microg/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[μg] / [ml],1.2,151307,DB00688,Mycophenolate mofetil
,16102443,C(2),"Mean C(2) values were 1.2 microg/ml during Year 1, 0.8 microg/ml during Years 1 to 3, and 0.5 microg/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[μg] / [ml],0.8,151308,DB00688,Mycophenolate mofetil
,16102443,C(2),"Mean C(2) values were 1.2 microg/ml during Year 1, 0.8 microg/ml during Years 1 to 3, and 0.5 microg/ml thereafter.",Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral). ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16102443/),[μg] / [ml],0.5,151309,DB00688,Mycophenolate mofetil
,33214342,AUC (0-12),"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[h·mg] / [l],62.2,151414,DB00688,Mycophenolate mofetil
,33214342,AUC (0-12),"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[h·mg] / [l],71.9,151415,DB00688,Mycophenolate mofetil
,33214342,C0,"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[mg] / [l],2.0,151416,DB00688,Mycophenolate mofetil
,33214342,C0,"The median AUC (0-12) and C0 results were 62.2 mg·h/L and 2.0 mg/L for the MMF group and 71.9 mg·h/L and 1.8 mg/L for the EC-MPS group (P = 0.160 and 0.225, respectively).",The impact of omeprazole on mycophenolate pharmacokinetics in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33214342/),[mg] / [l],1.8,151417,DB00688,Mycophenolate mofetil
,20224513,AUC,"Cyclosporine doses ranged from 250 mg to 430 mg/day, AUC from 3.85 to 8.39 mg.h/L, clearance from 19.1 to 48.1 L/h, and elimination half-life from 3.7 to 15.5 hours.",Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20224513/),[h·mg] / [l],3.85 to 8.39,151765,DB00688,Mycophenolate mofetil
,20224513,clearance,"Cyclosporine doses ranged from 250 mg to 430 mg/day, AUC from 3.85 to 8.39 mg.h/L, clearance from 19.1 to 48.1 L/h, and elimination half-life from 3.7 to 15.5 hours.",Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20224513/),[l] / [h],19.1 to 48.1,151766,DB00688,Mycophenolate mofetil
,20224513,elimination half-life,"Cyclosporine doses ranged from 250 mg to 430 mg/day, AUC from 3.85 to 8.39 mg.h/L, clearance from 19.1 to 48.1 L/h, and elimination half-life from 3.7 to 15.5 hours.",Prediction of intravenous cyclosporine area under the concentration-time curve after allogeneic stem cell transplantation. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20224513/),h,3.7 to 15.5,151767,DB00688,Mycophenolate mofetil
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],62.1-67.8,151954,DB00688,Mycophenolate mofetil
,16027400,AUC(0-12),"Total mycophenolic acid AUC(0-12) mcg x h/mL before day 60 was 62.1-67.8, declining to 33.6-64.7 thereafter (P = .61).",Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·mcg] / [ml],33.6-64.7,151955,DB00688,Mycophenolate mofetil
,16027400,total trough concentrations,Median total trough concentrations were 1.16-2.90 mcg/mL.,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[mcg] / [ml],1.16-2.90,151956,DB00688,Mycophenolate mofetil
,16027400,Unbound AUC(0-12),Unbound AUC(0-12) was 412-673 ng x h/mL and did not change over time (P = .30).,Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16027400/),[h·ng] / [ml],412-673,151957,DB00688,Mycophenolate mofetil
,31471014,AUC0-12,Mean MPA AUC0-12 of Immucept® was higher than CellCept® without statistical significance (48.27 ± 2.31 μg⋅hr/mL vs 42.19±15.20 μg⋅hr/mL; P value = .59).,A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],48.27,153177,DB00688,Mycophenolate mofetil
,31471014,AUC0-12,Mean MPA AUC0-12 of Immucept® was higher than CellCept® without statistical significance (48.27 ± 2.31 μg⋅hr/mL vs 42.19±15.20 μg⋅hr/mL; P value = .59).,A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],42.19,153178,DB00688,Mycophenolate mofetil
<,31471014,AUC0-12,"While on CellCept®, 5 patients (25%) had an MPA AUC0-12 < 30.0 μg⋅hr/mL, but 3 patients (15%) had MPA AUC0-12 < 30.0 μg⋅hr/mL when receiving Immucept®.",A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],30.0,153179,DB00688,Mycophenolate mofetil
>,31471014,AUC0-12,"However, 3 (15%) and 6 (30%) patients had MPA AUC0-12 > 60.0 μg⋅hr./mL when treated with CellCept® and Immucept®, respectively.",A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],60.0,153180,DB00688,Mycophenolate mofetil
more,31471014,AUC0-12,MPA AUC0-12 was more than 30.0 μg⋅hr/mL among most patients receiving MMF 1000 mg/day.,A Study of the Pharmacokinetic Comparison between the Generic and Original Form of Mycophenolate Mofetil Among Thai Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31471014/),[h·μg] / [ml],30.0,153181,DB00688,Mycophenolate mofetil
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],47.7,154308,DB00688,Mycophenolate mofetil
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],83.1,154309,DB00688,Mycophenolate mofetil
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],569,154310,DB00688,Mycophenolate mofetil
,24232127,area under the curve,CF patients had significantly lower MPA area under the curve (47.7 versus 83.1 mg·h·L(-1); P = 0.016) and MPAG area under the curve (569 versus 911 mg·h·L(-1); P = 0.047) when compared with NCF patients.,Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·mg] / [l],911,154311,DB00688,Mycophenolate mofetil
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],2.6,154312,DB00688,Mycophenolate mofetil
,24232127,C(0),"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],4.6,154313,DB00688,Mycophenolate mofetil
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],9.2,154314,DB00688,Mycophenolate mofetil
,24232127,maximum serum concentration,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[mg] / [l],20.3,154315,DB00688,Mycophenolate mofetil
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.26,154316,DB00688,Mycophenolate mofetil
,24232127,apparent oral clearance,"In addition, C(0) (2.6 versus 4.6 mg/L; P = 0.026) and maximum serum concentration (9.2 versus 20.3 mg/L; P = 0.016) were significantly lower, and apparent oral clearance (0.26 versus 0.13 L·h·kg(-1); P = 0.009) was significantly higher in CF patients.",Mycophenolic acid pharmacokinetics in lung transplant recipients with cystic fibrosis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24232127/),[h·l] / [kg],0.13,154317,DB00688,Mycophenolate mofetil
,16418701,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) of MPA was 86.4 +/- 41.4 minutes versus 52.8 +/- 31.8 minutes in D and ND patients respectively (P = 0.04) indicating a delay in MMF absorption.,Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418701/),min,86.4,154851,DB00688,Mycophenolate mofetil
,16418701,time to maximum concentration (Tmax),The time to maximum concentration (Tmax) of MPA was 86.4 +/- 41.4 minutes versus 52.8 +/- 31.8 minutes in D and ND patients respectively (P = 0.04) indicating a delay in MMF absorption.,Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16418701/),min,52.8,154852,DB00688,Mycophenolate mofetil
,18812562,steady-state minimum concentration (C(min)),Satisfactory steady-state minimum concentration (C(min)) of everolimus was achieved (approximately 5 ng/mL).,Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],5,154970,DB00688,Mycophenolate mofetil
,18812562,C(min),"At that time, the everolimus C(min) averaged approximately 3 ng/mL.",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [ml],3,154971,DB00688,Mycophenolate mofetil
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154972,DB00688,Mycophenolate mofetil
,18812562,concentration/dose ratio,"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154973,DB00688,Mycophenolate mofetil
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],3.49,154974,DB00688,Mycophenolate mofetil
,18812562,C(min),"The concentration/dose ratio of everolimus (ie, C(min) reached at steady-state for each milligram per kilogram of drug administered) was markedly lower during fluconazole versus voriconazole cotreatment (mean +/- SD, 3.49 +/- 0.29 vs 11.05 +/- 0.81 ng/mL per mg/kg/daily; p < 0.001).",Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18812562/),[ng] / [daily·kg·mg·ml],11.05,154975,DB00688,Mycophenolate mofetil
,17097975,AUC,"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,20.8,155609,DB00688,Mycophenolate mofetil
,17097975,predose,"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,20.8,155610,DB00688,Mycophenolate mofetil
,17097975,concentration (C0h),"The maximum mean values of MPA AUC and predose concentration (C0h) (20.8 +/- 11.8 and 2.3 +/- 1.8, respectively) were reached on the third day.",Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),,2.3,155611,DB00688,Mycophenolate mofetil
>/=,17097975,tmax,The single sample showing the greatest correlation with the MPA AUC was the one collected after 3 hours (r(2) = 0.575); 59.1% of profiles displayed a single peak with more than half showing a tmax >/= 3 hours.,Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17097975/),h,3,155612,DB00688,Mycophenolate mofetil
,20497746,clearance,"Typical mean value of tacrolimus clearance, estimated by the base model (without covariates), in our population was 1.03 l h-1.",Population pharmacokinetics of tacrolimus in kidney transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20497746/),[l] / [h],1.03,155926,DB00688,Mycophenolate mofetil
<,20498245,AUC,"Significantly more acute rejections (treated, biopsy-proven including and excluding borderline) occurred in patients with MPA AUC levels<30 mg.h/L compared with those >or=30 mg.h/L at day 5.","The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498245/),[h·mg] / [l],30,156812,DB00688,Mycophenolate mofetil
>,20498245,AUC,"Significantly more acute rejections (treated, biopsy-proven including and excluding borderline) occurred in patients with MPA AUC levels<30 mg.h/L compared with those >or=30 mg.h/L at day 5.","The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20498245/),[h·mg] / [l],30,156813,DB00688,Mycophenolate mofetil
,16120063,clearance,"Using this model, no statistically significant difference was observed in clearance of MPA between TACR and CsA co-administration (11.9 and 14.1 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],11.9,157933,DB00688,Mycophenolate mofetil
,16120063,clearance,"Using this model, no statistically significant difference was observed in clearance of MPA between TACR and CsA co-administration (11.9 and 14.1 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],14.1,157934,DB00688,Mycophenolate mofetil
,16120063,Total clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],1.45,157935,DB00688,Mycophenolate mofetil
,16120063,Total clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],0.92,157936,DB00688,Mycophenolate mofetil
,16120063,renal clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],1.09,157937,DB00688,Mycophenolate mofetil
,16120063,renal clearance,"Total clearance of MPAG was lower in case of CsA co-administration (1.45 and 0.92 l h(-1), respectively), while there was no difference in renal clearance of MPAG (1.09 and 0.92 l h(-1), respectively).",Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16120063/),[l] / [h],0.92,157938,DB00688,Mycophenolate mofetil
,17093994,C (max),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[mg] / [l],9.4,159212,DB00688,Mycophenolate mofetil
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[h·mg] / [l],0.7,159213,DB00688,Mycophenolate mofetil
,17093994,C (max),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[mg] / [l],97.3,159214,DB00688,Mycophenolate mofetil
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[h·mg] / [l],656.0,159215,DB00688,Mycophenolate mofetil
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[mg] / [l],29.9,159216,DB00688,Mycophenolate mofetil
,17093994,AUC(0-12h),"The mean C (max) and AUC(0-12h) of total and free MPA were 9.4 +/- 3.4 mg/L, 20.2 +/- 6.5 mg x h/L and 0.4 +/- 0.4 mg/L, 0.7 +/- 0.5 mg x h/L, respectively, whereas mean C (max) and AUC(0-12h) of total and free MPAG were 97.3 +/- 32.6 mg/L, 656.0 +/- 148.0 mg.h/L and 29.9 +/- 8.5 mg/L, 222.0 +/- 58.1 mg x h/L respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),[h·mg] / [l],222.0,159217,DB00688,Mycophenolate mofetil
,17093994,fractions,"The mean fractions of free MPA and MPAG were 3.5 +/- 2.0 and 34.6 +/- 8.0%, respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),%,3.5,159218,DB00688,Mycophenolate mofetil
,17093994,fractions,"The mean fractions of free MPA and MPAG were 3.5 +/- 2.0 and 34.6 +/- 8.0%, respectively.",Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17093994/),%,34.6,159219,DB00688,Mycophenolate mofetil
,30256137,area under the plasma concentration-time curve from 0 to 14 hours,"The MPA area under the plasma concentration-time curve from 0 to 14 hours ranged from 14.6 to 37.6 mg·h/L and from 14.4 to 22.3 mg·h/L after the first and last infusion, respectively.",Pharmacokinetics and pharmacodynamics of mycophenolic acid in healthy cats after twice-daily intravenous infusion of mycophenolate mofetil for three days. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30256137/),[h·mg] / [l],14.6 to 37.6,161563,DB00688,Mycophenolate mofetil
,30256137,area under the plasma concentration-time curve from 0 to 14 hours,"The MPA area under the plasma concentration-time curve from 0 to 14 hours ranged from 14.6 to 37.6 mg·h/L and from 14.4 to 22.3 mg·h/L after the first and last infusion, respectively.",Pharmacokinetics and pharmacodynamics of mycophenolic acid in healthy cats after twice-daily intravenous infusion of mycophenolate mofetil for three days. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30256137/),[h·mg] / [l],14.4 to 22.3,161564,DB00688,Mycophenolate mofetil
,20937266,m/,"The multiple reaction monitoring transitions used for quantification were m/z 321.04→303.02 for MPA, 524.09→303.02 for AcMPAG and MPAG and 324.03→306.04 for MPA-D3 in the electrospray positive ionization mode.",UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937266/),,321.04,161831,DB00688,Mycophenolate mofetil
,20937266,m/,"The multiple reaction monitoring transitions used for quantification were m/z 321.04→303.02 for MPA, 524.09→303.02 for AcMPAG and MPAG and 324.03→306.04 for MPA-D3 in the electrospray positive ionization mode.",UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937266/),,524.09,161832,DB00688,Mycophenolate mofetil
,20937266,m/,"The multiple reaction monitoring transitions used for quantification were m/z 321.04→303.02 for MPA, 524.09→303.02 for AcMPAG and MPAG and 324.03→306.04 for MPA-D3 in the electrospray positive ionization mode.",UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937266/),,303.02,161833,DB00688,Mycophenolate mofetil
,20937266,m/,"The multiple reaction monitoring transitions used for quantification were m/z 321.04→303.02 for MPA, 524.09→303.02 for AcMPAG and MPAG and 324.03→306.04 for MPA-D3 in the electrospray positive ionization mode.",UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937266/),,324.03,161834,DB00688,Mycophenolate mofetil
,20937266,Sample analysis time,Sample analysis time was reduced to 7 min including sample preparation.,UPLC MS/MS method for quantification of mycophenolic acid and metabolites in human plasma: Application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20937266/),min,7,161835,DB00688,Mycophenolate mofetil
,24923538,platelet nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,0 × 10(9),162089,DB00688,Mycophenolate mofetil
,24923538,leukocyte nadir,"Median platelet nadir amounted in all dogs to 0 × 10(9)/L (median, day +10; duration <50 × 10(9)/L, 22 days) and median leukocyte nadir was 1.0 × 10(9)/L (range, .1 to 2.5 × 10(9)/L; median, day +13).",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),,1.0 × 10(9),162090,DB00688,Mycophenolate mofetil
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [l],19.1,162091,DB00688,Mycophenolate mofetil
,24923538,trough levels,"Pharmacokinetics of RAD001 and MMF showed median trough levels of 19.1 (range, 10.5 to 43.2) μg/L and .3 (.1 to 1.3) mg/L, respectively.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[mg] / [l],.3,162092,DB00688,Mycophenolate mofetil
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[μg] / [h·l],325,162093,DB00688,Mycophenolate mofetil
,24923538,area under the curve,"The median area under the curve was 325 (range, 178 to 593) μg/L × hour for RAD001 and 29.6 (range, 7.9 to 40.5) ng/L × hour for MMF.",Everolimus in combination with mycophenolate mofetil as pre- and post-transplantation immunosuppression after nonmyeloablative hematopoietic stem cell transplantation in canine littermates. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24923538/),[ng] / [h·l],29.6,162094,DB00688,Mycophenolate mofetil
,11861442,AUC,"According to ROC analysis, an AUC value of 33.8 mg x h/L for MPA from t(0) to t(12h) (MPA-AUC(0-12)) determined by HPLC had a diagnostic sensitivity of 80% and a diagnostic specificity of 57%.",Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861442/),[h·mg] / [l],33.8,163321,DB00688,Mycophenolate mofetil
,11861442,Emit,The corresponding value of the Emit was 36.1 mg x h/L.,Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11861442/),[h·mg] / [l],36.1,163322,DB00688,Mycophenolate mofetil
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],2.19,163570,DB00688,Mycophenolate mofetil
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],2.36,163571,DB00688,Mycophenolate mofetil
,18978521,area under the concentration-time curve (AUC0-12),"The area under the concentration-time curve (AUC0-12) of MPA normalized to mycophenolate mofetil (MMF) dose (mg/kg) was significantly lower in LN patients and CyA-treated KT recipients than in Tac-treated KT recipients [median (range), 2.19 (0.87-4.23), 2.36 (1.13-5.74), and 4.86 (3.25-6.75) microg x h/mL per mg/kg, P < 0.05 and P < 0.01, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],4.86,163572,DB00688,Mycophenolate mofetil
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],35.0,163573,DB00688,Mycophenolate mofetil
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],51.6,163574,DB00688,Mycophenolate mofetil
,18978521,AUC0-12,"Dose-normalized MPAG AUC0-12 was significantly lower in LN patients and slightly lower in Tac-treated KT recipients than in CyA-treated KT recipients [median (range), 35.0 (8.34-69.8), 51.6 (34.4-94.8), and 84.1 (34.7-152) microg x h/mL per mg/kg, P < 0.05 and P = 0.13, respectively].",Comparison of pharmacokinetics of mycophenolic acid and its glucuronide between patients with lupus nephritis and with kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18978521/),[h·μg] / [kg·mg·ml],84.1,163575,DB00688,Mycophenolate mofetil
,19835971,time to myeloid,"Median time to myeloid and platelet engraftment was 18 and 31 days, respectively.",An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19835971/),d,18,164616,DB00688,Mycophenolate mofetil
,19835971,time to myeloid,"Median time to myeloid and platelet engraftment was 18 and 31 days, respectively.",An age-dependent pharmacokinetic study of intravenous and oral mycophenolate mofetil in combination with tacrolimus for GVHD prophylaxis in pediatric allogeneic stem cell transplantation recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19835971/),d,31,164617,DB00688,Mycophenolate mofetil
,15116056,AUC(0-12),"Finally, for recipients who did not simultaneously have a target tacrolimus AUC(0-12) of 150 ng x h/mL and a mycophenolic acid AUC(0-12) of 45 mg x h/L by day 7, the incidence of acute rejection tended to be higher (26.3%) compared with patients who reached both target values (7.7%) (P =.07).",Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116056/),[h·ng] / [ml],150,165572,DB00688,Mycophenolate mofetil
,15116056,AUC(0-12),"Finally, for recipients who did not simultaneously have a target tacrolimus AUC(0-12) of 150 ng x h/mL and a mycophenolic acid AUC(0-12) of 45 mg x h/L by day 7, the incidence of acute rejection tended to be higher (26.3%) compared with patients who reached both target values (7.7%) (P =.07).",Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15116056/),[h·mg] / [l],45,165573,DB00688,Mycophenolate mofetil
,31041728,absorption rate constant,The absorption rate constant was fixed at 1.1 h-1 and bioavailability was fixed at 0.895.,Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31041728/),1/[h],1.1,167064,DB00688,Mycophenolate mofetil
,31041728,bioavailability,The absorption rate constant was fixed at 1.1 h-1 and bioavailability was fixed at 0.895.,Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31041728/),,0.895,167065,DB00688,Mycophenolate mofetil
,31041728,clearance,"The typical values for voriconazole clearance and distribution volume were 9.52 L/h and 155 L, respectively.",Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31041728/),[l] / [h],9.52,167066,DB00688,Mycophenolate mofetil
,31041728,distribution volume,"The typical values for voriconazole clearance and distribution volume were 9.52 L/h and 155 L, respectively.",Population Pharmacokinetics of Voriconazole in Chinese Patients with Hematopoietic Stem Cell Transplantation. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31041728/),l,155,167067,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,0,168060,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,20,168061,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,40,168062,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,60,168063,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,90,168064,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,120,168065,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,180,168066,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,240,168067,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,360,168068,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,480,168069,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,600,168070,DB00688,Mycophenolate mofetil
,29746396,AUC12h,"We obtained 171 complete MPA-AUC12h (0, 20, 40, 60, 90, 120, 180, 240, 360, 480, 600, and 720 minutes) from 59 adult (54 ± 16 years) patients (29 men and 43 whites) who have been receiving stable doses of tacrolimus/enteric-coated mycophenolate sodium and steroids.",Development of an Abbreviated Mycophenolic Acid Area Under the Time-Concentration Curve for Renal Transplant Patients Under Enteric-Coated Mycophenolate Sodium: A Comparison With Critical Analysis of Available Equations. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29746396/),min,720,168071,DB00688,Mycophenolate mofetil
,20484171,trough concentration,Sirolimus concentrations obtained 3 days after initiation of dronedarone revealed a trough concentration that was increased by more than 3-fold (38.6 ng/mL) from his baseline trough concentration.,Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],38.6,168424,DB00688,Mycophenolate mofetil
,20484171,trough concentration,"After sirolimus was held for 6 days, the trough concentration was 7.8 ng/mL.",Significant sirolimus and dronedarone interaction in a kidney transplant recipient. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20484171/),[ng] / [ml],7.8,168425,DB00688,Mycophenolate mofetil
,19026038,absorption rate constant,EC-MPS was absorbed more slowly than MMF with respective absorption rate constant values of 3.0 h(-1) and 4.1 h(-1) (p < 0.001) [IIV 187%].,Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),1/[h],3.0,168847,DB00688,Mycophenolate mofetil
,19026038,absorption rate constant,EC-MPS was absorbed more slowly than MMF with respective absorption rate constant values of 3.0 h(-1) and 4.1 h(-1) (p < 0.001) [IIV 187%].,Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),1/[h],4.1,168848,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Following the morning dose of EC-MPS, the t(lag) values were 0.95, 1.88 and 4.83 h for 51%, 32% and 17% of the population (IIV 8%), respectively.",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,0.95,168849,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Following the morning dose of EC-MPS, the t(lag) values were 0.95, 1.88 and 4.83 h for 51%, 32% and 17% of the population (IIV 8%), respectively.",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,1.88,168850,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Following the morning dose of EC-MPS, the t(lag) values were 0.95, 1.88 and 4.83 h for 51%, 32% and 17% of the population (IIV 8%), respectively.",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,4.83,168851,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Following the morning dose of EC-MPS, the t(lag) values were 0.95, 1.88 and 4.83 h for 51%, 32% and 17% of the population (IIV 8%), respectively.",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),%,51,168852,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Following the morning dose of EC-MPS, the t(lag) values were 0.95, 1.88 and 4.83 h for 51%, 32% and 17% of the population (IIV 8%), respectively.",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),%,32,168853,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Following the morning dose of EC-MPS, the t(lag) values were 0.95, 1.88 and 4.83 h for 51%, 32% and 17% of the population (IIV 8%), respectively.",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),%,17,168854,DB00688,Mycophenolate mofetil
,19026038,t(lag),The morning t(lag) following EC-MPS administration was significantly different from both the t(lag) following MMF administration (0.30 h; p < 0.001 [IIV 11%]) and the t(lag) following the evening dose of EC-MPS (9.04 h; p < 0.001 [IIV 40%]).,Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,0.30,168855,DB00688,Mycophenolate mofetil
,19026038,t(lag),The morning t(lag) following EC-MPS administration was significantly different from both the t(lag) following MMF administration (0.30 h; p < 0.001 [IIV 11%]) and the t(lag) following the evening dose of EC-MPS (9.04 h; p < 0.001 [IIV 40%]).,Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,9.04,168856,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Post hoc analysis showed that the t(lag) was longer and more variable following EC-MPS administration (morning median 2.0 h [0.9-5.5 h], evening median 8.9 h [5.4-12.3 h]) than following MMF administration (median 0.30 h [0.26-0.34 h]; p < 0.001).",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,2.0,168857,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Post hoc analysis showed that the t(lag) was longer and more variable following EC-MPS administration (morning median 2.0 h [0.9-5.5 h], evening median 8.9 h [5.4-12.3 h]) than following MMF administration (median 0.30 h [0.26-0.34 h]; p < 0.001).",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,8.9,168858,DB00688,Mycophenolate mofetil
,19026038,t(lag),"Post hoc analysis showed that the t(lag) was longer and more variable following EC-MPS administration (morning median 2.0 h [0.9-5.5 h], evening median 8.9 h [5.4-12.3 h]) than following MMF administration (median 0.30 h [0.26-0.34 h]; p < 0.001).",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),h,0.30,168859,DB00688,Mycophenolate mofetil
,19026038,concentrations,"The morning MPA predose concentrations were higher and more variable following EC-MPS administration than following MMF administration, with respective values of 2.6 mg/L (0.4-24.4 mg/L) and 1.6 mg/L (0.2-7.6 mg/L).",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),[mg] / [l],2.6,168860,DB00688,Mycophenolate mofetil
,19026038,concentrations,"The morning MPA predose concentrations were higher and more variable following EC-MPS administration than following MMF administration, with respective values of 2.6 mg/L (0.4-24.4 mg/L) and 1.6 mg/L (0.2-7.6 mg/L).",Population pharmacokinetics of mycophenolic acid : a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19026038/),[mg] / [l],1.6,168861,DB00688,Mycophenolate mofetil
,29847459,AUC0-12h,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),[h·mg] / [l],43.0,169838,DB00688,Mycophenolate mofetil
,29847459,AUC0-12h,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),[h·mg] / [l],653,169839,DB00688,Mycophenolate mofetil
,29847459,AUC0-12h,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),[h·mg] / [l],1.368,169840,DB00688,Mycophenolate mofetil
,29847459,free fraction,"Normalized to 720 mg twice daily, the AUC0-12h of total MPA and MPAG was 43.0 ± 17.4 and 653 ± 329 mg·h/L, respectively, whereas the free MPA AUC0-12h was 1.368 ± 0.988 mg·h/L. The free fraction of MPA was 3.01% ± 3.15%.",Pharmacokinetics Evaluation of Mycophenolic Acid and Its Glucuronide Metabolite in Chinese Renal Transplant Recipients Receiving Enteric-Coated Mycophenolate Sodium and Tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29847459/),%,3.01,169841,DB00688,Mycophenolate mofetil
,9562232,clearance,The calculated clearance of MPA was higher (14.6 vs 8.1 ml/min/kg) on the day of peritoneal dialysis than during the dwell-free day.,Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9562232/),[ml] / [kg·min],14.6,170382,DB00688,Mycophenolate mofetil
,9562232,clearance,The calculated clearance of MPA was higher (14.6 vs 8.1 ml/min/kg) on the day of peritoneal dialysis than during the dwell-free day.,Pharmacokinetics of mycophenolate mofetil in renal transplant recipients on peritoneal dialysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9562232/),[ml] / [kg·min],8.1,170383,DB00688,Mycophenolate mofetil
,24250661,AUC 0-12,"Carriers of T-275A polymorphism had significant lower MPA AUC 0-12 in comparison with non-carriers or wild type (73.3±17.8 g/h/mL vs. 110.8±31.1 μg/h/mL, p = 0.006).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[g] / [h·ml],73.3,170831,DB00688,Mycophenolate mofetil
,24250661,AUC 0-12,"Carriers of T-275A polymorphism had significant lower MPA AUC 0-12 in comparison with non-carriers or wild type (73.3±17.8 g/h/mL vs. 110.8±31.1 μg/h/mL, p = 0.006).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[μg] / [h·ml],110.8,170832,DB00688,Mycophenolate mofetil
,24250661,AUC 6-12,"There was no significant difference in AUC 6-12 between the two groups although carriers of T-275A SNP had lower MPA AUC 6-12 (22.4±4.5 μg/h/mL vs. 26.8±10.2 μg/h/mL, p = 0.24).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[μg] / [h·ml],22.4,170833,DB00688,Mycophenolate mofetil
,24250661,AUC 6-12,"There was no significant difference in AUC 6-12 between the two groups although carriers of T-275A SNP had lower MPA AUC 6-12 (22.4±4.5 μg/h/mL vs. 26.8±10.2 μg/h/mL, p = 0.24).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[μg] / [h·ml],26.8,170834,DB00688,Mycophenolate mofetil
,24250661,Cmax,"Cmax was lower in the carriers of (20.2±9.0 μg/mL vs. 37.2±12.5 μg/mL, p=0.004).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[μg] / [ml],20.2,170835,DB00688,Mycophenolate mofetil
,24250661,Cmax,"Cmax was lower in the carriers of (20.2±9.0 μg/mL vs. 37.2±12.5 μg/mL, p=0.004).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[μg] / [ml],37.2,170836,DB00688,Mycophenolate mofetil
,24250661,C0,"There was no significant difference in C0 between two groups. (3.0±1.2 μg/mL vs. 3.9±1.6 μg/mL, p = 0.1).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[μg] / [ml],3.0,170837,DB00688,Mycophenolate mofetil
,24250661,C0,"There was no significant difference in C0 between two groups. (3.0±1.2 μg/mL vs. 3.9±1.6 μg/mL, p = 0.1).",Impact of UGT1A9 Polymorphism on Mycophenolic Acid Pharmacokinetic Parameters in Stable Renal Transplant Patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24250661/),[μg] / [ml],3.9,170838,DB00688,Mycophenolate mofetil
,9165564,oral plasma clearance,Mean (+/-SD) oral plasma clearance for mycophenolic acid alone and with ganciclovir was 3.11 +/- 0.72 and 3.19 +/- 0.72 ml/min/kg (p = 0.64).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],3.11,171525,DB00688,Mycophenolate mofetil
,9165564,oral plasma clearance,Mean (+/-SD) oral plasma clearance for mycophenolic acid alone and with ganciclovir was 3.11 +/- 0.72 and 3.19 +/- 0.72 ml/min/kg (p = 0.64).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],3.19,171526,DB00688,Mycophenolate mofetil
,9165564,serum clearance,Mean genciclovir serum clearance was 1.80 +/- 0.58 ml/min/kg for ganciclovir and 1.70 +/- 0.55 ml/min/kg for ganciclovir plus mycophenolate mofetil (p = 0.11; 10 patients).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.80,171527,DB00688,Mycophenolate mofetil
,9165564,serum clearance,Mean genciclovir serum clearance was 1.80 +/- 0.58 ml/min/kg for ganciclovir and 1.70 +/- 0.55 ml/min/kg for ganciclovir plus mycophenolate mofetil (p = 0.11; 10 patients).,Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.70,171528,DB00688,Mycophenolate mofetil
,9165564,Renal clearance,"Renal clearance of ganciclovir was decreased when the drugs were administered in combination, 1.43 +/- 0.54 (ganciclovir) and 1.26 +/- 0.44 (both drugs) ml/min/kg (p = 0.02; 10 patients).",Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.43,171529,DB00688,Mycophenolate mofetil
,9165564,Renal clearance,"Renal clearance of ganciclovir was decreased when the drugs were administered in combination, 1.43 +/- 0.54 (ganciclovir) and 1.26 +/- 0.44 (both drugs) ml/min/kg (p = 0.02; 10 patients).",Pharmacokinetics of mycophenolate mofetil and intravenous ganciclovir alone and in combination in renal transplant recipients. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9165564/),[ml] / [kg·min],1.26,171530,DB00688,Mycophenolate mofetil
,28836585,CL/F,The estimated population parameters (and interindividual variability) were CL/F 18.3 L/h (34.2%) and V1/F 27.9 L (21.3%).,Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28836585/),[l] / [h],18.3,171781,DB00688,Mycophenolate mofetil
,28836585,V1/F,The estimated population parameters (and interindividual variability) were CL/F 18.3 L/h (34.2%) and V1/F 27.9 L (21.3%).,Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in Chinese adult renal transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28836585/),l,27.9,171782,DB00688,Mycophenolate mofetil
<,22549498,AUC,"Similarly, the number of patients underexposed to MPA (AUC < 30 ng·h/mL) was higher at most periods in the PPI group but again not statistically significant.",Diminished mycophenolic acid exposure caused by omeprazole may be clinically relevant in the first week posttransplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22549498/),[h·ng] / [ml],30,171979,DB00688,Mycophenolate mofetil
,18641543,AUC,"The mean MPA AUC as well as the standard deviation was much greater in the SRL group, 56.4 +/- 23.5 mg.h/L, compared with 30.4 +/- 11.0 mg.h/L in the cyclosporine group (P < 0.001).",Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[h·mg] / [l],56.4,172406,DB00688,Mycophenolate mofetil
,18641543,AUC,"The mean MPA AUC as well as the standard deviation was much greater in the SRL group, 56.4 +/- 23.5 mg.h/L, compared with 30.4 +/- 11.0 mg.h/L in the cyclosporine group (P < 0.001).",Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[h·mg] / [l],30.4,172407,DB00688,Mycophenolate mofetil
,18641543,maximum concentration,Mean maximum concentration was also greater in the SRL group: 16.4 +/- 7.7 mg/L versus 11.7 +/- 7.1mg/L (P < 0.005).,Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[mg] / [l],16.4,172408,DB00688,Mycophenolate mofetil
,18641543,maximum concentration,Mean maximum concentration was also greater in the SRL group: 16.4 +/- 7.7 mg/L versus 11.7 +/- 7.1mg/L (P < 0.005).,Development of a predictive limited sampling strategy for estimation of mycophenolic acid area under the concentration time curve in patients receiving concomitant sirolimus or cyclosporine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18641543/),[mg] / [l],11.7,172409,DB00688,Mycophenolate mofetil
,10684356,trough concentration,"We recently published pharmacokinetic (PK) profiles of MMF in combination with tacrolimus (FK506): in order to keep the mycophenolic acid (MPA) pre-dose trough concentration between 2 and 5 microg/ml and to avoid side effects, mean MMF doses were reduced to 300 mg/m(2) b.i.d.",Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684356/),[μg] / [ml],2 and 5,173014,DB00688,Mycophenolate mofetil
,10684356,area under the curve (AUC),Mean area under the curve (AUC) in all PK profiles was 61.9+/-23.8 microgxh/ml.,Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684356/),[h·μg] / [ml],61.9,173015,DB00688,Mycophenolate mofetil
,25540593,AUC,"The mean AUC was 39.49 mg-h/L (28.39-89.58 mg-h/L), which was in the therapeutic range.",Mycophenolic acid AUC in Thai kidney transplant recipients receiving low dose mycophenolate and its association with UGT2B7 polymorphisms. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25540593/),[mg-h] / [l],39.49,173022,DB00688,Mycophenolate mofetil
,10720968,AUC,"Mean (+/- SD) AUC for MPA was 55.7 +/- 32.6 mg/L.h for hemodialysis patients and 44.7 +/- 14.7 mg/L.h for peritoneal dialysis patients, which is similar to expected values for subjects with normal renal function.",Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720968/),[mg] / [h·l],55.7,174323,DB00688,Mycophenolate mofetil
,10720968,AUC,"Mean (+/- SD) AUC for MPA was 55.7 +/- 32.6 mg/L.h for hemodialysis patients and 44.7 +/- 14.7 mg/L.h for peritoneal dialysis patients, which is similar to expected values for subjects with normal renal function.",Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720968/),[mg] / [h·l],44.7,174324,DB00688,Mycophenolate mofetil
,10720968,maximum plasma concentration (Cmax),"The mean (+/- SD) maximum plasma concentration (Cmax) for MPA was lower than would be expected for subjects with normal renal function (16.01 +/- 10.61 mg/L for hemodialysis, 11.48 +/- 4.98 mg/L for peritoneal dialysis).",Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720968/),[mg] / [l],16.01,174325,DB00688,Mycophenolate mofetil
,10720968,maximum plasma concentration (Cmax),"The mean (+/- SD) maximum plasma concentration (Cmax) for MPA was lower than would be expected for subjects with normal renal function (16.01 +/- 10.61 mg/L for hemodialysis, 11.48 +/- 4.98 mg/L for peritoneal dialysis).",Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720968/),[mg] / [l],11.48,174326,DB00688,Mycophenolate mofetil
,10720968,AUC,"MPAG clearance was prolonged with AUC approximately five times what would be expected in subjects with normal renal function (1565 +/- 596 mg/L.h for hemodialysis, 1386 +/- 410 mg/L.h for peritoneal dialysis).",Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720968/),[mg] / [h·l],1565,174327,DB00688,Mycophenolate mofetil
,10720968,AUC,"MPAG clearance was prolonged with AUC approximately five times what would be expected in subjects with normal renal function (1565 +/- 596 mg/L.h for hemodialysis, 1386 +/- 410 mg/L.h for peritoneal dialysis).",Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failure. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10720968/),[mg] / [h·l],1386,174328,DB00688,Mycophenolate mofetil
,22456298,apparent clearance (CL/F),The estimated mean apparent clearance (CL/F) was 14.5 l/h with an interindividual variability of 45.2%.,Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456298/),[l] / [h],14.5,175429,DB00688,Mycophenolate mofetil
,22456298,apparent volume of the central compartment,The estimated mean apparent volume of the central compartment was 12.2 l with an interindividual variability of 166%.,Population pharmacokinetics of mycophenolate mofetil in Thai lupus nephritis patients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22456298/),l,12.2,175430,DB00688,Mycophenolate mofetil
,12637655,Dose-corrected AUC((0-12)),Dose-corrected AUC((0-12)) of TAC decreased significantly from 180 ng/ml/h at baseline to 75.9 ng/ml/h after 2 weeks of SJW treatment.,Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637655/),[ng] / [h·ml],180,175941,DB00688,Mycophenolate mofetil
,12637655,Dose-corrected AUC((0-12)),Dose-corrected AUC((0-12)) of TAC decreased significantly from 180 ng/ml/h at baseline to 75.9 ng/ml/h after 2 weeks of SJW treatment.,Impact of St John's wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12637655/),[ng] / [h·ml],75.9,175942,DB00688,Mycophenolate mofetil
,2308896,oral bioavailability,"Thus, even though it can be converted rapidly to MPA by plasma and liver enzymes, it showed poor oral bioavailability (56% of MPA) in monkeys.",Bioavailability improvement of mycophenolic acid through amino ester derivatization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308896/),%,56,177770,DB00688,Mycophenolate mofetil
,2308896,bioavailability,"The bioavailability of the morpholinoethyl ester 4 and the acetyl morpholinoethyl ester 5, on the other hand, was found to be 236 and 150% that of MPA, respectively.",Bioavailability improvement of mycophenolic acid through amino ester derivatization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308896/),%,236,177771,DB00688,Mycophenolate mofetil
,2308896,bioavailability,"The bioavailability of the morpholinoethyl ester 4 and the acetyl morpholinoethyl ester 5, on the other hand, was found to be 236 and 150% that of MPA, respectively.",Bioavailability improvement of mycophenolic acid through amino ester derivatization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2308896/),%,150,177772,DB00688,Mycophenolate mofetil
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],4805,177950,DB00688,Mycophenolate mofetil
,27498124,area under the concentration-time curve from 0 to 12 hours,Mean (± SD) area under the concentration-time curve from 0 to 12 hours was 4805 ± 3265 hour * ng/mL on day 0 and 5917 ± 4048 hour * ng/mL on day +10.,A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27498124/),[h·ng] / [ml],5917,177951,DB00688,Mycophenolate mofetil
,21299636,AUC(12h),Only six of 24 patients had an MPA-AUC(12h) within the putative therapeutic range of 40-60 mg/L·h.,Pharmacokinetics and pharmacodynamics of mycophenolate sodium (EC-MPS) co-administered with cyclosporine in the early-phase post-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21299636/),[mg] / [h·l],40-60,180132,DB00688,Mycophenolate mofetil
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],39.95,182275,DB00688,Mycophenolate mofetil
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],25.24,182276,DB00688,Mycophenolate mofetil
,14632536,AUC,"Drug exposure as evaluated by AUC was 39.95 +/- 44.86, 25.24 +/- 25.68, and 43.96 +/- 38.67 micro g*h/mL during sampling periods 1, 2, and 3, respectively, (p > 0.05).",Mycophenolate pharmacokinetics in early period following lung or heart transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14632536/),[h·μg] / [ml],43.96,182277,DB00688,Mycophenolate mofetil
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],44.9,185175,DB00688,Mycophenolate mofetil
,16995869,AUC(0-9 h),"The mean mycophenolic acid AUC(0-9 h) in the sirolimus group was 44.9 mg h(-1) L(-1) (95% CI: 34.7-55.1), vs. 30.5 mg h(-1) L(-1) (95% CI: 25.4-35.6) in the ciclosporin group, corresponding to 1.5-fold dose-normalized difference (95% CI: 1.1-1.9; P < 0.05).",A comparison of the effect of ciclosporin and sirolimus on the pharmokinetics of mycophenolate in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16995869/),[mg] / [h·l],30.5,185176,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.47,185275,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.33,185276,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.57,185277,DB00688,Mycophenolate mofetil
,17211619,AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.15,185278,DB00688,Mycophenolate mofetil
,17211619,AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.00,185279,DB00688,Mycophenolate mofetil
,17211619,AUC(0-12),"The mean daytime dose-adjusted AUC(0-12) of MPA in UGT1A8*1/*1, *1/*2 and *2/*2 were 2.47, 2.33 and 2.57 ng.h/ml/mg/kg (P = 0.7711), and the mean nighttime AUC(0-12) were 2.15, 2.00 and 2.08 ng.h/ml/mg/kg (P = 0.4656).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.08,185280,DB00688,Mycophenolate mofetil
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.61,185281,DB00688,Mycophenolate mofetil
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.24,185282,DB00688,Mycophenolate mofetil
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.03,185283,DB00688,Mycophenolate mofetil
,17211619,daytime,"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.18,185284,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.61,185285,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.24,185286,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.03,185287,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],2.18,185288,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],1.94,185289,DB00688,Mycophenolate mofetil
,17211619,dose-adjusted AUC(0-12),"The mean daytime and nighttime dose-adjusted AUC(0-12) of MPA in UGT2B7*1/*1, *1/*2 and *2/*2 were 2.61, 2.24 and 2.03 ng.h/ml/mg/kg and 2.18, 1.94, and 1.45 ng.h/ml/mg/kg, respectively (P = 0.3475 and 0.2575).",Influence of UGT1A8 and UGT2B7 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17211619/),[h·ng] / [kg·mg·ml],1.45,185290,DB00688,Mycophenolate mofetil
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],31.9,186291,DB00688,Mycophenolate mofetil
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],26.2,186292,DB00688,Mycophenolate mofetil
,29511796,AUC0 - tau,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[h·μg] / [ml],21.0,186293,DB00688,Mycophenolate mofetil
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.25,186294,DB00688,Mycophenolate mofetil
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.35,186295,DB00688,Mycophenolate mofetil
,29511796,Ctrough,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],0.37,186296,DB00688,Mycophenolate mofetil
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],10.8,186297,DB00688,Mycophenolate mofetil
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],9.2,186298,DB00688,Mycophenolate mofetil
,29511796,Cmax,"The MPA AUC0 - tau was 31.9 ± 3.4, 26.2 ± 2.4, and 21.0 ± 2.2 µg*h/mL, the mean Ctrough was 0.25, 0.35, and 0.37 µg/mL, and the Cmax was 10.8, 9.2, and 5.5 µg/mL on days 2, 9, and 16, respectively.",Pharmacokinetics of intravenous mycophenolate mofetil in allogeneic hematopoietic stem cell-transplanted Japanese patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29511796/),[μg] / [ml],5.5,186299,DB00688,Mycophenolate mofetil
,10688252,AUC(0-12h),"As in adults, a time-dependent increase of t-MPA-AUC(0-12h) within the first 3 months posttransplant (35 versus 64 mg x h/L, [corrected] 3 weeks versus 3 months respectively; daily dosage: 0.6 g/m2 bid) was seen.",Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688252/),[h·mg] / [l],35,186306,DB00688,Mycophenolate mofetil
,10688252,AUC(0-12h),"As in adults, a time-dependent increase of t-MPA-AUC(0-12h) within the first 3 months posttransplant (35 versus 64 mg x h/L, [corrected] 3 weeks versus 3 months respectively; daily dosage: 0.6 g/m2 bid) was seen.",Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688252/),[h·mg] / [l],64,186307,DB00688,Mycophenolate mofetil
,10688252,AUC(0-12h),"A t-MPA-AUC(0-12h) of approximately 30-60 mg x h/L [corrected], as determined by HPLC, seems to be a reasonable target for the early posttransplant period.",Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688252/),[h·mg] / [l],30-60,186308,DB00688,Mycophenolate mofetil
> or =,10688252,AUC(0-12h),The risk for severe adverse events was increased at f-MPA- AUC(0-12h) values > or =600 microg x h/L [corrected].,Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10688252/),[h·μg] / [l],600,186309,DB00688,Mycophenolate mofetil
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],30.1,186660,DB00688,Mycophenolate mofetil
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],31.1,186661,DB00688,Mycophenolate mofetil
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],37.7,186662,DB00688,Mycophenolate mofetil
,14756266,AUC(0-8),"The concomitant administration of daclizumab and MMF had no effect on the pharmacokinetics of MPA: AUC(0-8) values (microg h/mL +/- SD) on day 28 were 30.1 +/- 13.3 for daclizumab-treat patients vs. 31.1 +/- 12.4 for placebo and on day 56, 37.7 +/- 18.2 for daclizumab-treated patients vs. 35.7 +/- 14.0 for placebo.",Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756266/),[h·μg] / [ml],35.7,186663,DB00688,Mycophenolate mofetil
,15518745,dose-normalized C(0),The mean dose-normalized C(0) was 2.13 +/- 0.91 ng/mL/mg.,Pharmacokinetic variability of sirolimus in Taiwanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518745/),[ng] / [mg·ml],2.13,188527,DB00688,Mycophenolate mofetil
,33425706,recoveries,The mean recoveries of the analytes ranged from 85.54% to 94.76% and the matrix factor ranged from 0.88-1.06.,Development and validation of an ultra-performance liquid chromatography mass spectrometry/mass spectrometry method for simultaneous quantification of total and free mycophenolic acid and its metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33425706/),%,85.54,188877,DB00688,Mycophenolate mofetil
,33425706,recoveries,The mean recoveries of the analytes ranged from 85.54% to 94.76% and the matrix factor ranged from 0.88-1.06.,Development and validation of an ultra-performance liquid chromatography mass spectrometry/mass spectrometry method for simultaneous quantification of total and free mycophenolic acid and its metabolites in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33425706/),%,94.76,188878,DB00688,Mycophenolate mofetil
,8785382,"terminal elimination half-life, t1/2 beta","After the intravenous injection of MPM at 16.7 mg kg-1, the terminal elimination half-life, t1/2 beta, was 4.74 +/- 0.33 (mean +/- SD)h, and the area under the plasma concentration versus time curve, AUC, was 48.78 +/- 6.01 micrograms h mL-1.","Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785382/),h,4.74,189239,DB00688,Mycophenolate mofetil
,8785382,"area under the plasma concentration versus time curve, AUC","After the intravenous injection of MPM at 16.7 mg kg-1, the terminal elimination half-life, t1/2 beta, was 4.74 +/- 0.33 (mean +/- SD)h, and the area under the plasma concentration versus time curve, AUC, was 48.78 +/- 6.01 micrograms h mL-1.","Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785382/),[h·μg] / [ml],48.78,189240,DB00688,Mycophenolate mofetil
,8785382,t1/2 beta,"After intraduodenal (ID) administration of MPM at 16.7 mg kg-1, t1/2 beta was 3.92 +/- 1.05 h, and the AUC was 38.08 +/- 8.30 micrograms h mL-1.","Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785382/),h,3.92,189241,DB00688,Mycophenolate mofetil
,8785382,AUC,"After intraduodenal (ID) administration of MPM at 16.7 mg kg-1, t1/2 beta was 3.92 +/- 1.05 h, and the AUC was 38.08 +/- 8.30 micrograms h mL-1.","Stability and pharmacokinetic studies of a new immunosuppressant, mycophenolate mofetil (RS-61443), in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785382/),[h·μg] / [ml],38.08,189242,DB00688,Mycophenolate mofetil
,18806697,activity,The activity of inosine 5'-monophosphate dehydrogenase (IMPDH) at time 0 ranged from 1.2 to 7.2 pmol per 10 cells/min.,Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806697/),pM,1.2 to 7.2,189351,DB00688,Mycophenolate mofetil
,18806697,EC50 (concentration required for 50% inhibition),IMPDH was strongly inhibited by MPA; MPA EC50 (concentration required for 50% inhibition) of 2.3 mg/L was determined by a pooled data analysis.,Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806697/),[mg] / [l],2.3,189352,DB00688,Mycophenolate mofetil
,18806697,AUC0-12h,"IMPDH activity AUC0-12h approached maximum reduction at MPA AUC0-12h 22 mg x h/L (corresponding to the 500 mg dose), whereas plasma concentrations exceeding approximately 6 mg/L did not further increase the IMPDH inhibition.",Pharmacodynamics of mycophenolic acid in CD4+ cells: a single-dose study of IMPDH and purine nucleotide responses in healthy individuals. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806697/),[h·mg] / [l],22,189353,DB00688,Mycophenolate mofetil
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],1550,191709,DB00688,Mycophenolate mofetil
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],3527,191710,DB00688,Mycophenolate mofetil
,16386526,trough,"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[μg] / [ml],0.023,191711,DB00688,Mycophenolate mofetil
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[μg] / [ml],0.094,191712,DB00688,Mycophenolate mofetil
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],0.87,191713,DB00688,Mycophenolate mofetil
,16386526,AUC(0-12 h),"The renal insufficiency group showed a significantly increased AUC(0-12 h) for MPAG (1550 +/- 392 vs 3527 +/- 1130 microg.h/mL, P < .001) and increased trough and AUC(0-12 h) values for f-MPA (0.023 +/- 0.02 vs 0.094 +/- 0.07 microg/mL, P = .003, and 0.87 +/- 0.3 vs 1.52 +/- 0.8 microg . h/mL, P = .016, respectively).",Pharmacokinetics of mycophenolate mofetil in kidney transplant patients with renal insufficiency. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16386526/),[h·μg] / [ml],1.52,191714,DB00688,Mycophenolate mofetil
,23792500,C0,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[μg] / [g·ml],1.04,191907,DB00688,Mycophenolate mofetil
,23792500,C0,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[μg] / [g·ml],0.84,191908,DB00688,Mycophenolate mofetil
,23792500,AUC0-12h,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[h·μg] / [g·ml],20.37,191909,DB00688,Mycophenolate mofetil
,23792500,AUC0-12h,Significantly higher levels of dose-normalized MPA C0 and AUC0-12h were associated with the events than with the absence of the events (C0: 1.04±0.42 vs. 0.84±0.85 µg/mL/g [p=0.047]; AUC0-12h: 20.37±3.21 vs. 14.97±1.13 µg × h/mL/g; [p=0.038]).,Dose-normalization for exposure to mycophenolic acid and the early clinical outcome in patients taking tacrolimus after heart transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23792500/),[h·μg] / [g·ml],14.97,191910,DB00688,Mycophenolate mofetil
,34032479,maximum plasma mycophenolic acid concentration,"For single-dose PO administration, mean ± SD maximum plasma mycophenolic acid concentration was 1,778.3 ± 441.5 ng/mL at 0.71 ± 0.29 hours.",Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34032479/),[ng] / [ml],"1,778.3",192640,DB00688,Mycophenolate mofetil
,34032479,systemic clearance,"For single-dose IV administration, mean systemic clearance and volume of distribution at steady state were 0.689 ± 0.194 L/h/kg and 1.57 ± 0.626 L/kg, respectively.",Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34032479/),[l] / [h·kg],0.689,192641,DB00688,Mycophenolate mofetil
,34032479,volume of distribution at steady state,"For single-dose IV administration, mean systemic clearance and volume of distribution at steady state were 0.689 ± 0.194 L/h/kg and 1.57 ± 0.626 L/kg, respectively.",Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34032479/),[l] / [kg],1.57,192642,DB00688,Mycophenolate mofetil
,34032479,terminal half-life,"Following single doses, mean terminal half-life was 3.99 ± 0.865 hours for IV administration and 4.02 ± 1.01 hours for PO administration.",Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34032479/),h,3.99,192643,DB00688,Mycophenolate mofetil
,34032479,terminal half-life,"Following single doses, mean terminal half-life was 3.99 ± 0.865 hours for IV administration and 4.02 ± 1.01 hours for PO administration.",Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34032479/),h,4.02,192644,DB00688,Mycophenolate mofetil
,34032479,accumulation index,"The accumulation index following long-term PO administration was 1.0 ± 0.002, and the terminal half-life was 4.59 ± 1.25 hours following the final dose on day 60.",Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34032479/),,1.0,192645,DB00688,Mycophenolate mofetil
,34032479,terminal half-life,"The accumulation index following long-term PO administration was 1.0 ± 0.002, and the terminal half-life was 4.59 ± 1.25 hours following the final dose on day 60.",Pharmacokinetics of mycophenolate mofetil following single-dose intravenous and single- and multiple-dose oral administration and clinicopathologic effects of mycophenolate mofetil following long-term oral administration in healthy horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/34032479/),h,4.59,192646,DB00688,Mycophenolate mofetil
,21056671,elimination constant ke,"Higher mean population parameter values and ranges of individual pharmacokinetic parameters were obtained with NPAG, especially for the elimination constant ke: mean 1.16 h(-1) (0.26-4.33 h(-1)) and 0.78 h(-1) (0.66-1.15 h(-1)) with NPAG and NONMEM, respectively.",Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056671/),1/[h],1.16,192850,DB00688,Mycophenolate mofetil
,21056671,elimination constant ke,"Higher mean population parameter values and ranges of individual pharmacokinetic parameters were obtained with NPAG, especially for the elimination constant ke: mean 1.16 h(-1) (0.26-4.33 h(-1)) and 0.78 h(-1) (0.66-1.15 h(-1)) with NPAG and NONMEM, respectively.",Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21056671/),1/[h],0.78,192851,DB00688,Mycophenolate mofetil
,14742982,AUC,"The mean+/-standard deviation MPA AUC measurements for the groups receiving no iron (n=13), iron and MMF together (n=14), and iron and MMF spaced apart (n=13) were 34.5+/-8.7, 33.7+/-11.4, and 32.1+/-8.1 microg/hr/mL, respectively (P=0.82).","The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742982/),[μg] / [h·ml],34.5,193448,DB00688,Mycophenolate mofetil
,14742982,AUC,"The mean+/-standard deviation MPA AUC measurements for the groups receiving no iron (n=13), iron and MMF together (n=14), and iron and MMF spaced apart (n=13) were 34.5+/-8.7, 33.7+/-11.4, and 32.1+/-8.1 microg/hr/mL, respectively (P=0.82).","The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742982/),[μg] / [h·ml],33.7,193449,DB00688,Mycophenolate mofetil
,14742982,AUC,"The mean+/-standard deviation MPA AUC measurements for the groups receiving no iron (n=13), iron and MMF together (n=14), and iron and MMF spaced apart (n=13) were 34.5+/-8.7, 33.7+/-11.4, and 32.1+/-8.1 microg/hr/mL, respectively (P=0.82).","The effect of oral iron admiinistration on mycophenolate mofetil absorption in renal transplant recipients: a randomized, controlled trial. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14742982/),[μg] / [h·ml],32.1,193450,DB00688,Mycophenolate mofetil
,17526858,peak concentration (Cmax,"After enteric-coated mycophenolate treatment, the mycophenolic acid peak concentration (Cmax = 12.8 vs 6.0 microg/mL, P < .05) and the overall exposure were significantly higher (AUC = 60.9 vs 40.7 microg.h/mL, P < .05), and the apparent clearance was significantly lower (CL/F = 7.9 vs 10.7 L/h, P < .05) as compared to that after mycophenolate mofetil.",Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17526858/),[μg] / [ml],12.8,193536,DB00688,Mycophenolate mofetil
,17526858,peak concentration (Cmax,"After enteric-coated mycophenolate treatment, the mycophenolic acid peak concentration (Cmax = 12.8 vs 6.0 microg/mL, P < .05) and the overall exposure were significantly higher (AUC = 60.9 vs 40.7 microg.h/mL, P < .05), and the apparent clearance was significantly lower (CL/F = 7.9 vs 10.7 L/h, P < .05) as compared to that after mycophenolate mofetil.",Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17526858/),[μg] / [ml],6.0,193537,DB00688,Mycophenolate mofetil
,17526858,AUC,"After enteric-coated mycophenolate treatment, the mycophenolic acid peak concentration (Cmax = 12.8 vs 6.0 microg/mL, P < .05) and the overall exposure were significantly higher (AUC = 60.9 vs 40.7 microg.h/mL, P < .05), and the apparent clearance was significantly lower (CL/F = 7.9 vs 10.7 L/h, P < .05) as compared to that after mycophenolate mofetil.",Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17526858/),[h·μg] / [ml],60.9,193538,DB00688,Mycophenolate mofetil
,17526858,AUC,"After enteric-coated mycophenolate treatment, the mycophenolic acid peak concentration (Cmax = 12.8 vs 6.0 microg/mL, P < .05) and the overall exposure were significantly higher (AUC = 60.9 vs 40.7 microg.h/mL, P < .05), and the apparent clearance was significantly lower (CL/F = 7.9 vs 10.7 L/h, P < .05) as compared to that after mycophenolate mofetil.",Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17526858/),[h·μg] / [ml],40.7,193539,DB00688,Mycophenolate mofetil
,17526858,CL/F,"After enteric-coated mycophenolate treatment, the mycophenolic acid peak concentration (Cmax = 12.8 vs 6.0 microg/mL, P < .05) and the overall exposure were significantly higher (AUC = 60.9 vs 40.7 microg.h/mL, P < .05), and the apparent clearance was significantly lower (CL/F = 7.9 vs 10.7 L/h, P < .05) as compared to that after mycophenolate mofetil.",Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17526858/),[l] / [h],7.9,193540,DB00688,Mycophenolate mofetil
,17526858,CL/F,"After enteric-coated mycophenolate treatment, the mycophenolic acid peak concentration (Cmax = 12.8 vs 6.0 microg/mL, P < .05) and the overall exposure were significantly higher (AUC = 60.9 vs 40.7 microg.h/mL, P < .05), and the apparent clearance was significantly lower (CL/F = 7.9 vs 10.7 L/h, P < .05) as compared to that after mycophenolate mofetil.",Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17526858/),[l] / [h],10.7,193541,DB00688,Mycophenolate mofetil
,29687456,extent of,"This study reveals that MPA is highly bound to plasma proteins (>90%) in dogs and cats, mean extent of binding of MPA at 15 μg/ml to plasma proteins being 96% (range, 95%-97%) and 92% (range, 90%-93%) for dogs and cats, respectively.",Ex vivo binding of the immunosuppressant mycophenolic acid to dog and cat plasma proteins and the effect of co-incubated dexamethasone and prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29687456/),%,96,194559,DB00688,Mycophenolate mofetil
,29687456,extent of,"This study reveals that MPA is highly bound to plasma proteins (>90%) in dogs and cats, mean extent of binding of MPA at 15 μg/ml to plasma proteins being 96% (range, 95%-97%) and 92% (range, 90%-93%) for dogs and cats, respectively.",Ex vivo binding of the immunosuppressant mycophenolic acid to dog and cat plasma proteins and the effect of co-incubated dexamethasone and prednisolone. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29687456/),%,92,194560,DB00688,Mycophenolate mofetil
,15012174,half-life stabilization time,"In the final model, the Dmax parameter is affected by plasmatic urea values and shows a half-life stabilization time of 90.90 days (95% CI: 52.60 to 250 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),d,90.90,194572,DB00688,Mycophenolate mofetil
,15012174,Dmax,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),[mg] / [kg],3,194573,DB00688,Mycophenolate mofetil
,15012174,Km,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),[ng] / [ml],93.60,194574,DB00688,Mycophenolate mofetil
,15012174,half-life,"Plasmatic urea values of 50 mg/dL are related to an initial Dmax value of 3 mg/kg daily (95% CI: 1.81 to 4.19 mg/kg daily) which decreases exponentially throughout the post-transplant period until it reaches a constant value of 2.16 mg/kg daily (95% CI: 1.41 to 2.91 mg/kg daily) In the same way, the Km parameter presents a central tendency value of 93.60 ng/mL (95% CI: 28.60 to 158.60 ng/mL) and the half-life necessary for its stabilization is 12.70 days (95% CI: 9.80 to 17.90 days).",[Cyclosporin pharmacokinetic modeling in renal transplant patients]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15012174/),d,12.70,194575,DB00688,Mycophenolate mofetil
greater,21695772,area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ),The aim of this study was to determine the MMF dosage required for pediatric liver transplant recipients to achieve an area under the plasma concentration-time curve from 0 to 12 hours (AUC(0-12) ) for mycophenolic acid (MPA) greater than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194863,DB00688,Mycophenolate mofetil
less,21695772,AUC(0-12),Thirteen of the 15 patients had an MPA AUC(0-12) value less than 30 mg hour/L.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194864,DB00688,Mycophenolate mofetil
greater,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194865,DB00688,Mycophenolate mofetil
,21695772,AUC(0-12),The MMF dosage required to reach an MPA AUC(0-12) value greater than the defined target of 30 mg hour/L ranged from 371 to 1014 mg/m(2) /day.,Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[mg] / [·d·m(2)],371 to 1014,194866,DB00688,Mycophenolate mofetil
greater,21695772,AUC(0-12),"In conclusion, an initial MMF dose of 600 mg/m(2) twice a day led to MPA AUC(0-12) values greater than the 30 mg hour/L threshold except when rifampin was coadministered.",Optimization of the dosing regimen of mycophenolate mofetil in pediatric liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21695772/),[h·mg] / [l],30,194867,DB00688,Mycophenolate mofetil
,31129889,AUC,The mycophenolic acid AUC was calculated by linear trapezoidal rule and compared with the target of 45 mg*h/L.,Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),[h·mg] / [l],45,195100,DB00688,Mycophenolate mofetil
,31129889,AUC,"Results Of 42 Thai kidney transplant recipiens, the mean mycophenolic acid AUC of 45.1 mg*h/L (SD 14.7) was comparable to the AUC target (P = 0.962).",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),[h·mg] / [l],45.1,195101,DB00688,Mycophenolate mofetil
,31129889,AUC,"Significant differences of the mycophenolic acid AUC were observed between patients with urine output of < 2400 mL and those with urine output ≥ 2400 mL (35.3 ± 6.6 and 47.4 ± 15.2, respectively; P = 0.002), and between patients with 24-h measured CrCl < 25 mL/min and those with CrCl ≥ 25 mL/min (38.0 (29.0, 42.2) and 49.2 ± 14.0, respectively; P = 0.017).",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),,35.3,195102,DB00688,Mycophenolate mofetil
,31129889,AUC,"Significant differences of the mycophenolic acid AUC were observed between patients with urine output of < 2400 mL and those with urine output ≥ 2400 mL (35.3 ± 6.6 and 47.4 ± 15.2, respectively; P = 0.002), and between patients with 24-h measured CrCl < 25 mL/min and those with CrCl ≥ 25 mL/min (38.0 (29.0, 42.2) and 49.2 ± 14.0, respectively; P = 0.017).",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),,47.4,195103,DB00688,Mycophenolate mofetil
,31129889,AUC,"Significant differences of the mycophenolic acid AUC were observed between patients with urine output of < 2400 mL and those with urine output ≥ 2400 mL (35.3 ± 6.6 and 47.4 ± 15.2, respectively; P = 0.002), and between patients with 24-h measured CrCl < 25 mL/min and those with CrCl ≥ 25 mL/min (38.0 (29.0, 42.2) and 49.2 ± 14.0, respectively; P = 0.017).",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),,38.0,195104,DB00688,Mycophenolate mofetil
,31129889,AUC,"Significant differences of the mycophenolic acid AUC were observed between patients with urine output of < 2400 mL and those with urine output ≥ 2400 mL (35.3 ± 6.6 and 47.4 ± 15.2, respectively; P = 0.002), and between patients with 24-h measured CrCl < 25 mL/min and those with CrCl ≥ 25 mL/min (38.0 (29.0, 42.2) and 49.2 ± 14.0, respectively; P = 0.017).",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),,49.,195105,DB00688,Mycophenolate mofetil
<,31129889,AUC,"Proportions of overall biopsy proven acute rejection among patients with mycophenolic acid AUC of < 45 and ≥ 45 mg*h/L were comparable (20.0% and 23.5%, respectively; P = 1.000).",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),[h·mg] / [l],45,195106,DB00688,Mycophenolate mofetil
≥,31129889,AUC,"Proportions of overall biopsy proven acute rejection among patients with mycophenolic acid AUC of < 45 and ≥ 45 mg*h/L were comparable (20.0% and 23.5%, respectively; P = 1.000).",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),[h·mg] / [l],45,195107,DB00688,Mycophenolate mofetil
,31129889,AUC,"Conclusions After the starting dosage of 1.5 g/d mycophenolate mofetil, the mean mycophenolic acid AUC on day 3 post-kidney transplantation is comparable with the target of 45 mg*h/L.",Early pharmacokinetics of low dosage mycophenolate exposure in Thai kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31129889/),[h·mg] / [l],45,195108,DB00688,Mycophenolate mofetil
,12687454,AUC,"The mean MPA AUC after a median of 39 days was 61.8+/-31.0 micro gxh/ml, median time to maximum concentration was 60 min, and mean maximum concentration was 18.5+/-8.4 micro g/ml.",Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687454/),[h·μg] / [ml],61.8,195608,DB00688,Mycophenolate mofetil
,12687454,time to maximum concentration,"The mean MPA AUC after a median of 39 days was 61.8+/-31.0 micro gxh/ml, median time to maximum concentration was 60 min, and mean maximum concentration was 18.5+/-8.4 micro g/ml.",Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687454/),min,60,195609,DB00688,Mycophenolate mofetil
,12687454,maximum concentration,"The mean MPA AUC after a median of 39 days was 61.8+/-31.0 micro gxh/ml, median time to maximum concentration was 60 min, and mean maximum concentration was 18.5+/-8.4 micro g/ml.",Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687454/),[μg] / [ml],18.5,195610,DB00688,Mycophenolate mofetil
,12687454,trough MPA concentration,"At last follow-up, mean MMF dose was 900+/-341 mg/m(2) per day, and mean trough MPA concentration was 3.1+/-1.1 (range 0.6-4.6) micro g/ml.",Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12687454/),[μg] / [ml],3.1,195611,DB00688,Mycophenolate mofetil
,25913040,dAUC,"MMF + PAN intake led to a lowest mean dAUC for MPA of 41.46 ng h ml(-1) mg(-1) [95% confidence interval (CI) 32.38, 50.54], while MPA exposure was highest for EC-MPS + PAN [dAUC: 46.30 ng h ml(-1) mg(-1) (95% CI 37.11, 55.49)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],41.46,196144,DB00688,Mycophenolate mofetil
,25913040,dAUC,"MMF + PAN intake led to a lowest mean dAUC for MPA of 41.46 ng h ml(-1) mg(-1) [95% confidence interval (CI) 32.38, 50.54], while MPA exposure was highest for EC-MPS + PAN [dAUC: 46.30 ng h ml(-1) mg(-1) (95% CI 37.11, 55.49)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],46.30,196145,DB00688,Mycophenolate mofetil
,25913040,dAUC,"Only for MMF [dAUC: 41.46 ng h ml(-1) mg(-1) (95% CI 32.38, 50.54)] and EC-MPS [dAUC: 43.39 ng h ml(-1) mg(-1) (95% CI 33.44, 53.34)] bioequivalence was established for dAUC [geometric mean ratio: 101.25% (90% CI 84.60, 121.17)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],41.46,196146,DB00688,Mycophenolate mofetil
,25913040,dAUC,"Only for MMF [dAUC: 41.46 ng h ml(-1) mg(-1) (95% CI 32.38, 50.54)] and EC-MPS [dAUC: 43.39 ng h ml(-1) mg(-1) (95% CI 33.44, 53.34)] bioequivalence was established for dAUC [geometric mean ratio: 101.25% (90% CI 84.60, 121.17)].",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),[h·ng] / [mg·ml],43.39,196147,DB00688,Mycophenolate mofetil
,25913040,time to Cmax (tmax),Simultaneous EC-MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2.0 h (min-max: 0.5-10.0)] than EC-MPS intake alone [3 h (1.5-12.0); P = 0.037].,No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,2.0,196148,DB00688,Mycophenolate mofetil
,25913040,time to Cmax (tmax),Simultaneous EC-MPS + PAN intake led to an earlier time to Cmax (tmax) [median: 2.0 h (min-max: 0.5-10.0)] than EC-MPS intake alone [3 h (1.5-12.0); P = 0.037].,No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,3,196149,DB00688,Mycophenolate mofetil
,25913040,Tmax,"Tmax was not affected for MMF [1.0 h (0.5-5.0)] ± pantoprazole [1.0 h (0.5-6.0), P = 0.928).",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,1.0,196150,DB00688,Mycophenolate mofetil
,25913040,Tmax,"Tmax was not affected for MMF [1.0 h (0.5-5.0)] ± pantoprazole [1.0 h (0.5-6.0), P = 0.928).",No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25913040/),h,1.0,196151,DB00688,Mycophenolate mofetil
,21440742,C0,"In fact, one patient who showed a low C0 (5.9 ng/mL) while receiving high doses of AVF (0.28 mg/kg), the AUC of 356 and 211 ng.h/mL performed on days 12 and 18 respectively showed exposure consistent with efficacy.",Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440742/),[ng] / [ml],5.9,197621,DB00688,Mycophenolate mofetil
,21440742,AUC,"In fact, one patient who showed a low C0 (5.9 ng/mL) while receiving high doses of AVF (0.28 mg/kg), the AUC of 356 and 211 ng.h/mL performed on days 12 and 18 respectively showed exposure consistent with efficacy.",Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440742/),[h·ng] / [ml],356,197622,DB00688,Mycophenolate mofetil
,21440742,AUC,"In fact, one patient who showed a low C0 (5.9 ng/mL) while receiving high doses of AVF (0.28 mg/kg), the AUC of 356 and 211 ng.h/mL performed on days 12 and 18 respectively showed exposure consistent with efficacy.",Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21440742/),[h·ng] / [ml],211,197623,DB00688,Mycophenolate mofetil
,18279479,population clearance (CL/F),"The typical population clearance (CL/F) estimates with its relative standard error for MPA and MPAG were 10.2 l h(-1) (5.7%) and 1.38 l h(-1) (6.9%), respectively.",Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18279479/),[l] / [h],10.2,197655,DB00688,Mycophenolate mofetil
,18279479,population clearance (CL/F),"The typical population clearance (CL/F) estimates with its relative standard error for MPA and MPAG were 10.2 l h(-1) (5.7%) and 1.38 l h(-1) (6.9%), respectively.",Population pharmacokinetic modelling for enterohepatic circulation of mycophenolic acid in healthy Chinese and the influence of polymorphisms in UGT1A9. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18279479/),[l] / [h],1.38,197656,DB00688,Mycophenolate mofetil
,16272406,partial clearance,"There was no difference in the half-life, hepatic extraction ratio (E(H)), clearance or partial clearance of MPA to MPAGe, but there was a difference in partial clearance to MPAGa between control and CsA groups (0.9 +/- 0.4 versus 0.5 +/- 0.1 ml/min).",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],0.9,197985,DB00688,Mycophenolate mofetil
,16272406,partial clearance,"There was no difference in the half-life, hepatic extraction ratio (E(H)), clearance or partial clearance of MPA to MPAGe, but there was a difference in partial clearance to MPAGa between control and CsA groups (0.9 +/- 0.4 versus 0.5 +/- 0.1 ml/min).",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],0.5,197986,DB00688,Mycophenolate mofetil
,16272406,E(H),"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),,0.59,197987,DB00688,Mycophenolate mofetil
,16272406,E(H),"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],0.95,197988,DB00688,Mycophenolate mofetil
,16272406,clearance,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],18,197989,DB00688,Mycophenolate mofetil
,16272406,clearance,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),[ml] / [min],29,197990,DB00688,Mycophenolate mofetil
,16272406,half-life,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),min,19.5,197991,DB00688,Mycophenolate mofetil
,16272406,half-life,"TR- rats had a lower E(H) (0.59 +/- 0.30 versus 0.95 +/- 0.30), a lower clearance (18 +/- 8 versus 29 +/- 7 ml/min), and a longer half-life (19.5 +/- 10.3 versus 10.1 +/- 2.4 min) than controls.",Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect of cyclosporine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16272406/),min,10.1,197992,DB00688,Mycophenolate mofetil
,16456831,C(max),"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],50.3,198837,DB00688,Mycophenolate mofetil
,16456831,trough levels,"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],21.8,198838,DB00688,Mycophenolate mofetil
,16456831,trough levels,"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],25.7,198839,DB00688,Mycophenolate mofetil
,16456831,trough levels,"Mean daclizumab C(max) was 50.3 microg/mL on day 1, and mean trough levels were 21.8, 25.7, and 9.9 microg/mL on days 3, 8, and 30, respectively.",A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16456831/),[μg] / [ml],9.9,198840,DB00688,Mycophenolate mofetil
,26102431,Ctrough,"Dose-normalized MPA Ctrough and area under the concentration-time curve from 0 to 12h (AUC12) were within 0.29-6.47 μg/mL/600 mg/m(2) and 9.97-105.52 μg h/mL/600 mg/m(2), respectively.",Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26102431/),[600·mg·ml·μg] / [m(2],0.29-6.47,199216,DB00688,Mycophenolate mofetil
,26102431,area under the concentration-time curve from 0 to 12h (AUC12),"Dose-normalized MPA Ctrough and area under the concentration-time curve from 0 to 12h (AUC12) were within 0.29-6.47 μg/mL/600 mg/m(2) and 9.97-105.52 μg h/mL/600 mg/m(2), respectively.",Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26102431/),[600·h·mg·ml·μg] / [m(2],9.97-105.52,199217,DB00688,Mycophenolate mofetil
<,26102431,Ctrough,It may be suggested MMF metabolites monitoring in children with proteinuric glomerulopathies is justified by MPA Ctrough<2 μg/mL in patients at risk of the proteinuria recurrence.,Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26102431/),[μg] / [ml],2,199218,DB00688,Mycophenolate mofetil
>,26102431,Ctrough,MPA Ctrough>3 μg/mL may be considered as an efficient one to avoid proteinuria recurrence.,Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26102431/),[μg] / [ml],3,199219,DB00688,Mycophenolate mofetil
exceed,26102431,target,"Finally, MPA target AUC12 should exceed 60 μg h/mL to ensure the safe and effective treatment in children with nephrotic syndrome, however, the upper limit is still to be established.",Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26102431/),[h·μg] / [ml],60,199220,DB00688,Mycophenolate mofetil
exceed,26102431,AUC12,"Finally, MPA target AUC12 should exceed 60 μg h/mL to ensure the safe and effective treatment in children with nephrotic syndrome, however, the upper limit is still to be established.",Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26102431/),[h·μg] / [ml],60,199221,DB00688,Mycophenolate mofetil
,15570185,Tmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,1.59,199867,DB00688,Mycophenolate mofetil
,15570185,Tmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,0.67,199868,DB00688,Mycophenolate mofetil
,15570185,time of Cmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,1.59,199869,DB00688,Mycophenolate mofetil
,15570185,time of Cmax,"However, in diabetic patients Tmax (time of Cmax, 1.59 hours) was higher than for nondiabetic patients (0.67 hours) on day 11 (P = 0.04).",Mycophenolic acid in diabetic renal transplant recipients: pharmacokinetics and application of a limited sampling strategy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15570185/),h,0.67,199870,DB00688,Mycophenolate mofetil
,19709321,peak,"In the following days, an increase in tacrolimus concentration was observed with a peak of 37 ng/mL.",Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),[ng] / [ml],37,200411,DB00688,Mycophenolate mofetil
,19709321,half-life,Tacrolimus half-life was 6.5 days and tacrolimus maintenance dose was 0.5 mg every 4 days.,Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipient. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19709321/),d,6.5,200412,DB00688,Mycophenolate mofetil
,11591896,area under the concentration-time curve (AUC),"As the majority of patients were treated with low doses of cyclosporine after adding MMF, the area under the concentration-time curve (AUC) for cyclosporine showed a wide scatter ranging from 296 to 6400 ng x h/mL.",Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591896/),[h·ng] / [ml],296 to 6400,201483,DB00688,Mycophenolate mofetil
greater,11591896,AUC,"When dividing the MPA profiles into two groups (11 and 12 patients) with a CyA AUC less than or greater than 1600 ng x h/mL, there was a significantly higher 8-hour concentration in the patients with the lower CyA AUC, secondary to a higher second peak.",Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11591896/),[h·ng] / [ml],1600,201484,DB00688,Mycophenolate mofetil
,27616538,dose-adjusted AUC0-12,"3. The median dose-adjusted AUC0-12 of MPA after renal transplantation was significantly lower than before transplantation (57.9 versus 76.5 μg h/mL, respectively, p = 0.002).",Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27616538/),[h·μg] / [ml],57.9,201675,DB00688,Mycophenolate mofetil
,27616538,dose-adjusted AUC0-12,"3. The median dose-adjusted AUC0-12 of MPA after renal transplantation was significantly lower than before transplantation (57.9 versus 76.5 μg h/mL, respectively, p = 0.002).",Effect of hepatic drug transporter polymorphisms on the pharmacokinetics of mycophenolic acid in patients with severe renal dysfunction before renal transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27616538/),[h·μg] / [ml],76.5,201676,DB00688,Mycophenolate mofetil
,17889132,Trough MMF levels,"Trough MMF levels were 3.6 mg/L, percentile (Pc) 25 1.6 mg/L, Pc 75 4.4 mg/L with intraindividual variability median of 65% (Pc 25 14%, Pc 75 79%).",Variability of mycophenolate mofetil trough levels in stable kidney transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889132/),[mg] / [l],3.6,202401,DB00688,Mycophenolate mofetil
,17889132,Trough MMF levels,"Trough MMF levels were 3.6 mg/L, percentile (Pc) 25 1.6 mg/L, Pc 75 4.4 mg/L with intraindividual variability median of 65% (Pc 25 14%, Pc 75 79%).",Variability of mycophenolate mofetil trough levels in stable kidney transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889132/),[mg] / [l],1.6,202402,DB00688,Mycophenolate mofetil
,17889132,Trough MMF levels,"Trough MMF levels were 3.6 mg/L, percentile (Pc) 25 1.6 mg/L, Pc 75 4.4 mg/L with intraindividual variability median of 65% (Pc 25 14%, Pc 75 79%).",Variability of mycophenolate mofetil trough levels in stable kidney transplant patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889132/),[mg] / [l],4.4,202403,DB00688,Mycophenolate mofetil
,23382105,clearance (CL),"The median MPA clearance (CL) and volume of the central compartment were 24.2 L/hour and 36.4 L, respectively, for a 70 kg patient receiving tacrolimus with a serum albumin of 3.4 g/dL.",Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23382105/),[l] / [h],24.2,202474,DB00688,Mycophenolate mofetil
,23382105,volume of the central compartment,"The median MPA clearance (CL) and volume of the central compartment were 24.2 L/hour and 36.4 L, respectively, for a 70 kg patient receiving tacrolimus with a serum albumin of 3.4 g/dL.",Population pharmacokinetics and dose optimization of mycophenolic acid in HCT recipients receiving oral mycophenolate mofetil. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23382105/),l,36.4,202475,DB00688,Mycophenolate mofetil
,20175802,area under the concentration curve from 0 to 12 h (AUC(0-12)),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],98,205062,DB00688,Mycophenolate mofetil
,20175802,area under the concentration curve from 0 to 12 h (AUC(0-12)),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],138,205063,DB00688,Mycophenolate mofetil
,20175802,AUC(0-6),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],63,205064,DB00688,Mycophenolate mofetil
,20175802,AUC(0-6),"The mean dose-adjusted area under the concentration curve from 0 to 12 h (AUC(0-12)) and AUC(0-6) of MPA co-administered with telmisartan were significantly lower than that without ARB (98 vs. 138 ng x h/mL/mg, P = 0.0353 and 63 vs. 96 ng x h/mL/mg, P = 0.0305).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[h·ng] / [mg·ml],96,205065,DB00688,Mycophenolate mofetil
,20175802,AUC ratio,"The AUC ratio of MPA glucuronide (MPAG)/MPA co-administered with telmisartan was higher than that without ARBs, but not significantly (14.2 vs. 9.1).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),,14.2,205066,DB00688,Mycophenolate mofetil
,20175802,AUC ratio,"The AUC ratio of MPA glucuronide (MPAG)/MPA co-administered with telmisartan was higher than that without ARBs, but not significantly (14.2 vs. 9.1).","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),,9.1,205067,DB00688,Mycophenolate mofetil
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],84,205068,DB00688,Mycophenolate mofetil
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],15,205069,DB00688,Mycophenolate mofetil
,20175802,maximum,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],2220,205070,DB00688,Mycophenolate mofetil
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],15,205071,DB00688,Mycophenolate mofetil
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],2220,205072,DB00688,Mycophenolate mofetil
,20175802,minimum plasma concentrations,"The mean maximum and minimum plasma concentrations of telmisartan (40 mg) after oral administration were 84 and 15 ng/mL, respectively, and that of valsartan (80 mg) 2220 and 441 ng/mL, respectively.","Effect of telmisartan, valsartan and candesartan on mycophenolate mofetil pharmacokinetics in Japanese renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20175802/),[ng] / [ml],441,205073,DB00688,Mycophenolate mofetil
,17139160,flow-rate,A flow-rate of 0.5 ml/min was used at ambient temperature and sample detection was carried out at 254 nm.,Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[ml] / [min],0.5,205472,DB00688,Mycophenolate mofetil
,17139160,time to reach the maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],11.7,205473,DB00688,Mycophenolate mofetil
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],4.5,205474,DB00688,Mycophenolate mofetil
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,2.6,205475,DB00688,Mycophenolate mofetil
,17139160,second peak,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,9.0,205476,DB00688,Mycophenolate mofetil
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),[μg] / [ml],10.5,205477,DB00688,Mycophenolate mofetil
,17139160,time to reach maximum,"The time to reach the maximum (11.7 microg/ml) and second peak (4.5 microg/ml) of MPA after morning 0.75 g MMF administration was 2.6 h and 9.0 h, and time to reach maximum (10.5 microg/ml) after evening 0.75 g administration was 4.0 h.",Quantification and 24-hour monitoring of mycophenolic acid by high-performance liquid chromatography in Japanese renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17139160/),h,4.0,205478,DB00688,Mycophenolate mofetil
,30537048,clearance,The clearance of MPA was 12.3 ± 1.14 L/h.,Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Exposure in Chinese Renal Allograft Recipients After Administration of EC-MPS. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30537048/),[l] / [h],12.3,207244,DB00688,Mycophenolate mofetil
,21209244,clearance,MPA clearance in African American males was 26.5 ± 14.4 L/h versus 17.9 ± 6.1 L/h in Caucasian males (P = .035) and 16.1 ± 4.6 L/h in Caucasian females (P = .024) with no difference noted in MPA troughs.,Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209244/),[l] / [h],26.5,207271,DB00688,Mycophenolate mofetil
,21209244,clearance,MPA clearance in African American males was 26.5 ± 14.4 L/h versus 17.9 ± 6.1 L/h in Caucasian males (P = .035) and 16.1 ± 4.6 L/h in Caucasian females (P = .024) with no difference noted in MPA troughs.,Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209244/),[l] / [h],17.9,207272,DB00688,Mycophenolate mofetil
,21209244,clearance,MPA clearance in African American males was 26.5 ± 14.4 L/h versus 17.9 ± 6.1 L/h in Caucasian males (P = .035) and 16.1 ± 4.6 L/h in Caucasian females (P = .024) with no difference noted in MPA troughs.,Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21209244/),[l] / [h],16.1,207273,DB00688,Mycophenolate mofetil
,11269567,maximum MPA plasma concentration,The mean (+/- SD) maximum MPA plasma concentration of 10.6 (+/- 7.5) mg/ml was achieved within 0.5 to 5 hours.,Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),[mg] / [ml],10.6,208347,DB00688,Mycophenolate mofetil
,11269567,steady-state area under the plasma concentration versus time curve (AUC(0-12)),The mean (+/- SD) steady-state area under the plasma concentration versus time curve (AUC(0-12)) was 40 (+/- 30.9) mg/ml/h.,Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),[mg] / [h·ml],40,208348,DB00688,Mycophenolate mofetil
,11269567,half-life,The mean (+/- SD) half-life was 5.8 (+/- 3.8) hours.,Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),h,5.8,208349,DB00688,Mycophenolate mofetil
,11269567,ratio of the AUC,"The mean (+/- SD) ratio of the AUC of mycophenolic acid glucuronide (MPAG) to MPA was 64 (+/- 84), which correlated significantly with serum creatinine (r = 0.72) but not with serum bilirubin concentrations (r = 0.309), indicating accumulation of MPAG in patients with renal dysfunction.",Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),,64,208350,DB00688,Mycophenolate mofetil
<,11269567,trough plasma concentrations,"In 7 primary liver transplant patients on the same dose of MMF, the trough plasma concentrations of MPA during the first week of therapy ranged from < 0.3 to 1.5 microg/ml.",Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11269567/),[μg] / [ml],0,208351,DB00688,Mycophenolate mofetil
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],44.40,209031,DB00688,Mycophenolate mofetil
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],158.01,209032,DB00688,Mycophenolate mofetil
,16387090,AUC12,"In 16 patients, AUC12 values were within the range of 44.40 ng x h/mL to 158.01 ng x h/mL (mean = 92.23 +/- 34.97 ng x h/mL).",Clinical pharmacokinetics of tacrolimus after the first oral administration in combination with mycophenolate mofetil and prednisone in Chinese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16387090/),[h·ng] / [ml],92.23,209033,DB00688,Mycophenolate mofetil
,24739663,EC50,The model estimated EC50 value (164.5 μL) is in good agreement with reported in vitro EC50 values.,Effects of unbound mycophenolic acid on inosine monophosphate dehydrogenase inhibition in pediatric kidney transplant patients. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24739663/),μl,164.5,209494,DB00688,Mycophenolate mofetil
,14703953,AUC0-12h,The mean AUC0-12h for mycophenolic acid was 2-fold higher in patients receiving long-term treatment with MMF (62.2 +/- 16.6 mg x h/ml) compared to dialysis patients receiving 1 g MMF for the first time (31.5 +/- 15.6 mg x h/ml).,Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703953/),[h·mg] / [ml],62.2,209987,DB00688,Mycophenolate mofetil
,14703953,AUC0-12h,The mean AUC0-12h for mycophenolic acid was 2-fold higher in patients receiving long-term treatment with MMF (62.2 +/- 16.6 mg x h/ml) compared to dialysis patients receiving 1 g MMF for the first time (31.5 +/- 15.6 mg x h/ml).,Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703953/),[h·mg] / [ml],31.5,209988,DB00688,Mycophenolate mofetil
,14703953,Minimal,Minimal IMPDH activity (1.62 +/- 1.23 vs. 1.77 +/- 1.49 nmol/h/mg protein) and maximal IMPDH inhibition (87.5 +/- 0.08 vs. 77.4 +/- 18.8%) during the dosing interval were similar.,Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703953/),[nM] / [h·mg],1.62,209989,DB00688,Mycophenolate mofetil
,14703953,Minimal,Minimal IMPDH activity (1.62 +/- 1.23 vs. 1.77 +/- 1.49 nmol/h/mg protein) and maximal IMPDH inhibition (87.5 +/- 0.08 vs. 77.4 +/- 18.8%) during the dosing interval were similar.,Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703953/),[nM] / [h·mg],1.77,209990,DB00688,Mycophenolate mofetil
,14703953,maximal,Minimal IMPDH activity (1.62 +/- 1.23 vs. 1.77 +/- 1.49 nmol/h/mg protein) and maximal IMPDH inhibition (87.5 +/- 0.08 vs. 77.4 +/- 18.8%) during the dosing interval were similar.,Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14703953/),%,87.5,209991,DB00688,Mycophenolate mofetil
>,33246587,AUC0-12,All patients >60 years had MPA AUC0-12 >30 μg·h/mL within 22 to 114 days after transplantation.,Pharmacokinetics of Enteric-Coated Mycophenolate Sodium Metabolites in Patients Over 60 Years Old Within the First Year After Renal Transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33246587/),[h·μg] / [ml],30,210103,DB00688,Mycophenolate mofetil
,17889135,trough plasma MPA levels,The trough plasma MPA levels increased from 1.5 +/- 1.1 microg/mL at baseline to 2.5 +/- 2.0 microg/mL at 1 month postconversion despite the equipotent EC-MPS doses not being increased.,Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889135/),[μg] / [ml],1.5,210372,DB00688,Mycophenolate mofetil
,17889135,trough plasma MPA levels,The trough plasma MPA levels increased from 1.5 +/- 1.1 microg/mL at baseline to 2.5 +/- 2.0 microg/mL at 1 month postconversion despite the equipotent EC-MPS doses not being increased.,Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889135/),[μg] / [ml],2.5,210373,DB00688,Mycophenolate mofetil
,32949050,AUC0-12 s,"The MPA AUC0-12 s in the no event, infection, and CLAD groups were 30.3 ± 6.5, 36.8 ± 10.7, and 20.6 ± 9.6 µg·h/mL, respectively (P = .0027), while the tacrolimus trough levels were similarly controlled in the groups.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],30.3,210468,DB00688,Mycophenolate mofetil
,32949050,AUC0-12 s,"The MPA AUC0-12 s in the no event, infection, and CLAD groups were 30.3 ± 6.5, 36.8 ± 10.7, and 20.6 ± 9.6 µg·h/mL, respectively (P = .0027), while the tacrolimus trough levels were similarly controlled in the groups.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],36.8,210469,DB00688,Mycophenolate mofetil
,32949050,AUC0-12 s,"The MPA AUC0-12 s in the no event, infection, and CLAD groups were 30.3 ± 6.5, 36.8 ± 10.7, and 20.6 ± 9.6 µg·h/mL, respectively (P = .0027), while the tacrolimus trough levels were similarly controlled in the groups.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],20.6,210470,DB00688,Mycophenolate mofetil
,32949050,AUC0-12,"The thresholds of MPA AUC0-12 for the occurrence of infection and CLAD were 40.5 and 22.8 µg·h/mL, respectively.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],40.5,210471,DB00688,Mycophenolate mofetil
,32949050,AUC0-12,"The thresholds of MPA AUC0-12 for the occurrence of infection and CLAD were 40.5 and 22.8 µg·h/mL, respectively.",Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),[h·μg] / [ml],22.8,210472,DB00688,Mycophenolate mofetil
,32949050,cumulative occurrence rate of adverse events,The cumulative occurrence rate of adverse events of adequate group (15.3%) was significantly lower than that of inadequate group (56.0%) (P = .0050).,Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),%,15.3,210473,DB00688,Mycophenolate mofetil
,32949050,cumulative occurrence rate of adverse events,The cumulative occurrence rate of adverse events of adequate group (15.3%) was significantly lower than that of inadequate group (56.0%) (P = .0050).,Plasma mycophenolic acid concentration and the clinical outcome after lung transplantation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32949050/),%,56.0,210474,DB00688,Mycophenolate mofetil
,28536776,area under the concentration-time curve from 0 to 12 h (AUC0-12),Simulations using the final model showed that a 70-kg subject with a creatinine clearance of 90 mL/min receiving concomitant CsA would require 1.25 g of MMF twice daily while a similar subject who did not receive concomitant CsA would require 0.75 g twice daily to achieve a MPA area under the concentration-time curve from 0 to 12 h (AUC0-12) of 45 mg·h/L.,Development of Improved Dosing Regimens for Mycophenolate Mofetil Based on Population Pharmacokinetic Analyses in Adults with Lupus Nephritis. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28536776/),[h·mg] / [l],45,211465,DB00688,Mycophenolate mofetil
,15740555,AUC(0-infinity),"Both EC-MPS doses delivered bioequivalent mean MPA exposure (AUC(0-infinity)) compared with 1000 mg MMF: 60.7 microg h/mL for 640 mg EC-MPS, 66.5 microg h/mL for 720 mg EC-MPS, and 63.7 microg h/mL for 1000 mg MMF.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),[h·μg] / [ml],60.7,211901,DB00688,Mycophenolate mofetil
,15740555,AUC(0-infinity),"Both EC-MPS doses delivered bioequivalent mean MPA exposure (AUC(0-infinity)) compared with 1000 mg MMF: 60.7 microg h/mL for 640 mg EC-MPS, 66.5 microg h/mL for 720 mg EC-MPS, and 63.7 microg h/mL for 1000 mg MMF.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),[h·μg] / [ml],66.5,211902,DB00688,Mycophenolate mofetil
,15740555,AUC(0-infinity),"Both EC-MPS doses delivered bioequivalent mean MPA exposure (AUC(0-infinity)) compared with 1000 mg MMF: 60.7 microg h/mL for 640 mg EC-MPS, 66.5 microg h/mL for 720 mg EC-MPS, and 63.7 microg h/mL for 1000 mg MMF.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),[h·μg] / [ml],63.7,211903,DB00688,Mycophenolate mofetil
,15740555,t(max),"Median t(max) was significantly delayed for both EC-MPS doses compared with MMF (2.0 h vs. 0.75 h, respectively; p < 0.01), consistent with a functional enteric coating of EC-MPS.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),h,2.0,211904,DB00688,Mycophenolate mofetil
,15740555,t(max),"Median t(max) was significantly delayed for both EC-MPS doses compared with MMF (2.0 h vs. 0.75 h, respectively; p < 0.01), consistent with a functional enteric coating of EC-MPS.",Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15740555/),h,0.75,211905,DB00688,Mycophenolate mofetil
,27669677,AUC0-12h,A PK curve of tacrolimus recorded ≤3 weeks after transplantation has been standard of care in our institution and aided in adjusting the dose in each patient to attain a target AUC0-12h of 210 μg h/l early after transplantation.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),[h·μg] / [l],210,212651,DB00688,Mycophenolate mofetil
,27669677,dose-corrected,Median dose-corrected AUCtau was 63 μg h/l. AUC target attainment was 37.5%.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),[h·μg] / [l],63,212652,DB00688,Mycophenolate mofetil
,27669677,AUCtau,Median dose-corrected AUCtau was 63 μg h/l. AUC target attainment was 37.5%.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),[h·μg] / [l],63,212653,DB00688,Mycophenolate mofetil
,27669677,AUC target attainment,Median dose-corrected AUCtau was 63 μg h/l. AUC target attainment was 37.5%.,A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27669677/),%,37.5,212654,DB00688,Mycophenolate mofetil
,16860172,AUCs,"In patients receiving CsA/MMF, MPA AUCs ranged from 19.67 to 81.80 mg/h.L (mean [SD], 41.92 [14.14] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],19.67 to 81.80,213191,DB00688,Mycophenolate mofetil
,16860172,AUCs,"In patients receiving CsA/MMF, MPA AUCs ranged from 19.67 to 81.80 mg/h.L (mean [SD], 41.92 [14.14] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],41.92,213192,DB00688,Mycophenolate mofetil
<,16860172,AUCs,"Co levels of 0.5 and 1.6 mg/L were correlated with AUCs of <30 and <40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],30,213193,DB00688,Mycophenolate mofetil
<,16860172,AUCs,"Co levels of 0.5 and 1.6 mg/L were correlated with AUCs of <30 and <40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],40,213194,DB00688,Mycophenolate mofetil
,16860172,AUCs,"In patients receiving RAPA/MMF, MPA AUCs ranged from 34.40 to 87.60 mg/h.L (mean, 51.07 [15.80] mg/h.L).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],51.07,213195,DB00688,Mycophenolate mofetil
,16860172,C0,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [l],1.0,213196,DB00688,Mycophenolate mofetil
,16860172,C0,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [l],2.3,213197,DB00688,Mycophenolate mofetil
,16860172,AUCs,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],30,213198,DB00688,Mycophenolate mofetil
,16860172,AUCs,"MPA C0 levels of 1.0 and 2.3 mg/L were correlated with AUCs of 30 and 40 mg/h.L, respectively.",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [h·l],40,213199,DB00688,Mycophenolate mofetil
,16860172,AUC,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·h·l],60.95,213200,DB00688,Mycophenolate mofetil
,16860172,AUC,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·h·l],31.92,213201,DB00688,Mycophenolate mofetil
,16860172,C0,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·l],5.10,213202,DB00688,Mycophenolate mofetil
,16860172,C0,"Statistically significant differences between RAPA/MMF and CsA/MMF were noted in the mean MMF dosage (1.90 [0.71] vs 2.87 [0.78] g/d, respectively; P<0.001), the mean dose-adjusted MPA AUC (60.95 [27.42] vs 31.92 [16.12] mg/h.L.g MMF; P<0.001), and mean dose-adjusted MPA C0 levels (5.10 [3.41] vs 1.41 [0.95] mg/L.g; P<0.001).",A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A-containing and cyclosporin A-free immunosuppressive regimens. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16860172/),[mg] / [g·l],1.41,213203,DB00688,Mycophenolate mofetil
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),[μg] / [h·ml],52.68,215239,DB00688,Mycophenolate mofetil
,17445555,area under the curve (AUC 0-6),"The area under the curve (AUC 0-6) of MPA was 52.68 +/- 17.5 microg/mL*hr, with 61.5% of basal determinations (Co) under 5 microg/mL (4.08 +/- 0.74).",Converting to a generic formulation of mycophenolate mofetil in stable kidney transplant recipients: 1 year of drug surveillance and outcome. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17445555/),,4,215240,DB00688,Mycophenolate mofetil
,12352931,trough levels,"Co-medication with CsA demanded higher MPA mofetil (MMF) doses to achieve equivalent trough levels than Tac (362 vs. 178 mg per mg/L, P= 0.004).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l·mg],362,215557,DB00688,Mycophenolate mofetil
,12352931,trough levels,"Co-medication with CsA demanded higher MPA mofetil (MMF) doses to achieve equivalent trough levels than Tac (362 vs. 178 mg per mg/L, P= 0.004).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l·mg],178,215558,DB00688,Mycophenolate mofetil
,12352931,C(0),"Median MPA C(0) (range) was significantly lower during CsA co-therapy when corrected for MMF dose (2.8 vs. 5.6 mg MPA/L for Tac, P= 0.006).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[Mpa·mg] / [l],2.8,215559,DB00688,Mycophenolate mofetil
,12352931,C(0),"Median MPA C(0) (range) was significantly lower during CsA co-therapy when corrected for MMF dose (2.8 vs. 5.6 mg MPA/L for Tac, P= 0.006).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[Mpa·mg] / [l],5.6,215560,DB00688,Mycophenolate mofetil
,12352931,AUC,"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [h·l],229,215561,DB00688,Mycophenolate mofetil
,12352931,AUC,"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [h·l],94,215562,DB00688,Mycophenolate mofetil
,12352931,ratio at C(0),"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),,0.10,215563,DB00688,Mycophenolate mofetil
,12352931,ratio at C(0),"The AUC of MPAG was correspondingly higher during CsA co-medication (229 vs. 94 mg/L/h for Tac, P = 0.012) with the MPA-to-MPAG ratio at C(0) correspondingly lower (0.10 vs. 0.14, respectively, P = 0.04).",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),,0.14,215564,DB00688,Mycophenolate mofetil
,12352931,trough levels,"Children with elevated aspartate transaminase (AST; but with no evidence of rejection on liver biopsy, n = 7) had significantly lower MPA trough levels compared with those in whom AST was normal (0. 77 vs. 1.76 mg/L, P = 0.05), but there was no difference in the MMF dose per body weight.",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l],0. 77,215565,DB00688,Mycophenolate mofetil
,12352931,trough levels,"Children with elevated aspartate transaminase (AST; but with no evidence of rejection on liver biopsy, n = 7) had significantly lower MPA trough levels compared with those in whom AST was normal (0. 77 vs. 1.76 mg/L, P = 0.05), but there was no difference in the MMF dose per body weight.",Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: effect of cyclosporine and tacrolimus comedication. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12352931/),[mg] / [l],1.76,215566,DB00688,Mycophenolate mofetil
,15518754,trough levels,"Oral tacrolimus was initiated at about 0.2 mg/kg/d, dose which was adjusted to achieve target trough levels of 10 to 20 ng/mL at 3 months and 5 to 10 ng/mL thereafter.",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[ng] / [ml],10 to 20,217652,DB00688,Mycophenolate mofetil
,15518754,trough levels,"Oral tacrolimus was initiated at about 0.2 mg/kg/d, dose which was adjusted to achieve target trough levels of 10 to 20 ng/mL at 3 months and 5 to 10 ng/mL thereafter.",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[ng] / [ml],5 to 10,217653,DB00688,Mycophenolate mofetil
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],40.5,217654,DB00688,Mycophenolate mofetil
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],44.4,217655,DB00688,Mycophenolate mofetil
,15518754,AUC,"Mean MPA AUC values at 1, 3, and 6 months were 40.5 +/- 9.4, 44.4 +/- 17.3, and 57.2 +/- 20.7 mug*h/mL, respectively (P = .0486, n = 7).",Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15518754/),[h·μg] / [ml],57.2,217656,DB00688,Mycophenolate mofetil
,17906856,area under the cuve (AUC)(6-12),"The dose-adjusted area under the cuve (AUC)(6-12) of MPA, an estimate of enterohepatic recirculation, was greater in SLCO1B3 T334G GG (or G699A AA) carriers than in TT carriers (or G699A GG) (40 vs. 25 ng h/mL per milligram, respectively, P = 0.0497).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[h·ng] / [milligram·ml],40,218043,DB00688,Mycophenolate mofetil
,17906856,area under the cuve (AUC)(6-12),"The dose-adjusted area under the cuve (AUC)(6-12) of MPA, an estimate of enterohepatic recirculation, was greater in SLCO1B3 T334G GG (or G699A AA) carriers than in TT carriers (or G699A GG) (40 vs. 25 ng h/mL per milligram, respectively, P = 0.0497).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[h·ng] / [milligram·ml],25,218044,DB00688,Mycophenolate mofetil
,17906856,oral clearance,"However, the oral clearance of MPA in recipients having both the SLCO1B3 T334G GG genotype and the ABCC2 C-24T T allele was significantly lower than in patients having both the SLCO1B3 T334G TT and ABCC2 C-24T CC genotypes (0.15 vs. 0.18 L/h per kilogram, respectively, P = 0.0010).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[l] / [h·kg],0.15,218045,DB00688,Mycophenolate mofetil
,17906856,oral clearance,"However, the oral clearance of MPA in recipients having both the SLCO1B3 T334G GG genotype and the ABCC2 C-24T T allele was significantly lower than in patients having both the SLCO1B3 T334G TT and ABCC2 C-24T CC genotypes (0.15 vs. 0.18 L/h per kilogram, respectively, P = 0.0010).","Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17906856/),[l] / [h·kg],0.18,218046,DB00688,Mycophenolate mofetil
>,20047618,C0 h,High MPA C0 h levels>10 μg/mL were rarely observed with both EC-MPS (1.8%) and MMF (0.6%).,Randomized crossover study to assess the inter- and intrasubject variability of morning mycophenolic acid concentrations from enteric-coated mycophenolate sodium and mycophenolate mofetil in stable renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20047618/),[μg] / [ml],10,218423,DB00688,Mycophenolate mofetil
,20814351,recovery,"Mean recovery of the two methods was 98.0% and 97.1%, respectively.",Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814351/),%,98.0,218500,DB00688,Mycophenolate mofetil
,20814351,recovery,"Mean recovery of the two methods was 98.0% and 97.1%, respectively.",Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814351/),%,97.1,218501,DB00688,Mycophenolate mofetil
,20814351,AUC0-12,"The AUC0-12 of tMPA and fMPA obtained by HPLC in 51 patients was 34.7 ± 11.1 and 0.72 ± 0.38 μg·h/mL, respectively.",Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814351/),[h·μg] / [ml],34.7,218502,DB00688,Mycophenolate mofetil
,20814351,AUC0-12,"The AUC0-12 of tMPA and fMPA obtained by HPLC in 51 patients was 34.7 ± 11.1 and 0.72 ± 0.38 μg·h/mL, respectively.",Establishment of high-performance liquid chromatography and enzyme multiplied immunoassay technology methods for determination of free mycophenolic acid and its application in Chinese liver transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20814351/),[h·μg] / [ml],0.72,218503,DB00688,Mycophenolate mofetil
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),%,38,219180,DB00688,Mycophenolate mofetil
,29753157,relapse,One-year relapse was 38% for AML and 13% for MDS.,"Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29753157/),,13,219181,DB00688,Mycophenolate mofetil
,10684355,plasma concentration of MPA at steady state,The mean plasma concentration of MPA at steady state was 4.7+/-1.3 microg/ml.,Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[μg] / [ml],4.7,220840,DB00688,Mycophenolate mofetil
,10684355,areas under the plasma concentration-time curves (AUCs) over 12 h,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],57.0,220841,DB00688,Mycophenolate mofetil
,10684355,areas under the plasma concentration-time curves (AUCs) over 12 h,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],"1,515",220842,DB00688,Mycophenolate mofetil
,10684355,apparent oral clearance,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[l] / [h],11.7,220843,DB00688,Mycophenolate mofetil
,10684355,apparent oral clearance,"The areas under the plasma concentration-time curves (AUCs) over 12 h (between two administrations) were 57.0+/-15.3 microg.h/ml for MPA and 1,515+/-722 microg.h/ml for MPAG, and the apparent oral clearance was 11.7+/-7.0 and 0.5+/-0.4 l/h for MPA and MPAG, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[l] / [h],0.5,220844,DB00688,Mycophenolate mofetil
,10684355,concentration at steady state,"Assuming that the pharmacokinetics of MPA was dose dependent, the mean concentration at steady state and the AUC for MPA were calculated for the recommended dosage schedule of 600 mg/m(2) every 12 h and were 6.3+/-2.7 microg/ml and 75.2+/-32.9 microg.h/ml, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[μg] / [ml],6.3,220845,DB00688,Mycophenolate mofetil
,10684355,AUC,"Assuming that the pharmacokinetics of MPA was dose dependent, the mean concentration at steady state and the AUC for MPA were calculated for the recommended dosage schedule of 600 mg/m(2) every 12 h and were 6.3+/-2.7 microg/ml and 75.2+/-32.9 microg.h/ml, respectively.",Pharmacokinetics and tolerance of mycophenolate mofetil in renal transplant children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10684355/),[h·μg] / [ml],75.2,220846,DB00688,Mycophenolate mofetil
,17038879,Tmax,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),h,1.9,221311,DB00688,Mycophenolate mofetil
,17038879,Tmax,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),h,1.5,221312,DB00688,Mycophenolate mofetil
,17038879,C2,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),[ng] / [ml],988,221313,DB00688,Mycophenolate mofetil
,17038879,C2,"At month 6 postsurgery, patients on EC-MPS had a shift to the right in the CsA peak concentration as compared to that in patients given MMF, an effect associated with significant differences in CsA Tmax (1.9 +/- 0.3 h vs. 1.5 +/- 0.6 h, P < 0.05), C2 (988 +/- 259 vs. 720 +/- 214 ng/mL, P < 0.01), and C3 levels (539 +/- 119 vs. 435 +/- 119 ng/mL, P < 0.05).",Mycophenolic acid formulation affects cyclosporine pharmacokinetics in stable kidney transplant recipients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17038879/),[ng] / [ml],720,221314,DB00688,Mycophenolate mofetil
,31055791,apparent oral clearance,"The apparent oral clearance estimate in the final model (population mean, relative standard error) was 2.87 L/h, 42.3%, which is lower than that reported for similar patients on corticosteroid-based regimens (11.9-26.3 L/h).",Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],2.87,221761,DB00688,Mycophenolate mofetil
,31055791,apparent oral clearance,"The apparent oral clearance estimate in the final model (population mean, relative standard error) was 2.87 L/h, 42.3%, which is lower than that reported for similar patients on corticosteroid-based regimens (11.9-26.3 L/h).",Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],11.9-26.3,221762,DB00688,Mycophenolate mofetil
,31055791,apparent oral clearance,Both mycophenolic acid-acyl-glucuronide trough concentration and the area under the concentration-time curve ratio were significant covariates that reduced mycophenolic acid apparent oral clearance from 16.5 (base model) to 2.87 L/h.,Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],16.5,221763,DB00688,Mycophenolate mofetil
,31055791,apparent oral clearance,Both mycophenolic acid-acyl-glucuronide trough concentration and the area under the concentration-time curve ratio were significant covariates that reduced mycophenolic acid apparent oral clearance from 16.5 (base model) to 2.87 L/h.,Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31055791/),[l] / [h],2.87,221764,DB00688,Mycophenolate mofetil
,17048977,transfer rate constant,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),1/[h],5.25,221778,DB00688,Mycophenolate mofetil
,17048977,transfer rate constant,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),l,218,221779,DB00688,Mycophenolate mofetil
,17048977,apparent volume of,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),l,218,221780,DB00688,Mycophenolate mofetil
,17048977,apparent volume of,"The mean pharmacokinetic parameter estimates were 5.25 h(-1), 218L and 292L for the transfer rate constant, the apparent volume of the central and peripheral compartments, respectively.",Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),l,292,221781,DB00688,Mycophenolate mofetil
,17048977,oral clearance,The CYP3A5*1/*3 polymorphism significantly influenced the apparent oral clearance: mean oral clearance = 14.1 L/h for CYP3A5 non expressers (CYP3A5*3/*3 genotype) versus 28.3 L/h for CYP3A5 expressers (CYP3A5*1/*3 and *1/*1 genotypes).,Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),[l] / [h],14.1,221782,DB00688,Mycophenolate mofetil
,17048977,oral clearance,The CYP3A5*1/*3 polymorphism significantly influenced the apparent oral clearance: mean oral clearance = 14.1 L/h for CYP3A5 non expressers (CYP3A5*3/*3 genotype) versus 28.3 L/h for CYP3A5 expressers (CYP3A5*1/*3 and *1/*1 genotypes).,Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17048977/),[l] / [h],28.3,221783,DB00688,Mycophenolate mofetil
,14748898,trough MPA concentration,Mean daily MMF dose was 24.5 +/- 6.3 mg/kg and mean trough MPA concentration was 2.9 +/- 1.9 microg/mL.,Monitoring trough plasma concentrations of mycophenolate mofetil in patients with uveitis. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14748898/),[μg] / [ml],2.9,222089,DB00688,Mycophenolate mofetil
,20840448,"AUC(0,12h)","Simulations (n= 1000) were conducted to assess the suitability of the MPA dose regimens to maintain total MPA AUC(0,12h) within the range 30 and 60mg l(-1) h associated with optimal outcome.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),[h·mg] / [l],30,224060,DB00688,Mycophenolate mofetil
,20840448,"AUC(0,12h)","Simulations (n= 1000) were conducted to assess the suitability of the MPA dose regimens to maintain total MPA AUC(0,12h) within the range 30 and 60mg l(-1) h associated with optimal outcome.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),[h·mg] / [l],60,224061,DB00688,Mycophenolate mofetil
,20840448,clearance,"Population mean estimates of MPA clearance, inter-compartmental clearance, volumes of distribution in the central and peripheral compartments, absorption rate constant and bioavailability were 6.42 l h(-1) , 3.74 l h(-1) , 7.24 l, 16.8l, 0.39h(-1) and 0.48, respectively.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),[l] / [h],6.42,224062,DB00688,Mycophenolate mofetil
,20840448,bioavailability,"Population mean estimates of MPA clearance, inter-compartmental clearance, volumes of distribution in the central and peripheral compartments, absorption rate constant and bioavailability were 6.42 l h(-1) , 3.74 l h(-1) , 7.24 l, 16.8l, 0.39h(-1) and 0.48, respectively.",Population pharmacokinetics of mycophenolic acid in children and young people undergoing blood or marrow and solid organ transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20840448/),,0.48,224063,DB00688,Mycophenolate mofetil
,29735215,peak concentration (Cmax),"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),[mg] / [l],7.0,225227,DB00688,Mycophenolate mofetil
,29735215,peak concentration (Cmax),"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),[mg] / [l],10.8,225228,DB00688,Mycophenolate mofetil
,29735215,time to peak concentration,"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),h,3.2,225229,DB00688,Mycophenolate mofetil
,29735215,time to peak concentration,"The peak concentration (Cmax) in the MMF dispersible tablets (MMFdt) group (7.0 ± 2.8) mg/L was reduced compared with that in the MMF capsules (MMFc) group (10.8 ± 6.2 mg/L; P = .012); time to peak concentration in the MMFdt group was 3.2 ± 2.3 hours, which was nonsignificantly elevated compared with that of the MMFc group (2.2 ± 1.7 hours).",Limited Sampling Strategy for Estimating Mycophenolic Acid Exposure on Day 7 Post-Transplant for Two Mycophenolate Mofetil Formulations Derived From 20 Chinese Renal Transplant Recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29735215/),h,2.2,225230,DB00688,Mycophenolate mofetil
<,22466911,AUC,Cardiac rejection was associated with low MPA AUC values with a threshold of <36.2 mg×h/L during the first two post-transplant weeks.,Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[h·mg] / [l],36.2,225359,DB00688,Mycophenolate mofetil
,22466911,trough level,A threshold of 2-weeks average MPA trough level of 1.43 mg/L provided a sensitivity 82% and a specificity of 60%.<br />,Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[mg] / [l],1.43,225360,DB00688,Mycophenolate mofetil
,22466911,trough,"For patients with Cyclosporine co-immunosuppression, we propose an MPA trough of 1.4 mg/L and an MPA AUC of 36 mg × h/L as threshold values for dose adjustments.",Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[mg] / [l],1.4,225361,DB00688,Mycophenolate mofetil
,22466911,AUC,"For patients with Cyclosporine co-immunosuppression, we propose an MPA trough of 1.4 mg/L and an MPA AUC of 36 mg × h/L as threshold values for dose adjustments.",Pharmacokinetic monitoring of mycophenolic acid in heart transplant patients: correlation the side-effects and rejections with pharmacokinetic parameters. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22466911/),[h·mg] / [l],36,225362,DB00688,Mycophenolate mofetil
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],63,225694,DB00688,Mycophenolate mofetil
,20926996,steady-state area under the concentration-time curve,"Based on individual estimates oral clearance from the population pharmacokinetic model, mean steady-state area under the concentration-time curve values for a mycophenolate mofetil dose of 1000 mg twice daily were 63 mg·hr/L (22%) and 59 mg·hr/L (36%) for the tasocitinib and tacrolimus groups, respectively.","Population pharmacokinetic analysis of mycophenolic acid coadministered with either tasocitinib (CP-690,550) or tacrolimus in adult renal allograft recipients. ",AUCSS-Q18,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20926996/),[h·mg] / [l],59,225695,DB00688,Mycophenolate mofetil
,16926592,area under the concentration-time curve (AUC0-12),"The daytime area under the concentration-time curve (AUC0-12) was larger than the nighttime AUC0-12 (55.09 vs. 50.54 microg.hr/ml, P=0.049).",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[h·μg] / [ml],55.09,226912,DB00688,Mycophenolate mofetil
,16926592,AUC0-12,"The daytime area under the concentration-time curve (AUC0-12) was larger than the nighttime AUC0-12 (55.09 vs. 50.54 microg.hr/ml, P=0.049).",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[h·μg] / [ml],50.54,226913,DB00688,Mycophenolate mofetil
,16926592,daytime,"The MMF single dose per body weight (12.46 mg/kg in patients with AR vs. 16.99 in patients without AR), daytime and nighttime AUC0-12 (32.41 vs. 62.00 and 24.44 vs. 57.88 microg.hr/ml) and morning trough level of MPA (1.03 vs. 3.83 microg/ml) were significantly lower in patients with AR than in those without AR.",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[h·μg] / [ml],32.41,226914,DB00688,Mycophenolate mofetil
,16926592,AUC0-12,"The MMF single dose per body weight (12.46 mg/kg in patients with AR vs. 16.99 in patients without AR), daytime and nighttime AUC0-12 (32.41 vs. 62.00 and 24.44 vs. 57.88 microg.hr/ml) and morning trough level of MPA (1.03 vs. 3.83 microg/ml) were significantly lower in patients with AR than in those without AR.",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[h·μg] / [ml],32.41,226915,DB00688,Mycophenolate mofetil
,16926592,AUC0-12,"The MMF single dose per body weight (12.46 mg/kg in patients with AR vs. 16.99 in patients without AR), daytime and nighttime AUC0-12 (32.41 vs. 62.00 and 24.44 vs. 57.88 microg.hr/ml) and morning trough level of MPA (1.03 vs. 3.83 microg/ml) were significantly lower in patients with AR than in those without AR.",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[h·μg] / [ml],62.00,226916,DB00688,Mycophenolate mofetil
,16926592,AUC0-12,"The MMF single dose per body weight (12.46 mg/kg in patients with AR vs. 16.99 in patients without AR), daytime and nighttime AUC0-12 (32.41 vs. 62.00 and 24.44 vs. 57.88 microg.hr/ml) and morning trough level of MPA (1.03 vs. 3.83 microg/ml) were significantly lower in patients with AR than in those without AR.",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[h·μg] / [ml],24.44,226917,DB00688,Mycophenolate mofetil
,16926592,AUC0-12,"The MMF single dose per body weight (12.46 mg/kg in patients with AR vs. 16.99 in patients without AR), daytime and nighttime AUC0-12 (32.41 vs. 62.00 and 24.44 vs. 57.88 microg.hr/ml) and morning trough level of MPA (1.03 vs. 3.83 microg/ml) were significantly lower in patients with AR than in those without AR.",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[h·μg] / [ml],57.88,226918,DB00688,Mycophenolate mofetil
,16926592,trough level,"The MMF single dose per body weight (12.46 mg/kg in patients with AR vs. 16.99 in patients without AR), daytime and nighttime AUC0-12 (32.41 vs. 62.00 and 24.44 vs. 57.88 microg.hr/ml) and morning trough level of MPA (1.03 vs. 3.83 microg/ml) were significantly lower in patients with AR than in those without AR.",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[μg] / [ml],1.03,226919,DB00688,Mycophenolate mofetil
,16926592,trough level,"The MMF single dose per body weight (12.46 mg/kg in patients with AR vs. 16.99 in patients without AR), daytime and nighttime AUC0-12 (32.41 vs. 62.00 and 24.44 vs. 57.88 microg.hr/ml) and morning trough level of MPA (1.03 vs. 3.83 microg/ml) were significantly lower in patients with AR than in those without AR.",Circadian pharmacokinetics of mycophenolic Acid and implication of genetic polymorphisms for early clinical events in renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16926592/),[μg] / [ml],3.83,226920,DB00688,Mycophenolate mofetil
,15905802,AUC,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],29.7,227067,DB00688,Mycophenolate mofetil
,15905802,AUCs,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],34.2,227068,DB00688,Mycophenolate mofetil
,15905802,AUCs,"The median MPA AUC on day 6 (29.7 mg.h/L) after the first oral dose was slightly lower than the AUCs on the other study days (34.2, 33.8, and 33.8 mg.h/L on days 3, 5, and 10, respectively).",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),[h·mg] / [l],33.8,227069,DB00688,Mycophenolate mofetil
,15905802,bioavailability,"The results of this study show that heart transplant recipients receiving the IV formulation of MMF (1.5 g BID) are not subject to a greater drug exposure than that seen with the oral formulation (1.5 g BID) and that the oral MMF formulation shows excellent, high, and consistent bioavailability (mean 95%) based on comparison with the IV formulation.",Pharmacokinetics and bioavailability of mycophenolic acid after intravenous administration and oral administration of mycophenolate mofetil to heart transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15905802/),%,95,227070,DB00688,Mycophenolate mofetil
,31974333,plasma concentrations,The mean MPA plasma concentrations were statistically significantly different between parenteral group (2.3±1.4 umg/mL) and oral group (3.1±2.2 umg/mL) (P=0.036) before immunosuppressive drug administration (C-0 time).,Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31974333/),[umg] / [ml],2.3,227733,DB00688,Mycophenolate mofetil
,31974333,plasma concentrations,The mean MPA plasma concentrations were statistically significantly different between parenteral group (2.3±1.4 umg/mL) and oral group (3.1±2.2 umg/mL) (P=0.036) before immunosuppressive drug administration (C-0 time).,Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31974333/),[umg] / [ml],3.1,227734,DB00688,Mycophenolate mofetil
,31974333,C-30,There was a statistically significant different drug concentration at the second sample time C-30 (30 minutes after drug intake) reaching 4.4±2.8 umg/mL versus 7.9±4.5 umg/mL (P<0.05).,Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31974333/),[umg] / [ml],4.4,227735,DB00688,Mycophenolate mofetil
,31974333,C-30,There was a statistically significant different drug concentration at the second sample time C-30 (30 minutes after drug intake) reaching 4.4±2.8 umg/mL versus 7.9±4.5 umg/mL (P<0.05).,Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31974333/),[umg] / [ml],7.9,227736,DB00688,Mycophenolate mofetil
,31974333,C-120,"There was no statistically significant difference in MPA plasma concentration at the 3rd measurement C-120 (10.7±4,9 umg/mL versus 9.8±5 umg/mL) (P=0.3).",Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31974333/),[umg] / [ml],10.7,227737,DB00688,Mycophenolate mofetil
,31974333,C-120,"There was no statistically significant difference in MPA plasma concentration at the 3rd measurement C-120 (10.7±4,9 umg/mL versus 9.8±5 umg/mL) (P=0.3).",Different Routes of Proton Pumps Inhibitors Co-Administration have Significant Impact on Mycophenolate Acid (MPA) Serum Levels in Heart Transplant Recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31974333/),[umg] / [ml],9.8,227738,DB00688,Mycophenolate mofetil
,10778939,flow-rate,"Chromatographic separation consisted of the mobile phase [acetonitrile-0.05% phosphate buffer, pH 3.4 (45:55, v/v)] running through the column (Techopak-10 C18) at flow-rate of 0.8 ml/min.",Simple and sensitive high-performance liquid chromatographic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778939/),[ml] / [min],0.8,228171,DB00688,Mycophenolate mofetil
,10778939,recoveries,"The mean recoveries of MPA and the internal standard at concentrations of 0.1 and 20 microg/ml were 89-98%, and 90-96%, respectively.",Simple and sensitive high-performance liquid chromatographic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778939/),%,89-98,228172,DB00688,Mycophenolate mofetil
,10778939,recoveries,"The mean recoveries of MPA and the internal standard at concentrations of 0.1 and 20 microg/ml were 89-98%, and 90-96%, respectively.",Simple and sensitive high-performance liquid chromatographic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778939/),%,90-96,228173,DB00688,Mycophenolate mofetil
,10778939,minimum detectable concentrations,The minimum detectable concentrations for both MPA and the internal standard in plasma were 0.005 microg/ml.,Simple and sensitive high-performance liquid chromatographic. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10778939/),[μg] / [ml],0.005,228174,DB00688,Mycophenolate mofetil
,29868602,steady state flux,MPA in solution exhibited a steady state flux (3.8 ± 0.1 µg/cm2/h) and permeability (1.1 × 10-7 ± 3.2 × 10-9 cm/s).,Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29868602/),[μg] / [cm2·h],3.8,229481,DB00688,Mycophenolate mofetil
,29868602,permeability,MPA in solution exhibited a steady state flux (3.8 ± 0.1 µg/cm2/h) and permeability (1.1 × 10-7 ± 3.2 × 10-9 cm/s).,Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29868602/),[cm] / [s],1.1 × 10-7,229482,DB00688,Mycophenolate mofetil
,29868602,steady state flux,"MPA in Lipoderm exhibited a steady state flux of 1.12 ± 0.24 µg/cm2/h, and permeability of 6.2 × 10-09 ± 1.3 × 10-9 cm/s across the biomimetic membrane.",Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29868602/),[μg] / [cm2·h],1.12,229483,DB00688,Mycophenolate mofetil
,29868602,permeability,"MPA in Lipoderm exhibited a steady state flux of 1.12 ± 0.24 µg/cm2/h, and permeability of 6.2 × 10-09 ± 1.3 × 10-9 cm/s across the biomimetic membrane.",Mycophenolic Acid for Topical Immunosuppression in Vascularized Composite Allotransplantation: Optimizing Formulation and Preliminary Evaluation of Bioavailability and Pharmacokinetics. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29868602/),[cm] / [s],6.2 × 10-09,229484,DB00688,Mycophenolate mofetil
,17192496,area under the curve (AUC),"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],28.3,229900,DB00688,Mycophenolate mofetil
,17192496,oral AUC,"Intravenous dosing resulted in a median area under the curve (AUC) of 28.3 microg x h/mL (range, 9.96-70.4) and an oral AUC of 16.7 microg x h/mL (range, 9.38-35.3).",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],16.7,229901,DB00688,Mycophenolate mofetil
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],12.18,229902,DB00688,Mycophenolate mofetil
,17192496,Cmax,"Cmax after intravenous and oral dosing was 12.18 and 5.29 microg/mL, respectively.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[μg] / [ml],5.29,229903,DB00688,Mycophenolate mofetil
,17192496,oral bioavailability,"The median oral bioavailability was 72.3% (20.5%-172%), with 8-fold variability.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,72.3,229904,DB00688,Mycophenolate mofetil
< or =,17192496,oral bioavailability,Five patients (28%) had an oral bioavailability < or = 50%.,Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),%,50,229905,DB00688,Mycophenolate mofetil
<,17192496,AUC(0-12),"At time of oral pharmacokinetics, 15 patients (83%) had an AUC(0-12) < 30 microg x h/mL.",Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17192496/),[h·μg] / [ml],30,229906,DB00688,Mycophenolate mofetil
,16647462,AUC0-12,Mean AUC0-12 of 4431 +/- 2400 microg x h/L at week 1 remained stable at week 3 (5119 +/- 1190 microg x h/L).,Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16647462/),[h·μg] / [l],4431,229962,DB00688,Mycophenolate mofetil
,16647462,AUC0-12,Mean AUC0-12 of 4431 +/- 2400 microg x h/L at week 1 remained stable at week 3 (5119 +/- 1190 microg x h/L).,Pharmacokinetic profiling of cyclosporine microemulsion during the first 3 weeks after simultaneous pancreas-kidney transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16647462/),[h·μg] / [l],5119,229963,DB00688,Mycophenolate mofetil
,31062373,AUC0-12h,Mycophenolic acid AUC0-12h was 1.70-fold greater with tacrolimus (68.9 ± 30.9 mg·h/L) relative to cyclosporine (40.8 ± 17.6 mg·h/L); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],68.9,230537,DB00688,Mycophenolate mofetil
,31062373,AUC0-12h,Mycophenolic acid AUC0-12h was 1.70-fold greater with tacrolimus (68.9 ± 30.9 mg·h/L) relative to cyclosporine (40.8 ± 17.6 mg·h/L); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],40.8,230538,DB00688,Mycophenolate mofetil
,31062373,AUC0-12h,Target mycophenolic acid AUC0-12h of 30-60 mg·h/L was achieved in 56.3% on cyclosporine compared with 34.3% receiving tacrolimus (P < .001).,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[h·mg] / [l],30-60,230539,DB00688,Mycophenolate mofetil
,31062373,clearance,Mycophenolic acid clearance was 48% slower with tacrolimus (10.6 ± 4.7 L/h) relative to cyclosporine (20.5 ± 10.0 L/h); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[l] / [h],10.6,230540,DB00688,Mycophenolate mofetil
,31062373,clearance,Mycophenolic acid clearance was 48% slower with tacrolimus (10.6 ± 4.7 L/h) relative to cyclosporine (20.5 ± 10.0 L/h); P < .001.,Influence of Calcineurin Inhibitor and Sex on Mycophenolic Acid Pharmacokinetics and Adverse Effects Post-Renal Transplant. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31062373/),[l] / [h],20.5,230541,DB00688,Mycophenolate mofetil
,19179297,apparent clearance (CL/F),Population mean estimates for MPA were apparent clearance (CL/F) of 10.6 L/h (interindividual variability [IIV] = 21.4%) and apparent volume of distribution of the central compartment (V(1)/F) of 25.9 L (IIV = 87.8%).,Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179297/),[l] / [h],10.6,231402,DB00688,Mycophenolate mofetil
,19179297,apparent volume of distribution of the central compartment (V(1)/F),Population mean estimates for MPA were apparent clearance (CL/F) of 10.6 L/h (interindividual variability [IIV] = 21.4%) and apparent volume of distribution of the central compartment (V(1)/F) of 25.9 L (IIV = 87.8%).,Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179297/),l,25.9,231403,DB00688,Mycophenolate mofetil
,19179297,elimination rate constants,"Mean elimination rate constants of MPAG and AcMPAG were 0.323 h(-1) (IIV = 29.1%) and 0.206 h(-1) (IIV = 48.8%), respectively.",Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179297/),1/[h],0.323,231404,DB00688,Mycophenolate mofetil
,19179297,elimination rate constants,"Mean elimination rate constants of MPAG and AcMPAG were 0.323 h(-1) (IIV = 29.1%) and 0.206 h(-1) (IIV = 48.8%), respectively.",Population pharmacokinetics of mycophenolic acid and its 2 glucuronidated metabolites in kidney transplant recipients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19179297/),1/[h],0.206,231405,DB00688,Mycophenolate mofetil
,30574862,t,"In this retrospective cohort study, the authors measured 182 MPA predose trough levels (1 - 45/patient, HPLC/MS/MS) in 10 patients aged 0.9 - 18 years with SRNS treated with MMF.",Nephrotic state substantially enhances apparent mycophenolic acid clearance . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574862/),1/[patient],1 - 45,233704,DB00688,Mycophenolate mofetil
,30574862,apparent clearance,"Median apparent clearance was 22.63 L/h (IQR 17.1, 32.47).",Nephrotic state substantially enhances apparent mycophenolic acid clearance . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574862/),[l] / [h],22.63,233705,DB00688,Mycophenolate mofetil
,30574862,CL/F,CL/F increased from a minimum of 2.4 L/h for the highest albumin levels to a maximum of 59.9 for albumin levels &lt; 25 g/L.,Nephrotic state substantially enhances apparent mycophenolic acid clearance . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574862/),[l] / [h],2.4,233706,DB00688,Mycophenolate mofetil
,30574862,CL/F,CL/F increased from a minimum of 2.4 L/h for the highest albumin levels to a maximum of 59.9 for albumin levels &lt; 25 g/L.,Nephrotic state substantially enhances apparent mycophenolic acid clearance . ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30574862/),,59.9,233707,DB00688,Mycophenolate mofetil
<,24697955,AUC/dose,"ROC curve analyses showed that AUC/dose <0.06 and AUC <4 mg l(-1) h were associated with a good sensitivity and specificity for active disease (78%/94% and 94%/56%, respectively).",Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697955/),,0.06,234142,DB00688,Mycophenolate mofetil
<,24697955,AUC,"ROC curve analyses showed that AUC/dose <0.06 and AUC <4 mg l(-1) h were associated with a good sensitivity and specificity for active disease (78%/94% and 94%/56%, respectively).",Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697955/),[h·mg] / [l],4,234143,DB00688,Mycophenolate mofetil
<,24697955,AUC,"When introduced in a logistic regression model, AUC <44 mg l(-1) h and AUC/dose <0.06 were associated with an increased risk of active disease (OR = 21.2, 95% CI 2.3, 196.1, P = 0.007 and OR = 59.5, 95% CI 5.9, 588.2, P = 0.0005 respectively].",Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697955/),[h·mg] / [l],44,234144,DB00688,Mycophenolate mofetil
<,24697955,AUC/dose,"When introduced in a logistic regression model, AUC <44 mg l(-1) h and AUC/dose <0.06 were associated with an increased risk of active disease (OR = 21.2, 95% CI 2.3, 196.1, P = 0.007 and OR = 59.5, 95% CI 5.9, 588.2, P = 0.0005 respectively].",Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24697955/),,0.06,234145,DB00688,Mycophenolate mofetil
,17889129,C0,"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[μg] / [ml],0.5,235561,DB00688,Mycophenolate mofetil
,17889129,C0,"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[μg] / [ml],1.6,235562,DB00688,Mycophenolate mofetil
,17889129,AUC(0-12h),"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[h·μg] / [ml],12,235563,DB00688,Mycophenolate mofetil
,17889129,AUC(0-12h),"Mean predose levels of AcMPAG-C0 and AcMPAG-AUC(0-12h) were much higher in group II than in group I (0.5 +/- 2 vs 1.6 +/- 1 microg/mL and 12 +/- 2 vs. 32 +/- 19 microg*h/mL respectively, P < .005).",Influence of renal insufficiency on pharmacokinetics of ACYL-glucuronide metabolite of mycophenolic acid in renal transplant patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17889129/),[h·μg] / [ml],32,235564,DB00688,Mycophenolate mofetil
,33914391,AUC0-24 h threshold,"That led to an AUC0-24 h threshold of 89 mg*h/L associated with excellent performances (AUC ROC = 0.828, Sen = 75%, Spe = 100%, P = 0.0001).",Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33914391/),[h·mg] / [l],89,235604,DB00688,Mycophenolate mofetil
,33914391,AUC0-24 h,Therapeutic drug monitoring can be proposed with an AUC0-24 h threshold of 89 mg*h/L.,Towards therapeutic drug monitoring of mycophenolic acid in mucous membrane pemphigoid: A retrospective single-centre study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33914391/),[h·mg] / [l],89,235605,DB00688,Mycophenolate mofetil
,33580714,Tmax,"The simultaneous quantification of MPA, and its metabolites MPA-7-O-glucuronide (MPAG), and acyl glucuronide (AcMPAG) was determined by liquid chromatography (LC)-mass spectrometry (MS)/MS. MPA peak concentrations were achieved rapidly (median Tmax of 0.5 h).",Single-dose pharmacokinetics of mycophenolic acid following administration of immediate-release mycophenolate mofetil in healthy Beagle dogs. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33580714/),h,0.5,236614,DB00688,Mycophenolate mofetil
,33580714,elimination half-life,The mean elimination half-life was rapid (5.8 hours) and notable variability was observed in all PK parameters.,Single-dose pharmacokinetics of mycophenolic acid following administration of immediate-release mycophenolate mofetil in healthy Beagle dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33580714/),h,5.8,236615,DB00688,Mycophenolate mofetil
,10519445,AUC0-12,"The median MPA-AUC0-12 values increased 2-fold from 32.4 (range, 13.9 to 57.0) mg x h/L at 3 weeks to 65.1 (range, 32.6 to 114) mg x h/L at 3 months after transplantation, whereas the median AUC0-12 values of free MPA did not significantly change over time.","Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519445/),[h·mg] / [l],32.4,236834,DB00688,Mycophenolate mofetil
,10519445,AUC0-12,"The median MPA-AUC0-12 values increased 2-fold from 32.4 (range, 13.9 to 57.0) mg x h/L at 3 weeks to 65.1 (range, 32.6 to 114) mg x h/L at 3 months after transplantation, whereas the median AUC0-12 values of free MPA did not significantly change over time.","Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: a longitudinal study in pediatric patients. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10519445/),[h·mg] / [l],65.1,236835,DB00688,Mycophenolate mofetil
,27538768,total plasma concentrations,"Results Median and interquartile range of predose total plasma concentrations of mycophenolic acid and mycophenolic acid phenolic glucuronide were 2.73 and 1.43-5.73 and 25.5 and 13.1-54.7 µg/mL, respectively.",Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538768/),[μg] / [ml],2.73,236872,DB00688,Mycophenolate mofetil
,27538768,total plasma concentrations,"Results Median and interquartile range of predose total plasma concentrations of mycophenolic acid and mycophenolic acid phenolic glucuronide were 2.73 and 1.43-5.73 and 25.5 and 13.1-54.7 µg/mL, respectively.",Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538768/),[μg] / [ml],1.43-5.73,236873,DB00688,Mycophenolate mofetil
,27538768,total plasma concentrations,"Results Median and interquartile range of predose total plasma concentrations of mycophenolic acid and mycophenolic acid phenolic glucuronide were 2.73 and 1.43-5.73 and 25.5 and 13.1-54.7 µg/mL, respectively.",Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538768/),[μg] / [ml],25.5,236874,DB00688,Mycophenolate mofetil
,27538768,total plasma concentrations,"Results Median and interquartile range of predose total plasma concentrations of mycophenolic acid and mycophenolic acid phenolic glucuronide were 2.73 and 1.43-5.73 and 25.5 and 13.1-54.7 µg/mL, respectively.",Mycophenolic acid exposure and complement fraction C3 influence inosine 5'-monophosphate dehydrogenase activity in systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27538768/),[μg] / [ml],13.1-54.7,236875,DB00688,Mycophenolate mofetil
less,16321615,area under the curve (AUC) from 0 to 6 hours,Subjects with an unbound MPA area under the curve (AUC) from 0 to 6 hours of less than 150 ng .,Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),ng,150,237129,DB00688,Mycophenolate mofetil
less,16321615,unbound AUC from 0 to 12 hours,"An unbound AUC from 0 to 12 hours of less than 300 ng . h/mL was also associated with more frequent acute graft versus host disease (58% versus 35%, P = .05).",Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),[h·ng] / [ml],300,237130,DB00688,Mycophenolate mofetil
,16321615,unbound AUC from 0 to 12 hours,"An unbound AUC from 0 to 12 hours of less than 300 ng . h/mL was also associated with more frequent acute graft versus host disease (58% versus 35%, P = .05).",Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),,35,237131,DB00688,Mycophenolate mofetil
greater,16321615,trough concentrations,A higher cumulative incidence of engraftment was associated with total MPA trough concentrations greater than 1 microg/mL (P < .01).,Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16321615/),[μg] / [ml],1,237132,DB00688,Mycophenolate mofetil
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],600,237179,DB00688,Mycophenolate mofetil
,20683390,steady-state predose blood concentrations,"Using a validated liquid chromatography method with tandem mass spectrometry, steady-state predose blood concentrations averaged approximately 600 and 900 ng/mL at these dose levels, respectively.",Overview of sotrastaurin clinical pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),[ng] / [ml],900,237180,DB00688,Mycophenolate mofetil
,20683390,elimination half-life,The elimination half-life of sotrastaurin averages 6 hours.,Overview of sotrastaurin clinical pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/20683390/),h,6,237181,DB00688,Mycophenolate mofetil
,17524942,Cmax,"The Cmax, Tmax, and AUC for MMF 500 were 10.14 ng/mL, 51.82 minutes, and 18.33 ng/mL/h vs 10.94 ng/mL, 49.09 minutes, and 17.46 ng/mL/h for CellCept, respectively.",Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17524942/),[ng] / [ml],10.14,237250,DB00688,Mycophenolate mofetil
,17524942,Tmax,"The Cmax, Tmax, and AUC for MMF 500 were 10.14 ng/mL, 51.82 minutes, and 18.33 ng/mL/h vs 10.94 ng/mL, 49.09 minutes, and 17.46 ng/mL/h for CellCept, respectively.",Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17524942/),min,51.82,237251,DB00688,Mycophenolate mofetil
,17524942,Tmax,"The Cmax, Tmax, and AUC for MMF 500 were 10.14 ng/mL, 51.82 minutes, and 18.33 ng/mL/h vs 10.94 ng/mL, 49.09 minutes, and 17.46 ng/mL/h for CellCept, respectively.",Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17524942/),[ng] / [ml],10.94,237252,DB00688,Mycophenolate mofetil
,17524942,Tmax,"The Cmax, Tmax, and AUC for MMF 500 were 10.14 ng/mL, 51.82 minutes, and 18.33 ng/mL/h vs 10.94 ng/mL, 49.09 minutes, and 17.46 ng/mL/h for CellCept, respectively.",Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17524942/),min,49.09,237253,DB00688,Mycophenolate mofetil
,17524942,AUC,"The Cmax, Tmax, and AUC for MMF 500 were 10.14 ng/mL, 51.82 minutes, and 18.33 ng/mL/h vs 10.94 ng/mL, 49.09 minutes, and 17.46 ng/mL/h for CellCept, respectively.",Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17524942/),[ng] / [h·ml],18.33,237254,DB00688,Mycophenolate mofetil
,17524942,AUC,"The Cmax, Tmax, and AUC for MMF 500 were 10.14 ng/mL, 51.82 minutes, and 18.33 ng/mL/h vs 10.94 ng/mL, 49.09 minutes, and 17.46 ng/mL/h for CellCept, respectively.",Bioavailability of a new generic formulation of mycophenolate mofetil MMF 500 versus CellCept in healthy adult volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17524942/),[ng] / [h·ml],17.46,237255,DB00688,Mycophenolate mofetil
,33920640,half-lives,"The mean half-lives of intravenous and oral administrations were 10.5 h and 7.4 h, respectively.","Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33920640/),h,10.5,237871,DB00688,Mycophenolate mofetil
,33920640,half-lives,"The mean half-lives of intravenous and oral administrations were 10.5 h and 7.4 h, respectively.","Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33920640/),h,7.4,237872,DB00688,Mycophenolate mofetil
,33920640,bioavailability,"The estimated bioavailability after oral and supralingual administration was 72.4% and 7.6%, respectively.","Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33920640/),%,72.4,237873,DB00688,Mycophenolate mofetil
,33920640,bioavailability,"The estimated bioavailability after oral and supralingual administration was 72.4% and 7.6%, respectively.","Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33920640/),%,7.6,237874,DB00688,Mycophenolate mofetil
,33920640,lag-time,There was a 0.5 h lag-time presented after supralingual administration.,"Pharmacokinetic Model Analysis of Supralingual, Oral and Intravenous Deliveries of Mycophenolic Acid. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33920640/),h,0.5,237875,DB00688,Mycophenolate mofetil
,20592648,clearance,"The population pharmacokinetic parameters were: clearance, 0.27 x WT (L/h) on Day 21 and 0.233 x WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg.",Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592648/),[l] / [h],0.27,238210,DB00688,Mycophenolate mofetil
,20592648,clearance,"The population pharmacokinetic parameters were: clearance, 0.27 x WT (L/h) on Day 21 and 0.233 x WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg.",Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592648/),[l] / [h],0.233,238211,DB00688,Mycophenolate mofetil
,20592648,central distribution volume,"The population pharmacokinetic parameters were: clearance, 0.27 x WT (L/h) on Day 21 and 0.233 x WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg.",Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592648/),l,47.6,238212,DB00688,Mycophenolate mofetil
,20592648,intercompartmental clearance,"The population pharmacokinetic parameters were: clearance, 0.27 x WT (L/h) on Day 21 and 0.233 x WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg.",Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592648/),[l] / [h],33.1,238213,DB00688,Mycophenolate mofetil
,20592648,peripheral distribution volume,"The population pharmacokinetic parameters were: clearance, 0.27 x WT (L/h) on Day 21 and 0.233 x WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg.",Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592648/),l,724,238214,DB00688,Mycophenolate mofetil
,20592648,duration of infusion,"The population pharmacokinetic parameters were: clearance, 0.27 x WT (L/h) on Day 21 and 0.233 x WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg.",Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592648/),,0.64,238215,DB00688,Mycophenolate mofetil
,20592648,binding capacity,"The population pharmacokinetic parameters were: clearance, 0.27 x WT (L/h) on Day 21 and 0.233 x WT (L/h) at 6 months (ISV, 51%; interoccasion variability, 47%); central distribution volume, 47.6 L (ISV, 31%); intercompartmental clearance, 33.1 L/h (ISV, 128%); peripheral distribution volume, 724 L; duration of infusion, 0.64 (hours), and binding capacity, 0.0012 L/mg.",Population pharmacokinetics analysis of mycophenolic acid in adult kidney transplant patients with chronic graft dysfunction. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20592648/),[l] / [mg],0.0012,238216,DB00688,Mycophenolate mofetil
≤,21040167,C(2),"The first postoperative tacrolimus dose was given either according to standard care (control group) or 0.15 mg/kg b.d. if the pre-transplant C(2) level was ≤20 ng/mL, 0.1 mg/kg b.d. if the C(2) level was 21-59 ng/mL or 0.05 mg/kg b.d. if the C(2) level was ≥60 ng/mL (T2 group).",Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],20,239026,DB00688,Mycophenolate mofetil
,21040167,C(2),"The first postoperative tacrolimus dose was given either according to standard care (control group) or 0.15 mg/kg b.d. if the pre-transplant C(2) level was ≤20 ng/mL, 0.1 mg/kg b.d. if the C(2) level was 21-59 ng/mL or 0.05 mg/kg b.d. if the C(2) level was ≥60 ng/mL (T2 group).",Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],21-59,239027,DB00688,Mycophenolate mofetil
≥,21040167,C(2),"The first postoperative tacrolimus dose was given either according to standard care (control group) or 0.15 mg/kg b.d. if the pre-transplant C(2) level was ≤20 ng/mL, 0.1 mg/kg b.d. if the C(2) level was 21-59 ng/mL or 0.05 mg/kg b.d. if the C(2) level was ≥60 ng/mL (T2 group).",Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],60,239028,DB00688,Mycophenolate mofetil
≥,21040167,trough levels,There was no difference in the proportion of subjects achieving tacrolimus trough levels ≥10 ng/mL (82.9% Control vs 93.0% T2; P=0.19) or between 10 and 15 ng/mL (41.5% Control vs 41.9% T2; P=0.97) at day 3 post transplant.,Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],10,239029,DB00688,Mycophenolate mofetil
,21040167,trough levels,There was no difference in the proportion of subjects achieving tacrolimus trough levels ≥10 ng/mL (82.9% Control vs 93.0% T2; P=0.19) or between 10 and 15 ng/mL (41.5% Control vs 41.9% T2; P=0.97) at day 3 post transplant.,Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],10 and 15,239030,DB00688,Mycophenolate mofetil
≥,21040167,trough levels,The T2 group achieved tacrolimus trough levels of ≥10 ng/mL significantly faster than the control group (100% achievement in 14 days (Control) versus 4 days (T2); P=0.01).,Pre-transplant pharmacokinetic profiling and tacrolimus requirements post-transplant. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21040167/),[ng] / [ml],10,239031,DB00688,Mycophenolate mofetil
,16359376,C2,"The acute rejection rate was lower (19% vs. 43%; P < 0.05) in patients achieving CsA C2 target range during the first week (1600-2000 microg/l), n = 26, compared with those who did not, n = 42.",Mycophenolic acid clinical pharmacokinetics influenced by a cyclosporine C2 based immunosuppressive regimen in renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16359376/),[μg] / [l],1600-2000,239046,DB00688,Mycophenolate mofetil
,15848554,Tmax,"EC-MPS demonstrated the typical pharmacokinetic profile of an enteric-coated formulation with a delayed release of MPA compared with MMF (Tmax 2.5 versus 1.0 hours, respectively).",Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848554/),h,2.5,239664,DB00688,Mycophenolate mofetil
,15848554,Tmax,"EC-MPS demonstrated the typical pharmacokinetic profile of an enteric-coated formulation with a delayed release of MPA compared with MMF (Tmax 2.5 versus 1.0 hours, respectively).",Mycophenolic acid metabolite profile in renal transplant patients receiving enteric-coated mycophenolate sodium or mycophenolate mofetil. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848554/),h,1.0,239665,DB00688,Mycophenolate mofetil
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],29,239826,DB00688,Mycophenolate mofetil
,11264639,clearance,Basiliximab clearance was 29+/-14 mL/h when coadministered with azathioprine and 18+/-8 mL/h with mycophenolate mofetil.,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],18,239827,DB00688,Mycophenolate mofetil
,11264639,clearance,Both were significantly lower compared with a clearance of 37+/-15 mL/h from a previous study of basiliximab with dual therapy (p<0.001).,Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),[ml] / [h],37,239828,DB00688,Mycophenolate mofetil
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239829,DB00688,Mycophenolate mofetil
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239830,DB00688,Mycophenolate mofetil
,11264639,durations,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239831,DB00688,Mycophenolate mofetil
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,50,239832,DB00688,Mycophenolate mofetil
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,59,239833,DB00688,Mycophenolate mofetil
,11264639,saturation,"As a consequence of the lower clearance of basiliximab, the durations of CD25 saturation were prolonged in the presence of azathioprine (50+/-20 d; range, 13--84) and mycophenolate mofetil (59+/-17 d; range, 28--94) compared with dual therapy (36+/-14 d; range, 12--91).",Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11264639/),d,36,239834,DB00688,Mycophenolate mofetil
,24342510,Extraction efficiencies,"Extraction efficiencies for MPA and PPA were approximately 97% and 86%, respectively, and matrix effects were minimal.",Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342510/),%,97,240499,DB00688,Mycophenolate mofetil
,24342510,Extraction efficiencies,"Extraction efficiencies for MPA and PPA were approximately 97% and 86%, respectively, and matrix effects were minimal.",Validation of an LC-MS/MS method for the quantification of mycophenolic acid in human kidney transplant biopsies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24342510/),%,86,240500,DB00688,Mycophenolate mofetil
,11148182,trough concentrations (C(min)),"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],1.63,241348,DB00688,Mycophenolate mofetil
,11148182,trough concentrations (C(min)),"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.29,241349,DB00688,Mycophenolate mofetil
,11148182,areas under the curve (AUCs) for,"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,39.80,241350,DB00688,Mycophenolate mofetil
,11148182,areas under the curve (AUCs) for,"For groups 1 and 2, the MPA trough concentrations (C(min)) were 1.63 +/- 1.07 and 2.29 +/- 1.16 mg/L, respectively (P = 0.06), and the areas under the curve (AUCs) for MPA from t(0) to t(12 h) (MPA-AUC(0-12h)) were 39.80 +/- 15.29 and 62.10 +/- 21.07 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,62.10,241351,DB00688,Mycophenolate mofetil
,11148182,C(min),"In this group, the MPA-C(min) and MPA-AUC were significantly lower by the time acute rejection occurred (1.00 +/- 0.45 mg/L and 25.00 +/- 6.20 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),,1.,241352,DB00688,Mycophenolate mofetil
,11148182,AUC,"In this group, the MPA-C(min) and MPA-AUC were significantly lower by the time acute rejection occurred (1.00 +/- 0.45 mg/L and 25.00 +/- 6.20 mg.",Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,25.00,241353,DB00688,Mycophenolate mofetil
,11148182,C(min),C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.22,241354,DB00688,Mycophenolate mofetil
,11148182,C(min),C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],2.17,241355,DB00688,Mycophenolate mofetil
,11148182,AUC,C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,66.82,241356,DB00688,Mycophenolate mofetil
,11148182,AUC,C:(min) and AUC did not differ between the two groups [C(min) = 2.22 +/- 1.13 vs 2.17 +/- 1.13 mg/L (P = 0.9); AUC = 66.82 +/- 29.87 vs 55.70 +/- 11.74 mg.,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),mg,55.70,241357,DB00688,Mycophenolate mofetil
,11148182,C(30),h/L (P = 0.11)]; and C(30) was significantly higher in group 2 than in group 1 (C(30) = 32.99 +/- 12.59 vs 7.45 +/- 5.40 mg/L; P <0.0001).,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],32.99,241358,DB00688,Mycophenolate mofetil
,11148182,C(30),h/L (P = 0.11)]; and C(30) was significantly higher in group 2 than in group 1 (C(30) = 32.99 +/- 12.59 vs 7.45 +/- 5.40 mg/L; P <0.0001).,Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11148182/),[mg] / [l],7.45,241359,DB00688,Mycophenolate mofetil
>,32516810,area,"A multicentre, randomized, prospective, double-blind placebo-controlled cross-over study was conducted to determine the effect of the PPI pantoprazole on the MPA and its metabolite MPA-glucuronide (MPA-G) area under the curve (AUC) >12 h (MPA-AUC12 h) in recipients maintained on mycophenolate mofetil (MMF) or enteric-coated mycophenolate sodium (EC-MPS).",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),,12,242314,DB00688,Mycophenolate mofetil
,32516810,AUC12 h,"For recipients on MMF, there was a significant reduction in the MPA-AUC12 h [geometric mean (95% confidence interval) placebo: 53.9 (44.0-65.9) mg*h/L versus pantoprazole: 43.8 (35.6-53.4) mg*h/L; P = 0.004] when pantoprazole was co-administered compared with placebo.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],53.9,242315,DB00688,Mycophenolate mofetil
,32516810,AUC12 h,"For recipients on MMF, there was a significant reduction in the MPA-AUC12 h [geometric mean (95% confidence interval) placebo: 53.9 (44.0-65.9) mg*h/L versus pantoprazole: 43.8 (35.6-53.4) mg*h/L; P = 0.004] when pantoprazole was co-administered compared with placebo.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],43.8,242316,DB00688,Mycophenolate mofetil
,32516810,AUC12 h,"In contrast, co-administration with pantoprazole significantly increased MPA-AUC12 h [placebo: 36.1 (26.5-49.2) mg*h/L versus pantoprazole: 45.9 (35.5-59.3) mg*h/L; P = 0.023] in those receiving EC-MPS.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],36.1,242317,DB00688,Mycophenolate mofetil
,32516810,AUC12 h,"In contrast, co-administration with pantoprazole significantly increased MPA-AUC12 h [placebo: 36.1 (26.5-49.2) mg*h/L versus pantoprazole: 45.9 (35.5-59.3) mg*h/L; P = 0.023] in those receiving EC-MPS.",Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32516810/),[h·mg] / [l],45.9,242318,DB00688,Mycophenolate mofetil
,12766573,protein bindings,Reported protein bindings are 97% for mycophenolic acid and 82% for mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),%,97,242825,DB00688,Mycophenolate mofetil
,12766573,protein bindings,Reported protein bindings are 97% for mycophenolic acid and 82% for mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),%,82,242826,DB00688,Mycophenolate mofetil
,12766573,Total concentrations,Total concentrations ranged from 0.57 to 16.2 microg/mL mycophenolic acid and 36 to 199 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[μg] / [ml],0.57 to 16.2,242827,DB00688,Mycophenolate mofetil
,12766573,Total concentrations,Total concentrations ranged from 0.57 to 16.2 microg/mL mycophenolic acid and 36 to 199 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[μg] / [ml],36 to 199,242828,DB00688,Mycophenolate mofetil
,12766573,Free concentrations,Free concentrations ranged from 13 to 210 ng/mL mycophenolic acid and 8 to 58 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[ng] / [ml],13 to 210,242829,DB00688,Mycophenolate mofetil
,12766573,Free concentrations,Free concentrations ranged from 13 to 210 ng/mL mycophenolic acid and 8 to 58 microg/mL mycophenolic acid glucuronide.,Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12766573/),[μg] / [ml],8 to 58,242830,DB00688,Mycophenolate mofetil
,19606088,area under the curve (AUC),"After 500 mg MMF, the mean MPA area under the curve (AUC) was significantly lower in sirolimus-treated patients than in those treated with tacrolimus (35.4 +/- 32.3 vs. 77.1 +/- 67.5 mg/l).",Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19606088/),[mg] / [l],35.4,242878,DB00688,Mycophenolate mofetil
,19606088,area under the curve (AUC),"After 500 mg MMF, the mean MPA area under the curve (AUC) was significantly lower in sirolimus-treated patients than in those treated with tacrolimus (35.4 +/- 32.3 vs. 77.1 +/- 67.5 mg/l).",Increased mycophenolic acid exposure in stable kidney transplant recipients on tacrolimus as compared with those on sirolimus: implications for pharmacokinetics. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19606088/),[mg] / [l],77.1,242879,DB00688,Mycophenolate mofetil
,17094777,t(max),"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),h,1.0,243590,DB00688,Mycophenolate mofetil
,17094777,t(max),"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),h,0.5,243591,DB00688,Mycophenolate mofetil
,17094777,maximum MPA concentration,"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [l],10.6,243592,DB00688,Mycophenolate mofetil
,17094777,maximum MPA concentration,"Delayed gastric emptying was associated with a significantly longer MPA t(max)[1.0 (0.33-2.0) h vs. 0.5 (0.33-1.0) h; mean difference 0.39 h, 95% confidence interval (CI) 0.03, 0.75; P = 0.0289] and with a significant decrease in the maximum MPA concentration after dosing [10.6 (6.5-21.3) mg l(-1)vs. 20.1 (10.7-28.5) mg l(-1); mean difference 6.5 mg l(-1), 95% CI 2.1, 10.9; P = 0.0075].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [l],20.1,243593,DB00688,Mycophenolate mofetil
,17094777,AUC(0-4),"Despite the substantial effect of delayed gastric emptying rates on MPA C(max) and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [h·l],20.4,243594,DB00688,Mycophenolate mofetil
,17094777,rate of gastric emptying,"Despite the substantial effect of delayed gastric emptying rates on MPA C(max) and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [h·l],20.4,243595,DB00688,Mycophenolate mofetil
,17094777,rate of gastric emptying,"Despite the substantial effect of delayed gastric emptying rates on MPA C(max) and t(max), total dose-interval exposure, measured by the MPA AUC(0-4), was not affected by the rate of gastric emptying [20.4 (13.9-43.0) mg h(-1) l(-1)vs. 22.4 (13.1-29.8) mg h(-1) l(-1)].",Effects of gastric emptying on oral mycophenolic acid pharmacokinetics in stable renal allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17094777/),[mg] / [h·l],22.4,243596,DB00688,Mycophenolate mofetil
,18751501,flow rate,"Chromatographic separation was achieved on a C18 column by isocratic elution with acetonitrile-water (pH 4.4) (50:50, v/v) at a flow rate of 1.0 mL/min.",High-performance liquid chromatography method for the determination of mycophenolic acid in human plasma and application to a pharmacokinetic study of mycophenolic acid dispersible tablet. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751501/),[ml] / [min],1.0,243962,DB00688,Mycophenolate mofetil
,18751501,relative bioavailability,The relative bioavailability was 96.42 +/- 15.5%.,High-performance liquid chromatography method for the determination of mycophenolic acid in human plasma and application to a pharmacokinetic study of mycophenolic acid dispersible tablet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18751501/),%,96.42,243963,DB00688,Mycophenolate mofetil
,17555465,trough concentrations,"Patients (n = 45) were randomized 2 : 1 to receive treatment with sirolimus (n = 30; dosed to maintain trough concentrations of 10-25 ng ml(-1) until week 8, and then 8-15 ng ml(-1) thereafter) or CsA (n = 15; administered as per centre practice) both in combination with daclizumab, oral MMF and corticosteroids.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[ng] / [ml],10-25,244711,DB00688,Mycophenolate mofetil
,17555465,trough concentrations,"Patients (n = 45) were randomized 2 : 1 to receive treatment with sirolimus (n = 30; dosed to maintain trough concentrations of 10-25 ng ml(-1) until week 8, and then 8-15 ng ml(-1) thereafter) or CsA (n = 15; administered as per centre practice) both in combination with daclizumab, oral MMF and corticosteroids.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[ng] / [ml],8-15,244712,DB00688,Mycophenolate mofetil
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],40.4,244713,DB00688,Mycophenolate mofetil
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],68.5,244714,DB00688,Mycophenolate mofetil
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],722,244715,DB00688,Mycophenolate mofetil
,17555465,"AUC(0,12 h)","MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],485,244716,DB00688,Mycophenolate mofetil
,17555465,exposure,"MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],722,244717,DB00688,Mycophenolate mofetil
,17555465,exposure,"MPA exposure was 39-50% lower (month 6 mean AUC(0,12 h) (95%CI): 40.4 (33.8, 47.0) vs. 68.5 (54.9, 82.0) microg ml(-1) h) and MPAG exposure was 25-52% higher (722 (607, 838) vs. 485 (402, 569) microg ml(-1) h at month 6) in the presence of CsA compared with sirolimus across visits.","Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17555465/),[h·μg] / [ml],485,244718,DB00688,Mycophenolate mofetil
,20860916,AUC0-36,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),[h·μg] / [ml],21.14,245170,DB00688,Mycophenolate mofetil
,20860916,AUC0-36,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),[h·μg] / [ml],20.86,245171,DB00688,Mycophenolate mofetil
,20860916,AUC0-inf,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),[h·μg] / [ml],24.92,245172,DB00688,Mycophenolate mofetil
,20860916,AUC0-inf,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),[h·μg] / [ml],24.18,245173,DB00688,Mycophenolate mofetil
,20860916,Cmax,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),[μg] / [ml],11.86,245174,DB00688,Mycophenolate mofetil
,20860916,Cmax,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),[μg] / [ml],10.76,245175,DB00688,Mycophenolate mofetil
,20860916,Cmax/AUC0-36,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),1/[h],0.51,245176,DB00688,Mycophenolate mofetil
,20860916,Cmax/AUC0-36,"The means (test and reference) were 21.14 and 20.86 µg × h × ml-1 for AUC0-36, 24.92 and 24.18 µg × h × ml-1 for AUC0-inf, 11.86 and 10.76 µg × ml-1 for Cmax and 0.51 and 0.54 h-1 for Cmax/AUC0-36.",Comparative bioavailability of two oral formulations of mycophenolate mofetil in healthy adult Uruguayan subjects: a case of highly variable rate of drug absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20860916/),1/[h],0.54,245177,DB00688,Mycophenolate mofetil
,15848558,AUC0-12,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],54.1,245397,DB00688,Mycophenolate mofetil
,15848558,AUC0-12,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],51.7,245398,DB00688,Mycophenolate mofetil
,15848558,C0,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],3,245399,DB00688,Mycophenolate mofetil
,15848558,C0,"While patients on SRL were receiving 0.75 g MMF twice a day, mean AUC0-12 and C0 values of MPA were comparable to those of patients receiving CsA and 1 g MMF twice a day (54.1 +/- 17.6 and 3 +/- 1.87 vs 51.7 +/- 16.7 mg.h/L and 2.76 +/- 1.57 mg/L, respectively).",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],2.76,245400,DB00688,Mycophenolate mofetil
,15848558,AUC0-12,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],32.3,245401,DB00688,Mycophenolate mofetil
,15848558,C0,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],2.32,245402,DB00688,Mycophenolate mofetil
,15848558,AUC0-12,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[h·mg] / [l],70.9,245403,DB00688,Mycophenolate mofetil
,15848558,C0,"On the other hand, 0.5 g MMF twice a day with SRL therapy resulted in AUC0-12 and C0 values of MPA of 32.3 +/- 12.6 mg.h/L and 2.32 +/- 1.72 mg/L, respectively, whereas, 1 g MMF twice a day with SRL resulted in AUC0-12 and C0 values of MPA of 70.9 +/- 19.3 mg.h/L and 4.7 +/- 2.44 mg/L, respectively.",Pharmacokinetics of mycophenolic acid in kidney transplant patients receiving sirolimus versus cyclosporine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848558/),[mg] / [l],4.7,245404,DB00688,Mycophenolate mofetil
,17723081,area under the concentration-time curve from 0-12 hours (AUC(0-12)),"We found no significant differences in the dose-standardized area under the concentration-time curve from 0-12 hours (AUC(0-12)) for MPA between the control phase (39.66 +/- 8.70 mg mg x hr/L) and the concomitant ferrous sulfate or dose-separated ferrous sulfate (37.56 +/- 9.95 or 32.84 +/- 8.43 mg x hr/L, respectively, p>0.05) phases.",Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723081/),[h·mg·mg] / [l],39.66,246516,DB00688,Mycophenolate mofetil
,17723081,area under the concentration-time curve from 0-12 hours (AUC(0-12)),"We found no significant differences in the dose-standardized area under the concentration-time curve from 0-12 hours (AUC(0-12)) for MPA between the control phase (39.66 +/- 8.70 mg mg x hr/L) and the concomitant ferrous sulfate or dose-separated ferrous sulfate (37.56 +/- 9.95 or 32.84 +/- 8.43 mg x hr/L, respectively, p>0.05) phases.",Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723081/),[h·mg] / [l],37.56,246517,DB00688,Mycophenolate mofetil
,17723081,area under the concentration-time curve from 0-12 hours (AUC(0-12)),"We found no significant differences in the dose-standardized area under the concentration-time curve from 0-12 hours (AUC(0-12)) for MPA between the control phase (39.66 +/- 8.70 mg mg x hr/L) and the concomitant ferrous sulfate or dose-separated ferrous sulfate (37.56 +/- 9.95 or 32.84 +/- 8.43 mg x hr/L, respectively, p>0.05) phases.",Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723081/),[h·mg] / [l],32.84,246518,DB00688,Mycophenolate mofetil
,17723081,AUC(0-12),"Dose-standardized AUC(0-12) values for MPA did not significantly differ after the concomitant administration of polysaccharide iron complex from that of the control phase (48.46 +/- 9.68 and 43.80 +/- 9.46 mg x hr/L, respectively, p=0.065).",Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723081/),[h·mg] / [l],48.46,246519,DB00688,Mycophenolate mofetil
,17723081,AUC(0-12),"Dose-standardized AUC(0-12) values for MPA did not significantly differ after the concomitant administration of polysaccharide iron complex from that of the control phase (48.46 +/- 9.68 and 43.80 +/- 9.46 mg x hr/L, respectively, p=0.065).",Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723081/),[h·mg] / [l],43.80,246520,DB00688,Mycophenolate mofetil
,17723081,AUC(0-12),"However, the AUC(0-12) for MPA significantly increased when polysaccharide iron complex was administered 2 hours after MMF (53.41 +/- 11.75 mg x hr/L, p=0.012).",Lack of an effect of oral iron administration on mycophenolic acid pharmacokinetics in stable renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17723081/),[h·mg] / [l],53.41,246521,DB00688,Mycophenolate mofetil
<,18315786,total area under the observed plasma concentration-time curve (AUC(0-12)),Acute rejection was over twice more common in recipients with a total area under the observed plasma concentration-time curve (AUC(0-12)) of MPA <70 microg x h/mL than in those with higher values AUC(0-12) values (17% vs. 7%).,No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),[h·μg] / [ml],70,246719,DB00688,Mycophenolate mofetil
<,18315786,C(0),"There were also no significant differences in the MPA pharmacokinetic parameters among three tacrolimus C(0) groups: 5 < or = C(0) < 10, 10 < or = C(0) < 15 and 15 < or =C(0) < 20 ng/mL.",No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),,10,246720,DB00688,Mycophenolate mofetil
<,18315786,C(0),"There were also no significant differences in the MPA pharmacokinetic parameters among three tacrolimus C(0) groups: 5 < or = C(0) < 10, 10 < or = C(0) < 15 and 15 < or =C(0) < 20 ng/mL.",No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),,15,246721,DB00688,Mycophenolate mofetil
<,18315786,C(0),"There were also no significant differences in the MPA pharmacokinetic parameters among three tacrolimus C(0) groups: 5 < or = C(0) < 10, 10 < or = C(0) < 15 and 15 < or =C(0) < 20 ng/mL.",No pharmacokinetic interactions between mycophenolic acid and tacrolimus in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18315786/),[ng] / [ml],20,246722,DB00688,Mycophenolate mofetil
,12895192,apparent oral clearance,"The best base model was a two-compartment model with a lag time (apparent oral clearance was 27 l h(-1), and apparent volume of the central compartment 98 l).",Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895192/),[l] / [h],27,247381,DB00688,Mycophenolate mofetil
,12895192,apparent volume of the central compartment,"The best base model was a two-compartment model with a lag time (apparent oral clearance was 27 l h(-1), and apparent volume of the central compartment 98 l).",Population pharmacokinetic analysis of mycophenolic acid in renal transplant recipients following oral administration of mycophenolate mofetil. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12895192/),l,98,247382,DB00688,Mycophenolate mofetil
,11793083,area under concentration-time curve (AUC0-12),The dosing regimen of MMF 600 mg/m2 b.i.d. achieved the targeted early post-transplantation MPA 12-h area under concentration-time curve (AUC0-12) of 27.2 microg h per ml.,The use of mycophenolate mofetil suspension in pediatric renal allograft recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11793083/),[h·μg] / [ml],27.2,247467,DB00688,Mycophenolate mofetil
,21468916,flow rate,"The HPLC methods included a gradient elution consisting of acetonitrile and phosphate buffer at a flow rate of 1.2 mL/min, with UV detection at 254 nm.",Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21468916/),[ml] / [min],1.2,247643,DB00688,Mycophenolate mofetil
,21468916,extraction efficiencies,"The average extraction efficiencies for MPA, MPAG and AcMPAG were 85.3%, 100.1%, and 94.7% in plasma, and 88.0%, 67.3%, and 68.3% in bile, respectively.",Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21468916/),%,85.3,247644,DB00688,Mycophenolate mofetil
,21468916,extraction efficiencies,"The average extraction efficiencies for MPA, MPAG and AcMPAG were 85.3%, 100.1%, and 94.7% in plasma, and 88.0%, 67.3%, and 68.3% in bile, respectively.",Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21468916/),%,100.1,247645,DB00688,Mycophenolate mofetil
,21468916,extraction efficiencies,"The average extraction efficiencies for MPA, MPAG and AcMPAG were 85.3%, 100.1%, and 94.7% in plasma, and 88.0%, 67.3%, and 68.3% in bile, respectively.",Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21468916/),%,94.7,247646,DB00688,Mycophenolate mofetil
,21468916,extraction efficiencies,"The average extraction efficiencies for MPA, MPAG and AcMPAG were 85.3%, 100.1%, and 94.7% in plasma, and 88.0%, 67.3%, and 68.3% in bile, respectively.",Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21468916/),%,88.0,247647,DB00688,Mycophenolate mofetil
,21468916,extraction efficiencies,"The average extraction efficiencies for MPA, MPAG and AcMPAG were 85.3%, 100.1%, and 94.7% in plasma, and 88.0%, 67.3%, and 68.3% in bile, respectively.",Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21468916/),%,67.3,247648,DB00688,Mycophenolate mofetil
,21468916,extraction efficiencies,"The average extraction efficiencies for MPA, MPAG and AcMPAG were 85.3%, 100.1%, and 94.7% in plasma, and 88.0%, 67.3%, and 68.3% in bile, respectively.",Simultaneous determination of mycophenolic acid and its metabolites by HPLC and pharmacokinetic studies in rat plasma and bile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21468916/),%,68.3,247649,DB00688,Mycophenolate mofetil
,20145258,time,"The median posttransplantation time was 12 days (A, n = 26 pharmacokinetic sessions), 36 days (B, n = 25), and 867 days (C, n = 21).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),d,36,248110,DB00688,Mycophenolate mofetil
,20145258,time,"The median posttransplantation time was 12 days (A, n = 26 pharmacokinetic sessions), 36 days (B, n = 25), and 867 days (C, n = 21).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),d,867,248111,DB00688,Mycophenolate mofetil
,20145258,AUC(0-12),"The median MPA AUC(0-12) in group A (26.8 mg x h/L) was significantly lower than in groups B (45.2 mg x h/L, P = .031) and C (43.5 mg x h/L, P = .004).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),[h·mg] / [l],26.8,248112,DB00688,Mycophenolate mofetil
,20145258,AUC(0-12),"The median MPA AUC(0-12) in group A (26.8 mg x h/L) was significantly lower than in groups B (45.2 mg x h/L, P = .031) and C (43.5 mg x h/L, P = .004).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),[h·mg] / [l],45.2,248113,DB00688,Mycophenolate mofetil
,20145258,AUC(0-12),"The median MPA AUC(0-12) in group A (26.8 mg x h/L) was significantly lower than in groups B (45.2 mg x h/L, P = .031) and C (43.5 mg x h/L, P = .004).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),[h·mg] / [l],43.5,248114,DB00688,Mycophenolate mofetil
,20145258,AUC(0-12),"Free MPA AUC(0-12) was comparable whatever the time (0.41, 0.34, and 0.33 mg x h/L, respectively).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),[h·mg] / [l],0.41,248115,DB00688,Mycophenolate mofetil
,20145258,AUC(0-12),"Free MPA AUC(0-12) was comparable whatever the time (0.41, 0.34, and 0.33 mg x h/L, respectively).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),[h·mg] / [l],0.34,248116,DB00688,Mycophenolate mofetil
,20145258,AUC(0-12),"Free MPA AUC(0-12) was comparable whatever the time (0.41, 0.34, and 0.33 mg x h/L, respectively).",Variability in free mycophenolic acid exposure in adult liver transplant recipients during the early posttransplantation period. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20145258/),[h·mg] / [l],0.33,248117,DB00688,Mycophenolate mofetil
,18377332,C(max),"Overall, no significant difference was found between both groups for their 0 - 12 h and 0 - 24 h areas under the concentration-time curve, C(max), T(max), C(0 h), C(12 h) and C(24 h), although the mean C(max) was numerically higher by 39% in the autoimmune disease patients (autoimmune disease 27.3 +/- 17.4 mg/l and renal transplant 19.6 +/- 15.7 mg/l).",Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18377332/),[mg] / [l],27.3,248554,DB00688,Mycophenolate mofetil
,18377332,C(max),"Overall, no significant difference was found between both groups for their 0 - 12 h and 0 - 24 h areas under the concentration-time curve, C(max), T(max), C(0 h), C(12 h) and C(24 h), although the mean C(max) was numerically higher by 39% in the autoimmune disease patients (autoimmune disease 27.3 +/- 17.4 mg/l and renal transplant 19.6 +/- 15.7 mg/l).",Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18377332/),[mg] / [l],19.6,248555,DB00688,Mycophenolate mofetil
,18377332,C,The mycophenolic acid trough levels did not reflect the systemic exposure to mycophenolic acid adequately; a limited sampling strategy for estimating mycophenolic acid exposure in autoimmune disease patients should include times around C(1.5 h) and/or C(2 h) reflecting T(max) if further studies confirm its usefulness.,Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18377332/),h,1.5,248556,DB00688,Mycophenolate mofetil
,19881404,-,"The median MMF dose was 431 mg/m2 per day (range, 189-833 mg/m2 per day) leading to a median estimated MPA-AUC0-12h of 27 mg/h/L (range, 17-79 mg/h/L).",Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19881404/),[mg] / [h·l],27,248653,DB00688,Mycophenolate mofetil
,19881404,AUC0-12h,"The median MMF dose was 431 mg/m2 per day (range, 189-833 mg/m2 per day) leading to a median estimated MPA-AUC0-12h of 27 mg/h/L (range, 17-79 mg/h/L).",Age-related variability of mycophenolate mofetil exposure in stable pediatric liver transplant recipients and influences of donor characteristics. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19881404/),[mg] / [h·l],27,248654,DB00688,Mycophenolate mofetil
,32959916,is,"The chromatographic separation was performed with the Hypersil GOLD C18 column, using a mobile phase consisting of 0.1% formic acid in water and acetonitrile (60:40, v/v) at an isocratic flow rate of 0.4 ml/min.",Validated LC-MS/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959916/),[ml] / [min],0.4,249712,DB00688,Mycophenolate mofetil
,32959916,free fraction,"The mean free fraction of MPA in our patients was 0.89% (ranging from 0.62 to 1.25%) and albumin level played a major role in the variability of free fraction of MPA, thus, in pediatric patients with hypoproteinemia, close free drug monitoring and dose adjustments should be considered to prevent toxicity.",Validated LC-MS/MS method for quantitation of total and free mycophenolic acid concentration and its application to a pharmacokinetic study in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32959916/),%,0.89,249713,DB00688,Mycophenolate mofetil
,15848720,C0h,"Evening doses of CsA (25/50/75 or 100 mg) and MMF (250/500 or 1000 mg) produced C0h levels as follows: CsA, 162 +/- 12 ng/mL; MPA, 1.7 +/- 0.2 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[ng] / [ml],162,249927,DB00688,Mycophenolate mofetil
,15848720,C0h,"Evening doses of CsA (25/50/75 or 100 mg) and MMF (250/500 or 1000 mg) produced C0h levels as follows: CsA, 162 +/- 12 ng/mL; MPA, 1.7 +/- 0.2 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[mg] / [l],1.7,249928,DB00688,Mycophenolate mofetil
,15848720,C2h,"Morning doses of CsA (50/75 or 100 mg) and MMF (250/500/1000 or 1500 mg) produced C2h-levels as follows: CsA, 589 +/- 56 ng/mL and MPA, 7.4 +/- 1.3 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[ng] / [ml],589,249929,DB00688,Mycophenolate mofetil
,15848720,C2h,"Morning doses of CsA (50/75 or 100 mg) and MMF (250/500/1000 or 1500 mg) produced C2h-levels as follows: CsA, 589 +/- 56 ng/mL and MPA, 7.4 +/- 1.3 mg/L.",C0h/C2h monitoring of the pharmacodynamics of cyclosporin plus mycophenolate mofetil in human heart transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15848720/),[mg] / [l],7.4,249930,DB00688,Mycophenolate mofetil
,19715905,area under-concentration time curve (AUC),The pharmacokinetics studies showed that carriers of T-275A and/or C-2152T displayed a smaller area under-concentration time curve (AUC): 57.8 +/- 4.3 vs 78.9 +/- 10.8 mg/L*h (P < .03).,The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715905/),[mg] / [h·l],57.8,249980,DB00688,Mycophenolate mofetil
,19715905,area under-concentration time curve (AUC),The pharmacokinetics studies showed that carriers of T-275A and/or C-2152T displayed a smaller area under-concentration time curve (AUC): 57.8 +/- 4.3 vs 78.9 +/- 10.8 mg/L*h (P < .03).,The prevalence of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19715905/),[mg] / [h·l],78.9,249981,DB00688,Mycophenolate mofetil
,17587705,AUC(0-12 h) h,The MPA AUC(0-12 h) h values in the cyclosporine (CsA) and tacrolimus (FK) groups ranged from 13.11 to 50.98 mug .,Limited sampling strategy for mycophenolic acid in Japanese heart transplant recipients: comparison of cyclosporin and tacrolimus treatment. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17587705/),μg,13.11 to 50.98,251342,DB00688,Mycophenolate mofetil
,18695635,dose-adjusted AUC0-12,"On the other hand, the median dose-adjusted AUC0-12 of MPAG in SLCO1B1 1a/1a+1a/1b+1b+1b (n = 53) and 1a/*15 + 1b/*15+*15/*15 (n = 27) were 1549 and 1134 mg.h L g, respectively (P = 0.03004 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1549,251844,DB00688,Mycophenolate mofetil
,18695635,dose-adjusted AUC0-12,"On the other hand, the median dose-adjusted AUC0-12 of MPAG in SLCO1B1 1a/1a+1a/1b+1b+1b (n = 53) and 1a/*15 + 1b/*15+*15/*15 (n = 27) were 1549 and 1134 mg.h L g, respectively (P = 0.03004 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1134,251845,DB00688,Mycophenolate mofetil
,18695635,dose,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1191,251846,DB00688,Mycophenolate mofetil
,18695635,dose,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1580,251847,DB00688,Mycophenolate mofetil
,18695635,AUC0-12,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1191,251848,DB00688,Mycophenolate mofetil
,18695635,AUC0-12,"The median dose-adjusted AUC0-12 of MPAG in SLCO1B3 334T/T+T/G (699G/G+G/A, n = 46) and 334G/G (699A/A, n = 34) was 1191 and 1580 mg.h L g, respectively (P = 0.02792 in multivariate analysis).",Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18695635/),g·h·l·mg,1580,251849,DB00688,Mycophenolate mofetil
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],3.88,252560,DB00688,Mycophenolate mofetil
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.54,252561,DB00688,Mycophenolate mofetil
,18466432,trough daclizumab levels,"Median (range) estimated trough daclizumab levels achieved on day 56 (before dose 5) were 3.88 microg/mL (2.48-8.78), 4.54 microg/mL (1.79-18.7), and 4.94 microg/mL (0.05-10.6) in the less than or equal to five yr (n = 15), 6-12 yr (n = 17), and 13-17 yr (n = 22) age groups, respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[μg] / [ml],4.94,252562,DB00688,Mycophenolate mofetil
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2040,252563,DB00688,Mycophenolate mofetil
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],2757,252564,DB00688,Mycophenolate mofetil
,18466432,exposure,"Steady-state median (range) daclizumab exposures were 2040 mg x h/mL (1585-3778), 2757 mg x h/mL (1873-3494) and 3297 mg x h/mL (1705-6453), respectively.",Safety and pharmacokinetics of daclizumab in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18466432/),[h·mg] / [ml],3297,252565,DB00688,Mycophenolate mofetil
,33527141,Cmax,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[μg] / [ml],16.5,253015,DB00688,Mycophenolate mofetil
,33527141,Cmax,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[μg] / [ml],15.8,253016,DB00688,Mycophenolate mofetil
,33527141,AUC0-12,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[h·μg] / [ml],39.1,253017,DB00688,Mycophenolate mofetil
,33527141,AUC0-12,"In 24 patients, MPA exposure (Cmax and AUC0-12) was similar in the presence and absence of voclosporin, with treatment ratios of 0.94 and 1.09, respectively (Cmax: 16.5 μg/mL [Day 1] vs.15.8 μg/mL [Day 7], AUC0-12: 39.1 μg.h/mL [Day 1] vs. 40.8 μg.h/mL [Day 7].",Voclosporin: a novel calcineurin inhibitor without impact on mycophenolic acid in patients with SLE. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33527141/),[h·μg] / [ml],40.8,253018,DB00688,Mycophenolate mofetil
,18296555,area under the concentration-time curve (AUC)(0-8),"The median (range) total mycophenolic acid area under the concentration-time curve (AUC)(0-8) was 12.6 mcg.h/mL (4.9-49.2), and unbound mycophenolic acid AUC(0-8) was 0.274 mcg.h/mL (0.037-1.4).",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[h·mcg] / [ml],12.6,253071,DB00688,Mycophenolate mofetil
,18296555,AUC(0-8),"The median (range) total mycophenolic acid area under the concentration-time curve (AUC)(0-8) was 12.6 mcg.h/mL (4.9-49.2), and unbound mycophenolic acid AUC(0-8) was 0.274 mcg.h/mL (0.037-1.4).",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[h·mcg] / [ml],0.274,253072,DB00688,Mycophenolate mofetil
,18296555,Total,"Total and unbound mycophenolic acid trough concentrations were 0.27 (0.03-2.9) and 0.005 (0-0.034) mcg/mL, respectively.",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[mcg] / [ml],0.27,253073,DB00688,Mycophenolate mofetil
,18296555,unbound,"Total and unbound mycophenolic acid trough concentrations were 0.27 (0.03-2.9) and 0.005 (0-0.034) mcg/mL, respectively.",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[mcg] / [ml],0.27,253074,DB00688,Mycophenolate mofetil
,18296555,trough concentrations,"Total and unbound mycophenolic acid trough concentrations were 0.27 (0.03-2.9) and 0.005 (0-0.034) mcg/mL, respectively.",Higher mycophenolate dose requirements in children undergoing hematopoietic cell transplant (HCT). ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18296555/),[mcg] / [ml],0.005,253075,DB00688,Mycophenolate mofetil
,26643991,Free fractions,"Free fractions of MPA in the control rats and NARs were 2.09 and 24.8%, respectively.",Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643991/),%,2.09,253268,DB00688,Mycophenolate mofetil
,26643991,Free fractions,"Free fractions of MPA in the control rats and NARs were 2.09 and 24.8%, respectively.",Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643991/),%,24.8,253269,DB00688,Mycophenolate mofetil
,26643991,half-maximal inhibitory concentration,The half-maximal inhibitory concentration based on free MPA was estimated as 163 ng/mL for both rats.,Pharmacokinetics and pharmacodynamics of mycophenolic acid in Nagase analbuminemic rats: Evaluation of protein binding effects using the modeling and simulation approach. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26643991/),[ng] / [ml],163,253270,DB00688,Mycophenolate mofetil
,11510021,bioavailability,The bioavailability of MPA was reduced during compared with after the regimen (14.5 +/- 3.5 v 21.1 +/- 9.8 mg. h/mL; P =.07).,The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510021/),[h·mg] / [ml],14.5,253307,DB00688,Mycophenolate mofetil
,11510021,bioavailability,The bioavailability of MPA was reduced during compared with after the regimen (14.5 +/- 3.5 v 21.1 +/- 9.8 mg. h/mL; P =.07).,The effect of selective bowel decontamination on the pharmacokinetics of mycophenolate mofetil in liver transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11510021/),[h·mg] / [ml],21.1,253308,DB00688,Mycophenolate mofetil
,22053944,CL(1) /F,"The PK estimates for MPA were CL(1) /F 25.3 l h(-1), V(3) /F 20.9 l, V(4) /F 234 l and CL(2) /F 19.8 l h(-1).",Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22053944/),[l] / [h],25.3,254264,DB00688,Mycophenolate mofetil
,22053944,V(3) /F,"The PK estimates for MPA were CL(1) /F 25.3 l h(-1), V(3) /F 20.9 l, V(4) /F 234 l and CL(2) /F 19.8 l h(-1).",Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22053944/),l,20.9,254265,DB00688,Mycophenolate mofetil
,22053944,V(4) /F,"The PK estimates for MPA were CL(1) /F 25.3 l h(-1), V(3) /F 20.9 l, V(4) /F 234 l and CL(2) /F 19.8 l h(-1).",Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22053944/),l,234,254266,DB00688,Mycophenolate mofetil
,22053944,CL(2) /F,"The PK estimates for MPA were CL(1) /F 25.3 l h(-1), V(3) /F 20.9 l, V(4) /F 234 l and CL(2) /F 19.8 l h(-1).",Development of population PK model with enterohepatic circulation for mycophenolic acid in patients with childhood-onset systemic lupus erythematosus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22053944/),[l] / [h],19.8,254267,DB00688,Mycophenolate mofetil
,11903387,area under the concentration curve (AUC),"Morning doses were adjusted to reach a day-time area under the concentration curve (AUC) of 7,800 ng hour/ml (utilizing 2 hour and 6 hour levels) and evening doses were adjusted to a morning trough of 300 ng/ml.",Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903387/),[h·ng] / [ml],"7,800",254508,DB00688,Mycophenolate mofetil
,11903387,trough,"Morning doses were adjusted to reach a day-time area under the concentration curve (AUC) of 7,800 ng hour/ml (utilizing 2 hour and 6 hour levels) and evening doses were adjusted to a morning trough of 300 ng/ml.",Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11903387/),[ng] / [ml],300,254509,DB00688,Mycophenolate mofetil
,24304103,AUC(0-12),The median (range) MPA AUC(0-12) was 50·55 (30·9-105·4) mg/h/l.,Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis: a prospective pharmacokinetics and clinical study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24304103/),[mg] / [h·l],50·55,254977,DB00688,Mycophenolate mofetil
,16176120,absorption rate constant (k(a)),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),1/[h],4.1,256210,DB00688,Mycophenolate mofetil
,16176120,central volume of distribution (V1),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),l,91,256211,DB00688,Mycophenolate mofetil
,16176120,peripheral volume of distribution (V2),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),l,237,256212,DB00688,Mycophenolate mofetil
,16176120,clearance (CL),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),[l] / [h],33,256213,DB00688,Mycophenolate mofetil
,16176120,intercompartment clearance (Q),"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),[l] / [h],35,256214,DB00688,Mycophenolate mofetil
,16176120,absorption lag time,"The following population parameters were estimated: absorption rate constant (k(a)) 4.1h(-1), central volume of distribution (V1) 91 L, peripheral volume of distribution (V2) 237 L, clearance (CL) 33 L/h, intercompartment clearance (Q) 35 L/h and absorption lag time 0.21 h.",Population pharmacokinetics of mycophenolic acid in renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16176120/),h,0.21,256215,DB00688,Mycophenolate mofetil
,15795646,AUC level,"In the CC group, MMF doses were adjusted based on the calculated AUC, targeting at an AUC level of 45 mg.h/L.",Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795646/),[h·mg] / [l],45,256570,DB00688,Mycophenolate mofetil
,15795646,AUC,"On day 7 after transplantation, significantly more AUC values were on target (AUC range 30-60 mg.h/L) in the CC group than in the FD group: 76% versus 13%, respectively, P < 0.001.",Predicting the usefulness of therapeutic drug monitoring of mycophenolic acid: a computer simulation. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15795646/),[h·mg] / [l],30-60,256571,DB00688,Mycophenolate mofetil
,20412508,total mean score,The GSRS total mean score was 16 +/- 12 with MMF vs. 8 +/- 5 with EC-MPA (p < 0.05).,Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20412508/),,16,256682,DB00688,Mycophenolate mofetil
,20412508,total mean score,The GSRS total mean score was 16 +/- 12 with MMF vs. 8 +/- 5 with EC-MPA (p < 0.05).,Efficacy and safety of conversion of mycophenolate mofetil to enteric-coated mycophenolate sodium in Mexican renal transplant children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20412508/),,8,256683,DB00688,Mycophenolate mofetil
,12021631,AUC(12h),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[h·mg] / [l],10.1,257284,DB00688,Mycophenolate mofetil
,12021631,C(0),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],0.48,257285,DB00688,Mycophenolate mofetil
,12021631,C(max),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],1.95,257286,DB00688,Mycophenolate mofetil
,12021631,AUC(12h),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[h·mg] / [l],3.54,257287,DB00688,Mycophenolate mofetil
,12021631,C(0),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],0.25,257288,DB00688,Mycophenolate mofetil
,12021631,C(max),"Values (median [range]) of AcMPAG-AUC(12h) (10.1 [3.30-30.1] mg.h/L), AcMPAG-C(0) (0.48 [0.08-1.43] mg/L), and AcMPAG-C(max) (1.95 [0.88-5.35] mg/L) were significantly (p < 0.05) higher in the stable phase than in the initial phase: 3.54 [2.07-20.0] mg.h/L for AUC(12h); 0.25 [<0.04-0.97] mg/L for C(0), and 1.12 [0.32-2.44] mg/L for C(max).",Pharmacokinetics and protein adduct formation of the pharmacologically active acyl glucuronide metabolite of mycophenolic acid in pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12021631/),[mg] / [l],1.12,257289,DB00688,Mycophenolate mofetil
,15041382,C2,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[μg] / [l],388,257636,DB00688,Mycophenolate mofetil
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[μg] / [l],497.5,257637,DB00688,Mycophenolate mofetil
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),h,2,257638,DB00688,Mycophenolate mofetil
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),%,3.92,257639,DB00688,Mycophenolate mofetil
,15041382,CNa,"There were no significant differences in median CsA C2 values and CNa between the CsA alone and the CsA+MMF groups (388 microg/L and 497.5 microg/L and CNa 2h; 3.92% alkaline phosphatase [AP]; 3.94% AP, respectively).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),%,3.94,257640,DB00688,Mycophenolate mofetil
,15041382,IL-2,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],280.52,257641,DB00688,Mycophenolate mofetil
,15041382,IL-2,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],169.48,257642,DB00688,Mycophenolate mofetil
,15041382,2h,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],280.52,257643,DB00688,Mycophenolate mofetil
,15041382,2h,"In vitro production of IL-2 was significantly lower in the CsA+MMF group than in the CsA group (median IL-2 2h: 280.52 ng/L, 169.48 ng/L, P<.001).",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[ng] / [l],169.48,257644,DB00688,Mycophenolate mofetil
below,15041382,C2,"In stable renal transplant patients, median CsA C2 values below 500 microg/L were associated with inhibition of CNa and IL-2 synthesis.",New concepts in cyclosporine pharmacokinetic and dynamic monitoring: the impact of concomitant immunosuppression on target C2 concentrations. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15041382/),[μg] / [l],500,257645,DB00688,Mycophenolate mofetil
higher,15522544,Ana,"Analytical recoveries were higher than 98 and 89% at concentrations ranging from 1 to 25 and 20 to 200mg/L for MPA and MPAG, respectively.",HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522544/),%,98,257803,DB00688,Mycophenolate mofetil
higher,15522544,Ana,"Analytical recoveries were higher than 98 and 89% at concentrations ranging from 1 to 25 and 20 to 200mg/L for MPA and MPAG, respectively.",HPLC determination of mycophenolic acid and mycophenolic acid glucuronide in human plasma with hybrid material. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15522544/),%,89,257804,DB00688,Mycophenolate mofetil
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,80.7,258222,DB00688,Mycophenolate mofetil
,17201457,Oral bioavailability,"Oral bioavailability of MPA, subsequent to mycophenolate mofetil administration, ranges from 80.7% to 94%.",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,94,258223,DB00688,Mycophenolate mofetil
,17201457,absolute bioavailability,EC-mycophenolate sodium has an absolute bioavailability of MPA of approximately 72%.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),%,72,258224,DB00688,Mycophenolate mofetil
,17201457,lag time in absorption,EC-mycophenolate sodium exhibits a median lag time in absorption of MPA from 0.25 to 1.25 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,0.25 to 1.25,258225,DB00688,Mycophenolate mofetil
,17201457,elimination half-life,The mean elimination half-life of MPA ranges from 9 to 17 hours.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),h,9 to 17,258226,DB00688,Mycophenolate mofetil
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],14.1 to 34.9,258227,DB00688,Mycophenolate mofetil
,17201457,CL/F,"In population pharmacokinetic studies, MPA CL/F in adults ranges from 14.1 to 34.9 L/h (ciclosporin co-therapy) and from 11.9 to 25.4 L/h (tacrolimus co-therapy).",Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),[l] / [h],11.9 to 25.4,258228,DB00688,Mycophenolate mofetil
,17201457,AUC from 0 to 12 hours (AUC12),Targeting a total MPA AUC from 0 to 12 hours (AUC12) of 30-60 mg.,Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17201457/),mg,30-60,258229,DB00688,Mycophenolate mofetil
,23507258,Maximum concentrations,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),μ,6.2,258730,DB00688,Mycophenolate mofetil
,23507258,terminal half-lives,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),μ,6.2,258731,DB00688,Mycophenolate mofetil
,23507258,dose-normalized AUC,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),[dayg] / [ml],374,258732,DB00688,Mycophenolate mofetil
,23507258,dose-normalized AUC,"Maximum concentrations and terminal half-lives were similar between the two groups but at month 3 Group 1 had significantly lower values for total rATG (concentration was 6.2±1.1μg/mL versus 10.2±2.9μg/mL in Group 2, p=0.027) and total rATG dose-normalized AUC (374±83dayg/mL versus 508±149dayg/mL in Group 2, p=0.046).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),[dayg] / [ml],508,258733,DB00688,Mycophenolate mofetil
<,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,1,258734,DB00688,Mycophenolate mofetil
,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,18.75,258735,DB00688,Mycophenolate mofetil
,23507258,Time to sub-therapeutic levels,"Time to sub-therapeutic levels (<1μg/mL) of active rATG was significantly shorter in Group 1 (18.75±6.9days versus 20±7.5days in Group 2, p<0.001).",Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23507258/),d,20,258736,DB00688,Mycophenolate mofetil
,30377942,apparent clearance,"The apparent clearance value for tacrolimus was 17.9 l/h (6.95% relative standard error) in our model, which is lower compared with similar subjects on corticosteroid-based therapy.",Population Pharmacokinetic Analysis of Immediate-Release Oral Tacrolimus Co-administered with Mycophenolate Mofetil in Corticosteroid-Free Adult Kidney Transplant Recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30377942/),[l] / [h],17.9,259008,DB00688,Mycophenolate mofetil
,22054177,bioavailability,"In lung transplant recipients, the bioavailability was, on average, 31% lower in patients with cystic fibrosis than in patients without cystic fibrosis (p < 0.001).","Bayesian estimation of mycophenolate mofetil in lung transplantation, using a population pharmacokinetic model developed in kidney and lung transplant recipients. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22054177/),%,31,259227,DB00688,Mycophenolate mofetil
,16573602,C0,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],96.2,259396,DB00688,Mycophenolate mofetil
,16573602,C2,Mean C0 and C2 were 96.2 +/- 59.5 and 504 +/- 305.4 ng/mL respectively.,Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16573602/),[ng] / [ml],504,259397,DB00688,Mycophenolate mofetil
,28025957,Hill coefficient H,The pharmacodynamic parameters of the action of tacrolimus were estimated with the Hill coefficient H at 1.5 and the CE50 at 6.7 ng/mL.,Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],1.5,259787,DB00688,Mycophenolate mofetil
,28025957,CE50,The pharmacodynamic parameters of the action of tacrolimus were estimated with the Hill coefficient H at 1.5 and the CE50 at 6.7 ng/mL.,Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],6.7,259788,DB00688,Mycophenolate mofetil
,28025957,ceiling concentration,"Accordingly, the pharmacodynamic threshold concentration was estimated at 0.9 ng/mL and the ceiling concentration at 48 ng/mL, indicating a wide span between target trough and peak levels.",Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients . ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28025957/),[ng] / [ml],48,259789,DB00688,Mycophenolate mofetil
,24935294,C0,"In this phase 3, multicenter, randomized, open-label study, patients were randomized (1:1) to 1 of the 2 groups: everolimus 1.5 mg (targeted C0 of 3-8 ng/mL) plus reduced-dose cyclosporine or mycophenolate mofetil 2 g/d plus standard-dose cyclosporine.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3-8,259795,DB00688,Mycophenolate mofetil
,24935294,trough concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],4.307,259796,DB00688,Mycophenolate mofetil
,24935294,peak concentration,"Everolimus mean trough concentration was 4.307 ± 1.2459 ng/mL and mean peak concentration was 13.539 ± 3.5330 ng/mL, which peaked at 1 to 2 hours postdose.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],13.539,259797,DB00688,Mycophenolate mofetil
,24935294,area under the concentration-time curve,"The average concentration was 7.558 ± 1.4723 ng/mL, area under the concentration-time curve was 90.70 ± 17.667 ng·h/mL, and peak-trough fluctuation was 122.6%.",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[h·ng] / [ml],90.70,259798,DB00688,Mycophenolate mofetil
,24935294,trough levels,"The mean everolimus trough levels were within the target ranges at all time points ranging from 3.4 to 5.5 ng/mL (everolimus 0.75 mg twice a day, safety population).",Pharmacokinetics of everolimus when combined with cyclosporine in Japanese de novo renal transplant recipients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24935294/),[ng] / [ml],3.4 to 5.5,259799,DB00688,Mycophenolate mofetil
,20210680,C(max),"Means of dose-normalized MMF- or EC-MPS-MPA C(max) were 64.6 +/- 25 and 61.4 +/- 27.1 h mg/l, respectively.",Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210680/),[h·mg] / [l],64.6,259822,DB00688,Mycophenolate mofetil
,20210680,C(max),"Means of dose-normalized MMF- or EC-MPS-MPA C(max) were 64.6 +/- 25 and 61.4 +/- 27.1 h mg/l, respectively.",Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20210680/),[h·mg] / [l],61.4,259823,DB00688,Mycophenolate mofetil
,19377515,Survival,"Survival at 6 and 12 months after the start of MMF was 37 and 16%, respectively.",Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19377515/),%,37,259824,DB00688,Mycophenolate mofetil
,19377515,Survival,"Survival at 6 and 12 months was 55 and 52%, respectively.",Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19377515/),%,55,259825,DB00688,Mycophenolate mofetil
,19377515,Survival,"Survival at 6 and 12 months was 55 and 52%, respectively.",Therapy with mycophenolate mofetil for refractory acute and chronic GVHD. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19377515/),%,52,259826,DB00688,Mycophenolate mofetil
above,30430214,Dose-normalized total C0,Dose-normalized total C0 above 2.76 μg/mL·g may indicate patients with eGFR < 81 mL/min with sensitivity of 83.3% and specificity of 75.0%.,Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30430214/),[μg] / [g·ml],2.76,260251,DB00688,Mycophenolate mofetil
,30430214,free fraction,Hypoalbuminemic LN patients demonstrated significantly elevated MPA free fraction when compared with patients with serum albumin concentration ≥ 3.5 g/dL (1.49 ± 0.64% vs 1.08 ± 0.75%).,Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30430214/),%,1.49,260252,DB00688,Mycophenolate mofetil
,30430214,free fraction,Hypoalbuminemic LN patients demonstrated significantly elevated MPA free fraction when compared with patients with serum albumin concentration ≥ 3.5 g/dL (1.49 ± 0.64% vs 1.08 ± 0.75%).,Pharmacokinetics of free and total mycophenolic acid in adult lupus nephritis patients-implications for therapeutic drug monitoring. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30430214/),%,1.08,260253,DB00688,Mycophenolate mofetil
,24548445,AUC0-12 h,There were variable MPA AUC0-12 h levels between 14 and 67 mg×h/L (mean: 37 ± 14).,[Use of limited sampling strategy for estimating area under concentration-versus-time curve of mycophenolate sodium in renal allograft recipients]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24548445/),,37,260384,DB00688,Mycophenolate mofetil
,17640939,"AUC(ss, 0-12)","An AUC(ss, 0-12) of 45 mg h/l could be attained with an MMF dose of 12 mg/kg BD.",Is a standard fixed dose of mycophenolate mofetil ideal for all patients? ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17640939/),[h·mg] / [l],45,260907,DB00688,Mycophenolate mofetil
,18502461,C(max),"The mean prednisolone C(max) for recipients (n=14) having both the ABCB1 3435CC genotype and the CYP3A5*3/*3 genotype was significantly higher than those (n=11) having both ABCB1 3435TT and CYP3A5*3/*3 genotypes (180ng/mL versus 129ng/mL, P=0.0392).","Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502461/),[ng] / [ml],180,261505,DB00688,Mycophenolate mofetil
,18502461,C(max),"The mean prednisolone C(max) for recipients (n=14) having both the ABCB1 3435CC genotype and the CYP3A5*3/*3 genotype was significantly higher than those (n=11) having both ABCB1 3435TT and CYP3A5*3/*3 genotypes (180ng/mL versus 129ng/mL, P=0.0392).","Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18502461/),[ng] / [ml],129,261506,DB00688,Mycophenolate mofetil
,9255667,g,"MPM administration at 5 and 10 mg/kg/day significantly prolonged the graft survival time from 7.1 days to 18.5 days and 85.0 days, respectively.",Pharmacokinetic studies of mycophenolate mofetil in rat kidney allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255667/),d,7.1,261755,DB00688,Mycophenolate mofetil
,9255667,g,"MPM administration at 5 and 10 mg/kg/day significantly prolonged the graft survival time from 7.1 days to 18.5 days and 85.0 days, respectively.",Pharmacokinetic studies of mycophenolate mofetil in rat kidney allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255667/),d,18.5,261756,DB00688,Mycophenolate mofetil
,9255667,g,"MPM administration at 5 and 10 mg/kg/day significantly prolonged the graft survival time from 7.1 days to 18.5 days and 85.0 days, respectively.",Pharmacokinetic studies of mycophenolate mofetil in rat kidney allograft recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255667/),d,85.0,261757,DB00688,Mycophenolate mofetil
,9255667,AUC,"The AUC values on day 7 after transplantation were 32.7 micrograms.h/mL and 38.6 micrograms.h/mL in rats receiving 5 and 10 mg/kg/day, respectively.",Pharmacokinetic studies of mycophenolate mofetil in rat kidney allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255667/),[h·μg] / [ml],32.7,261758,DB00688,Mycophenolate mofetil
,9255667,AUC,"The AUC values on day 7 after transplantation were 32.7 micrograms.h/mL and 38.6 micrograms.h/mL in rats receiving 5 and 10 mg/kg/day, respectively.",Pharmacokinetic studies of mycophenolate mofetil in rat kidney allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255667/),[h·μg] / [ml],38.6,261759,DB00688,Mycophenolate mofetil
,9255667,AUC,"However, in rats receiving 15 mg/kg/day of MPM or more, the AUC value at 7 days was 78.8 micrograms.h/mL, and almost all of these rats died from gastrointestinal toxicity.",Pharmacokinetic studies of mycophenolate mofetil in rat kidney allograft recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9255667/),[h·μg] / [ml],78.8,261760,DB00688,Mycophenolate mofetil
more,17538999,bioavailability,"The bioavailability of mycophenolic acid (MPA) after oral administration of mycophenolate mofetil (MMF) has been reported to be more than 90% in healthy volunteers, and in kidney and thoracic organ transplant patients.",Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),%,90,262070,DB00688,Mycophenolate mofetil
,17538999,peak plasma concentrations,The mean peak plasma concentrations and the area under the plasma concentration vs. time curve (AUC) were significantly higher after IV MMF compared to oral MMF (peak plasma concentrations of 10.7 +/- 2.1 microg/mL for IV vs. 4.5 +/- 2.8 microg/mL for oral; P = 0.0001; and AUC of 28.9 +/- 7.1 microg . hr/mL for IV vs. 12.8 +/- 4.2 microg . hr/mL for oral; P = 0.0001).,Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),[μg] / [ml],10.7,262071,DB00688,Mycophenolate mofetil
,17538999,peak plasma concentrations,The mean peak plasma concentrations and the area under the plasma concentration vs. time curve (AUC) were significantly higher after IV MMF compared to oral MMF (peak plasma concentrations of 10.7 +/- 2.1 microg/mL for IV vs. 4.5 +/- 2.8 microg/mL for oral; P = 0.0001; and AUC of 28.9 +/- 7.1 microg . hr/mL for IV vs. 12.8 +/- 4.2 microg . hr/mL for oral; P = 0.0001).,Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),[μg] / [ml],4.5,262072,DB00688,Mycophenolate mofetil
,17538999,AUC,The mean peak plasma concentrations and the area under the plasma concentration vs. time curve (AUC) were significantly higher after IV MMF compared to oral MMF (peak plasma concentrations of 10.7 +/- 2.1 microg/mL for IV vs. 4.5 +/- 2.8 microg/mL for oral; P = 0.0001; and AUC of 28.9 +/- 7.1 microg . hr/mL for IV vs. 12.8 +/- 4.2 microg . hr/mL for oral; P = 0.0001).,Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),[h·μg] / [ml],28.9,262073,DB00688,Mycophenolate mofetil
,17538999,AUC,The mean peak plasma concentrations and the area under the plasma concentration vs. time curve (AUC) were significantly higher after IV MMF compared to oral MMF (peak plasma concentrations of 10.7 +/- 2.1 microg/mL for IV vs. 4.5 +/- 2.8 microg/mL for oral; P = 0.0001; and AUC of 28.9 +/- 7.1 microg . hr/mL for IV vs. 12.8 +/- 4.2 microg . hr/mL for oral; P = 0.0001).,Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),[h·μg] / [ml],12.8,262074,DB00688,Mycophenolate mofetil
,17538999,oral bioavailability,The oral bioavailability of MPA was 48.5 +/- 18.7%.,Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),%,48.5,262075,DB00688,Mycophenolate mofetil
,17538999,systemic clearance,"The systemic clearance, half-life, and steady state volume of distribution of MPA were 26.9 +/- 6 L/hour, 5.5 hours, and 85 liters, respectively.",Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),[l] / [h],26.9,262076,DB00688,Mycophenolate mofetil
,17538999,half-life,"The systemic clearance, half-life, and steady state volume of distribution of MPA were 26.9 +/- 6 L/hour, 5.5 hours, and 85 liters, respectively.",Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),h,5.5,262077,DB00688,Mycophenolate mofetil
,17538999,steady state volume of distribution,"The systemic clearance, half-life, and steady state volume of distribution of MPA were 26.9 +/- 6 L/hour, 5.5 hours, and 85 liters, respectively.",Pharmacokinetics of mycophenolic acid in liver transplant patients after intravenous and oral administration of mycophenolate mofetil. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17538999/),l,85,262078,DB00688,Mycophenolate mofetil
,21574884,ma68,"Algorithm calculated and trapezoidal extrapolated AUC(0-12) values showed high correlation (r=0.995) and acceptable dispersion (ma68=0.71 μg·h/mL), median prediction error (6.6%) and median absolute prediction error (12.6%).",Diagnostic efficiency of truncated area under the curve from 0 to 2 h (AUC₀₋₂) of mycophenolic acid in kidney transplant recipients receiving mycophenolate mofetil and concomitant tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21574884/),[h·μg] / [ml],0.71,263267,DB00688,Mycophenolate mofetil
,21574884,ma68,"However, due to the high inter-individual variation of the drug absorption-rate, the dispersion between both pharmacokinetic variables (ma68=6.9 μg·h/mL) was unacceptable.",Diagnostic efficiency of truncated area under the curve from 0 to 2 h (AUC₀₋₂) of mycophenolic acid in kidney transplant recipients receiving mycophenolate mofetil and concomitant tacrolimus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21574884/),[h·μg] / [ml],6.9,263268,DB00688,Mycophenolate mofetil
,16269051,t(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,2.5,264550,DB00688,Mycophenolate mofetil
,16269051,t(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,3.25,264551,DB00688,Mycophenolate mofetil
,16269051,C(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),[μg] / [ml],67.7,264552,DB00688,Mycophenolate mofetil
,16269051,C(max),"After a brief lag phase (t(lag) 0.75 h), MPA was rapidly absorbed (t(max) 2.5 h) and rapidly converted to MPAG (t(max) 3.25 h), with relatively high plasma concentrations of MPAG (C(max) 67.7 microg/mL) compared with MPA (C(max) 36.3 microg/mL).",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),[μg] / [ml],36.3,264553,DB00688,Mycophenolate mofetil
,16269051,elimination half-life,"The elimination half-life for MPAG was slightly longer than for MPA (approximately 13 h vs. 8.5 h), and the apparent oral clearance of MPA was approximately 0.2 L/h/kg.",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,13,264554,DB00688,Mycophenolate mofetil
,16269051,elimination half-life,"The elimination half-life for MPAG was slightly longer than for MPA (approximately 13 h vs. 8.5 h), and the apparent oral clearance of MPA was approximately 0.2 L/h/kg.",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),h,8.5,264555,DB00688,Mycophenolate mofetil
,16269051,apparent oral clearance,"The elimination half-life for MPAG was slightly longer than for MPA (approximately 13 h vs. 8.5 h), and the apparent oral clearance of MPA was approximately 0.2 L/h/kg.",Pharmacokinetics of enteric-coated mycophenolate sodium in stable pediatric renal transplant recipients. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16269051/),[l] / [h·kg],0.2,264556,DB00688,Mycophenolate mofetil
,14749696,peak plasma concentration (C(max)),"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[ng] / [ml],122.2,265126,DB00688,Mycophenolate mofetil
,14749696,area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)],"The mean peak plasma concentration (C(max)) of pravastatin was 122.2 +/- 88.2 ng/mL (range, 11.4-305.0 ng/mL), and the area under the plasma concentration-time curve of pravastatin from 0 to 10 hours [AUC(0-10)] was 264.1 +/- 192.4 ng.h/mL (range, 30.8-701.6 ng.h/mL).",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),[h·ng] / [ml],264.1,265127,DB00688,Mycophenolate mofetil
,14749696,time of peak concentration (t(max)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.1,265128,DB00688,Mycophenolate mofetil
,14749696,elimination half-life (t(1/2)),"The time of peak concentration (t(max)) of pravastatin was 1.1 +/- 0.4 hours (range, 0.5-2 hours), and the mean elimination half-life (t(1/2)) was 1.2 +/- 0.3 hours (range, 0.7-2.2 hours); these parameters were similar to those in the hypercholesterolemic children.",Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14749696/),h,1.2,265129,DB00688,Mycophenolate mofetil
,24673717,AUC,"The mean (range) MPA AUC was 42 ± 14.67 (29.29-75.95) mg/l h after the first dose, and 44.72 ± 14.57 (32.06-80.79) mg/l h on day 4 after operation.",Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673717/),[mg] / [h·l],42,265447,DB00688,Mycophenolate mofetil
,24673717,AUC,"The mean (range) MPA AUC was 42 ± 14.67 (29.29-75.95) mg/l h after the first dose, and 44.72 ± 14.57 (32.06-80.79) mg/l h on day 4 after operation.",Lower dosing of enteric-coated mycophenolate sodium (Myfortic) can achieve target mycophenolic acid exposure rapidly in most Chinese renal transplant patients: a pilot study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24673717/),[mg] / [h·l],44.72,265448,DB00688,Mycophenolate mofetil
,12948276,AUC(0-12),The mean values of AUC(0-12) were 37.54 + 0.80 microg x h/ml.,Pharmacokinetics of mycophenolic acid in kidney transplant recipients treated with a low dose (1 gram/day) of mycophenolate mofetil. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12948276/),[h·μg] / [ml],37.54,265886,DB00688,Mycophenolate mofetil
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],3145,266003,DB00688,Mycophenolate mofetil
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],384,266004,DB00688,Mycophenolate mofetil
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],4218,266005,DB00688,Mycophenolate mofetil
,17358097,area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)),"The mean area under the plasma concentration-time curves from 0 to infinity (AUC(infinity)) of (R)- and (S)-lansoprazole in recipients with the CYP3A5*1 allele were 3145 and 384 ng * h/mL, respectively, compared with 4218 and 587 ng * h/mL in recipients with the CYP3A5*3/*3 genotype.",Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),[h·ng] / [ml],587,266006,DB00688,Mycophenolate mofetil
,17358097,R/S ratio,The mean R/S ratio for AUC of lansoprazole in each CYP3A5 genotype group was the same (12.6).,Influence of cytochrome P450 (CYP) 3A5 polymorphisms on the pharmacokinetics of lansoprazole enantiomers in CYP2C19 extensive metaboliser renal transplant recipients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17358097/),,12.6,266007,DB00688,Mycophenolate mofetil
>,17827076,recoveries,"Mean recoveries in plasma and urine samples were >85%, and the lower limits of quantification for MPA, MPAG and AcMPAG were 0.05, 0.05 and 0.01 mg/L, respectively.",Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17827076/),%,85,266169,DB00688,Mycophenolate mofetil
,17827076,recoveries,"Mean recoveries in plasma and urine samples were >85%, and the lower limits of quantification for MPA, MPAG and AcMPAG were 0.05, 0.05 and 0.01 mg/L, respectively.",Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17827076/),[mg] / [l],0.05,266170,DB00688,Mycophenolate mofetil
,17827076,recoveries,"Mean recoveries in plasma and urine samples were >85%, and the lower limits of quantification for MPA, MPAG and AcMPAG were 0.05, 0.05 and 0.01 mg/L, respectively.",Sensitive high-performance liquid chromatography-tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17827076/),[mg] / [l],0.01,266171,DB00688,Mycophenolate mofetil
,22500920,AUC((0-6h)),Estimates for AUC((0-6h)) were 0.923 (0.865; 0.984) h*μg/ml and 0.985 (0.877; 1.106) μg/ml for C(min).,Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500920/),[h·μg] / [ml],0.923,267057,DB00688,Mycophenolate mofetil
,22500920,C(min),Estimates for AUC((0-6h)) were 0.923 (0.865; 0.984) h*μg/ml and 0.985 (0.877; 1.106) μg/ml for C(min).,Comparative pharmacokinetic study of two mycophenolate mofetil formulations in stable kidney transplant recipients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22500920/),[μg] / [ml],0.985,267058,DB00688,Mycophenolate mofetil
,28030534,-,"Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L·mg, 0.09-0.19; P = 0.04).",Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28030534/),[h·mg] / [l·m·mg],0.18,267154,DB00688,Mycophenolate mofetil
,28030534,AUC,"Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L·mg, 0.09-0.19; P = 0.04).",Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28030534/),[h·mg] / [l·m·mg],0.18,267155,DB00688,Mycophenolate mofetil
,28030534,AUC,"Patients off steroids had a higher dose-adjusted MPA-AUC (0.18 mg·h/L per mg/m, 0.012-0.27) compared with patients on steroids (0.12 mg·h·L·mg, 0.09-0.19; P = 0.04).",Single-Nucleotide Polymorphism of CYP3A5 Impacts the Exposure to Tacrolimus in Pediatric Renal Transplant Recipients: A Pharmacogenetic Substudy of the TWIST Trial. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28030534/),h·l·mg·mg,0.12,267156,DB00688,Mycophenolate mofetil
,22423584,Area under the concentration versus time curve (AUC),Area under the concentration versus time curve (AUC) is used for therapeutic drug monitoring and recommended levels are 30-60 microg x hr/L.,Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22423584/),[h·μg] / [l],30-60,267603,DB00688,Mycophenolate mofetil
,22423584,AUC0-12h,"The median AUC0-12h was 20.3 microg x hr/L, median Cmax = 0.7 microg/mL.",Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22423584/),[h·μg] / [l],20.3,267604,DB00688,Mycophenolate mofetil
,22423584,Cmax,"The median AUC0-12h was 20.3 microg x hr/L, median Cmax = 0.7 microg/mL.",Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22423584/),[μg] / [ml],0.7,267605,DB00688,Mycophenolate mofetil
>,22423584,AUC,"Two children (20%) had no detectable levels of mycophenolic acid after a single mycophenolate mofetil dose, other two patients had AUC > 60 microg x hr/L.",Pre-transplant mycophenolate mofetil pharmacokinetics in Mexican children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22423584/),[h·μg] / [l],60,267606,DB00688,Mycophenolate mofetil
,31805655,AUC,"The mean AUC on the day with plasmapheresis was lower than that on the day without plasmapheresis (28.22 ± 8.21 vs. 36.79 ± 10.29 mg × h/L, p = 0.001), and the percentage of AUC reduction was 19.49 ± 24.83%.",Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC0-12 in Kidney Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31805655/),[h·mg] / [l],28.22,269619,DB00688,Mycophenolate mofetil
,31805655,AUC,"The mean AUC on the day with plasmapheresis was lower than that on the day without plasmapheresis (28.22 ± 8.21 vs. 36.79 ± 10.29 mg × h/L, p = 0.001), and the percentage of AUC reduction was 19.49 ± 24.83%.",Plasmapheresis Reduces Mycophenolic Acid Concentration: A Study of Full AUC0-12 in Kidney Transplant Recipients. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31805655/),[h·mg] / [l],36.79,269620,DB00688,Mycophenolate mofetil
,22765258,systemic clearance,"For the typical patient (52 years of age, creatinine clearance 86 ml min(-1)), the median estimated values [coefficient of variation, %, (CV)] of systemic clearance, intercompartmental clearance, central and peripheral volumes of MPA were 1610 l h(-1) (37.4%), 541 l h(-1) (75.6%), 1230 l (37.5%), and 6140 l (120%), respectively.",Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765258/),[l] / [h],1610,270792,DB00688,Mycophenolate mofetil
,22765258,intercompartmental clearance,"For the typical patient (52 years of age, creatinine clearance 86 ml min(-1)), the median estimated values [coefficient of variation, %, (CV)] of systemic clearance, intercompartmental clearance, central and peripheral volumes of MPA were 1610 l h(-1) (37.4%), 541 l h(-1) (75.6%), 1230 l (37.5%), and 6140 l (120%), respectively.",Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765258/),[l] / [h],541,270793,DB00688,Mycophenolate mofetil
,22765258,intercompartmental clearance,"For the typical patient (52 years of age, creatinine clearance 86 ml min(-1)), the median estimated values [coefficient of variation, %, (CV)] of systemic clearance, intercompartmental clearance, central and peripheral volumes of MPA were 1610 l h(-1) (37.4%), 541 l h(-1) (75.6%), 1230 l (37.5%), and 6140 l (120%), respectively.",Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765258/),l,1230,270794,DB00688,Mycophenolate mofetil
,22765258,central,"For the typical patient (52 years of age, creatinine clearance 86 ml min(-1)), the median estimated values [coefficient of variation, %, (CV)] of systemic clearance, intercompartmental clearance, central and peripheral volumes of MPA were 1610 l h(-1) (37.4%), 541 l h(-1) (75.6%), 1230 l (37.5%), and 6140 l (120%), respectively.",Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765258/),l,1230,270795,DB00688,Mycophenolate mofetil
,22765258,peripheral volumes,"For the typical patient (52 years of age, creatinine clearance 86 ml min(-1)), the median estimated values [coefficient of variation, %, (CV)] of systemic clearance, intercompartmental clearance, central and peripheral volumes of MPA were 1610 l h(-1) (37.4%), 541 l h(-1) (75.6%), 1230 l (37.5%), and 6140 l (120%), respectively.",Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765258/),l,6140,270796,DB00688,Mycophenolate mofetil
,22765258,bioavailability,"After oral dosing, bioavailability was low (0.56) and highly variable (CV 46%).",Population pharmacokinetics of unbound mycophenolic acid in adult allogeneic haematopoietic cell transplantation: effect of pharmacogenetic factors. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22765258/),,0.56,270797,DB00688,Mycophenolate mofetil
,19005405,saturation duration,A cross-study comparison revealed that MMF reduced basiliximab clearance and prolonged CD25 saturation duration from approximately 5 weeks in the absence of MMF to 10 weeks in the presence of MMF.,Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19005405/),weeks,5,273332,DB00688,Mycophenolate mofetil
,19005405,saturation duration,A cross-study comparison revealed that MMF reduced basiliximab clearance and prolonged CD25 saturation duration from approximately 5 weeks in the absence of MMF to 10 weeks in the presence of MMF.,Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19005405/),weeks,10,273333,DB00688,Mycophenolate mofetil
,8249046,terminal half-life,Mycophenolic acid is rapidly cleared with a terminal half-life of approximately 1.0 h.,Single-dose pharmacokinetics of the new immunosuppressant RS-61443 in the rabbit. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249046/),h,1.0,273556,DB00688,Mycophenolate mofetil
,28649788,Cmax,"Plasma MPA Cmax (mean ± SD, 9.33 ± 7.04 μg/ml) occurred at <1 hr.",Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649788/),[μg] / [ml],9.33,273726,DB00688,Mycophenolate mofetil
,28649788,AUC0-∞,"The AUC0-∞ (mean ± SD, 12.84±6.62 hr*μg/ml), MRTinf (mean ± SD, 11.09 ± 9.63 min), T1/2 (harmonic mean ± PseudoSD 5.50 ± 3.80 min), and k/d (mean ± SD, 0.002 ± 0.001 1/min).",Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649788/),[h·μg] / [ml],12.84,273727,DB00688,Mycophenolate mofetil
,28649788,MRTinf,"The AUC0-∞ (mean ± SD, 12.84±6.62 hr*μg/ml), MRTinf (mean ± SD, 11.09 ± 9.63 min), T1/2 (harmonic mean ± PseudoSD 5.50 ± 3.80 min), and k/d (mean ± SD, 0.002 ± 0.001 1/min).",Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649788/),min,11.09,273728,DB00688,Mycophenolate mofetil
,28649788,T1/2,"The AUC0-∞ (mean ± SD, 12.84±6.62 hr*μg/ml), MRTinf (mean ± SD, 11.09 ± 9.63 min), T1/2 (harmonic mean ± PseudoSD 5.50 ± 3.80 min), and k/d (mean ± SD, 0.002 ± 0.001 1/min).",Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649788/),min,5.50,273729,DB00688,Mycophenolate mofetil
,28649788,k/d,"The AUC0-∞ (mean ± SD, 12.84±6.62 hr*μg/ml), MRTinf (mean ± SD, 11.09 ± 9.63 min), T1/2 (harmonic mean ± PseudoSD 5.50 ± 3.80 min), and k/d (mean ± SD, 0.002 ± 0.001 1/min).",Pharmacokinetics and dynamics of mycophenolate mofetil after single-dose oral administration in juvenile dachshunds. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28649788/),[1] / [min],0.002,273730,DB00688,Mycophenolate mofetil
